



National  
Comprehensive  
Cancer  
Network®

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)**

# **Non-Small Cell Lung Cancer**

Version 3.2017 — November 16, 2016

**NCCN.org**

**NCCN Guidelines for Patients® available at [www.nccn.org/patients](http://www.nccn.org/patients)**

**Continue**



National  
Comprehensive  
Cancer  
Network®

# NCCN Guidelines Version 3.2017 Panel Members

## Non-Small Cell Lung Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

\*David S. Ettinger, MD/Chair †  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

\*Douglas E. Wood, MD/Vice Chair ¶  
Fred Hutchinson Cancer Research  
Center/Seattle Cancer Care Alliance

Dara L. Aisner, MD, PhD ≠  
University of Colorado Cancer Center

Wallace Akerley, MD †  
Huntsman Cancer Institute  
at the University of Utah

Jessica Bauman, MD ‡  
Fox Chase Cancer Center

Lyudmila A. Bazhenova, MD † ‡  
UC San Diego Moores Cancer Center

Lucian R. Chirieac, MD ≠  
Dana-Farber/Brigham and Women's  
Cancer Center

Thomas A. D'Amico, MD ¶  
Duke Cancer Institute

Malcolm M. DeCamp, MD ¶  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

Thomas J. Dilling, MD, MS §  
Moffitt Cancer Center

Michael Dobelbower, MD, PhD §  
University of Alabama at Birmingham  
Comprehensive Cancer Center

Robert C. Doebele, MD, PhD †  
University of Colorado Cancer Center

Ramaswamy Govindan, MD †  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

Matthew A. Gubens, MD, MS †  
UCSF Helen Diller Family Comprehensive  
Cancer Center

Mark Hennon, MD ¶  
Roswell Park Cancer Institute

Leora Horn, MD, MSc †  
Vanderbilt-Ingram Cancer Center

Ritsuko Komaki, MD §  
The University of Texas  
MD Anderson Cancer Center

Rudy P. Lackner, MD ¶  
Fred & Pamela Buffett Cancer Center

Michael Lanuti, MD ¶  
Massachusetts General Hospital Cancer Center

Ticiana A. Leal, MD †  
University of Wisconsin Carbone Cancer Center

Leah J. Leisch, MD ¶  
University of Alabama at Birmingham  
Comprehensive Cancer Center

Rogério Lilenbaum, MD †  
Yale Cancer Center/Smilow Cancer Hospital

Jules Lin, MD ¶  
University of Michigan  
Comprehensive Cancer Center

Billy W. Loo, Jr., MD, PhD §  
Stanford Cancer Institute

Renato Martins, MD, MPH †  
Fred Hutchinson Cancer Research Center/  
Seattle Cancer Care Alliance

Gregory A. Otterson, MD †  
The Ohio State University Comprehensive  
Cancer Center - James Cancer Hospital  
and Solove Research Institute

Karen Reckamp, MD, MS † ‡  
City of Hope Comprehensive Cancer Center

Gregory J. Riely, MD, PhD † ¶  
Memorial Sloan Kettering Cancer Center

Steven E. Schild, MD §  
Mayo Clinic Cancer Center

Theresa A. Shapiro, MD, PhD ≠  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

Neelesh Sharma, MD, PhD † ‡  
Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer Center and  
Cleveland Clinic Taussig Cancer Institute

James Stevenson, MD †  
Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer Center and  
Cleveland Clinic Taussig Cancer Institute

Scott J. Swanson, MD ¶  
Dana-Farber/Brigham and Women's  
Cancer Center

Kurt Tauer, MD †  
St. Jude Children's Research Hospital/  
University of Tennessee Health Science Center

Stephen C. Yang, MD ¶  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

**NCCN**  
Kristina Gregory, RN, MSN, OCN  
Miranda Hughes, PhD

**Continue**

† Medical oncology	Ⓞ Diagnostic/Interventional radiology
¶ Surgery/Surgical oncology	¥ Patient advocate
§ Radiation oncology/Radiotherapy	Ⓟ Internal medicine
≠ Pathology	*Discussion Section Writing Committee
‡ Hematology/Hematology oncology	

[NCCN Guidelines Panel Disclosures](#)

# NCCN Guidelines Version 3.2017 Table of Contents

## Non-Small Cell Lung Cancer

### [NCCN Non-Small Cell Lung Cancer Panel Members](#)

#### [Summary of Guidelines Updates](#)

#### [Lung Cancer Prevention and Screening \(PREV-1\)](#)

#### [Clinical Presentation and Risk Assessment \(DIAG-1\)](#)

#### [Initial Evaluation and Clinical Stage \(NSCL-1\)](#)

#### [Evaluation and Treatment:](#)

- [Stage I \(T1ab-2a, N0\), Stage II \(T1ab-2ab, N1; T2b, N0\), Stage IIB \(T3, N0\), and Stage IIIA \(T3, N1\) \(NSCL-2\)](#)
- [Stage IIB \(T3 invasion, N0\) and Stage IIIA \(T4 extension, N0-1; T3, N1\) \(NSCL-4\)](#)
- [Stage IIIA \(T1-3, N2\) and Separate Pulmonary Nodules \(Stage IIB, IIIA, IV\) \(NSCL-7\)](#)
- [Multiple Lung Cancers \(NSCL-10\)](#)
- [Stage IIB \(T1-3, N3\) \(NSCL-11\)](#)
- [Stage IIB \(T4, N2-3\) and Stage IV, M1a: Pleural or Pericardial Effusion \(NSCL-12\)](#)
- [Stage IV, M1b: Limited Sites \(NSCL-13\)](#)
- [Surveillance After Completion of Definitive Therapy \(NSCL-15\)](#)
- [Therapy for Recurrence and Metastasis \(NSCL-16\)](#)
- [Systemic Therapy for Metastatic Disease \(NSCL-17\)](#)

#### [Principles of Pathologic Review \(NSCL-A\)](#)

#### [Principles of Surgical Therapy \(NSCL-B\)](#)

#### [Principles of Radiation Therapy \(NSCL-C\)](#)

#### [Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy \(NSCL-D\)](#)

#### [Chemotherapy Regimens Used with Radiation Therapy \(NSCL-E\)](#)

#### [Systemic Therapy for Advanced or Metastatic Disease \(NSCL-F\)](#)

#### [Cancer Survivorship Care \(NSCL-G\)](#)

#### [Emerging Targeted Agents for Patients With Genetic Alterations \(NSCL-H\)](#)

#### [Staging \(ST-1\)](#)

**Clinical Trials:** NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical\\_trials/physician.html](#).

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2016.



# NCCN Guidelines Version 3.2017 Updates

## Non-Small Cell Lung Cancer

Updates in Version 3.2017 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 2.2017 include:

### [MS-1](#)

- The Discussion section has been updated to reflect the changes in the algorithm.

Updates in Version 2.2017 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 1.2017 include:

### [NSCL-17](#)

- Testing results modified: "*PD-L1* positive and *EGFR*, *ALK*, *ROS1* negative or unknown."

### [NSCL-24](#)

- Subsequent Therapy; PS 0-2: Atezolizumab added as a treatment option. Reference added: Barlesi F, Park K, Ciardiello F, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC [abstract]. ESMO Congress; Copenhagen. ESMO 2016: LBA44. (also applies to NSCL-25)
- Erlotinib removed as a treatment option in subsequent therapy and maintenance therapy.
- Footnote "ww" modified: Pembrolizumab is approved for patients with NSCLC tumors with PD-L1 expression *levels*  $\geq 1\%$ , as determined by an FDA-approved test. ~~for PD-L1 with use of pembrolizumab.~~ (also applies to NSCL-25)
- Footnote "aaa" modified: If not already given, options for PS 0-2 include (nivolumab, pembrolizumab, or atezolizumab), ~~erlotinib~~, docetaxel (category 2B), pemetrexed (category 2B), gemcitabine (category 2B), or ramucirumab + docetaxel (category 2B); options for PS 3-4 include best supportive care. Options for further progression are best supportive care or clinical trial.

### [NSCL-25](#)

- Footnote "bbb" modified: If not already given, options for PS 0-2 include (nivolumab, pembrolizumab, or atezolizumab), docetaxel (category 2B), gemcitabine (category 2B), or ramucirumab + docetaxel (category 2B); options for PS 3-4 include best supportive care. Options for further progression are best supportive care or clinical trial.

Updates in Version 1.2017 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 4.2016 include:

### [PREV-1](#)

- Link added to the NCCN Guidelines for Smoking Cessation.

### [DIAG-2](#) and [DIAG-3](#)

- These pages were revised and adapted from the Fleischner Society Guidelines.

### [NSCL-2](#)

- Stage IA: "Consider" added to "pathologic mediastinal lymph node evaluation."
- Stage IB; Brain MRI: category 2B removed and "optional" listed.
- Medically inoperable; N0: Consider adjuvant chemotherapy for high-risk stages IB-IIIA clarified as stages IB-IIB.
- Footnote "j" modified with addition of first sentence: PET/CT performed skull base to knees or whole body. (also applies to NSCL-4, NSCL-7, NSCL-9, NSCL-11 through NSCL-13)



# NCCN Guidelines Version 3.2017 Updates

## Non-Small Cell Lung Cancer

Updates in Version 1.2017 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 4.2016 include:

### [NSCL-2](#)

- Footnote "p" modified: Examples of high-risk factors may include poorly differentiated tumors (including lung neuroendocrine tumors [excluding well-differentiated neuroendocrine tumors]), vascular invasion, wedge resection, tumors >4 cm, visceral pleural involvement, and ~~incomplete lymph node sampling~~ *unknown lymph node status (Nx)*. These factors independently may not be an indication and may be considered when determining treatment with adjuvant chemotherapy. (also applies to NSCL-3)

### [NSCL-5](#)

- Surgical reevaluation clarified: including chest CT with or without contrast ± PET/CT.

### [NSCL-8](#)

- T1-3, N0-1: Surgery removed, as this is already noted in the Initial Treatment column.
  - ▶ Adjuvant treatment linked back to NSCL-3 for N0-1 and N2.
- T1-2,T3 (other than invasive), N2 nodes positive and T3 (invasion), N2 nodes positive changed to include M0.
  - ▶ Brain MRI and FDG PET/CT removed, as they are already noted on previous page.
  - ▶ Metastatic disease removed, as this is already noted on previous page.
- Footnote "w" is new to the page: "Chest CT with contrast and/or PET/CT to evaluate progression."

### [NSCL-10](#)

- Definitive local therapy not possible: "Consider" removed from "palliative chemotherapy ± local palliative therapy" and "Observe" added.
- Footnote "aa" modified: "Lung-sparing resection is preferred, but tumor distribution and institutional expertise should guide individual treatment planning. *Patients should be evaluated in a multidisciplinary setting (ie, surgery, radiation oncology, medical oncology).*"

### [NSCL-13](#)

- Significant revisions for the management of limited metastases. Now covers pages NSCL-13 and NSCL-14.

### [NSCL-15](#)

- Surveillance title modified: "SURVEILLANCE AFTER COMPLETION OF DEFINITIVE THERAPY"
- Recommendations differentiated based on primary therapy.
  - ▶ *Stage I-II (primary treatment included surgery ± chemotherapy)*  
H&P and chest CT ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non-contrast-enhanced chest CT annually
  - ▶ *Stage I-II (primary treatment included RT) or Stage III or Stage IV (oligometastatic with all sites treated with definitive intent)*  
H&P and chest CT ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non-contrast-enhanced chest CT annually
    - ◊ *Residual or new radiographic abnormalities may require more frequent imaging"*
- Recommendations for stage IV not included.
- "PET/CT or brain MRI is not *routinely* indicated"

### [NSCL-16](#)

- Locoregional recurrence post therapy: The following imaging was added to evaluate for disseminated disease: "Chest CT with contrast; Brain MRI with contrast; PET/CT."
- Distant metastasis; Bone metastasis; Recommendations reordered: "If risk of fracture, orthopedic stabilization + palliative external-beam RT."



# NCCN Guidelines Version 3.2017 Updates

## Non-Small Cell Lung Cancer

Updates in Version 1.2017 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 4.2016 include:

### [NSCL-17](#)

- Testing added for ROS1 and PD-L1.
- Squamous cell carcinoma: "Consider EGFR mutation testing and ALK testing ~~especially~~ in never smokers or small biopsy specimens, or mixed histology."
- Footnote "ff" added: "If repeat biopsy is not feasible, plasma biopsy should be considered."
- Footnote "gg" modified: "The NCCN NSCLC Guidelines Panel strongly ~~endorses~~ *advises* broader molecular profiling..."
- Footnote "kk" added: "PD-L1 expression levels of  $\geq 50\%$  are a positive test for first-line pembrolizumab therapy."
- Footnote removed since the content was added to the algorithm: Consider ROS1 testing; if positive, may treat with crizotinib.

### [NSCL-18](#)

- EGFR mutation discovered during first-line chemotherapy: "Interrupt or complete planned chemotherapy, followed by..." changed to "Complete planned chemotherapy, including maintenance therapy, or interrupt, followed by..." (also applies to NSCL-20)

### [NSCL-19](#)

- "T790M testing" added with footnote "nn": "If tissue biopsy is not feasible, plasma biopsy should be considered."
- Asymptomatic: "Consider local therapy" added as a treatment option.
- Brain: "Osimertinib" added as a treatment option.
- Asymptomatic, brain lesions, or symptomatic and isolated systemic lesions: progression directed to treatment for multiple lesions.
- Systemic isolated or multiple lesions:
  - ▶ T790M+ added with treatment recommendation of osimertinib.
  - ▶ T790M- added with referral to first-line therapy options for adenocarcinoma, squamous cell carcinoma, or PD-L1 expression positive ( $\geq 50\%$ ).
- Footnote "pp" modified: "Osimertinib is ~~approved~~ an option for patients..."
- Footnote "qq" added: "For rapid radiologic progression or threatened organ function, alternate therapy should be instituted."

### [NSCL-21](#)

- Asymptomatic: "Consider local therapy" added as an option.
- Brain and systemic isolated lesions: "continue ALK inhibitor" clarified as "continue crizotinib."
- Symptomatic systemic progression after local therapies and/or switching to ceritinib or alectinib changed to "progression."

### [NSCL-22](#)

- New page added for ROS1 rearrangement positive. Crizotinib is noted as a category 2A recommendation.

### [NSCL-23](#)

- New page added for PD-L1 expression positive. Pembrolizumab is noted as a category 1 recommendation.

### [NSCL-24](#)

- First-line therapy: Doublet chemotherapy and bevacizumab + chemotherapy changed to "Systemic therapy," as specific recommendations are noted on NSCL-F. Associated footnotes moved to NSCL-F.
- Subsequent Therapy; PS 3-4: Erlotinib, afatinib, gefitinib, crizotinib removed as treatment options. Associated footnotes removed.
- Footnote "v" added: "If pembrolizumab not previously given." (also applies to NSCL-25)
- Footnote "xx" added: "If not previously given" (also applies to NSCL-25)



# NCCN Guidelines Version 3.2017 Updates

## Non-Small Cell Lung Cancer

Updates in Version 1.2017 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 4.2016 include:

### [NSCL-A \(1 of 5\)](#)

- Pathologic Evaluation, bullet 3 modified: "The pathology diagnostic report should include the histologic classification *in resection specimens or small biopsies* as described by the WHO for carcinomas of the lung. ~~The recently published classification of adenocarcinoma should be used for this tumor subtype in resection specimens and small biopsies.~~"
- Pathologic Evaluation, bullet 6 modified: "Limited use of IHC studies in small tissue samples is strongly recommended *in samples that cannot be reliably classified on the basis of routine histology alone*, thereby preserving critical tumor tissue for molecular studies, particularly in patients with advanced-stage disease. A limited panel of one squamous cell carcinoma marker (eg, p63, p40) and one adenocarcinoma marker (eg, TTF-1, napsin A) should suffice for most diagnostic problems."

### [NSCL-A \(3 of 5\)](#)

- ALK; bullet 1: "alectinib" added to third sentence.
- ALK; bullet 2: "translocations" changed to "rearrangements".
- ALK; bullet 3 modified: The current standard method for detecting ALK NSCLC is fluorescence in situ hybridization (FISH); ~~although other methods are currently being evaluated, including polymerase chain reaction (PCR) and IHC.~~

### [NSCL-A \(4 of 5\)](#)

- New sections were added for ROS-1 and PD-L1.

### [NSCL-A \(5 of 5\)](#)

- The following references were updated: 6, 7. The following references added: 33–38.

### [NSCL-B 1 of 4](#)

- Bullet 6 added: Patients who are active smokers should be provided counseling and smoking cessation support (NCCN Guidelines for Smoking Cessation). While active smokers have a mildly increased incidence of postoperative pulmonary complications, these should not be considered a prohibitive risk for surgery. Surgeons should not deny surgery to patients solely due to smoking status, as surgery provides the predominant opportunity for prolonged survival in patients with early-stage lung cancer."

### [NSCL-C \(1 of 10\)](#)

- General Principles; bullet 5 modified: "Useful references include the ~~ACR-ASTRO Practice Guidelines for Radiation Oncology Practice Parameters and Technical Standards...~~"
- General Principles; bullet 4 modified with addition of sentence: In a prospective trial of definitive chemo/RT for stage III NSCLC (RTOG 0617), IMRT was associated with a nearly 60% decrease in high-grade radiation pneumonitis and similar survival and tumor control outcomes despite a higher proportion of stage IIIB and larger treatment volumes compared to 3D-CRT; as such, IMRT is preferred over 3D-CRT in this setting.



# NCCN Guidelines Version 3.2017 Updates

## Non-Small Cell Lung Cancer

Updates in Version 1.2017 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 4.2016 include:

### [NSCL-C \(3 of 10\)](#)

- Node-Negative Early-Stage SABR; bullet 2 modified: "In the United States, only regimens of ≤5 fractions meet the arbitrary billing code definition of SBRT, but slightly more protracted regimens are appropriate as well. ~~For centrally located tumors (defined as within 2 cm of the proximal bronchial tree), 4 to 10 fraction risk-adapted SABR regimens appear to be effective and safe, while 54 to 60 Gy in 3 fractions is unsafe and should be avoided. The dose for 5-fraction regimens is being studied prospectively in RTOG 0813. For centrally located tumors (defined variably as within 2 cm of the proximal bronchial tree and/or abutting mediastinal pleura) and even ultra-central tumors (defined as abutting the proximal bronchial tree), 4 to 10 fraction risk-adapted SABR regimens appear to be effective and safe, while 54 to 60 Gy in 3 fractions is unsafe and should be avoided. The maximum tolerated dose for 5-fraction regimens was studied prospectively in RTOG 0813, preliminarily demonstrating no high-grade toxicities at 50 Gy in 5 fractions while final results are pending.~~"

### [NSCL-C \(4 of 10\)](#)

- Locally Advanced Stage/Conventionally Fractionated RT; bullet 2 modified: "Dose escalation in RT alone, sequential chemo/RT, or concurrent chemo/RT is associated with better survival in non-randomized comparisons. ~~While doses of up to 74 Gy with concurrent chemotherapy can be delivered safely when normal tissue dose constraints are respected, results from RTOG 0617, comparing 60 versus 74 Gy with concurrent chemotherapy, found that 74 Gy does not improve overall survival, and might be potentially harmful. While optimal RT dose intensification remains a valid question, higher doses of 74 Gy are not currently recommended for routine use.~~"
- Advanced Stage/Palliative RT; last sentence modified: "When higher doses (>30 Gy) are warranted, *technologies to reduce normal tissue irradiation (at least 3D-CRT and including IMRT or proton therapy as appropriate) should be used.*"

### [NSCL-C \(7 of 10\)](#)

- "Please note - Tables 2–5 provide doses and constraints used commonly or in past clinical trials as useful references rather than specific recommendations." (also applies to NSCL-C 8 of 10)

### [NSCL-C \(8 of 10\)](#)

- Table 5: Footnote "\*" added: "RTOG 0617 data suggest that even lower radiation doses to the heart than previously appreciated may be detrimental to survival after thoracic RT, and more stringent constraints may be appropriate."

### [NSCL-C \(9 of 10\)](#)

- The following reference was added: 5, 17.

### [NSCL-C \(10 of 10\)](#)

- The following references were added: 52, 53, 55, 89.

### [NSCL-E](#)

- Concurrent Chemotherapy/RT Regimens
  - ▶ Bullet 4 modified: "Cisplatin 75 mg/m<sup>2</sup> on day 1, pemetrexed 500 mg/m<sup>2</sup> on day 1 every 21 days for 3 cycles; concurrent thoracic RT (nonsquamous) ± *additional 4 cycles of pemetrexed 500 mg/m<sup>2</sup>*"
  - ▶ Bullet 5 modified: "Paclitaxel 45–50 mg/m<sup>2</sup> weekly; carboplatin AUC 2, concurrent thoracic RT ± *additional 2 cycles of paclitaxel 200 mg/m<sup>2</sup> and carboplatin AUC 6*"
- "Concurrent Chemotherapy/RT Followed by Chemotherapy" removed.
  - ▶ Cisplatin/etoposide with concurrent RT followed by cisplatin/etoposide removed.





# NCCN Guidelines Version 3.2017 Updates

## Non-Small Cell Lung Cancer

Updates in Version 1.2017 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 4.2016 include:

### [NSCL-F \(1 of 4\)](#)

- **First-line therapy; bullet 4 modified:** "Response assessment after 4-2 cycles, then every 2–4 cycles *with CT of known sites with or without contrast or when clinically indicated.*"
- **Subsequent therapy; bullets removed for the following agents:** nivolumab, pembrolizumab, docetaxel, pemetrexed, ramucirumab + docetaxel, erlotinib. This information is included in detail in the discussion.
- **Subsequent therapy; bullet added:** "Response assessment with CT of known sites with or without contrast every 6–12 weeks."

### [NSCL-F \(2 of 4\)](#)

- **First-line Systemic Therapy Options; Adenocarcinoma, Large cell, NSCLC NOS (PS 0-1);** the following regimens removed: carboplatin/vinorelbine, cisplatin/vinorelbine.
- **First-line Systemic Therapy Options; Adenocarcinoma, Large cell, NSCLC NOS (PS 2);** the following regimens removed: carboplatin/vinorelbine, etoposide, irinotecan, vinorelbine.

### [NSCL-F \(3 of 4\)](#)

- **First-line Systemic Therapy Options; Squamous cell carcinoma (PS 0-1);** the following regimens removed: carboplatin/etoposide, carboplatin/vinorelbine, cisplatin/gemcitabine/necitumumab, cisplatin/vinorelbine.
- **First-line Systemic Therapy Options; Squamous cell carcinoma (PS 2);** the following regimens removed: carboplatin/vinorelbine, cisplatin/gemcitabine/necitumumab, etoposide, irinotecan, vinorelbine.
- **Footnote added:** "Cisplatin/gemcitabine/necitumumab in the first-line setting and erlotinib or afatinib in the second-line setting are not used at NCCN institutions for these indications related to the efficacy and safety of these agents compared to the efficacy and safety of other available agents."

### [NSCL-H](#)

- **Emerging Targeted Agents for Patients with Genetic Alterations**
  - ▶ **RET rearrangements:** vandetanib added as an option.
  - ▶ **ROS1 rearrangements** were removed, as this information has been added to the algorithm.
  - ▶ **Footnotes references updated:** 3, 4. **Footnote references added:** 9, 12.

**LUNG CANCER PREVENTION AND SCREENING**

- Lung cancer is a unique disease in that the major etiologic agent is an addictive product that is made and promoted by an industry. Approximately 85% to 90% of cases are caused by voluntary or involuntary (second-hand) cigarette smoking. Reduction of lung cancer mortality will require effective public health policies to prevent initiation of smoking, U.S. Food and Drug Administration (FDA) oversight of tobacco products, and other tobacco control measures.
- Persistent smoking is associated with second primary cancers, treatment complications, drug interactions, other tobacco-related medical conditions, diminished quality of life, and reduced survival.
- Reports from the Surgeon General on both active smoking ([http://www.cdc.gov/tobacco/data\\_statistics/sgr/2004/pdfs/executivesummary.pdf](http://www.cdc.gov/tobacco/data_statistics/sgr/2004/pdfs/executivesummary.pdf)) and second-hand smoke show that both cause lung cancer. The evidence shows a 20% to 30% increase in the risk for lung cancer from second-hand smoke exposure associated with living with a smoker (<http://www.ncbi.nlm.nih.gov/books/NBK44324/>). Every person should be informed of the health consequences, addictive nature, and mortal threat posed by tobacco consumption and exposure to tobacco smoke, and effective legislative, executive, administrative, or other measures should be contemplated at the appropriate governmental level to protect all persons from exposure to tobacco smoke ([www.who.int/tobacco/framework/final\\_text/en/](http://www.who.int/tobacco/framework/final_text/en/)).
- Further complicating this problem, the delivery system of lung carcinogens also contains the highly addictive substance, nicotine. Reduction of lung cancer mortality will require widespread implementation of Agency for Healthcare Research and Quality (AHRQ) Guidelines (<http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/index.html>) to identify, counsel, and treat patients with nicotine habituation.
- Patients who are current or former smokers have significant risk for the development of lung cancer; chemoprevention agents are not yet established for these patients. When possible, these patients should be encouraged to enroll in chemoprevention trials.
- Lung cancer screening using low-dose CT (LDCT) is recommended in select high-risk smokers and former smokers (see the [NCCN Guidelines for Lung Cancer Screening](#)).
- See the [NCCN Guidelines for Smoking Cessation](#).


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### CLINICAL PRESENTATION

### RISK ASSESSMENT<sup>b</sup>



<sup>a</sup>Multidisciplinary evaluation including thoracic surgeons, thoracic radiologists, and pulmonologists to determine the likelihood of a cancer diagnosis and the optimal diagnostic or follow-up strategy.

<sup>b</sup>Risk calculators can be used to quantify individual patient and radiologic factors but do not replace evaluation by a multidisciplinary diagnostic team with substantial experience in the diagnosis of lung cancer.

<sup>c</sup>[See Principles of Diagnostic Evaluation \(DIAG-A 1 of 2\).](#)

<sup>d</sup>The most important radiologic factor is change or stability compared with a previous imaging study.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

- Lung nodules in asymptomatic, high-risk patients detected during lung cancer screening with LDCT, see the [NCCN Guidelines for Lung Cancer Screening](#).
- For incidentally detected lung nodules, see below.

### FINDINGS

### FOLLOW-UP<sup>c,d,g,h</sup>



<sup>c</sup>See Principles of Diagnostic Evaluation (DIAG-A 1 of 2).

<sup>d</sup>The most important radiologic factor is change or stability compared with a previous imaging study.

<sup>e</sup>Low risk = minimal or absent history of smoking or other known risk factors.

<sup>f</sup>High risk = history of smoking or other known risk factors. Known risk factors include history of lung cancer in a first-degree relative; exposure to asbestos, radon, or uranium.

<sup>g</sup>Non-solid, partially solid, or ground-glass nodules may require longer follow-up to exclude indolent adenocarcinoma.

<sup>h</sup>Adapted from Fleischner Society Guidelines: MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. *Radiology* 2005;237:395-400. © Radiological Society of North America. Fleischner Society Guidelines do not direct whether or not contrast is necessary or if an LDCT is appropriate. LDCT is preferred unless there is a reason for contrast enhancement for better diagnostic resolution.

<sup>i</sup>PET/CT performed skull base to knees or whole body. A positive PET result is defined as a standardized uptake value (SUV) in the lung nodule greater than the baseline mediastinal blood pool. A positive PET scan finding can be caused by infection or inflammation, including absence of lung cancer with localized infection, presence of lung cancer with associated (eg, postobstructive) infection, and presence of lung cancer with related inflammation (eg, nodal, parenchymal, pleural). A false-negative PET scan can be caused by a small nodule, low cellular density (nonsolid nodule or ground-glass opacity [GGO]), or low tumor avidity for FDG (eg, adenocarcinoma in situ [previously known as bronchoalveolar carcinoma], carcinoid tumor).

<sup>j</sup>Patients with a suspicion of lung cancer after PET/CT require histologic confirmation before any nonsurgical therapy. When a biopsy is not possible, a multidisciplinary evaluation should be done including radiation oncology, surgery, and interventional pulmonology.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

- Lung nodules in asymptomatic, high-risk patients detected during lung cancer screening with LDCT, see the [NCCN Guidelines for Lung Cancer Screening](#).
- For incidentally detected lung nodules, see below.



<sup>c</sup>See [Principles of Diagnostic Evaluation \(DIAG-A 1 of 2\)](#).

<sup>d</sup>The most important radiologic factor is change or stability compared with a previous imaging study.

<sup>g</sup>Non-solid, partially solid, or ground-glass nodules may require longer follow-up to exclude indolent adenocarcinoma.

<sup>k</sup>Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected on CT: A statement from the Fleischner Society.

Radiology 2013;266:304-317. Guidelines do not direct whether or not contrast is necessary or if an LDCT is appropriate. LDCT is preferred unless there is a reason for contrast enhancement for better diagnostic resolution.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF DIAGNOSTIC EVALUATION**

- **Patients with a strong clinical suspicion of stage I or II lung cancer (based on risk factors and radiologic appearance) do not require a biopsy before surgery.**
  - ▶ **A biopsy adds time, costs, and procedural risk and may not be needed for treatment decisions.**
  - ▶ **A preoperative biopsy may be appropriate if a non-lung cancer diagnosis is strongly suspected that can be diagnosed by core biopsy or fine-needle aspiration (FNA).**
  - ▶ **A preoperative biopsy may be appropriate if an intraoperative diagnosis appears difficult or very risky.**
  - ▶ **If a preoperative tissue diagnosis has not been obtained, then an intraoperative diagnosis (ie, wedge resection, needle biopsy) is necessary before lobectomy, bilobectomy, or pneumonectomy.**
- **Bronchoscopy should preferably be performed during the planned surgical resection, rather than as a separate procedure.**
  - ▶ **Bronchoscopy is required before surgical resection ([see NSCL-2](#)).**
  - ▶ **A separate bronchoscopy may not be needed for treatment decisions before the time of surgery and adds time, costs, and procedural risk.**
  - ▶ **A preoperative bronchoscopy may be appropriate if a central tumor requires pre-resection evaluation for biopsy, surgical planning (eg, potential sleeve resection), or preoperative airway preparation (eg, coring out an obstructive lesion).**
- **Invasive mediastinal staging is recommended before surgical resection for most patients with clinical stage I or II lung cancer ([see NSCL-2](#)).**
  - ▶ **Patients should preferably undergo invasive mediastinal staging as the initial step before the planned resection (during the same anesthetic procedure), rather than as a separate procedure.**
  - ▶ **A separate staging procedure adds time, costs, coordination of care, inconvenience, and an additional anesthetic risk.**
  - ▶ **Preoperative invasive mediastinal staging may be appropriate for a strong clinical suspicion of N2 or N3 nodal disease or when intraoperative cytology or frozen section analysis is not available.**
- **In patients with suspected non-small cell lung cancer (NSCLC), many techniques are available for tissue diagnosis.**
  - ▶ **Diagnostic tools that should be routinely available include:**
    - ◊ **Sputum cytology**
    - ◊ **Bronchoscopy with biopsy and transbronchial needle aspiration (TBNA)**
    - ◊ **Image-guided transthoracic needle core biopsy (preferred) or FNA**
    - ◊ **Thoracentesis**
    - ◊ **Mediastinoscopy**
    - ◊ **Video-assisted thoracic surgery (VATS) and open surgical biopsy**
  - ▶ **Diagnostic tools that provide important additional strategies for biopsy include:**
    - ◊ **Endobronchial ultrasound (EBUS)–guided biopsy**
    - ◊ **Endoscopic ultrasound (EUS)–guided biopsy**
    - ◊ **Navigational bronchoscopy**

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF DIAGNOSTIC EVALUATION**

- **The preferred diagnostic strategy for an individual patient depends on the size and location of the tumor, the presence of mediastinal or distant disease, patient characteristics (such as pulmonary pathology and/or other significant comorbidities), and local experience and expertise.**
  - ▶ **Factors to be considered in choosing the optimal diagnostic step include:**
    - ◊ **Anticipated diagnostic yield (sensitivity)**
    - ◊ **Diagnostic accuracy including specificity and particularly the reliability of a negative diagnostic study (ie, true negative)**
    - ◊ **Adequate volume of tissue specimen for diagnosis and molecular testing**
    - ◊ **Invasiveness and risk of procedure**
    - ◊ **Efficiency of evaluation**
      - **Access and timeliness of procedure**
      - **Concomitant staging is beneficial, because it avoids additional biopsies or procedures. It is preferable to biopsy the pathology that would confer the highest stage (ie, to biopsy a suspected metastasis or mediastinal lymph node rather than the pulmonary lesion). Therefore, PET imaging is frequently best performed before a diagnostic biopsy site is chosen in cases of high clinical suspicion for aggressive, advanced-stage tumors.**
    - ◊ **Technologies and expertise available**
    - ◊ **Tumor viability at proposed biopsy site from PET imaging.**
  - ▶ **Decisions about the optimal diagnostic steps for suspected stage I to III lung cancer should be made by thoracic radiologists, interventional radiologists, and board-certified thoracic surgeons who devote a significant portion of their practice to thoracic oncology. Multidisciplinary evaluation should also include a pulmonologist or thoracic surgeon with expertise in advanced bronchoscopic techniques for diagnosis.**
  - ▶ **The least invasive biopsy with the highest yield is preferred as the first diagnostic study.**
    - ◊ **Patients with central masses and suspected endobronchial involvement should undergo bronchoscopy.**
    - ◊ **Patients with peripheral (outer one-third) nodules may benefit from navigational bronchoscopy, radial EBUS, or transthoracic needle aspiration (TTNA).**
    - ◊ **Patients with suspected nodal disease should be biopsied by EBUS, EUS, navigational bronchoscopy, or mediastinoscopy.**
      - **EBUS provides access to nodal stations 2R/2L, 4R/4L, 7, 10R/10L, and other hilar nodal stations if necessary.**
      - **EUS–guided biopsy provides additional access to stations 5, 7, 8, and 9 lymph nodes if these are clinically suspicious.**
      - **TTNA and anterior mediastinotomy (ie, Chamberlain procedure) provide additional access to anterior mediastinal (station 5 and 6) lymph nodes if these are clinically suspicious.**
    - ◊ **EUS also provides reliable access to the left adrenal gland.**
    - ◊ **Lung cancer patients with an associated pleural effusion should undergo thoracentesis and cytology. A negative cytology result on initial thoracentesis does not exclude pleural involvement. An additional thoracentesis and/or thoracoscopic evaluation of the pleura should be considered before starting curative intent therapy.**
    - ◊ **Patients suspected of having a solitary site of metastatic disease should have tissue confirmation of that site if feasible.**
    - ◊ **Patients suspected of having metastatic disease should have confirmation from one of the metastatic sites if feasible.**
    - ◊ **Patients who may have multiple sites of metastatic disease—based on a strong clinical suspicion—should have biopsy of the primary lung lesion or mediastinal lymph nodes if it is technically difficult or very risky to biopsy a metastatic site.**

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer


### PATHOLOGIC DIAGNOSIS OF NSCLC

### INITIAL EVALUATION

### CLINICAL STAGE

NSCLC →

- Pathology review<sup>a</sup>
  - H&P (include performance status + weight loss)<sup>b</sup>
  - CT chest and upper abdomen with contrast, including adrenals
  - CBC, platelets
  - Chemistry profile
  - Smoking cessation advice, counseling, and pharmacotherapy
  - Integrate palliative care<sup>c</sup> (See [NCCN Guidelines for Palliative Care](#))
- ▶ Use the 5 A's Framework: Ask, Advise, Assess, Assist, Arrange  
<http://www.ahrq.gov/clinic/tobacco/5steps.htm>



<sup>a</sup>See [Principles of Pathologic Review \(NSCL-A\)](#).

<sup>b</sup>Enhanced frailty or geriatric assessments may predict complications better following treatment modalities, particularly surgery. A preferred frailty assessment system has not been established.

<sup>c</sup>Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small cell lung cancer. *N Engl J Med* 2010;363:733-742.

<sup>d</sup>Based on the CT of the chest: Peripheral = outer third of lung; Central = inner two thirds of lung.

<sup>e</sup>T3, N0 related to size or satellite nodules.

<sup>f</sup>For patients considered to have stage IIB and stage III tumors, where more than one treatment modality (surgery, radiation therapy, or chemotherapy) is usually considered, a multidisciplinary evaluation should be performed.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer



<sup>e</sup>T3, N0 related to size or satellite nodules.

<sup>g</sup>Testing is not listed in order of priority and is dependent on clinical circumstances, institutional processes, and judicious use of resources.

<sup>h</sup>Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.

<sup>i</sup>Solid tumors <1 cm and purely non-solid tumors <3 cm that are CT and PET negative have a low likelihood of positive mediastinal lymph nodes and pre-resection pathologic mediastinal evaluation is optional.

<sup>j</sup>PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

<sup>k</sup>[See Principles of Surgical Therapy \(NSCL-B\).](#)

<sup>l</sup>[See Principles of Radiation Therapy \(NSCL-C\).](#)

<sup>m</sup>Interventional radiology ablation is an option for selected patients.

<sup>n</sup>After surgical evaluation, patients likely to receive adjuvant chemotherapy may be treated with induction chemotherapy as an alternative.

<sup>o</sup>[See Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy \(NSCL-D\).](#)

<sup>p</sup>Examples of high-risk factors may include poorly differentiated tumors (including lung neuroendocrine tumors [excluding well-differentiated neuroendocrine tumors]), vascular invasion, wedge resection, tumors >4 cm, visceral pleural involvement, and unknown lymph node status (Nx). These factors independently may not be an indication and may be considered when determining treatment with adjuvant chemotherapy.

<sup>q</sup>[See Chemotherapy Regimens Used with Radiation Therapy \(NSCL-E\).](#)


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer



<sup>l</sup>See Principles of Radiation Therapy (NSCL-C).

<sup>o</sup>See Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy (NSCL-D).

<sup>p</sup>Examples of high-risk factors may include poorly differentiated tumors (including lung neuroendocrine tumors [excluding well-differentiated neuroendocrine tumors]), vascular invasion, wedge resection, tumors >4 cm, visceral pleural involvement, and unknown lymph node status (Nx). These factors independently may not be an indication and may be considered when determining treatment with adjuvant chemotherapy.

<sup>q</sup>See Chemotherapy Regimens Used with Radiation Therapy (NSCL-E).

<sup>r</sup>R0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic residual tumor.

<sup>s</sup>Increasing size is an important variable when evaluating the need for adjuvant chemotherapy.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### CLINICAL ASSESSMENT

### PRETREATMENT EVALUATION

### CLINICAL EVALUATION

Stage IIB (T3 invasion, N0)  
Stage IIIA (T4 extension,  
N0-1; T3, N1)

- PFTs (if not previously done)
- Bronchoscopy
- Pathologic mediastinal lymph node evaluation<sup>h</sup>
- Brain MRI with contrast
- MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine or subclavian vessels
- FDG PET/CT scan<sup>j</sup> (if not previously done)

Superior sulcus tumor → [See Treatment \(NSCL-5\)](#)

Chest wall → [See Treatment \(NSCL-6\)](#)

Proximal airway or mediastinum → [See Treatment \(NSCL-6\)](#)

Unresectable disease → [See Treatment \(NSCL-6\)](#)

Metastatic disease → [See Treatment for Metastasis limited sites \(NSCL-13\) or distant disease \(NSCL-16\)](#)

<sup>h</sup>Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.


<sup>j</sup>PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer



<sup>k</sup>See Principles of Surgical Therapy (NSCL-B).

<sup>l</sup>See Principles of Radiation Therapy (NSCL-C).

<sup>o</sup>See Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy (NSCL-D).

<sup>q</sup>See Chemotherapy Regimens Used with Radiation Therapy (NSCL-E).

<sup>t</sup>RT should continue to definitive dose without interruption if patient is not a surgical candidate.


<sup>u</sup>If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 2 cycles of full-dose chemotherapy.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer



<sup>k</sup>See Principles of Surgical Therapy (NSCL-B).

<sup>l</sup>See Principles of Radiation Therapy (NSCL-C).

<sup>o</sup>See Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy (NSCL-D).

<sup>q</sup>See Chemotherapy Regimens Used with Radiation Therapy (NSCL-E).

<sup>r</sup>R0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic residual tumor.

<sup>t</sup>RT should continue to definitive dose without interruption if patient is not a surgical candidate.

<sup>u</sup>If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 2 cycles of full-dose chemotherapy.

<sup>v</sup>Consider RT boost if chemoradiation is given as initial treatment.


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer



<sup>h</sup>Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.

<sup>j</sup>PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### MEDIASTINAL BIOPSY FINDINGS

### INITIAL TREATMENT

### ADJUVANT TREATMENT



<sup>k</sup>See Principles of Surgical Therapy (NSCL-B).

<sup>l</sup>See Principles of Radiation Therapy (NSCL-C).

<sup>n</sup>After surgical evaluation, patients likely to receive adjuvant chemotherapy may be treated with induction chemotherapy as an alternative.

<sup>o</sup>See Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy (NSCL-D).

<sup>q</sup>See Chemotherapy Regimens Used with Radiation Therapy (NSCL-E).


<sup>w</sup>Chest CT with contrast and/or PET/CT to evaluate progression.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

### CLINICAL PRESENTATION


Separate pulmonary nodule(s), same lobe (T3, N0-1), or ipsilateral non-primary lobe (T4, N0-1)



Stage IV (N0, M1a): Contralateral lung (solitary nodule)

Treat as two primary lung tumors if both curable → [See Evaluation \(NSCL-1\)](#)

Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)<sup>x,y</sup>



<sup>h</sup>Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.

<sup>j</sup>PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

<sup>k</sup>[See Principles of Surgical Therapy \(NSCL-B\)](#).

<sup>l</sup>[See Principles of Radiation Therapy \(NSCL-C\)](#).

<sup>o</sup>[See Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy \(NSCL-D\)](#).

<sup>q</sup>[See Chemotherapy Regimens Used with Radiation Therapy \(NSCL-E\)](#).

<sup>r</sup>R0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic residual tumor.

<sup>x</sup>Lesions with different cell types (eg, squamous cell carcinoma, adenocarcinoma) may be different primary tumors. This analysis may be limited by small biopsy samples. However, lesions of the same cell type are not necessarily metastases.

<sup>y</sup>For guidance regarding the evaluation, workup, and management of subsolid pulmonary nodules, please see the diagnostic evaluation of a nodule suspicious for lung cancer ([DIAG-1](#)).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.






# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### CLINICAL PRESENTATION

### INITIAL TREATMENT



<sup>k</sup>See Principles of Surgical Therapy (NSCL-B).

<sup>l</sup>See Principles of Radiation Therapy (NSCL-C).

<sup>z</sup>Lesions at low risk of becoming symptomatic can be observed (eg, small subsolid nodules with slow growth). However, if the lesion(s) becomes symptomatic or becomes high risk for producing symptoms (eg, subsolid nodules with accelerating growth or increasing solid component or increasing FDG uptake, even while small), treatment should be considered.

<sup>aa</sup>Lung-sparing resection is preferred, but tumor distribution and institutional expertise should guide individual treatment planning. Patients should be evaluated in a multidisciplinary setting (ie, surgery, radiation oncology, medical oncology).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### CLINICAL ASSESSMENT

### PRETREATMENT EVALUATION

### INITIAL TREATMENT



<sup>j</sup>PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan positive in the mediastinum, lymph node status needs pathologic confirmation.

<sup>l</sup>See [Principles of Radiation Therapy \(NSCL-C\)](#).

<sup>q</sup>See [Chemotherapy Regimens Used with Radiation Therapy \(NSCL-E\)](#).

<sup>u</sup>If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 2 cycles of full-dose chemotherapy.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### CLINICAL ASSESSMENT

### PRETREATMENT EVALUATION

### INITIAL TREATMENT



<sup>j</sup>PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

<sup>l</sup>See [Principles of Radiation Therapy \(NSCL-C\)](#).

<sup>q</sup>See [Chemotherapy Regimens Used with Radiation Therapy \(NSCL-E\)](#).

<sup>u</sup>If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 2 cycles of full-dose chemotherapy.

<sup>bb</sup>While most pleural effusions associated with lung cancer are due to tumor, there are a few patients in whom multiple cytopathologic examinations of pleural fluid are negative for tumor and fluid is non-bloody and not an exudate. When these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element. Pericardial effusion is classified using the same criteria.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

**CLINICAL ASSESSMENT**

**PRETREATMENT EVALUATION**

**INITIAL TREATMENT<sup>cc</sup>**



<sup>j</sup>PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation.


<sup>cc</sup>[See NCCN Guidelines for Central Nervous System Cancers.](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### TREATMENT OF THORACIC DISEASE



<sup>h</sup>Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.

<sup>k</sup>See [Principles of Surgical Therapy \(NSCL-B\)](#).

<sup>l</sup>See [Principles of Radiation Therapy \(NSCL-C\)](#).


<sup>q</sup>See [Chemotherapy Regimens Used with Radiation Therapy \(NSCL-E\)](#).

<sup>dd</sup>Typically, RT (including SABR) or surgical resection.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**SURVEILLANCE AFTER COMPLETION  
OF DEFINITIVE THERAPY****No evidence of clinical/radiographic disease**

- Stage I–II (primary treatment included surgery ± chemotherapy)
  - H&P and chest CT ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non-contrast-enhanced chest CT annually
- Stage I–II (primary treatment included RT) or Stage III or Stage IV (oligometastatic with all sites treated with definitive intent)
  - H&P and chest CT ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non-contrast-enhanced chest CT annually
    - ◊ Residual or new radiographic abnormalities may require more frequent imaging
- Smoking cessation advice, counseling, and pharmacotherapy
- PET/CT<sup>ee</sup> or brain MRI is not routinely indicated
- [See Cancer Survivorship Care \(NSCL-G\)](#)



<sup>ee</sup>FDG PET/CT is currently not warranted in the routine surveillance and follow-up of patients with NSCLC. However, many benign conditions (such as atelectasis, consolidation, and radiation fibrosis) are difficult to differentiate from neoplasm on standard CT imaging, and FDG PET/CT can be used to differentiate true malignancy in these settings. However, if FDG PET/CT is to be used as a problem-solving tool in patients after radiation therapy, histopathologic confirmation of recurrent disease is needed because areas previously treated with radiation therapy can remain FDG avid for up to 2 years.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### THERAPY FOR RECURRENCE AND METASTASIS



<sup>k</sup>See Principles of Surgical Therapy (NSCL-B).

<sup>l</sup>See Principles of Radiation Therapy (NSCL-C).

<sup>m</sup>Interventional radiology ablation is an option for selected patients.

<sup>q</sup>See Chemotherapy Regimens Used with Radiation Therapy (NSCL-E).


<sup>cc</sup>See NCCN Guidelines for Central Nervous System Cancers.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer



<sup>a</sup>[See Principles of Pathologic Review \(NSCL-A\)](#).

<sup>c</sup>Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733-742.

<sup>ff</sup>If repeat biopsy is not feasible, plasma biopsy should be considered.

<sup>gg</sup>The NCCN NSCLC Guidelines Panel strongly advises broader molecular profiling with the goal of identifying rare driver mutations for which effective drugs may already be available, or to appropriately counsel patients regarding the availability of clinical trials. Broad molecular profiling is a key component of the improvement of care of patients with NSCLC. [See Emerging Targeted Agents for Patients With Genetic Alterations \(NSCL-H\)](#).

<sup>hh</sup>In patients with squamous cell carcinoma, the observed incidence of EGFR mutations is 2.7% with a confidence that the true incidence of mutations is less than 3.6%. This frequency of EGFR mutations does not justify routine testing of all tumor specimens. Forbes SA, Bharna G, Bamford S, et al. The catalogue of somatic mutations in cancer (COSMIS). *Curr Protoc Hum Genet* 2008;chapter 10:unit 10.11.

<sup>ii</sup>Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. *Mol Cancer Ther* 2012;11:2535-2540.

<sup>jj</sup>Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small cell lung cancer. *N Engl J Med* 2014;371:1963-1971.

<sup>kk</sup>PD-L1 expression levels of ≥50% are a positive test result for first-line pembrolizumab therapy.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





### SENSITIZING EGFR MUTATION POSITIVE<sup>a</sup>

#### FIRST-LINE THERAPY



<sup>a</sup>See [Principles of Pathologic Review \(NSCL-A\)](#).

<sup>||</sup>For performance status 0-4.


**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### SENSITIZING EGFR MUTATION POSITIVE<sup>a</sup>



<sup>a</sup>See Principles of Pathologic Review (NSCL-A).

<sup>mm</sup>Beware of flare phenomenon in subset of patients who discontinue EGFR TKI. If disease flare occurs, restart EGFR TKI.

<sup>nn</sup>If tissue biopsy is not feasible, plasma biopsy should be considered.

<sup>oo</sup>Consider pulse erlotinib for carcinomatosis meningitis.

<sup>pp</sup>Osimertinib is an option for patients with metastatic EGFR T790M mutation-positive tumors, as determined by an FDA-approved test or other validated laboratory-developed test performed in a CLIA-approved laboratory.


<sup>qq</sup>For rapid radiologic progression or threatened organ function, alternate therapy should be instituted.

<sup>rr</sup>Afatinib + cetuximab may be considered in patients with disease progression on EGFR TKI therapy.

**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



### ALK REARRANGEMENT POSITIVE<sup>a</sup>




<sup>a</sup>See [Principles of Pathologic Review \(NSCL-A\)](#).

<sup>||</sup>For performance status 0-4.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### ALK REARRANGEMENT POSITIVE<sup>a</sup>



<sup>a</sup>See [Principles of Pathologic Review \(NSCL-A\)](#).

<sup>qq</sup>For rapid radiologic progression or threatened organ function, alternate therapy should be instituted.

<sup>SS</sup>Patients who are intolerant to crizotinib may be switched to ceritinib or alectinib.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




### ROS1 REARRANGEMENT POSITIVE<sup>a</sup>

#### FIRST-LINE THERAPY

#### SUBSEQUENT THERAPY

*ROS1*  
rearrangement  
positive



Crizotinib

Progression

See First-line therapy options  
[Adenocarcinoma \(NSCL-24\)](#)  
[Squamous cell carcinoma \(NSCL-25\)](#)  
or  
*PD-L1* expression positive (≥50%)  
[See First-Line Therapy \(NSCL-23\)](#)

<sup>a</sup>[See Principles of Pathologic Review \(NSCL-A\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### PD-L1 EXPRESSION POSITIVE<sup>a</sup>

#### FIRST-LINE THERAPY

#### SUBSEQUENT THERAPY



<sup>a</sup>See [Principles of Pathologic Review \(NSCL-A\)](#).

<sup>tt</sup>Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. *N Engl J Med* 2016;375:1823-1833.


**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### ADENOCARCINOMA, LARGE CELL, NSCLC NOS FIRST-LINE THERAPY



<sup>uu</sup>See [Systemic Therapy for Advanced or Metastatic Disease \(NSCLC-F\)](#).

<sup>vv</sup>If pembrolizumab not previously given.

<sup>ww</sup>Pembrolizumab is approved for patients with NSCLC tumors with PD-L1 expression levels  $\geq 1\%$ , as determined by an FDA-approved test.

<sup>xx</sup>If not previously given.

<sup>yy</sup>Barlesi F, Park K, Ciardiello F, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC [abstract]. ESMO Congress; Copenhagen. ESMO 2016: LBA44.

<sup>zz</sup>If bevacizumab was used with a first-line pemetrexed/platinum chemotherapy regimen.

<sup>aaa</sup>If not already given, options for PS 0-2 include (nivolumab, pembrolizumab, or atezolizumab), docetaxel (category 2B), pemetrexed (category 2B), gemcitabine (category 2B), or ramucirumab + docetaxel (category 2B); options for PS 3-4 include best supportive care. Options for further progression are best supportive care or clinical trial.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### SQUAMOUS CELL CARCINOMA

#### FIRST-LINE THERAPY



<sup>uu</sup>[See Systemic Therapy for Advanced or Metastatic Disease \(NSCL-F\).](#)

<sup>vv</sup>If pembrolizumab not previously given.

<sup>ww</sup>Pembrolizumab is approved for patients with NSCLC tumors with PD-L1 expression levels  $\geq 1\%$ , as determined by an FDA-approved test.

<sup>xx</sup>If not previously given.

<sup>yy</sup>Barlesi F, Park K, Ciardiello F, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC [abstract]. ESMO Congress; Copenhagen. ESMO 2016: LBA44.

<sup>bbb</sup>If not already given, options for PS 0-2 include (nivolumab, pembrolizumab, or atezolizumab), docetaxel (category 2B), gemcitabine (category 2B), or ramucirumab + docetaxel (category 2B); options for PS 3-4 include best supportive care. Options for further progression are best supportive care or clinical trial.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



**PRINCIPLES OF PATHOLOGIC REVIEW (1 of 5)****Pathologic Evaluation**

- The purpose of pathologic evaluation is to classify the histologic type of lung cancer and to determine all staging parameters as recommended by the AJCC,<sup>1</sup> including tumor size, the extent of invasion (pleural and bronchial), adequacy of surgical margins, and presence or absence of lymph node metastasis.<sup>2,3</sup> Further, determination of the specific molecular abnormalities of the tumor is critical for predicting sensitivity or resistance to an increasing number of drugable targets, primarily tyrosine kinase inhibitors (TKIs) (see *Molecular Diagnostic Studies in Lung Cancer* in this section).<sup>4,5</sup>
- The WHO tumor classification system has historically provided the foundation for the classification of lung tumors, including histologic types, clinical features, staging considerations, and the molecular, genetic, and epidemiologic aspects of lung cancer.<sup>6,7</sup>
- The pathology diagnostic report should include the histologic classification in resection specimens or small biopsies as described by the WHO for carcinomas of the lung. Use of bronchioloalveolar carcinoma (BAC) terminology is strongly discouraged.
- The generic term “non-small cell lung cancer (NSCLC)” should be avoided as a single diagnostic term. In small biopsies of poorly differentiated carcinomas where immunohistochemistry (IHC) is used, the following terms are acceptable: “NSCLC favor adenocarcinoma” or “NSCLC favor squamous cell carcinoma.”<sup>8</sup> Mutational testing (eg, epidermal growth factor receptor [EGFR]) is strongly recommended in all NSCLC favor adenocarcinomas.
- Formalin-fixed paraffin-embedded tumor is acceptable for most molecular analyses.
- Limited use of IHC studies in small tissue samples is strongly recommended in samples that cannot be reliably classified on the basis of routine histology alone, thereby preserving critical tumor tissue for molecular studies, particularly in patients with advanced-stage disease. A limited panel of one squamous cell carcinoma marker (eg, p63, p40) and one adenocarcinoma marker (eg, TTF-1, napsin A) should suffice for most diagnostic problems.<sup>8</sup>

**Adenocarcinoma Classification**<sup>8</sup>

- Adenocarcinoma in situ (AIS; formerly BAC): ≤3 cm nodule, lepidic growth, mucinous, non-mucinous, or mixed mucinous/non-mucinous types.
- Minimally invasive adenocarcinoma (MIA): ≤3 cm nodule with ≤5 mm of invasion, lepidic growth, mucinous, non-mucinous, or mixed mucinous/non-mucinous types.
- Invasive adenocarcinoma, predominant growth pattern: lepidic >5 mm of invasion, acinar, papillary, micropapillary, or solid with mucin.
- Invasive adenocarcinoma variants: mucinous adenocarcinoma, colloid, fetal, and enteric morphologies.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF PATHOLOGIC REVIEW (2 of 5)****Immunohistochemical Staining**

- **Judicious use of IHC is strongly recommended to preserve tissue for molecular testing. IHC should be utilized only after consideration of all data including routine H&E histology, clinical findings, imaging studies, and patient's history.**
- **Although the concordance is generally good between the histologic subtype and the immunophenotype seen in small biopsies compared with surgical resection specimens, caution is advised in attempting to subtype small biopsies with limited material or cases with an ambiguous immunophenotype.**
- **IHC should be used to differentiate primary pulmonary adenocarcinoma from the following: squamous cell carcinoma, large cell carcinoma, metastatic carcinoma, and malignant mesothelioma; to determine whether neuroendocrine differentiation is present.<sup>9-11</sup>**
- **Primary pulmonary adenocarcinoma**
  - ▶ **In patients for whom the primary origin of the carcinoma is uncertain, an appropriate panel of immunohistochemical stains is recommended to exclude metastatic carcinoma to the lung.<sup>12</sup>**
  - ▶ **TTF-1 is a homeodomain-containing nuclear transcription protein of the *Nkx2* gene family that is expressed in epithelial cells of the embryonal and mature lung and thyroid. TTF-1 immunoreactivity is seen in primary pulmonary adenocarcinoma in the majority (70%–100%) of non-mucinous adenocarcinoma subtypes.<sup>13</sup> Metastatic adenocarcinoma to the lung is virtually always negative for TTF-1 except in metastatic thyroid malignancies, in which case thyroglobulin is also positive.**
  - ▶ **Napsin A - an aspartic proteinase expressed in normal type II pneumocytes and in proximal and distal renal tubules - appears to be expressed in >80% of lung adenocarcinomas and may be a useful adjunct to TTF-1.<sup>12</sup>**
  - ▶ **The panel of TTF-1 (or alternatively napsin A) and p63 (or alternatively p40) may be useful in refining the diagnosis to either adenocarcinoma or squamous cell carcinoma in small biopsy specimens previously classified as NSCLC NOS.<sup>8</sup>**
- **Neuroendocrine differentiation**
  - ▶ **CD56, chromogranin, and synaptophysin are used to identify neuroendocrine tumors.**
- **Malignant mesothelioma versus pulmonary adenocarcinoma**
  - ▶ **The distinction between pulmonary adenocarcinoma and malignant mesothelioma (epithelial type) can be made by correlation of the histology with the clinical impression, imaging studies, and a limited panel of immunomarkers if needed.<sup>11</sup>**
    - ◊ **Immunostains relatively sensitive and specific for mesothelioma include WT-1, calretinin, D2-40, HMBE-1, and cytokeratin 5/6 (negative in adenocarcinoma).<sup>14,15</sup>**
    - ◊ **Antibodies immunoreactive in adenocarcinoma include CEA, B72.3, Ber-EP4, MOC31, CD15, claudin-4, and TTF-1 (negative in mesothelioma).<sup>8,11</sup>**

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF PATHOLOGIC REVIEW (3 of 5)****Molecular Diagnostic Studies in Lung Cancer****• EGFR and KRAS**

- ▶ **EGFR** is normally found on the surface of epithelial cells and is often overexpressed in a variety of human malignancies. Presence of **EGFR**-activating mutations represents a critical biological determinant for proper therapy selection in patients with lung cancer.
- ▶ There is a significant association between **EGFR** mutations—especially exon 19 deletion and exon 21 (L858R, L861), exon 18 (G719X, G719), and exon 20 (S768I) mutations—and sensitivity to EGFR TKIs.<sup>16-19</sup>
- ▶ The exon 20 insertion mutation may predict resistance to clinically achievable levels of TKIs.<sup>20,21</sup>
- ▶ Overlapping **EGFR** and **KRAS** mutations occur in <1% of patients with lung cancer.<sup>22</sup>
- ▶ **KRAS** mutations are associated with intrinsic EGFR TKI resistance, and **KRAS** gene sequencing could be useful for the selection of patients as candidates for EGFR TKI therapy.<sup>23</sup> **KRAS** testing may identify patients who may not benefit from further molecular diagnostic testing.
- ▶ The prevalence of **EGFR** mutations in adenocarcinomas is 10% of Western and up to 50% of Asian patients, with higher **EGFR** mutation frequency in non-smokers, women, and non-mucinous cancers. **KRAS** mutations are most common in non-Asians, smokers, and in mucinous adenocarcinoma.<sup>24</sup> The most common **EGFR** mutations result in an arginine for leucine substitution at amino acid 858 in exon 21 (L858R) and in frame deletions at exon 19. Mutations are more common in non-mucinous lung adenocarcinoma with lepidic pattern (former BAC pattern) and in lung adenocarcinoma with papillary (and or micropapillary) pattern.
- ▶ Primary resistance to EGFR TKI therapy is associated with **KRAS** mutation. Acquired resistance is associated with second-site mutations within the **EGFR** kinase domain (such as T790M), amplification of alternative kinases (such as **MET**), histologic transformation from NSCLC to SCLC, and epithelial to mesenchymal transition (EMT).

**• ALK**

- ▶ Anaplastic lymphoma kinase (**ALK**) gene rearrangements represent the fusion between **ALK** and various partner genes, including echinoderm microtubule-associated protein-like 4 (**EML4**).<sup>25</sup> **ALK** fusions have been identified in a subset of patients with NSCLC and represent a unique subset of NSCLC patients for whom **ALK** inhibitors may represent a very effective therapeutic strategy.<sup>26</sup> Crizotinib, ceritinib, and alectinib are oral **ALK** inhibitors that are approved by the FDA for patients with metastatic NSCLC who have the **ALK** gene rearrangement (ie, **ALK** positive).
- ▶ **ALK** NSCLC occurs most commonly in a unique subgroup of NSCLC patients who share many of the clinical features of NSCLC patients likely to harbor **EGFR** mutations.<sup>27,28</sup> However, for the most part, **ALK** rearrangements and **EGFR** mutations are mutually exclusive.<sup>27, 29-31</sup>
- ▶ The current standard method for detecting **ALK** NSCLC is fluorescence in situ hybridization (FISH). The appropriate antibody and detection method for **ALK** protein expression can be used for rapid prescreening of **ALK**-rearranged lung adenocarcinomas and selection of cases that will subsequently be confirmed by FISH testing.<sup>32</sup>

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF PATHOLOGIC REVIEW (4 of 5)****Molecular Diagnostic Studies in Lung Cancer.****• ROS-1**

- ▶ Although ROS1 is a distinct receptor tyrosine kinase, ROS1 has a high degree of homology with ALK (approximately 50% within the kinase domain and 75% within the ATP-binding site).<sup>33</sup>
- ▶ The majority of patients with ROS1-positive NSCLC respond to the first-generation ALK inhibitor crizotinib; however, certain other ALK inhibitors such as alectinib do not appear to have activity against ROS1-positive NSCLC.<sup>34</sup>
- ▶ ROS1 rearrangements occur in 1%–2% of patients with NSCLC.<sup>34</sup> Similar to testing for ALK rearrangements, testing for ROS1 is also done using FISH.<sup>35</sup>

**• PD-L1**

- ▶ Immune checkpoint inhibitors target programmed death receptor 1 (PD-1) or its ligand, programmed death ligand 1 (PD-L1).<sup>36</sup>
- ▶ PD-1 is expressed by T-cells and regulates the activation of T-cells in peripheral tissues. PD-1 has two ligands, PD-L1 (also known as B7-H1 or CD274) and PD-L2 (B7-DC or CD273). These ligands are expressed on a wide range of immune effector cells, antigen-presenting cells, and tumor cells. PD-1 activation by ligand binding with PD-L1 on the tumor cells produces a number of intracellular effects that result in T-cell inactivity and reduced proliferation.
- ▶ The therapeutic focus in NSCLC has been to interrupt the interaction of PD-1 and its ligand PD-L1 between tumor cells and immune effectors cells using monoclonal antibodies against PD-L1 or PD-1.<sup>37</sup>
- ▶ Anti-PD-L1 IHC may be a biomarker used to select patients with NSCLC more likely to respond to immune checkpoint inhibitors, but the development of a variety of therapeutics, each with a different anti-PD-L1 IHC assay, has raised concerns among both pathologists and oncologists.<sup>37,38</sup>
- ▶ The definition of a positive PD-L1 test result varies depending on which biomarker assay is used.<sup>37</sup> PD-L1 expression levels of ≥50% are a positive test result for first-line pembrolizumab therapy.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF PATHOLOGIC REVIEW (5 of 5) - References**

- <sup>1</sup>Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.
- <sup>2</sup>Fossella FV, Putnam JB, Komaki R, eds. Lung Cancer. M.D. Anderson Cancer Care Series. New York: Springer; 2003:316.
- <sup>3</sup>Schrump DS, Carter D, Kelsey CR, et al. Non-small cell lung cancer. In: DeVita Jr. VT, Lawrence TS, Rosenberg SA, et al., eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2011.
- <sup>4</sup>Cappuzzo F, Ligorio C, Toschi L, et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2007;2:423-429.
- <sup>5</sup>Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol* 2005;23:5900-5909.
- <sup>6</sup>Travis WD. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2015.
- <sup>7</sup>Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumours. *J Thorac Oncol* 2015;10:1243-1260.
- <sup>8</sup>Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011;6:244-285.
- <sup>9</sup>Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. *Mod Pathol* 2011;24:1348-1359.
- <sup>10</sup>Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. *Am J Surg Pathol* 2011;35:15-25.
- <sup>11</sup>Husain AN, Colby T, Ordóñez N, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group. *Arch Pathol Lab Med* 2013;137:647-667.
- <sup>12</sup>Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. *Arch Pathol Lab Med* 2008;132:384-396.
- <sup>13</sup>Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. *Am J Clin Pathol* 2001;116:319-325.
- <sup>14</sup>Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. *Hum Pathol* 2005;36:372-380.
- <sup>15</sup>Chirieac LR, Pinkus GS, Pinkus JL, et al. The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. *Am J Cancer Res* 2011;1:14-24.
- <sup>16</sup>Cappuzzo F, Finocchiaro G, Metro G, et al. Clinical experience with gefitinib: an update. *Crit Rev Oncol Hematol* 2006;58:31-45.
- <sup>17</sup>Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497-1500.
- <sup>18</sup>Sequist LV, Joshi VA, Janne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. *Oncologist* 2007;12:90-98.
- <sup>19</sup>Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. *Cancer Cell* 2006;9:485-495.
- <sup>20</sup>Lund-Iverson M, Kleinber L, Fjellbirkeland L, Helland A, et al. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. *J Thorac Oncol* 2012;7:1471-1413.
- <sup>21</sup>Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small cell lung cancer: preclinical data and clinical implications. *Lancet Oncol* 2012;13:e23-31.
- <sup>22</sup>Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. *Clin Cancer Res* 2006;12:7232-7241.
- <sup>23</sup>Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. *Int J Cancer* 2006;118:257-262.
- <sup>24</sup>Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. *J Mol Diagn* 2007;9:320-326.
- <sup>25</sup>Cataldo KA, Jalal SM, Law ME, et al. Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. *Am J Surg Pathol* 1999;23:1386-1392.
- <sup>26</sup>Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693-1703.
- <sup>27</sup>Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol* 2009;27:4247-4253.
- <sup>28</sup>Koivunen JP, Kim J, Lee J, et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. *Br J Cancer* 2008;99:245-252.
- <sup>29</sup>Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res* 2008;14:4275-4283.
- <sup>30</sup>Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. *Proc Natl Acad Sci U S A* 2008;105:19893-19897.
- <sup>31</sup>Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. *Mod Pathol* 2009;22:508-515.
- <sup>32</sup>Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. *J Thorac Oncol* 2014;9(5):631-638.
- <sup>33</sup>Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. *Oncogene* 2000;19:5548-5557.
- <sup>34</sup>Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med* 2014;371:1963-1971.
- <sup>35</sup>Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol* 2012;30:863-870.
- <sup>36</sup>Melosky B, Chu Q, Juergens R, et al. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. *J Clin Oncol* 2016;34:1676-1688.
- <sup>37</sup>Kerr KM, Tsao MS, Nicholson AG, et al. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? *J Thoracic Oncol* 2015;10:985-989.
- <sup>38</sup>Kerr KM, Nicolson MC. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. *Arch Pathol Lab Med* 2016;140:249-254.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF SURGICAL THERAPY (1 of 4)****Evaluation**

- **Determination of resectability, surgical staging, and *pulmonary resection should be performed by board-certified thoracic surgeons who perform lung cancer surgery as a prominent part of their practice.***
- CT and PET used for staging should be within 60 days before proceeding with surgical evaluation.
- Resection is the preferred local treatment modality (other modalities include radiofrequency ablation, cryotherapy, and SABR). Thoracic surgical oncology consultation should be part of the evaluation of any patient being considered for curative local therapy. In cases where SABR is considered for high-risk patients, a multidisciplinary evaluation (including a radiation oncologist) is recommended.
- The overall plan of treatment as well as needed imaging studies should be determined before any non-emergency treatment is initiated.
- Thoracic surgeons should actively participate in multidisciplinary discussions and meetings regarding lung cancer patients (eg, multidisciplinary clinic and/or tumor board).
- Patients who are active smokers should be provided counseling and smoking cessation support ([NCCN Guidelines for Smoking Cessation](#)). While active smokers have a mildly increased incidence of postoperative pulmonary complications, these should not be considered a prohibitive risk for surgery. Surgeons should not deny surgery to patients solely due to smoking status, as surgery provides the predominant opportunity for prolonged survival in patients with early-stage lung cancer.

**Resection**

- Anatomic pulmonary resection is preferred for the majority of patients with NSCLC.
- Sublobar resection - Segmentectomy and wedge resection should achieve parenchymal resection margins  $\geq 2$  cm or  $\geq$  the size of the nodule.
- Sublobar resection should also sample appropriate N1 and N2 lymph node stations unless not technically feasible without substantially increasing the surgical risk.
- Segmentectomy (preferred) or wedge resection is appropriate in selected patients for the following reasons:
  - ▶ Poor pulmonary reserve or other major comorbidity that contraindicates lobectomy
  - ▶ Peripheral nodule<sup>1</sup>  $\leq 2$  cm with at least one of the following:
    - ◊ Pure AIS histology
    - ◊ Nodule has  $\geq 50\%$  ground-glass appearance on CT
    - ◊ Radiologic surveillance confirms a long doubling time ( $\geq 400$  days)
- VATS or minimally invasive surgery (including robotic-assisted approaches) should be strongly considered for patients with no anatomic or surgical contraindications, as long as there is no compromise of standard oncologic and dissection principles of thoracic surgery.
- In high-volume centers with significant VATS experience, VATS lobectomy in selected patients results in improved early outcomes (ie, decreased pain, reduced hospital length of stay, more rapid return to function, fewer complications) without compromise of cancer outcomes.
- Lung-sparing anatomic resection (sleeve lobectomy) is preferred over pneumonectomy, if anatomically appropriate and margin-negative resection is achieved.
- T3 (invasion) and T4 local extension tumors require en-bloc resection of the involved structure with negative margins. If a surgeon or center is uncertain about potential complete resection, consider obtaining an additional surgical opinion from a high-volume specialized center.

**Margins and Nodal Assessment (see [NSCL-B 2 of 4](#))**<sup>1</sup>Peripheral is defined as the outer one third of the lung parenchyma.**The Role of Surgery in Patients With Stage IIIA (N2) NSCLC (see [NSCL-B 2 of 4](#) through [NSCL-B 4 of 4](#))****Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF SURGICAL THERAPY (2 of 4)****Margins and Nodal Assessment**

- **Surgical pathologic correlation is critical to assess apparent close or positive margins, as these may not represent true margins or may not truly represent areas of risk for local recurrence (eg, medial surface of mainstem or bronchus intermedius when separate subcarinal lymph node dissection has been performed; pleural margin adjacent to aorta when no attachment to aorta is present).**
- **N1 and N2 node resection and mapping should be a routine component of lung cancer resections—a minimum of three N2 stations sampled or complete lymph node dissection.**
- **Formal ipsilateral mediastinal lymph node dissection is indicated for patients undergoing resection for stage IIIA (N2) disease.**
- **Complete resection requires free resection margins, systematic node dissection or sampling, and the highest mediastinal node negative for tumor. The resection is defined as incomplete whenever there is involvement of resection margins, unremoved positive lymph nodes, or positive pleural or pericardial effusions. A complete resection is referred to as R0, microscopically positive resection as R1, and macroscopic residual tumor as R2.**
- **Patients with pathologic stage II or greater should be referred to medical oncology for evaluation.**
- **Consider referral to a radiation oncologist for resected stage IIIA.**

**The Role of Surgery in Patients With Stage IIIA (N2) NSCLC**

The role of surgery in patients with pathologically documented N2 disease remains controversial.<sup>1</sup> Two randomized trials evaluated the role of surgery in this population, but neither showed an overall survival benefit with the use of surgery.<sup>2,3</sup> However, this population is heterogeneous and the panel believes that these trials did not sufficiently evaluate the nuances present with the heterogeneity of N2 disease and the likely oncologic benefit of surgery in specific clinical situations.

- **The presence or absence of N2 disease should be vigorously determined by both radiologic and invasive staging prior to the initiation of therapy since the presence of mediastinal nodal disease has a profound impact on prognosis and treatment decisions. (NSCL-1, NSCL-2, and NSCL-6)**
- **Patients with occult-positive N2 nodes discovered at the time of pulmonary resection should continue with the planned resection along with formal mediastinal lymph node dissection. If N2 disease is noted in patients undergoing VATS, the surgeon may consider stopping the procedure so that induction therapy can be administered before surgery; however, continuing the procedure is also an option.**
- **The determination of the role of surgery in a patient with N2-positive lymph nodes should be made prior to the initiation of any therapy by a multidisciplinary team, including a board-certified thoracic surgeon who has a major part of his/her practice dedicated to thoracic oncology.<sup>4</sup>**
- **The presence of N2-positive lymph nodes substantially increases the likelihood of positive N3 lymph nodes. Pathologic evaluation of the mediastinum must include evaluation of the subcarinal station and contralateral lymph nodes. EBUS +/- EUS are additional techniques for minimally invasive pathologic mediastinal staging that are complementary to mediastinoscopy. Even when these modalities are employed it is important to have an adequate evaluation of the number of stations involved and biopsy and documentation of negative contralateral lymph node involvement prior to a final treatment decision.**

The Role of Surgery in Patients With Stage IIIA (N2) NSCLC is continued on [NSCL-B 3 of 4](#) through [NSCL-B 4 of 4](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF SURGICAL THERAPY (3 of 4)****The Role of Surgery in Patients With Stage IIIA (N2) NSCLC**

- Repeat mediastinoscopy, while possible, is technically difficult and has a lower accuracy compared to primary mediastinoscopy. One possible strategy is to perform EBUS (± EUS) in the initial pretreatment evaluation and reserve mediastinoscopy for nodal restaging after neoadjuvant therapy.<sup>5</sup>
- Patients with a single lymph node smaller than 3 cm can be considered for a multimodality approach that includes surgical resection.<sup>1,6,7</sup>
- Restaging after induction therapy is difficult to interpret, but CT +/- PET should be performed to exclude disease progression or interval development of metastatic disease.
- Patients with negative mediastinum after neoadjuvant therapy have a better prognosis.<sup>7,8</sup>
- Neoadjuvant chemoradiotherapy is used in 50% of the NCCN Member Institutions, while neoadjuvant chemotherapy is used in the other 50%. Overall survival appears similar provided RT is given postoperatively, if not given preoperatively.<sup>5,9</sup> Neoadjuvant chemoradiotherapy is associated with higher rates of pathologic complete response and negative mediastinal lymph nodes.<sup>10</sup> However, that is achieved at the expense of higher rates of acute toxicity and increased cost.
- When neoadjuvant chemoradiotherapy is used with doses lower than those used for standard definitive therapy, all efforts should be made to minimize any possible breaks in radiotherapy for surgical evaluation. Treatment breaks of more than 1 week are considered unacceptable.
- When timely surgical evaluation is not available, the strategy of neoadjuvant chemoradiotherapy should not be used. Another option in individual cases, and with the agreement of the thoracic surgeon, is to complete definitive chemoradiotherapy prior to re-evaluation and consideration for surgery.<sup>11,12</sup> If a surgeon or center is uncertain about the feasibility or safety of resection after definitive doses of radiation, consider obtaining an additional surgical opinion from a high-volume specialized center. These operations may also benefit from additional considerations of soft tissue flap coverage in the radiation field at the time of resection.
- Data from a large multi-institutional trial indicate that pneumonectomy after neoadjuvant chemoradiotherapy has unacceptable morbidity and mortality.<sup>2</sup> However, it is not clear if this is also true with neoadjuvant chemotherapy alone. Further, many groups have challenged that cooperative group finding with single-institution experiences demonstrating safety of pneumonectomy after induction therapy.<sup>13-16</sup> In addition, there is no evidence that adding RT to induction regimens for patients with operable stage IIIA (N2) disease improves outcomes compared to induction chemotherapy.<sup>17</sup>

A questionnaire was submitted to the NCCN Member Institutions in 2010 regarding their approach to patients with N2 disease. Their responses indicate the patterns of practice when approaching this difficult clinical problem.

- a) Would consider surgery in patients with one N2 lymph node station involved by a lymph node smaller than 3 cm: (90.5%)
- b) Would consider surgery with more than one N2 lymph node station involved, as long as no lymph node was bigger than 3 cm: (47.6%)
- c) Uses EBUS (+/- EUS) in the initial evaluation of the mediastinum: (80%)
- d) Uses pathologic evaluation of the mediastinum, after neoadjuvant therapy, to make a final decision before surgery: (40.5%)
- e) Would consider neoadjuvant therapy followed by surgery when a patient is likely, based on initial evaluation, to require a pneumonectomy: (54.8%)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



**PRINCIPLES OF SURGICAL THERAPY (4 of 4)****The Role of Surgery in Patients With Stage IIIA (N2) NSCLC - References**

- <sup>1</sup>Martins RG, D'Amico TA, Loo BW Jr, et al. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. *J Natl Compr Canc Netw* 2012;10:599-613.
- <sup>2</sup>Albain K, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial. *Lancet* 2009;374:379-386.
- <sup>3</sup>van Meerbeek JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. *J Natl Cancer Inst* 2007;99:442-450.
- <sup>4</sup>Farjah F, Flum DR, Varghese TK Jr, et al. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. *Ann Thorac Surg* 2009;87:995-1006.
- <sup>5</sup>Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. *Lancet Oncol* 2008;9:607-608.
- <sup>6</sup>Andre F, Grunenwald D, Pignon J, et al. Survival of patients with resected N2 non-small-cell lung Cancer: Evidence for a subclassification and implications. *J Clin Oncol* 2000;18:2981-2989.
- <sup>7</sup>Decaluwé H, De Leyn P, Vansteenkiste J, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. *Eur J Cardiothorac Surg* 2009;36:433-439.
- <sup>8</sup>Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. *Ann Thorac Surg* 2000;70:1826-1831.
- <sup>9</sup>Higgins K, Chino JP, Marks LB, et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2009;75:1462-1467.
- <sup>10</sup>de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. *J Thorac Oncol* 2010;5:389-398.
- <sup>11</sup>Bauman JE, Mulligan MS, Martins RG, et al. Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. *Ann Thorac Surg* 2008;86:1632-1639.
- <sup>12</sup>Sonett JR, Suntharalingam M, Edelman MJ, et al. Pulmonary Resection After Curative Intent Radiotherapy (>59 Gy) and Concurrent Chemotherapy in Non-Small-Cell Lung Cancer. *Ann Thorac Surg* 2004;78:1200-1205.
- <sup>13</sup>Evans NR 3rd, Li S, Wright CD, et al. The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer. *J Thorac Cardiovasc Surg* 2010;139:991-996.
- <sup>14</sup>Gaissert HA, Keum DY, Wright CD, et al. POINT: Operative risk of pneumonectomy—Influence of preoperative induction therapy. *J Thorac Cardiovasc Surg* 2009;138:289-294.
- <sup>15</sup>Mansour Z, Kochetkova EA, Ducrocq X, et al. Induction chemotherapy does not increase the operative risk of pneumonectomy! *Eur J Cardiothorac Surg* 2007;31:181-185.
- <sup>16</sup>Weder W, Collaud S, Eberhardt WEE, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. *J Thorac Cardiovasc Surg* 2010;139:1424-1430.
- <sup>17</sup>Shah AA, Berry M, Tzao C, et al. Induction chemoradiotherapy is not superior to induction chemotherapy alone in stage IIIA lung cancer: a systematic review and meta-analysis. *Ann Thorac Surg* 2012;93:1807-1812.

**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

**PRINCIPLES OF RADIATION THERAPY (1 of 10)****General Principles (see [Table 1. Commonly Used Abbreviations in Radiation Therapy](#))**

- Determination of the appropriateness of radiation therapy (RT) should be made by board-certified radiation oncologists who perform lung cancer RT as a prominent part of their practice.
- RT has a potential role in all stages of NSCLC, as either definitive or palliative therapy. Radiation oncology input as part of a multidisciplinary evaluation or discussion should be provided for all patients with NSCLC.
- The critical goals of modern RT are to maximize tumor control and to minimize treatment toxicity. A minimum technologic standard is CT-planned 3D-CRT.<sup>1</sup>
- More advanced technologies are appropriate when needed to deliver curative RT safely. These technologies include (but are not limited to) 4D-CT and/or PET/CT simulation, IMRT/VMAT, IGRT, motion management, and proton therapy (<https://www.astro.org/Daily-Practice/Reimbursement/Model-Policies/Model-Policies/>). Nonrandomized comparisons of using advanced technologies versus older techniques demonstrate reduced toxicity and improved survival.<sup>2-4</sup> In a prospective trial of definitive chemo/RT for stage III NSCLC (RTOG 0617), IMRT was associated with a nearly 60% decrease in high-grade radiation pneumonitis and similar survival and tumor control outcomes despite a higher proportion of stage IIIB and larger treatment volumes compared to 3D-CRT;<sup>5</sup> as such, IMRT is preferred over 3D-CRT in this setting.
- Centers using advanced technologies should implement and document modality-specific quality assurance measures. The ideal is external credentialing of both treatment planning and delivery such as required for participation in RTOG clinical trials employing advanced technologies. Useful references include the ACR Practice Parameters and Technical Standards (<http://www.acr.org/~media/ACR/Documents/PGTS/toc.pdf>).

**Early-Stage NSCLC (Stage I, selected node negative Stage IIA)**

- SABR (also known as SBRT) is recommended for patients who are medically inoperable or who refuse to have surgery after thoracic surgery evaluation. SABR has achieved primary tumor control rates and overall survival, comparable to lobectomy and higher than 3D-CRT in nonrandomized and population-based comparisons in medically inoperable or older patients.<sup>6-11</sup>
- SABR is also an appropriate option for patients with high surgical risk (able to tolerate sublobar resection but not lobectomy [eg, age ≥75 years], poor lung function). SABR and sublobar resection achieve comparable cancer-specific survival and primary tumor control.<sup>12-13</sup>
- A combined analysis of two randomized trials (that individually did not complete accrual) of SABR vs. lobectomy in operable patients found similar cancer-specific outcomes and improved toxicity profile and survival for SABR compared to surgery.<sup>14</sup> This analysis does not provide sufficient data to change the standard of care for good surgical candidates but strengthens the indication for SABR in patients with relative contraindications for surgery or who refuse surgery.
- For institutions without an established SABR program, more modestly hypofractionated or dose-intensified conventionally fractionated 3D-CRT regimens are less preferred alternatives.<sup>15-17</sup>
- In patients treated with surgery, postoperative radiotherapy (PORT) is not recommended unless there are positive margins or upstaging to N2 (see *Locally Advanced NSCLC* in this section).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF RADIATION THERAPY (2 of 10)****Locally Advanced NSCLC (Stage II-III)**

- The standard of care for patients with inoperable stage II (node positive) and stage III is concurrent chemotherapy/RT.<sup>18-20</sup> RT interruptions and dose reductions for manageable acute toxicities should be avoided by employing supportive care.
- Sequential chemotherapy/RT or RT alone is appropriate for frail patients unable to tolerate concurrent therapy.<sup>21,22</sup> Accelerated RT regimens may be beneficial, particularly if concurrent chemotherapy would not be tolerated (ie, in a sequential or RT-only approach).<sup>23,24</sup>
- RT has a role before or after surgery.
  - ▶ Preoperative concurrent chemotherapy/RT is an option for patients with resectable stage IIIA (minimal N2 and treatable with lobectomy)<sup>25</sup> and is recommended for resectable superior sulcus tumors.<sup>26,27</sup>
  - ▶ Preoperative chemotherapy and postoperative RT is an alternative for patients with resectable stage IIIA.<sup>28,29</sup> The optimal timing of RT in trimodality therapy (preoperative with chemotherapy or postoperative) is not established and is controversial.<sup>30,31</sup>
  - ▶ The determination of resectability in trimodality therapy should be made prior to initiation of all treatment. Upfront multidisciplinary consultation is particularly important when considering surgical treatment of stage III NSCLC.
  - ▶ In patients with clinical stage I/II upstaged surgically to N2+, PORT appears to improve survival significantly as an adjunct to postoperative chemotherapy in non-randomized analyses.<sup>32,33</sup> Although the optimal sequence is not established, PORT is generally administered after postoperative chemotherapy. PORT with concurrent chemotherapy can be administered safely in medically fit patients<sup>34-36</sup> and is recommended for positive resection margins.<sup>37</sup>
  - ▶ PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques.<sup>38</sup>

**Advanced/Metastatic NSCLC (Stage IV)**

- RT is recommended for local palliation or prevention of symptoms (such as pain, bleeding, or obstruction).
- Definitive local therapy to isolated or limited metastatic sites (oligometastases) (including but not limited to brain, lung, and adrenal gland) achieves prolonged survival in a small proportion of well-selected patients with good performance status who have also received radical therapy to the intrathoracic disease. Definitive RT to oligometastases, particularly SABR, is an appropriate option in such cases if it can be delivered safely to the involved sites.<sup>39,40</sup>
- See the [NCCN Guidelines for Central Nervous System Cancers](#) regarding RT for brain metastases.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF RADIATION THERAPY (3 of 10)****Target Volumes, Prescription Doses, and Normal Tissue Dose Constraints** ([See Tables 2–5 on NSCL-C 7 of 10](#) and [NSCL-C 8 of 10](#))

- ICRU Reports 62 and 83 detail the current definitions of target volumes for 3D-RT and IMRT. GTV comprises the known extent of disease (primary and nodal) on imaging and pathologic assessment, CTV includes regions of presumed microscopic extent or dissemination, and PTV comprises the ITV (which includes margin for target motion) plus a setup margin for positioning and mechanical variability. <http://www.rtog.org/CoreLab/ContouringAtlases/LungAtlas.aspx>
- PTV margin can be decreased by immobilization, motion management, and IGRT techniques.
- Consistent delineation of normal structures is critical for evaluating plans for safety. The RTOG consensus lung-contouring atlas is a useful resource. <http://www.rtog.org/CoreLab/ContouringAtlases/LungAtlas.aspx>
- Commonly used prescription doses and normal tissue dose constraints are summarized in Tables 2 through 5. These are based on published experience, ongoing trials, historical data, modeling, and empirical judgment.<sup>41,42</sup> Useful references include the recent reviews of normal organ dose responses from the QUANTEC project.<sup>43-47</sup>

**Node-Negative Early-Stage SABR**

- The high-dose intensity and conformity of SABR require minimizing the PTV.
- For SABR, intensive regimens of BED  $\geq 100$  Gy are associated with significantly better local control and survival than less intensive regimens.<sup>48</sup> In the United States, only regimens of  $\leq 5$  fractions meet the arbitrary billing code definition of SBRT, but slightly more protracted regimens are appropriate as well.<sup>48,49</sup> For centrally located tumors (defined variably as within 2 cm of the proximal bronchial tree and/or abutting mediastinal pleura) and even ultra-central tumors (defined as abutting the proximal bronchial tree), 4 to 10 fraction risk-adapted SABR regimens appear to be effective and safe,<sup>50-53</sup> while 54 to 60 Gy in 3 fractions is unsafe and should be avoided.<sup>54</sup> The maximum tolerated dose for 5-fraction regimens was studied prospectively in RTOG 0813, preliminary results demonstrate no high-grade toxicities at 50 Gy in 5 fractions.<sup>55</sup>
- SABR is most commonly used for tumors up to 5 cm in size, though selected larger isolated tumors can be treated safely if normal tissue constraints are respected.<sup>54,56</sup>
- Prescription doses incompletely describe the actual delivered doses, which also strongly depend on how the dose is prescribed (to the isocenter vs. an isodose volume covering a proportion of the PTV), the degree of dose heterogeneity, whether tissue density heterogeneity corrections are used, and the type of dose calculation algorithm.<sup>57,58</sup> All of these must be considered when interpreting or emulating regimens from prior studies.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF RADIATION THERAPY (4 of 10)****Locally Advanced Stage/Conventionally Fractionated RT**

- IFI omitting ENI allows tumor dose escalation and is associated with a low risk of isolated nodal relapse, particularly in PET/CT–staged patients.<sup>59-63</sup> Two randomized trials found improved survival for IFI versus ENI, possibly because it enabled dose escalation.<sup>64</sup> IFI is reasonable in order to optimize definitive dosing to the tumor.<sup>65</sup>
- The most commonly prescribed doses for definitive RT are 60 to 70 Gy in 2 Gy fractions. Doses of at least 60 Gy should be given.<sup>66</sup> Dose escalation in RT alone,<sup>67</sup> sequential chemo/RT,<sup>68</sup> or concurrent chemo/RT<sup>69</sup> is associated with better survival in non-randomized comparisons. While optimal RT dose intensification remains a valid question, higher doses of 74 Gy are not currently recommended for routine use.<sup>70-74</sup> A meta-analysis demonstrated improved survival with accelerated fractionation RT regimens,<sup>75</sup> and individualized accelerated RT dose intensification is now being evaluated in a randomized trial (RTOG 1106).
- Doses of 45 to 54 Gy in 1.8 to 2 Gy fractions are standard preoperative doses.<sup>76</sup> Definitive RT doses delivered as preoperative chemoRT can safely be administered and achieve promising nodal clearance and survival rates,<sup>77-80</sup> but require experience in thoracic surgical techniques to minimize the risk of surgical complications after high-dose RT.
- In PORT, the CTV includes the bronchial stump and high-risk draining lymph node stations.<sup>81</sup> Standard doses after complete resection are 50 to 54 Gy in 1.8 to 2 Gy fractions, but a boost may be administered to high-risk regions including areas of nodal extracapsular extension or microscopic positive margins.<sup>32,33,82</sup> Lung dose constraints should be more conservative as tolerance appears to be reduced after surgery. The ongoing European LungART trial provides useful guidelines for PORT technique.<sup>83</sup>

**Advanced Stage/Palliative RT**

- The dose and fractionation of palliative RT should be individualized based on goals of care, symptoms, performance status, and logistical considerations. Shorter courses of RT provide similar pain relief as longer courses, but with a higher potential need for retreatment,<sup>84-87</sup> and are preferred for patients with poor performance status and/or shorter life expectancy. For palliation of thoracic symptoms, higher dose/longer-course thoracic RT (eg, ≥30 Gy in 10 fractions) is associated with modestly improved survival and symptoms, particularly in patients with good performance status.<sup>88,89</sup> When higher doses (>30 Gy) are warranted, technologies to reduce normal tissue irradiation (at least 3D-CRT and including IMRT or proton therapy as appropriate) should be used.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF RADIATION THERAPY (5 of 10)****Radiation Therapy Simulation, Planning, and Delivery**

- **Simulation should be performed using CT scans obtained in the RT treatment position with appropriate immobilization devices. IV contrast with or without oral contrast is recommended for better target/organ delineation whenever possible in patients with central tumors or nodal disease. Because IV contrast can affect tissue heterogeneity correction calculations, density masking or use of a pre-contrast scan may be needed when intense enhancement is present.**
- **PET/CT significantly improves targeting accuracy,<sup>90</sup> especially for patients with significant atelectasis and when IV CT contrast is contraindicated. A randomized trial of PET/CT versus CT-only RT planning demonstrated improved preemption of futile radical RT, decreased recurrences, and a trend toward improved overall survival with PET/CT RT planning.<sup>91</sup> Given the potential for rapid progression of NSCLC,<sup>92,93</sup> PET/CT should be obtained preferably within 4 weeks before treatment. It is ideal to obtain PET/CT in the treatment position.**
- **Tumor and organ motion, especially owing to breathing, should be assessed or accounted for at simulation. Options include fluoroscopy, inhale/exhale or slow scan CT, or, ideally, 4D-CT.**
- **Photon beam energy should be individualized based on the anatomic location of the tumors and beam paths. In general, photon energies between 4 to 10 MV are recommended for beams passing through low-density lung tissue before entering the tumor. When there is no air gap before the beam enters the tumor (such as for some large mediastinal tumors or tumors attached to the chest wall), higher energies may improve the dose distribution, especially when using a smaller number of fixed beam angles.**
- **Tissue heterogeneity correction and accurate dose calculation algorithms that account for buildup and lateral electron scatter effects in heterogeneous density tissues are recommended. Heterogeneity correction with simple pencil beam algorithms is not recommended.<sup>60</sup>**
- **Respiratory motion should be managed when motion is excessive. This includes (but is not limited to) forced shallow breathing with abdominal compression, accelerator beam gating with the respiratory cycle, dynamic tumor tracking, active breathing control (ABC), or coaching/biofeedback techniques. If motion is minimal or the ITV is small, motion-encompassing targeting is appropriate. A useful resource for implementation of respiratory motion management is the report of AAPM Task Group 76.<sup>94</sup>**
- **IGRT—including (but not limited to) orthogonal pair planar imaging and volumetric imaging (such as CBCT or CT on rails)—is recommended when using SABR and 3D-CRT/IMRT with steep dose gradients around the target, when OARs are in close proximity to high-dose regions, and when using complex motion management techniques.**

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**NCCN Guidelines Version 3.2017**  
**Non-Small Cell Lung Cancer****PRINCIPLES OF RADIATION THERAPY (6 of 10)****Table 1. Commonly Used Abbreviations in Radiation Therapy**

<b>RT</b>	<b>Radiation Therapy or Radiotherapy</b>	<b>ICRU</b>	<b>International Commission on Radiation Units and Measurements</b>
<b>2D-RT</b>	<b>2-Dimensional RT</b>	<b>IFI</b>	<b>Involved Field Irradiation</b>
<b>3D-CRT</b>	<b>3-Dimensional Conformal RT</b>	<b>IGRT</b>	<b>Image-Guided RT</b>
<b>4D-CT</b>	<b>4-Dimensional Computed Tomography</b>	<b>IMRT</b>	<b>Intensity-Modulated RT</b>
<b>AAPM</b>	<b>American Association of Physicists in Medicine</b>	<b>ITV*</b>	<b>Internal Target Volume</b>
<b>ABC</b>	<b>Active Breathing Control</b>	<b>OAR</b>	<b>Organ at Risk</b>
<b>ACR</b>	<b>American College of Radiology</b>	<b>OBI</b>	<b>On-Board Imaging</b>
<b>ASTRO</b>	<b>American Society for Radiation Oncology</b>	<b>PORT</b>	<b>Postoperative RT</b>
<b>BED</b>	<b>Biologically Effective Dose</b>	<b>PTV*</b>	<b>Planning Target Volume</b>
<b>CBCT</b>	<b>Cone-Beam CT</b>	<b>QUANTEC</b>	<b>Quantitative Analysis of Normal Tissue Effects in the Clinic</b>
<b>CTV*</b>	<b>Clinical Target Volume</b>	<b>ROG</b>	<b>Radiation Therapy Oncology Group now part of NRG Oncology</b>
<b>ENI</b>	<b>Elective Nodal Irradiation</b>	<b>SABR</b>	<b>Stereotactic Ablative RT, also known as Stereotactic Body RT (SBRT)</b>
<b>GTV*</b>	<b>Gross Tumor Volume</b>	<b>VMAT</b>	<b>Volumetric Modulated Arc Therapy</b>

\*Refer to ICRU Report 83 for detailed definitions.

**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### PRINCIPLES OF RADIATION THERAPY (7 of 10)

**Table 2. Commonly Used Doses for SABR**

Total Dose	# Fractions	Example Indications
25–34 Gy	1	Peripheral, small (<2 cm) tumors, esp. >1 cm from chest wall
45–60 Gy	3	Peripheral tumors and >1 cm from chest wall
48–50 Gy	4	Central or peripheral tumors <4–5 cm, especially <1 cm from chest wall
50–55 Gy	5	Central or peripheral tumors, especially <1 cm from chest wall
60–70 Gy	8–10	Central tumors

**Table 3. Maximum Dose Constraints for SABR\***

OAR/Regimen	1 Fraction	3 Fractions	4 Fractions	5 Fractions
Spinal Cord	14 Gy	18 Gy (6 Gy/fx)	26 Gy (6.5 Gy/fx)	30 Gy (6 Gy/fx)
Esophagus	15.4 Gy	27 Gy (9 Gy/fx)	30 Gy (7.5 Gy/fx)	105% of PTV prescription <sup>^</sup>
Brachial Plexus	17.5 Gy	24 Gy (8 Gy/fx)	27.2 Gy (6.8 Gy/fx)	32 Gy (6.4 Gy/fx)
Heart/ Pericardium	22 Gy	30 Gy (10 Gy/fx)	34 Gy (8.5 Gy/fx)	105% of PTV prescription <sup>^</sup>
Great Vessels	37 Gy	NS	49 Gy (12.25 Gy/fx)	105% of PTV prescription <sup>^</sup>
Trachea & Proximal Bronchi	20.2 Gy	30 Gy (10 Gy/fx)	34.8 Gy (8.7 Gy/fx)	105% of PTV prescription <sup>^</sup>
Rib	30 Gy	30 Gy (10 Gy/fx)	40 Gy (10 Gy/fx)	NS
Skin	26 Gy	24 Gy (8 Gy/fx)	36 Gy (9 Gy/fx)	32 Gy (6.4 Gy/fx)
Stomach	12.4 Gy	NS	27.2 Gy (6.8 Gy/fx)	NS

\*Based on constraints used in recent RTOG SABR trials (RTOG 0618, 0813, &amp; 0915).

<sup>^</sup>for central tumor location. NS = not specified

**Please note - Tables 2–5 provide doses and constraints used commonly or in past clinical trials as useful references rather than specific recommendations.**

**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### PRINCIPLES OF RADIATION THERAPY (8 of 10)

**Table 4. Commonly Used Doses for Conventionally Fractionated and Palliative RT**

Treatment Type	Total Dose	Fraction Size	Treatment Duration	
Definitive RT with or without chemotherapy	60–70 Gy	2 Gy	6–7 weeks	
Preoperative RT	45–54 Gy	1.8–2 Gy	5 weeks	
Postoperative RT	50–54 Gy	1.8–2 Gy	5–6 weeks	
	• Negative margins			
	• Extracapsular nodal extension or microscopic positive margins	54–60 Gy	1.8–2 Gy	6 weeks
• Gross residual tumor	60–70 Gy	2 Gy	6–7 weeks	
Palliative RT	• Obstructive disease (SVC syndrome or obstructive pneumonia)	30–45 Gy	3 Gy	2–3 weeks
	• Bone metastases with soft tissue mass	20–30 Gy	4–3 Gy	1–2 weeks
	• Bone metastases without soft tissue mass	8–30 Gy	8–3 Gy	1 day–2 weeks
	• Brain metastases	<a href="#">CNS GLs*</a>	<a href="#">CNS GLs*</a>	<a href="#">CNS GLs*</a>
	• Symptomatic chest disease in patients with poor PS	17 Gy	8.5 Gy	1–2 weeks
	• Any metastasis in patients with poor PS	8–20 Gy	8–4 Gy	1 day–1 week

\*[NCCN Guidelines for Central Nervous System Cancers](#)

Please note: Tables 2–5 provide doses and constraints used commonly or in past clinical trials as useful references rather than specific recommendations.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.


**Table 5. Normal Tissue Dose-Volume Constraints for Conventionally Fractionated RT**

OAR	Constraints in 30–35 Fractions
Spinal cord	Max ≤50 Gy
Lung	V20 ≤35%; V5 ≤65%; MLD ≤20 Gy
Heart**	V40 ≤80%; V45 ≤60%; V60 ≤30%; Mean ≤35 Gy
Esophagus	Mean ≤34 Gy; Max ≤105% of prescription dose
Brachial plexus	Max ≤66 Gy

Vxx = % of the whole OAR receiving ≥xx Gy.

\*\*RT0G 0617 data suggest that even lower radiation doses to the heart than previously appreciated may be detrimental to survival after thoracic RT, and more stringent constraints may be appropriate.

**Figure 1. ICRU Report 62 Schema of Target Volume Definitions**



©Journal of the ICRU. Report 62 Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50) 1999, Figure 2.16 from p 16.

**NCCN Guidelines Version 3.2017**  
**Non-Small Cell Lung Cancer**

- <sup>1</sup>Chen AB, Neville BA, Sher DJ, et al. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. *J Clin Oncol* 2011;29:2305-2311.
- <sup>2</sup>Liao ZX, Komaki RR, Thames HD, et al. Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 2010;76:775-781.
- <sup>3</sup>Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for non-small cell lung cancer. *Cancer* 2011;117:3004-3013.
- <sup>4</sup>Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. *Cancer* 2011;117:4707-4713.
- <sup>5</sup>Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. *J Clin Oncol* 2016; October 3 Epub.
- <sup>6</sup>Timmerman R, Paulus R, Galvin J, et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. *JAMA* 2010;303:1070-1076.
- <sup>7</sup>Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. *J Clin Oncol* 2009;27:3290-3296.
- <sup>8</sup>Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? *Int J Radiat Oncol Biol Phys* 2011;81:1352-1358.
- <sup>9</sup>Grutters JPC, Kessels AGH, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. *Radiother Oncol* 2010;95:32-40.
- <sup>10</sup>Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. *J Clin Oncol* 2010;28:5153-5159.
- <sup>11</sup>Shrivani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. *Int J Radiat Oncol Biol Phys* 2012;84:1060-1070.
- <sup>12</sup>Grills IS, Mangona VS, Welsh R, et al. Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer. *J Clin Oncol* 2010;28:928-935.
- <sup>13</sup>Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2010;140:377-386.
- <sup>14</sup>Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: a pooled analysis of two randomized trials. *Lancet Oncol* 2015;16:630-637.
- <sup>15</sup>Bogart JA, Hodgson L, Seagren SL, et al. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. *J Clin Oncol* 2010;28:202-206.
- <sup>16</sup>Zhao L, West BT, Hayman JA, et al. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2007;68:103-110.
- <sup>17</sup>Cheung P, Faria S, Ahmed S, et al. Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. *J Natl Cancer Inst* 2014;106:1-8.
- <sup>18</sup>Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol* 2010;28:2181-2190.
- <sup>19</sup>O'Rourke N, Roqué I, Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. *Cochrane Database Syst Rev* 2010;CD002140.
- <sup>20</sup>Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst* 2011;103:1452-1460.
- <sup>21</sup>Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. *Chest* 2000;117:358-364.
- <sup>22</sup>Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. *J Natl Cancer Inst* 1996;88:1210-1215.
- <sup>23</sup>Baumann M, Herrmann T, Koch R, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). *Radiother Oncol* 2011;100:76-85.
- <sup>24</sup>Mauguen A, Le Péchoux C, Saunders MI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. *J Clin Oncol* 2012;30:2788-2797.
- <sup>25</sup>Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet* 2009;374:379-386.
- <sup>26</sup>Kunitoh H, Kato H, Tsuboi M, et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. *J Clin Oncol* 2008;26:644-649.
- <sup>27</sup>Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *J Clin Oncol* 2007;25:313-318.
- <sup>28</sup>Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomized trial in stage III non-small-cell lung cancer. *Lancet Oncol* 2008;9:607-608.
- <sup>29</sup>Higgins K, Chino JP, Marks LB, et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. *Int J Radiat Biol Phys* 2009;75:1462-1467.
- <sup>30</sup>Sher DJ, Fidler MJ, Liptay MJ, & Koshy M. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. *Lancet Oncol* 2015;88:267-274.
- <sup>31</sup>Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. *Ann Thorac Surg* 2012;93:1807-1812.
- <sup>32</sup>Douillard J-Y, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. *Int J Radiat Oncol Biol Phys* 2008;72:695-701.
- <sup>33</sup>Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. *J Clin Oncol* 2006;24:2998-3006.
- <sup>34</sup>Feigenberg SJ, Hanlon AL, Langer C, et al. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. *J Thorac Oncol* 2007;2:287-292.
- <sup>35</sup>Bradley JD, Paulus R, Graham MV, et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. *J Clin Oncol* 2005;23:3480-3487.
- <sup>36</sup>Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. *N Engl J Med* 2000;343:1217-1222.
- <sup>37</sup>Hancock JG, Rosen JE, Antonicelli A, et al. Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery. *Ann Thorac Surg* 2015;99:406-416.
- <sup>38</sup>Burdett S, Stewart L, Group PM-a. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. *Lung Cancer* 2005;47:81-83.
- <sup>39</sup>Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. *Am J Clin Oncol* 2010;33:157-163.
- <sup>40</sup>Salama JK, Chmura SJ, Mehta N, et al. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. *Clin Cancer Res* 2008;14:5255-5259.
- <sup>41</sup>Kong FM, Pan C, Eisbruch A, Ten Haken RK. Physical models and simpler dosimetric descriptors of radiation late toxicity. *Semin Radiat Oncol* 2007;17:108-120.
- <sup>42</sup>Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. *Semin Radiat Oncol* 2008;18:215-222.
- <sup>43</sup>Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. *Int J Radiat Oncol Biol Phys* 2010;76:S10-19.
- <sup>44</sup>Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys* 2010;76:S70-76.
- <sup>45</sup>Werner-Wasik M, Yorke E, Deasy J, et al. Radiation dose-volume effects in the esophagus. *Int J Radiat Oncol Biol Phys* 2010;76:S86-93.
- <sup>46</sup>Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. *Int J Radiat Oncol Biol Phys* 2010;76:S77-85.
- <sup>47</sup>Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. *Int J Radiat Oncol Biol Phys* 2010;76:S42-49.
- <sup>48</sup>Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. *J Thorac Oncol* 2007; 2:S94-100.
- <sup>49</sup>Lagerwaard FJ, Haasbeek CJA, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2008;70:685-692.
- <sup>50</sup>Chang JY, Li QQ, Xu QY, et al. Stereotactic body radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small-cell lung cancer: how to fly in a "no fly zone". *Int J Radiat Oncol Biol Phys* 2014;88:1120-1128.

**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



- <sup>51</sup>Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *J Clin Oncol* 2006; 24:4833-4839.
- <sup>52</sup>Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy for treatment of central and ultra-central lung tumors. *Lung Cancer* 2015;89:50-56.
- <sup>53</sup>Haseltine JM, Rimner A, Gelblum DY, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. *Pract Radiat Oncol* 2016;6:e27-33.
- <sup>54</sup>Woody NM, Stephans KL, Marwaha G, et al. Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: safety and efficacy. *Int J Radiat Oncol Biol Phys* 2015;92:325-331.
- <sup>55</sup>Bezjak A, Paulus R, Gaspar LE, et al. Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy for centrally located non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2016;94:5-6.
- <sup>56</sup>Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. *Int J Radiat Oncol Biol Phys* 2009;75:677-682.
- <sup>57</sup>Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2009;73:1235-1242.
- <sup>58</sup>Liu MB, Eclov NC, Trakul N, et al. Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. *Practical Radiation Oncology* 2012 In press.
- <sup>59</sup>Belderbos JS, Kepka L, Kong FM, et al. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small cell lung cancer (NSCLC). *Int J Radiat Oncol Biol Phys* 2008;72:335-342.
- <sup>60</sup>Bradley J, Bae K, Choi N, et al. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of radiation therapy oncology group (RTOG) 0515. *Int J Radiat Oncol Biol Phys* 2012;82:435-441.
- <sup>61</sup>Sanuki-Fujimoto N, Sumi M, Ito Y, et al. Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses. *Radiother Oncol* 2009; 91:433-437.
- <sup>62</sup>Sulman EP, Komaki R, Klopp AH, et al. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. *Radiat Oncol* 2009;4:5-11.
- <sup>63</sup>Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. *J Clin Oncol* 2007;25:5557-5561.
- <sup>64</sup>Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. *Am J Clin Oncol* 2007;30:239-244.
- <sup>65</sup>Chen M, Bao Y, Ma HL, et al. Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study. *Biomed Res Int* 2013;37:11819.
- <sup>66</sup>Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. *Cancer* 1987; 59:1874-1881.
- <sup>67</sup>Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. *Int J Radiat Oncol Biol Phys* 2005;63:324-333.
- <sup>68</sup>Rengan R, Rosenzweig KE, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2004;60:741-747.
- <sup>69</sup>Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved Outcomes for Locally Advanced Non-Small Cell Lung Carcinoma Treated with Chemoradiation: An Analysis of the radiation therapy oncology group. *Int J Radiat Oncol Biol Phys* 2012;82:425-434.
- <sup>70</sup>Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2006; 65:1106-1111.
- <sup>71</sup>Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. *J Clin Oncol* 2008;26:2457-2463.
- <sup>72</sup>Stinchcombe TE, Lee CB, Moore DT, et al. Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer. *J Thorac Oncol* 2008; 3:1279-1285.
- <sup>73</sup>Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. *J Clin Oncol* 2010;28:2475-2480.
- <sup>74</sup>Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol* 2015;16:187-199.
- <sup>75</sup>Maugen A, Le Pechoux C, Saunders M, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. *J Clin Oncol* 2012;30:2788-2797.
- <sup>76</sup>Sher DJ, Fidler MJ, Seder CW, et al. Relationship between radiation therapy dose and outcome in patients treated with neoadjuvant chemoradiation therapy and surgery for stage IIIA non-small cell lung cancer: a population-based, comparative effectiveness analysis. *Int J Radiat Oncol Biol Phys* 2015;92:307-316.
- <sup>77</sup>Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. *Eur J Cardiothorac Surg* 2009; 35:718-723; discussion 723.
- <sup>78</sup>Kwong KF, Edelman MJ, Suntharalingam M, et al. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. *J Thorac Cardiovasc Surg* 2005;129:1250-1257.
- <sup>79</sup>Sonett JR, Suntharalingam M, Edelman MJ, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. *Ann Thorac Surg* 2004;78:1200-1205.
- <sup>80</sup>Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. *Int J Radiat Oncol Biol Phys* 2012;84:456-463.
- <sup>81</sup>Kelsey CR, Light KL, Marks LB. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. *Int J Radiat Oncol Biol Phys* 2006;65:1097-1105.
- <sup>82</sup>Corso CD, Rutter CE, Wilson LD, et al. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. *J Thorac Oncol* 2015;10:148-155.
- <sup>83</sup>Spiegelstein FOB, Senan S, Le Pechoux C, et al. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. *Int J Radiat Oncol Biol Phys* 2010; 76:1106-1113.
- <sup>84</sup>Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. *J Clin Oncol* 2007;25:1423-1436.
- <sup>85</sup>Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. *Int J Radiat Oncol Biol Phys* 2011;79:965-976.
- <sup>86</sup>Cross CK, Berman S, Buswell L, et al. Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2004; 58:1098-1105.
- <sup>87</sup>Medical Research Council Lung Cancer Working Party. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. *Medical Research Council Lung Cancer Working Party. Br J Canc* 1992; 65:934-941.
- <sup>88</sup>Rodrigues G, Videtic GMM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. *Pract Radiat Oncol* 2011;1:60-71.
- <sup>89</sup>Koshy M, Malik R, Mahmood U, et al. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer. *Pract Radiat Oncol* 2015;5:374-382.
- <sup>90</sup>MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. *Radiother Oncol* 2009;91:85-94.
- <sup>91</sup>Ung YC, Gu C-S, Cline K, et al. An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage 3 non-small cell lung cancer (NSCLC): impact of PET on radiation treatment volumes [Abstract]. *J Thorac Oncol* 2011;6:S428.
- <sup>92</sup>Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease progression detected on serial pretreatment positroniumglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. *Cancer* 2010;116:5030-5037.
- <sup>93</sup>Mohammed N, Kestin LL, Grills IS, et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2011;79:466-472.
- <sup>94</sup>Keall PJ, Mageras GS, Balter JM, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. *Med Phys* 2006;33:3874-3900.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### CHEMOTHERAPY REGIMENS FOR NEOADJUVANT AND ADJUVANT THERAPY

- Cisplatin 50 mg/m<sup>2</sup> days 1 and 8; vinorelbine 25 mg/m<sup>2</sup> days 1, 8, 15, 22, every 28 days for 4 cycles<sup>a</sup>
- Cisplatin 100 mg/m<sup>2</sup> day 1; vinorelbine 30 mg/m<sup>2</sup> days 1, 8, 15, 22, every 28 days for 4 cycles<sup>b,c</sup>
- Cisplatin 75–80 mg/m<sup>2</sup> day 1; vinorelbine 25–30 mg/m<sup>2</sup> days 1 + 8, every 21 days for 4 cycles
- Cisplatin 100 mg/m<sup>2</sup> day 1; etoposide 100 mg/m<sup>2</sup> days 1–3, every 28 days for 4 cycles<sup>b</sup>
- Cisplatin 75 mg/m<sup>2</sup> day 1; gemcitabine 1250 mg/m<sup>2</sup> days 1, 8, every 21 days for 4 cycles<sup>d</sup>
- Cisplatin 75 mg/m<sup>2</sup> day 1; docetaxel 75 mg/m<sup>2</sup> day 1 every 21 days for 4 cycles<sup>e</sup>
- Cisplatin 75 mg/m<sup>2</sup> day 1, pemetrexed 500 mg/m<sup>2</sup> day 1 for nonsquamous every 21 days for 4 cycles<sup>f</sup>

#### Chemotherapy Regimens for Patients with Comorbidities or Patients Not Able to Tolerate Cisplatin

Paclitaxel 200 mg/m<sup>2</sup> day 1, carboplatin AUC 6 day 1, every 21 days<sup>g</sup>

<sup>a</sup>Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-lung cancer. *N Engl J Med* 2005;352:2589-2597.

<sup>b</sup>Arriagada R, Bergman B, Dunant A, et al. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. *N Engl J Med* 2004;350:351-360.

<sup>c</sup>Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIa non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006;7:719-727.

<sup>d</sup>Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2012;30:3516-3524.

<sup>e</sup>Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003;21:3016-3024.

<sup>f</sup>Kreuter M, Vansteenkiste J, Fishcer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. *Ann Oncol* 2013;24:986-992.

<sup>g</sup>Strauss GM, Herndon III JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. *J Clin Oncol* 2008;26:5043-5051.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**CHEMOTHERAPY REGIMENS USED WITH RADIATION THERAPY****Concurrent Chemotherapy/RT Regimens**

- Cisplatin 50 mg/m<sup>2</sup> on days 1, 8, 29, and 36; etoposide 50 mg/m<sup>2</sup> days 1–5, 29–33; concurrent thoracic RT<sup>a,b,\*,\*\*</sup>
- Cisplatin 100 mg/m<sup>2</sup> days 1 and 29; vinblastine 5 mg/m<sup>2</sup>/weekly x 5; concurrent thoracic RT<sup>b,\*,\*\*</sup>
- Carboplatin AUC 5 on day 1, pemetrexed 500 mg/m<sup>2</sup> on day 1 every 21 days for 4 cycles; concurrent thoracic RT<sup>c</sup> (nonsquamous)<sup>\*,\*\*</sup>
- Cisplatin 75 mg/m<sup>2</sup> on day 1, pemetrexed 500 mg/m<sup>2</sup> on day 1 every 21 days for 3 cycles; concurrent thoracic RT<sup>d,e</sup> (nonsquamous)<sup>\*,\*\*</sup> ± additional 4 cycles of pemetrexed 500 mg/m<sup>2</sup><sup>\*\*</sup>
- Paclitaxel 45–50 mg/m<sup>2</sup> weekly; carboplatin AUC 2, concurrent thoracic RT<sup>f,\*,\*\*</sup> ± additional 2 cycles of paclitaxel 200 mg/m<sup>2</sup> and carboplatin AUC 6<sup>\*\*</sup>

**Sequential Chemotherapy/RT Regimens (Adjuvant)**

- Cisplatin 100 mg/m<sup>2</sup> on days 1 and 29; vinblastine 5 mg/m<sup>2</sup>/weekly on days 1, 8, 15, 22, and 29; followed by RT<sup>b</sup>
- Paclitaxel 200 mg/m<sup>2</sup> over 3 hours on day 1; carboplatin AUC 6 over 60 minutes on day 1 every 3 weeks for 2 cycles followed by thoracic RT<sup>g</sup>

\*Regimens can be used as neoadjuvant/preoperative/induction chemoradiotherapy.

\*\*Regimens can be used as adjuvant or definitive concurrent chemotherapy/RT.

<sup>a</sup>Albain KS, Crowley JJ, Turrisi AT III, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019. *J Clin Oncol* 2002;20:3454-3460.

<sup>b</sup>Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst*. 2011;103:1452-1460.

<sup>c</sup>Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. *J Clin Oncol* 2011;29:3120-3125.

<sup>d</sup>Choy H, Gerber DE, Bradley JD, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. *Lung Cancer* 2015;87:232-240

<sup>e</sup>Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2016;34:953-962.

<sup>f</sup>Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol* 2015;16:187-199.

<sup>g</sup>Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. *J Clin Oncol*. 2005;23:5883-5891.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (1 OF 4)

#### ADVANCED DISEASE:

- The drug regimen with the highest likelihood of benefit with toxicity deemed acceptable to both the physician and the patient should be given as initial therapy for advanced lung cancer.
- Stage, weight loss, performance status, and gender predict survival.
- Platinum-based chemotherapy prolongs survival, improves symptom control, and yields superior quality of life compared to best supportive care.
- Histology of NSCLC is important in the selection of systemic therapy.
- New agent/platinum combinations have generated a plateau in overall response rate ( $\approx 25\%$ – $35\%$ ), time to progression (4–6 mo), median survival (8–10 mo), 1-year survival rate (30%–40%), and 2-year survival rate (10%–15%) in fit patients.
- Unfit patients of any age (performance status 3–4) do not benefit from cytotoxic treatment, except erlotinib, afatinib, or gefitinib for *EGFR* mutation-positive and crizotinib for *ALK*-positive tumors of nonsquamous NSCLC or NSCLC NOS.

#### First-line Therapy

- There is superior efficacy and reduced toxicity for cisplatin/pemetrexed in patients with nonsquamous histology, in comparison to cisplatin/gemcitabine.
- There is superior efficacy for cisplatin/gemcitabine in patients with squamous histology, in comparison to cisplatin/pemetrexed.
- Two drug regimens are preferred; a third cytotoxic drug increases response rate but not survival. Single-agent therapy may be appropriate in select patients.
- Response assessment after 2 cycles, then every 2–4 cycles with CT of known sites of disease with or without contrast or when clinically indicated.

#### Maintenance Therapy

- Continuation maintenance refers to the use of at least one of the agents given in first line, beyond 4–6 cycles, in the absence of disease progression. Switch maintenance refers to the initiation of a different agent, not included as part of the first-line regimen, in the absence of disease progression, after 4–6 cycles of initial therapy.

#### Subsequent Therapy

- Response assessment with CT of known sites of disease with or without contrast every 6–12 weeks.

[See First-line Systemic Therapy Options for Adenocarcinoma, Large cell, NSCLC NOS on NSCL-F \(2 of 4\)](#)

[See First-line Systemic Therapy Options for Squamous Cell Carcinoma on NSCL-F \(3 of 4\)](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (2 of 4)†****First-line Systemic Therapy Options****Adenocarcinoma, Large Cell, NSCLC NOS (PS 0-1)**

- Bevacizumab/carboplatin/paclitaxel (category 1)<sup>1,\*,\*\*,\*\*\*</sup>
- Bevacizumab/carboplatin/pemetrexed<sup>2,\*,\*\*,\*\*\*</sup>
- Bevacizumab/cisplatin/pemetrexed<sup>3,\*\*,\*\*\*</sup>
- Carboplatin/albumin-bound paclitaxel (category 1)<sup>4</sup>
- Carboplatin/docetaxel (category 1)<sup>5</sup>
- Carboplatin/etoposide (category 1)<sup>6,7</sup>
- Carboplatin/gemcitabine (category 1)<sup>8</sup>
- Carboplatin/paclitaxel (category 1)<sup>9</sup>
- Carboplatin/pemetrexed (category 1)<sup>10</sup>
- Cisplatin/docetaxel (category 1)<sup>5</sup>
- Cisplatin/etoposide (category 1)<sup>11</sup>
- Cisplatin/gemcitabine (category 1)<sup>9,12</sup>
- Cisplatin/paclitaxel (category 1)<sup>13</sup>
- Cisplatin/pemetrexed (category 1)<sup>12</sup>
- Gemcitabine/docetaxel (category 1)<sup>14</sup>
- Gemcitabine/vinorelbine (category 1)<sup>15</sup>

**Adenocarcinoma, Large Cell, NSCLC NOS (PS 2)**

- Albumin-bound paclitaxel<sup>16</sup>
- Carboplatin/albumin-bound paclitaxel<sup>17,18</sup>
- Carboplatin/docetaxel<sup>5</sup>
- Carboplatin/etoposide<sup>6,7</sup>
- Carboplatin/gemcitabine<sup>8</sup>
- Carboplatin/paclitaxel<sup>9</sup>
- Carboplatin/pemetrexed<sup>10</sup>
- Docetaxel<sup>19,20</sup>
- Gemcitabine<sup>21-23</sup>
- Gemcitabine/docetaxel<sup>14</sup>
- Gemcitabine/vinorelbine<sup>15</sup>
- Paclitaxel<sup>24-26</sup>
- Pemetrexed<sup>27</sup>

†Albumin-bound paclitaxel may be substituted for either paclitaxel or docetaxel in patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or for patients where the standard premedications (ie, dexamethasone, H2 blockers, H1 blockers) are contraindicated.

\*Bevacizumab should be given until progression.

\*\*Any regimen with a high risk of thrombocytopenia and the potential risk of bleeding should be used with caution in combination with bevacizumab.

\*\*\*Criteria for treatment with bevacizumab: non-squamous NSCLC, and no recent history of hemoptysis. Bevacizumab should not be given as a single agent, unless as maintenance if initially used with chemotherapy.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (3 of 4)<sup>†,††</sup>

#### First-line Systemic Therapy Options

##### Squamous Cell Carcinoma (PS 0-1)

- Carboplatin/albumin-bound paclitaxel (category 1)<sup>4</sup>
- Carboplatin/docetaxel (category 1)<sup>5</sup>
- Carboplatin/gemcitabine (category 1)<sup>8</sup>
- Carboplatin/paclitaxel (category 1)<sup>9</sup>
- Cisplatin/docetaxel (category 1)<sup>5</sup>
- Cisplatin/etoposide (category 1)<sup>11</sup>
- Cisplatin/gemcitabine (category 1)<sup>9,12</sup>
- Cisplatin/paclitaxel (category 1)<sup>13</sup>
- Gemcitabine/docetaxel (category 1)<sup>14</sup>
- Gemcitabine/vinorelbine (category 1)<sup>15</sup>

##### Squamous Cell Carcinoma (PS 2)

- Albumin-bound paclitaxel<sup>16</sup>
- Carboplatin/albumin-bound paclitaxel<sup>17,18</sup>
- Carboplatin/docetaxel<sup>5</sup>
- Carboplatin/etoposide<sup>6,7</sup>
- Carboplatin/gemcitabine<sup>8</sup>
- Carboplatin/paclitaxel<sup>9</sup>
- Docetaxel<sup>19,20</sup>
- Gemcitabine<sup>21-23</sup>
- Gemcitabine/docetaxel<sup>14</sup>
- Gemcitabine/vinorelbine<sup>15</sup>
- Paclitaxel<sup>24-26</sup>

<sup>†</sup>Albumin-bound paclitaxel may be substituted for either paclitaxel or docetaxel in patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or for patients where the standard premedications (ie, dexamethasone, H2 blockers, H1 blockers) are contraindicated.

<sup>††</sup>Cisplatin/gemcitabine/necitumumab in the first-line setting and erlotinib or afatinib in the second-line setting are not used at NCCN institutions for these indications related to the efficacy and safety of these agents compared to the efficacy and safety of other available agents.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (4 of 4)

- <sup>1</sup>Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. *N Engl J Med* 2006;355:2542-2550.
- <sup>2</sup>Patel JD, Socinski MA, Garon EB, et al. Pointbreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small cell lung cancer. *J Clin Oncol* 2013;31:4349-4357.
- <sup>3</sup>Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small cell lung cancer: AVAPERL. *J Clin Oncol* 2013;31:3004-3011.
- <sup>4</sup>Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062.
- <sup>5</sup>Fossella F, Periera JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003;21(16):3016-3024.
- <sup>6</sup>Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. *J Clin Oncol* 1990;8:1556-1562.
- <sup>7</sup>Frasci G, Comella P, Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. *Eur J Cancer* 1998;34:1710-1714.
- <sup>8</sup>Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung carcinoma. *Cancer* 2003;98:542-553.
- <sup>9</sup>Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol* 2007;18:317-323.
- <sup>10</sup>Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. *Clin Cancer Res* 2005;11:690-696.
- <sup>11</sup>Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. *J Clin Oncol* 1999;17:12-18.
- <sup>12</sup>Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage NSCLC. *J Clin Oncol* 2008;26:3543-3551.
- <sup>13</sup>Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. *Ann Oncol* 2005;16:602-610.
- <sup>14</sup>Tan EH, Szczesna A, Krzakowski M, et al. Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. *Lung Cancer* 2005;49:233-240.
- <sup>15</sup>Green M, Manikhas G, Orlov S, et al. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. *Ann Oncol* 2006;17:1263-1268.
- <sup>16</sup>Rizvi N, Riely G, Azzoli C, et al. Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non-Small-Cell Lung Cancer. *J Clin Oncol* 2008;26:639-643.
- <sup>17</sup>Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062.
- <sup>18</sup>Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol* 2000;18:2354-2362.
- <sup>19</sup>Fidias PM, Dakhlil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. *J Clin Oncol* 2009;27:591-598.
- <sup>20</sup>Zatloukal P, Kanitz E, Magyar P, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. *Lung Cancer* 1998;22:243-250.
- <sup>21</sup>Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: the Swedish Lung Cancer Study group. *J Clin Oncol* 2005;23:8380-8288.
- <sup>22</sup>Perol M, Chouaid C, Perol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small cell lung cancer. *J Clin Oncol* 2012;30:3516-3524.
- <sup>23</sup>Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and leukemia group B (study 9730). *J Clin Oncol* 2005;23:190-196.
- <sup>24</sup>Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. *Lung Cancer* 2004;44:231-239.
- <sup>25</sup>Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. *Oncology* 2004;66:347-352.
- <sup>26</sup>Hanna NH, Sheperd FA, Fossella FV, et al. Randomized phase III study of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. *J Clin Oncol* 2004;22:1589-1597.
- <sup>27</sup>Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. *N Engl J Med* 2002;346:92-98.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### CANCER SURVIVORSHIP CARE

#### NSCLC Long-term Follow-up Care

- **Cancer Surveillance**
  - ▶ H&P and a chest CT scan ± contrast every 6–12 months for 2 years, then H&P and a non-contrast–enhanced chest CT scan annually
  - ▶ Smoking status assessment at each visit; counseling and referral for cessation as needed.
- **Immunizations**
  - ▶ Annual influenza vaccination
  - ▶ Herpes zoster vaccine
  - ▶ Pneumococcal vaccination with revaccination as appropriate

#### Counseling Regarding Health Promotion and Wellness<sup>1</sup>

- **Maintain a healthy weight**
- **Adopt a physically active lifestyle (Regular physical activity: 30 minutes of moderate-intensity physical activity on most days of the week)**
- **Consume a healthy diet with emphasis on plant sources**
- **Limit consumption of alcohol if one consumes alcoholic beverages**

#### Additional Health Monitoring

- **Routine blood pressure, cholesterol, and glucose monitoring**
- **Bone health: Bone density testing as appropriate**
- **Dental health: Routine dental examinations**
- **Routine sun protection**

#### Resources

- **National Cancer Institute Facing Forward: Life After Cancer Treatment**  
<http://www.cancer.gov/cancertopics/life-after-treatment/allpages>

#### Cancer Screening Recommendations<sup>2,3</sup>

These recommendations are for average-risk individuals and high-risk patients should be individualized.

- **Colorectal Cancer:**  
[See NCCN Guidelines for Colorectal Cancer Screening](#)
- **Prostate Cancer:**  
[See NCCN Guidelines for Prostate Cancer Early Detection](#)
- **Breast Cancer:**  
[See NCCN Guidelines for Breast Cancer Screening](#)

<sup>1</sup>ACS Guidelines on Nutrition and Physical Activity for Cancer Prevention:

<http://www.cancer.org/healthy/eathealthygetactive/acsguidelinesonnutritionphysicalactivityforcancerprevention/index?sitearea=PED>.

<sup>2</sup>Memorial Sloan Kettering Cancer Center Screening Guidelines: <https://www.mskcc.org/cancer-care/risk-assessment-screening/screening-guidelines>.

<sup>3</sup>American Cancer Society Guidelines for Early Detection of Cancer:

<http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer?sitearea=PED>.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

### EMERGING TARGETED AGENTS FOR PATIENTS WITH GENETIC ALTERATIONS

Genetic Alteration (ie, Driver event)	Available Targeted Agents with Activity Against Driver Event in Lung Cancer
<b><i>BRAF</i> V600E mutation*</b> *Non-V600E mutations have variable kinase activity and response to these agents.	vemurafenib <sup>1,2</sup> dabrafenib <sup>2,3</sup> dabrafenib + trametinib <sup>4</sup>
<b>High-level <i>MET</i> amplification or <i>MET</i> exon 14 skipping mutation</b>	crizotinib <sup>5-9</sup>
<b><i>RET</i> rearrangements</b>	cabozantinib <sup>10,11</sup> vandetanib <sup>12</sup>
<b><i>HER2</i> mutations</b>	trastuzumab <sup>13</sup> (category 2B) afatinib <sup>14</sup> (category 2B)

<sup>1</sup>Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. *N Engl J Med* 2015;373:726-736.

<sup>2</sup>Gautschi O, Milia J, Cabarro B, et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. *J Thorac Oncol* 2015;10:1451-1457.

<sup>3</sup>Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAF (V600E)-positive advanced non-small-cell lung cancer: a single arm, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2016;17:642-650.

<sup>4</sup>Planchard D, Besse B, Groen HJ, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol* 2016;17:984-993.

<sup>5</sup>Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. *J Thorac Oncol* 2011;6:942-946.

<sup>6</sup>Camidge RD, Ou S-HI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer. *J Clin Oncol* 2014;32(Suppl 5): Abstract 8001.

<sup>7</sup>Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. *Cancer Discov* 2015;5:850-859.

<sup>8</sup>Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. *Cancer Discov* 2015;5:842-849.

<sup>9</sup>Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and cMET overexpression. *J Clin Oncol* 2016;34:721-730.

<sup>10</sup>Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. *Cancer Discov* 2013; 3:630-635.

<sup>11</sup>Drilon AE, Sima CS, Somwar R, et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. *J Clin Oncol* 2015;33: Abstract 8007.

<sup>12</sup>Lee S-H, Lee J-K, Ahn M-J, et al. A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement [abstract]. *J Clin Oncol* 2016;34: Abstract 9013.

<sup>13</sup>Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. *N Engl J Med* 2006;354:2619-2621.

<sup>14</sup>Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. *J Clin Oncol* 2013;31:1997-2003.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 3.2017 Staging Non-Small Cell Lung Cancer

**Table 1. Definitions for T, N, M\***

<b>T</b>	<b>Primary Tumor</b>	<b>N</b>	<b>Regional Lymph Nodes</b>
TX	Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy	NX	Regional lymph nodes cannot be assessed
T0	No evidence of primary tumor	N0	No regional lymph node metastasis
Tis	Carcinoma in situ	N1	Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension
T1	Tumor ≤3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus) <sup>a</sup>	N2	Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
	T1a Tumor ≤2 cm in greatest dimension	N3	Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)
	T1b Tumor >2 cm but ≤3 cm in greatest dimension		
T2	Tumor >3 cm but ≤7 cm or tumor with any of the following features: <sup>b</sup>	<b>M</b>	<b>Distant Metastasis</b>
	Involves main bronchus, ≥2 cm distal to the carina	MX	Distant metastasis cannot be assessed
	Invades visceral pleura	M0	No distant metastasis
	Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung	M1	Distant metastasis
	T2a Tumor >3 cm but ≤5 cm in greatest dimension	M1a	Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion <sup>c</sup>
	T2b Tumor >5 cm but ≤7 cm in greatest dimension	M1b	Distant metastasis
T3	Tumor >7 cm or one that directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus <2 cm distal to the carina <sup>a</sup> but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe		
T4	Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; separate tumor nodule(s) in a different ipsilateral lobe		

<sup>a</sup>The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus, is also classified as T1.

<sup>b</sup>T2 tumors with these features are classified T2a if ≤5 cm or if size cannot be determined, and T2b if >5 cm but ≤7 cm.

<sup>c</sup>Most pleural (and pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple cytopathologic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element and the patient should be classified as T1, T2, T3, or T4.

\*Used with permission. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. *J Thorac Oncol* 2007;2:706-714.



# NCCN Guidelines Version 3.2017 Staging Non-Small Cell Lung Cancer

**Table 2. Anatomic Stage and Prognostic Groups**

<b>Occult Carcinoma</b>	<b>TX</b>	<b>N0</b>	<b>M0</b>	<b>Stage IIIA</b>	<b>T1a</b>	<b>N2</b>	<b>M0</b>	
					<b>T1b</b>	<b>N2</b>	<b>M0</b>	
<b>Stage 0</b>	<b>Tis</b>	<b>N0</b>	<b>M0</b>		<b>T2a</b>	<b>N2</b>	<b>M0</b>	
<b>Stage IA</b>	<b>T1a</b>	<b>N0</b>	<b>M0</b>		<b>T2b</b>	<b>N2</b>	<b>M0</b>	
	<b>T1b</b>	<b>N0</b>	<b>M0</b>		<b>T3</b>	<b>N1</b>	<b>M0</b>	
<b>Stage IB</b>	<b>T2a</b>	<b>N0</b>	<b>M0</b>		<b>T3</b>	<b>N2</b>	<b>M0</b>	
					<b>T4</b>	<b>N0</b>	<b>M0</b>	
<b>Stage IIA</b>	<b>T2b</b>	<b>N0</b>	<b>M0</b>		<b>T4</b>	<b>N1</b>	<b>M0</b>	
	<b>T1a</b>	<b>N1</b>	<b>M0</b>		<b>Stage IIIB</b>	<b>T1a</b>	<b>N3</b>	<b>M0</b>
	<b>T1b</b>	<b>N1</b>	<b>M0</b>			<b>T1b</b>	<b>N3</b>	<b>M0</b>
<b>T2a</b>	<b>N1</b>	<b>M0</b>	<b>T2a</b>	<b>N3</b>		<b>M0</b>		
<b>Stage IIB</b>	<b>T2b</b>	<b>N1</b>	<b>M0</b>	<b>T2b</b>		<b>N3</b>	<b>M0</b>	
	<b>T3</b>	<b>N0</b>	<b>M0</b>	<b>T3</b>		<b>N3</b>	<b>M0</b>	
				<b>T4</b>	<b>N2</b>	<b>M0</b>		
				<b>T4</b>	<b>N3</b>	<b>M0</b>		
<b>Stage IV</b>	<b>Any T</b>	<b>Any N</b>	<b>M1a</b>	<b>Stage IV</b>	<b>Any T</b>	<b>Any N</b>	<b>M1a</b>	
	<b>Any T</b>	<b>Any N</b>	<b>M1b</b>		<b>Any T</b>	<b>Any N</b>	<b>M1b</b>	

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.



# NCCN Guidelines Version 3.2017 Staging Non-Small Cell Lung Cancer

**Table 3. Descriptors, T and M Categories, and Stage Grouping\***

6th Edition T/M Descriptor	7th Edition T/M	N0	N1	N2	N3
T1 (≤2 cm)	T1a	IA	IIA	IIIA	IIIB
T1 (<2–3 cm)	T1b	IA	IIA	IIIA	IIIB
T2 (≤5 cm)	T2a	IB	<b>IIA</b>	IIIA	IIIB
T2 (<5–7 cm)	T2b	<b>IIA</b>	IIB	IIIA	IIIB
T2 (>7 cm)	T3	<b>IIB</b>	<b>IIIA</b>	IIIA	IIIB
T3 invasion		IIB	IIIA	IIIA	IIIB
T4 (same lobe nodules)		<b>IIB</b>	<b>IIIA</b>	<b>IIIA</b>	IIIB
T4 extension	T4	<b>IIIA</b>	<b>IIIA</b>	IIIB	IIIB
M1 (ipsilateral lung)		<b>IIIA</b>	<b>IIIA</b>	<b>IIIB</b>	<b>IIIB</b>
T4 (pleural effusion)	M1a	<b>IV</b>	<b>IV</b>	<b>IV</b>	<b>IV</b>
M1 (contralateral lung)		IV	IV	IV	IV
M1 (distant)	M1b	IV	IV	IV	IV

**Cells in bold indicate a change from the sixth edition for a particular TNM category.**

\*Used with permission. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007;2:706-714.

## Discussion

### NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

**All recommendations are category 2A unless otherwise noted.**

## Table of Contents

<a href="#">Overview</a>	MS-3
Literature Search Criteria and Guidelines Update Methodology	3
Risk Factors	MS-3
Smoking Cessation	MS-4
Lung Cancer Screening	MS-5
Classification and Prognostic Factors	MS-5
<a href="#">Diagnostic Evaluation</a>	MS-5
Incidental Lung Nodules	MS-5

Larger Tumors	MS-6
<a href="#">Pathologic Evaluation of Lung Cancer</a>	MS-7
Adenocarcinoma	MS-8
Immunohistochemical Staining	MS-8
<a href="#">Staging</a>	MS-9
<a href="#">Predictive and Prognostic Biomarkers</a>	MS-10
EGFR Mutations	MS-11
ALK Gene Rearrangements	MS-13
ROS1 Rearrangements	MS-15
KRAS Mutations	MS-15
<a href="#">Treatment Approaches</a>	MS-15
Surgery	MS-15
Lymph Node Dissection	MS-16
Stage IIIA N2 Disease	MS-17
Thorascopic Lobectomy	MS-17
<a href="#">Radiation Therapy</a>	MS-18
General Principles	MS-18
Target Volumes, Prescription Doses, and Normal Tissue Dose Constraints	19
Radiation Simulation, Planning, and Delivery	MS-20
Stereotactic Ablative Radiotherapy	MS-20
Whole Brain RT and Stereotactic Radiosurgery	MS-22



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

Combined Modality Therapy.....	MS-23	Additional Pretreatment Evaluation.....	MS-38
Surgery Followed by Chemotherapy: Trial Data.....	MS-23	Mediastinoscopy.....	MS-38
Neoadjuvant Chemotherapy Followed by Surgery: Trial Data .....	MS-24	Other Imaging Studies .....	MS-39
Chemoradiation: Trial Data.....	MS-25	<b>Initial Therapy.....</b>	<b>MS-39</b>
Chemotherapy: Trial Data.....	MS-26	Stage I, Stage II, and Stage IIIA Disease.....	MS-40
Targeted Therapies .....	MS-28	Multiple Lung Cancers.....	MS-41
Bevacizumab.....	MS-28	Stage IIIB Disease .....	MS-42
Erlotinib and Gefitinib .....	MS-28	Stage IV Disease .....	MS-42
Afatinib.....	MS-29	<b>Adjuvant Treatment .....</b>	<b>MS-43</b>
Osimertinib.....	MS-30	Chemotherapy or Chemoradiation .....	MS-43
Crizotinib.....	MS-31	Radiation Therapy.....	MS-45
Ceritinib.....	MS-31	<b>Surveillance.....</b>	<b>MS-46</b>
Alectinib .....	MS-31	<b>Treatment of Recurrences and Distant Metastases .....</b>	<b>MS-47</b>
Cetuximab.....	MS-32	Trial Data .....	MS-50
Nivolumab.....	MS-32	Number of Cycles of First-Line Systemic Therapy.....	MS-51
Pembrolizumab .....	MS-33	Maintenance Therapy.....	MS-51
Atezolizumab .....	MS-35	Continuation of Erlotinib, Gefitinib, or Afatinib After Progression ...	52
Ramucirumab.....	MS-35	Second-Line and Beyond (Subsequent) Systemic Therapy .....	53
Maintenance Therapy.....	MS-35	<b>References.....</b>	<b>MS-57</b>
Continuation Maintenance Therapy .....	MS-36		
Switch Maintenance Therapy .....	MS-37		
<b>Clinical Evaluation .....</b>	<b>MS-37</b>		



### Overview

Lung cancer is the leading cause of cancer death in the United States.<sup>1</sup> In 2016, an estimated 224,390 new cases (117,920 in men and 106,470 in women) of lung and bronchial cancer will be diagnosed, and 158,080 deaths (85,920 in men and 72,160 in women) are estimated to occur because of the disease.<sup>2</sup> Only 17.7% of all patients with lung cancer are alive 5 years or more after diagnosis.<sup>3</sup> However, much progress has been made recently for lung cancer such as screening, minimally invasive techniques for diagnosis and treatment, and advances in radiation therapy (RT) including stereotactic ablative radiotherapy (SABR), targeted therapies, and immunotherapies.<sup>4-7</sup> Common symptoms of lung cancer include cough, dyspnea, weight loss, and chest pain; patients with symptoms are more likely to have chronic obstructive pulmonary disease.<sup>8</sup>

The NCCN Guidelines® for Non-Small Cell Lung Cancer (NSCLC) are updated at least once a year by the NCCN Panel (eg, there were 6 updates from October 2015 to October 2016). These NCCN Guidelines® were first published in 1996.<sup>9</sup> The *Summary of the Guidelines Updates* describes the most recent revisions to the algorithms, which have been incorporated into this updated Discussion text. By definition, the NCCN Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments.

### Literature Search Criteria and Guidelines Update Methodology

Before the update of this version of the NCCN Guidelines for NSCLC, an electronic search of the PubMed database was performed to obtain key literature in NSCLC, published between July 1, 2015 and July 1, 2016 using the following search term: non-small cell lung cancer. The PubMed database was chosen, because it is the most widely used

resource for medical literature and indexes only peer-reviewed biomedical literature. The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase 2; Clinical Trial, Phase 3; Clinical Trial, Phase 4; Guideline; Meta-Analysis; Randomized Controlled Trial; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 176 citations and their potential relevance was examined. The data from key PubMed articles selected by the NCCN Panel for review during the NCCN Guidelines update meeting, as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the NCCN Panel, have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). If high-level evidence is lacking, recommendations are based on the panel's review of lower-level evidence and expert opinion. The complete details of the development and update of the NCCN Guidelines are available on the NCCN [webpage](#).

### Risk Factors

The primary risk factor for lung cancer is smoking tobacco, which accounts for most lung cancer-related deaths.<sup>1,10-14</sup> Cigarette smoke contains many carcinogenic chemicals (eg, nitrosamines, benzo(a)pyrene diol epoxide).<sup>13,15</sup> The risk for lung cancer increases with the number of packs of cigarettes smoked per day and with the number of years spent smoking (ie, pack-years of smoking history). Exposed nonsmokers also have an increased relative risk (RR = 1.24) of developing lung cancer from *secondhand smoke*; other studies have reported a modest risk (hazard ratio [HR], 1.05).<sup>11,15-18</sup>

Other possible risk factors for lung cancer include disease history (eg, COPD), cancer history, family history of lung cancer, and exposure to

other carcinogens (see the NCCN Guidelines for Lung Cancer Screening, available at [NCCN.org](http://NCCN.org)).<sup>19,20</sup> The International Agency for Research on Cancer lists several agents known to cause lung cancer, including arsenic, chromium, asbestos, nickel, cadmium, beryllium, silica, and diesel fumes.<sup>21-23</sup> Asbestos is a known carcinogen that increases the risk for lung cancer in people exposed to airborne fibers, especially in individuals who smoke. It is estimated that about 3% to 4% of lung cancers are caused by asbestos exposure.<sup>24</sup> Asbestos also causes malignant pleural mesothelioma (see the NCCN Guidelines for Malignant Pleural Mesothelioma, available at [NCCN.org](http://NCCN.org)). Radon gas, a radioactive gas that is produced by the decay of radium 226, also seems to cause lung cancer.

It is not clear whether hormone replacement therapy (HRT) affects the risk for lung cancer in women. More than 20 studies have been published, but the results have been inconsistent. In a large randomized controlled study,<sup>25</sup> no increase in the incidence of lung cancer was found among postmenopausal women treated with estrogen plus progestin HRT; however, the risk of death from NSCLC increased.<sup>25</sup> In women who received estrogen alone, the incidence or risk of death from lung cancer did not increase.<sup>26</sup>

### Smoking Cessation

Approximately 85% to 90% of cases of lung cancer are caused by cigarette smoking.<sup>12</sup> Active smoking and secondhand smoke both cause lung cancer. There is a causal relationship between active smoking and lung cancer and also between other cancers (eg, esophageal, oral cavity, laryngeal, pharyngeal, bladder, pancreatic, gastric, kidney, ovarian cancer, colorectal, and cervical cancers) and other diseases and conditions.<sup>12</sup> Smoking harms nearly every organ in the body; smokers have increased mortality compared with nonsmokers.<sup>27</sup> Those

who live with someone who smokes have an increased risk for lung cancer.<sup>16</sup> Further complicating this problem, cigarettes also contain nicotine, which is a highly addictive substance.

Oncologists should encourage smoking cessation, especially in patients with cancer (see the NCCN Guidelines for Smoking Cessation, available at [NCCN.org](http://NCCN.org)).<sup>28-31</sup> The 5 A's framework is a useful tool (that is, Ask, Advise, Assess, Assist, Arrange).<sup>32</sup> It is in the best interest of patients to quit smoking. Persistent smoking is associated with second primary cancers, treatment complications, and decreased survival.<sup>33</sup> Some surgeons will not operate on a current smoker, because active smoking may increase postoperative pulmonary complications.<sup>34</sup> However, active smoking should not be used to exclude patients with early-stage lung cancer from surgical treatment that will prolong survival. Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useful.<sup>35</sup> The American Cancer Society (ACS) has a *Guide to Quitting Smoking*.

Agents that can be used to promote smoking cessation include nicotine replacement (eg, gum, inhaler, lozenge, nasal spray, patch), bupropion sustained release, and varenicline.<sup>36,37</sup> A study suggests that cytisine is more efficacious than nicotine replacement therapy, although more side effects were reported with cytisine such as nausea, vomiting, and sleep disorders.<sup>38</sup> Studies have shown that varenicline is better than bupropion or nicotine patch for smoking cessation.<sup>39-41</sup> The effectiveness of varenicline for preventing relapse has not been clearly established.<sup>42</sup> The FDA has issued an alert for varenicline regarding neuropsychiatric symptoms. Varenicline has also been associated with other disorders (eg, visual disturbances, movement disorders, unconsciousness, cardiovascular disorders), and therefore is banned in truck and bus drivers, pilots, and air traffic controllers.<sup>43-46</sup> Other side effects with

varenicline include nausea, abnormal dreams, insomnia, and headache.<sup>41,47,48</sup> Bupropion may also be associated with similar serious neuropsychiatric symptoms. Nicotine replacement has fewer adverse effects than varenicline or bupropion.<sup>49</sup> However, in spite of the potential adverse effects, it is probably more beneficial for motivated patients to use agents to promote smoking cessation.<sup>49</sup>

### Lung Cancer Screening

Lung cancer is the leading cause of cancer death worldwide in men, and late diagnosis is a major obstacle to improving lung cancer outcomes.<sup>1,50,51</sup> Because localized cancer can be managed with curative intent and because the mortality rate in other solid tumors (eg, cervix, colon) seems to be decreased by screening and early detection, lung cancer is an appropriate candidate for a population-based screening approach.

The National Lung Screening Trial (NLST) (ACRIN Protocol A6654) was a randomized controlled study involving more than 53,000 current or former heavy smokers that assessed the risks and benefits of low-dose CT scans compared with chest radiographs for detecting lung cancer.<sup>52</sup> Data from the NLST showed that screening individuals with high-risk factors using low-dose CT decreased the mortality rate from lung cancer by 20%.<sup>53</sup> Individuals with high-risk factors were either current or former smokers with a 30 or more pack-year smoking history (former smokers had quit up to 15 years before enrollment), were 55 to 74 years of age, and had no evidence of lung cancer.<sup>52,54</sup> The NCCN, ACS, U.S. Preventive Services Task Force (USPSTF), American College of Chest Physicians, European Society for Medical Oncology (ESMO), and other organizations recommend lung cancer screening using low-dose CT for select high-risk current and former smokers (see the NCCN Guidelines for Lung Cancer Screening, available at [NCCN.org](#)).<sup>55-58</sup>

Low-dose CT screening and follow-up are not a substitute for smoking cessation; patients should be offered smoking cessation counseling (see NCCN Guidelines for Smoking Cessation, available at [NCCN.org](#)).

### Classification and Prognostic Factors

The WHO divides lung cancer into 2 major classes based on its biology, therapy, and prognosis: NSCLC (discussed in this guideline) and small cell lung cancer (SCLC) (see the NCCN Guidelines for Small Cell Lung Cancer, available at [NCCN.org](#)).<sup>59,60</sup> NSCLC accounts for more than 80% of all lung cancer cases, and it includes 2 major types: 1) non-squamous carcinoma (including adenocarcinoma, large-cell carcinoma, and other cell types); and 2) squamous cell (epidermoid) carcinoma.<sup>3</sup> Adenocarcinoma is the most common type of lung cancer seen in the United States and is also the most frequently occurring histology in nonsmokers. In 2011, an international panel revised the classification of lung adenocarcinoma (see the *Pathologic Evaluation of Lung Cancer* in this Discussion), which has been adopted by the WHO.<sup>59-61</sup> Certain prognostic factors are predictive of survival in patients with NSCLC. Good prognostic factors include early-stage disease at diagnosis, good performance status (PS) (ECOG 0, 1, or 2), no significant weight loss (not more than 5%), and female gender.<sup>62</sup>

### Diagnostic Evaluation

#### Incidental Lung Nodules

Lung cancer screening is recommended for early diagnosis in asymptomatic patients at high risk. Risk assessment is used to determine which individuals are at high risk for lung cancer and thus are candidates for screening with low-dose CT.<sup>63</sup> Clinicians are referred to the NCCN Guidelines for Lung Cancer Screening for risk assessment criteria to determine which patients are eligible for screening and for how to evaluate and follow up on low-dose CT screening findings.<sup>64</sup> The

NCCN Guidelines for Lung Cancer Screening were recently revised to harmonize with the LungRADs system developed by the American College of Radiology with the goal of decreasing the false-positive low-dose CT screening results reported in the NLST.<sup>65</sup>

The diagnostic algorithm for pulmonary nodules in the NCCN Guidelines for NSCLC incorporates information from the NCCN Guidelines for Lung Cancer Screening. For the 2017 update (Version 1), the NCCN Panel revised the diagnostic algorithm to focus on incidental solid and subsolid lung nodules detected on chest CT (see the NCCN Guidelines for NSCLC).<sup>66-69</sup> Note that the Fleischner Society Guidelines do not specify whether a CT with contrast is necessary for follow-up or whether a low-dose CT is sufficient. Low-dose CT is preferred unless contrast enhancement is needed for better diagnostic resolution.

Solid and subsolid nodules are the 2 main types of pulmonary nodules that may be seen on chest CT scans. The Fleischner Society has recommendations for patients with solid and subsolid nodules.<sup>66,67</sup> Subsolid nodules include 1) nonsolid nodules also known as ground-glass opacities (GGOs) or ground-glass nodules (GGNs); and 2) part-solid nodules, which contain both ground-glass and solid components.<sup>67,70-72</sup> Nonsolid nodules are mainly adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA), formerly known as bronchioloalveolar carcinoma (BAC) (see *Adenocarcinoma* in this Discussion); patients have 5-year disease-free survival of 100% if these nonsolid nodules are completely resected.<sup>61,67,70,71,73-75</sup> Data suggest that many nonsolid nodules discovered incidentally on CT imaging will resolve and many of those that persist may not progress to clinically significant cancer.<sup>73,76,77</sup> Solid and part-solid nodules are more likely to be invasive, faster-growing cancers, factors that are reflected in the

increased suspicion and follow-up of these nodules (see the NCCN Guidelines for Lung Cancer Screening, available at [NCCN.org](#)).<sup>64,66,67</sup>

All findings and factors for a patient need to be carefully evaluated in a multidisciplinary diagnostic team before establishing a diagnosis of lung cancer and before starting treatment. The NCCN Guidelines recommend biopsy or surgical excision for highly suspicious nodules seen on low-dose CT scans or further surveillance for nodules with a low suspicion of cancer depending on the type of nodule and a multidisciplinary evaluation of other patient factors (see the NCCN Guidelines for Lung Cancer Screening, available at [NCCN.org](#)). For patients having repeat scans, the most important radiologic factor is change or stability of a nodule when compared with a previous imaging study. False-positive results (eg, benign intrapulmonary lymph nodes, noncalcified granulomas) frequently occurred with low-dose CT when using the original cutoffs for nodule size deemed suspicious for malignancy from the NLST.<sup>53</sup> However, the revised cutoff values for suspicious nodules recommended by the American College of Radiology and incorporated into the LungRADs system have been reported to decrease the false-positive rate from low-dose CT.<sup>78-80</sup>

### Larger Tumors

The NCCN Guidelines recommend that the diagnostic strategy should be individualized for each patient depending on the size and location of the tumor, the presence of mediastinal or distant disease, patient characteristics (eg, comorbidities), and local expertise. The diagnostic strategy needs to be decided in a multidisciplinary setting. Decisions regarding whether a biopsy (including what type of biopsy) or surgical excision is appropriate depend on several factors as outlined in the NSCLC algorithm (see *Principles of Diagnostic Evaluation* in the NCCN Guidelines for NSCLC). For example, a preoperative biopsy may be

appropriate if an intraoperative diagnosis seems to be difficult or very risky. The preferred biopsy technique depends on the site of disease and is described in the NSCLC algorithm (see *Principles of Diagnostic Evaluation*). For example, radial endobronchial ultrasound (EBUS; also known as endosonography), navigational bronchoscopy, or transthoracic needle aspiration (TTNA) are recommended for patients with suspected peripheral nodules.<sup>81</sup> PET/CT imaging is useful before selecting a biopsy site, because it is better to biopsy the site that will confer the highest stage. Patients with suspected nodal disease should be assessed by endoscopic ultrasound–guided fine-needle aspiration (EUS-FNA), EBUS–guided transbronchial needle aspiration (EBUS-TBNA), navigational bronchoscopy, or mediastinoscopy (see *Mediastinoscopy* in this Discussion and *Principles of Diagnostic Evaluation* in the NCCN Guidelines for NSCLC). EBUS provides access to nodal stations 2R/2L, 4R/4L, 7, 10R/10L, and other hilar nodal stations. EUS provides access to nodal stations 5, 7, 8, and 9.

If pathology results from biopsy or surgical excision indicate a diagnosis of NSCLC, then further evaluation and staging need to be done so that the patient's health care team can determine the most appropriate and effective treatment plan (see *Pathologic Evaluation of Lung Cancer and Staging* in this Discussion and the NCCN Guidelines for NSCLC). Diagnosis, staging, and planned resection (eg, lobectomy) are ideally one operative procedure for patients with early-stage disease (see the *Principles of Diagnostic Evaluation* in the NCCN Guidelines for NSCLC). A preoperative or intraoperative tissue diagnosis of lung cancer should be established before doing a lobectomy.

### Pathologic Evaluation of Lung Cancer

Pathologic evaluation is performed to classify the histologic type of the lung cancer, determine the extent of invasion, determine whether it is

primary lung cancer or metastatic cancer, establish the cancer involvement status of the surgical margins (ie, positive or negative margins), and do molecular diagnostic studies to determine whether certain gene alterations are present (eg, epidermal growth factor receptor [EGFR] mutations) (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC).<sup>82</sup> Data show that targeted therapy is potentially very effective in patients with specific gene mutations or rearrangements (see *EGFR Mutations, ALK Gene Rearrangements, and ROS1 Rearrangements* in this Discussion).<sup>6,83-88</sup> Preoperative evaluations include examination of the following: bronchial brushings, bronchial washings, sputum, FNA biopsy, core needle biopsy, endobronchial biopsy, and transbronchial biopsy.<sup>81,89</sup> Minimally invasive techniques can be used to obtain specimens in patients with advanced unresectable NSCLC;<sup>90,91</sup> however, diagnosis may be more difficult when using small biopsies and cytology.<sup>74</sup> The mediastinal lymph nodes are systematically sampled to determine the staging and therapeutic options. Other lung diseases also need to be ruled out (eg, tuberculosis, sarcoidosis).<sup>92,93</sup>

Lobectomy or pneumonectomy specimens are evaluated intraoperatively to determine the surgical resection margin status, diagnose incidental nodules discovered at the time of surgery, or evaluate the regional lymph nodes. Postoperative evaluation provides the pathology characteristics necessary for the classification of tumor type, staging, and prognostic factors. The surgical pathology report should include the WHO histologic classification for carcinomas of the lung.<sup>59,60,94</sup> In 2011, the classification for lung adenocarcinoma was revised by an international panel, which has been adopted by the WHO (see *Adenocarcinoma* in this Discussion).<sup>59-61</sup> The revised classification recommends immunohistochemical (IHC) and molecular studies (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC).<sup>95</sup>

In addition, the revised classification recommends that use of general categories (eg, NSCLC) should be minimized, because more effective treatment can be selected when the histology is known.

### Adenocarcinoma

In the revised classification for adenocarcinoma, the categories of BAC or mixed subtype adenocarcinoma are no longer used.<sup>61</sup> If necessary, *former BAC* can be used. The categories for adenocarcinoma include: 1) AIS (formerly BAC), which is a preinvasive lesion; 2) MIA; 3) invasive adenocarcinoma (includes formerly nonmucinous BAC); and 4) variants of invasive adenocarcinoma (includes formerly mucinous BAC). Both AIS and MIA are associated with excellent survival if they are resected. The international panel and NCCN recommend that all patients with adenocarcinoma be tested for EGFR mutations; the NCCN Panel also recommends that these patients be tested for anaplastic lymphoma kinase (ALK) gene rearrangements, ROS1 rearrangements, and programmed death (PD-1) receptor expression levels. The panel also advises testing for other genetic alterations to identify rare driver mutations for which effective therapy may be available such as BRAF V600E. The terms—*AIS*, *MIA*, and *large cell carcinoma*—should not be used for small samples because of challenges with cytology specimens.<sup>61</sup>

### Immunohistochemical Staining

Immunostains are used to differentiate primary pulmonary adenocarcinoma from metastatic adenocarcinoma to the lung (eg, breast, prostate, colorectal), to distinguish adenocarcinoma from malignant mesothelioma, and to determine the neuroendocrine status of tumors. IHC staining is described in the NSCLC algorithm (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC). However, limited use of IHC in small tissue samples is recommended to

conserve tumor tissue for molecular studies, especially in patients with advanced disease.<sup>91,96</sup> The NCCN Panel recommends that IHC should be judiciously used to preserve tissue for molecular testing. Before using IHC, all findings should be assessed including routine H&E histology, clinical findings, imaging studies, and the patient's history. Although cytology can be used to distinguish adenocarcinomas from squamous cell carcinomas, IHC is also useful for poorly differentiated NSCLC in small biopsy and/or cytology specimens.<sup>61,97</sup> Squamous cell carcinomas are often TTF-1 negative and p63 positive, whereas adenocarcinomas are usually TTF-1 positive.<sup>61</sup> These 2 markers may be sufficient to distinguish adenocarcinomas from squamous cell carcinomas.<sup>61,97</sup> Other markers (eg, p40, Napsin A) may also be useful in distinguishing adenocarcinoma from squamous cell carcinoma.<sup>98,99</sup>

An appropriate panel of IHC stains is recommended to rule out metastatic carcinoma to the lung if the primary origin of the carcinoma is uncertain. TTF-1 is very important for distinguishing primary lung adenocarcinoma from metastatic adenocarcinoma, because most primary adenocarcinomas are TTF-1 positive. TTF-1 is typically negative for squamous cell carcinoma.<sup>97</sup> However, TTF-1 is positive in tumors from patients with thyroid cancer.<sup>100</sup> In addition, thyroglobulin is present in tumors from patients with thyroid cancer, while it is negative in lung cancer tumors. Pulmonary adenocarcinoma of the lung is usually CK7+ and CK20-, whereas metastatic adenocarcinoma of the colorectum is usually CK7- and CK20+. CDX2 is a marker for metastatic gastrointestinal malignancies that can be used to differentiate them from primary lung tumors. All typical and atypical carcinoid tumors are positive for chromogranin and synaptophysin, whereas SCLC is negative in 25% of cases.

Malignant pleural mesothelioma is a rare disease; IHC is valuable for distinguishing between malignant mesothelioma and lung

adenocarcinoma.<sup>101,102</sup> However, the NCCN Panel feels that malignant mesothelioma and lung adenocarcinoma can be distinguished using clinical impression, imaging, and a limited panel of immunomarkers (if needed) to preserve tissue for molecular testing. The stains that are positive for adenocarcinoma include carcinoembryonic antigen (CEA), B72.3, Ber-EP4, MOC-31, CD15, claudin-4, and TTF-1; these stains are negative for mesothelioma.<sup>103</sup> Stains that are sensitive and specific for mesothelioma include WT-1, calretinin, D2-40 (podoplanin antibody),<sup>104</sup> HMBW-1, and cytokeratin 5/6.<sup>101,102</sup> If needed, a panel of 4 markers can be used to distinguish mesothelioma from adenocarcinoma—2 are positive in mesothelioma and 2 are positive in adenocarcinoma but negative in mesothelioma—including calretinin, cytokeratin 5/6 (or WT-1), CEA, and MOC-31 (or B72.3, Ber-EP4, or BG-8).<sup>101,102,105</sup>

Although the cytologic diagnosis of NSCLC is generally reliable, it is more difficult to diagnose SCLC.<sup>81,97,106</sup> However, many patients with SCLC have characteristic CT and clinical findings (eg, massive lymphadenopathy, mediastinal invasion). Most SCLCs are immunoreactive for TTF-1; they are typically negative for CK34βE12 and p63.<sup>107,108</sup> Many SCLCs also stain positively for markers of neuroendocrine differentiation, including chromogranin A, neuron-specific enolase, neural cell adhesion molecule, and synaptophysin. However, these markers alone cannot be used to distinguish SCLC from NSCLC, because approximately 10% of NSCLCs are immunoreactive for at least one of these neuroendocrine markers.<sup>109</sup> Data suggest that microRNA expression can be used to distinguish SCLC from NSCLC.<sup>110</sup>

### Staging

A new edition of the AJCC Cancer Staging Manual (8th edition) was published in late 2016 and will be effective for all cancer cases

recorded on or after January 1, 2018.<sup>111</sup> The NCCN Guidelines will use the AJCC (7<sup>th</sup> edition) staging system for lung cancer until January 1, 2018.<sup>112</sup> The definitions for TNM and the stage grouping are summarized in Tables 1 and 2 of the staging tables (see *Definitions for T,N,M* and *Staging* in the NCCN Guidelines for NSCLC). The descriptors of the TNM classification scheme are summarized in Table 3 of the staging tables (see *Staging*). The lung cancer staging system was revised by the International Association for the Study of Lung Cancer (IASLC).<sup>113-115</sup> and was adopted by the AJCC.<sup>116,117</sup> With the AJCC staging, locally advanced disease is stage III; advanced disease is stage IV. Pathologic staging uses both clinical staging information (which is noninvasive and includes medical history, physical examination, and imaging) and other invasive staging procedures (eg, thoracotomy, examination of lymph nodes using mediastinoscopy).<sup>112</sup>

From 2006 to 2012, the overall 5-year relative survival rate for lung cancer was 17.7% in the United States.<sup>3</sup> Of lung and bronchial cancer cases, 16% were diagnosed while the cancer was still confined to the primary site; 22% were diagnosed after the cancer had spread to regional lymph nodes or directly beyond the primary site; 57% were diagnosed after the cancer had already metastasized; and for the remaining 5% the staging information was unknown. The corresponding 5-year relative survival rates were 55% for localized, 28% for regional, 4.3% for distant, and 7.4% for unstaged.<sup>3</sup> However, these data include SCLC, which has a poorer prognosis.

Five-year survival after lobectomy for pathologic stage I NSCLC ranges from 45% to 65%, depending on whether the patient has stage 1A or 1B disease and on the location of the tumor.<sup>118</sup> Another study in patients with stage I disease (n = 19,702) found that 82% had surgical resection and their 5-year overall survival was 54%; however, for untreated stage I NSCLC, 5-year overall survival was only 6%.<sup>119</sup> Of patients with stage I

disease who refused surgery (although it was recommended), 78% died of lung cancer within 5 years.

### Predictive and Prognostic Biomarkers

Several biomarkers have emerged as predictive and prognostic markers for NSCLC. A *predictive* biomarker is indicative of therapeutic efficacy, because there is an interaction between the biomarker and therapy on patient outcome. A *prognostic* biomarker is indicative of patient survival independent of the treatment received, because the biomarker is an indicator of the innate tumor aggressiveness (see *KRAS Mutations* at the end of this section).

Predictive biomarkers include the ALK fusion oncogene (fusion between ALK and other genes [eg, echinoderm microtubule-associated protein-like 4]), ROS1 gene rearrangements, and sensitizing EGFR mutations (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC). Emerging biomarkers include HER2 (also known as ERBB2) and BRAF V600E mutations, RET gene rearrangements, and high-level MET amplifications or MET exon 14 skipping mutations (see *Emerging Targeted Agents for Patients with Genetic Alterations* in the NCCN Guidelines for NSCLC). The presence of EGFR exon 19 deletions or exon 21 L858R mutations is predictive of treatment benefit from EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy (ie, erlotinib, gefitinib, afatinib); therefore, these mutations are referred to as *sensitizing EGFR mutations* (see *EGFR Mutations* in this Discussion).<sup>120,121</sup> However, the presence of EGFR exon 19 deletions (LREA) or exon 21 L858R mutations does not appear to be prognostic of survival for patients with NSCLC, independent of therapy.<sup>122</sup> ALK fusion oncogenes (ie, ALK gene rearrangements) and ROS1 rearrangements are predictive biomarkers that have been identified in a small subset of patients with NSCLC; both predict for benefit from

crizotinib (see *ALK Gene Rearrangements* and *ROS1 Gene Rearrangements* in this Discussion and *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC). For the 2017 update (Version 1), the NCCN Panel added a new section on *ROS1 Gene Rearrangements* to the pathology recommendations (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC) Other gene rearrangements (ie, gene fusions) have recently been identified (such RET) that are susceptible to targeted therapies (see *Emerging Targeted Agents for Patients with Genetic Alterations* in the NCCN Guidelines for NSCLC).<sup>123-128</sup>

Testing for ALK gene rearrangements and EGFR mutations is recommended (category 1 for both) in the NSCLC algorithm for patients with non-squamous NSCLC or NSCLC not otherwise specified (NOS) so that patients with these genetic abnormalities can receive effective treatment with targeted agents such as erlotinib, gefitinib, afatinib, and crizotinib (see *Targeted Therapies* in this Discussion and the NCCN Guidelines for NSCLC).<sup>129-133</sup> Testing for ROS1 rearrangements (category 2A) is also recommended in the NCCN Guidelines. Although rare, patients with ALK rearrangements or EGFR mutations can have mixed squamous cell histology.<sup>134,135</sup> Therefore, testing for ALK rearrangements, ROS1 rearrangements, and EGFR mutations can be considered in patients with squamous cell histology if they are never smokers, small biopsy specimens were used for testing, or mixed histology was reported. EGFR, KRAS, ROS1, and ALK genetic alterations do not usually overlap.<sup>123,136,137</sup>

Patients with NSCLC may have other genetic alterations (see *Emerging Targeted Agents for Patients with Genetic Alterations* in the NCCN Guidelines for NSCLC).<sup>83,138,139</sup> Mutation screening assays for detecting multiple biomarkers simultaneously (eg, Sequenom's MassARRAY® system, SNaPshot® Multiplex System) have been developed that can



detect more than 50 point mutations, including EGFR.<sup>140,141</sup> However, these multiplex polymerase chain reaction (PCR) systems do not detect gene rearrangements, because they are not point mutations. ROS1 and ALK gene rearrangements can be detected using fluorescence in situ hybridization (FISH) (see *ALK Gene Rearrangements* and *ROS1 Gene Rearrangements* in this Discussion). Broad molecular profiling systems, such as next-generation sequencing (NGS) (also known as massively parallel sequencing), can detect panels of mutations and gene rearrangements if the NGS platforms have been designed and validated to detect these genetic alterations.<sup>142-149</sup> It is important to recognize that NGS requires quality control as much as any other diagnostic technique; because it is primer dependent, the panel of genes and abnormalities detected with NGS will vary depending on the design of the NGS platform. For example, some NGS platforms can detect both mutations and gene rearrangements, as well as copy number variation, but they are not uniformly present in all NGS assays being conducted either commercially or in institutional laboratories.

Other driver mutations and gene rearrangements (ie, driver events) are being identified such as BRAF V600E mutations, RET gene rearrangements, high-level MET amplification or MET exon 14 skipping mutation, and HER2 (also known as ERBB2).<sup>123,124,126,128,150-161</sup> Targeted agents are available for patients with NSCLC who have these other genetic alterations, although they are FDA approved for other indications (see *Emerging Targeted Agents for Patients with Genetic Alterations* in the NCCN Guidelines for NSCLC).<sup>147,162</sup> Thus, the NCCN Panel strongly advises broader molecular profiling (also known as precision medicine) to identify rare driver mutations to ensure that patients receive the most appropriate treatment; patients may be eligible for clinical trials for some of these targeted agents.<sup>132</sup> Several online resources are available that describe NSCLC driver events such

as DIRECT (DNA-mutation Inventory to Refine and Enhance Cancer Treatment)<sup>163</sup> and *My Cancer Genome*.<sup>140,164</sup> The KRAS oncogene is a prognostic biomarker. The presence of KRAS mutations is prognostic of poor survival for patients with NSCLC when compared to the absence of KRAS mutations, independent of therapy (see *KRAS Mutations* in this Discussion).<sup>165</sup> KRAS mutations are also predictive of lack of benefit from platinum/vinorelbine chemotherapy or EGFR TKI therapy.<sup>120,166,167</sup> EGFR, KRAS, ROS1, and ALK genetic alterations do not usually overlap.<sup>136,137,168</sup> Sensitizing EGFR TKI therapy is not effective in patients with KRAS mutations, ALK gene rearrangements, or ROS1 rearrangements.

### EGFR Mutations

In patients with NSCLC, the most commonly found EGFR mutations are deletions in exon 19 (Exon19del [with conserved deletion of the LREA sequence] in 45% of patients with EGFR mutations) and a mutation in exon 21 (L858R in 40%). Both mutations result in activation of the tyrosine kinase domain, and both are associated with sensitivity to the small molecule TKIs, such as erlotinib, gefitinib, and afatinib (see *Targeted Therapies* in this Discussion).<sup>169</sup> Thus, these mutations are referred to as sensitizing EGFR mutations. Previously, erlotinib was commonly used in the United States in patients with sensitizing EGFR mutations because of restrictions on the use of gefitinib. However, gefitinib was recently re-approved by the FDA based on a phase 4 study and is now available in the United States.<sup>130</sup> Afatinib is an oral TKI that inhibits the entire ErbB/HER family of receptors including EGFR and HER2.<sup>170,171</sup> The FDA has approved afatinib for first-line treatment of patients with metastatic non-squamous NSCLC who have sensitizing EGFR mutations.<sup>172,173</sup>

These sensitizing EGFR mutations are found in approximately 10% of Caucasian patients with NSCLC and up to 50% of Asian patients.<sup>174</sup> Other drug-sensitive mutations include point mutations at exon 21 (L861Q) and exon 18 (G719X).<sup>175</sup> Primary resistance to TKI therapy is associated with KRAS mutations and ALK or ROS1 gene rearrangements. Patients with exon 20 insertion mutations are also resistant to TKIs.<sup>176-179</sup> EGFR T790M is a mutation associated with acquired resistance to EGFR TKI therapy and has been reported in about 60% of patients with disease progression after initial response to erlotinib, gefitinib, or afatinib.<sup>146,180-186</sup> Most patients with sensitizing EGFR mutations become resistant to erlotinib, gefitinib, or afatinib after about 8 to 16 months of EGFR TKI therapy.<sup>181</sup> However, studies suggest T790M may also occur in patients who have not previously received EGFR TKI therapy, although this is a rare event.<sup>187</sup> Osimertinib is recommended as second-line and beyond (subsequent) therapy for patients with EGFR T790M who have progressed on sensitizing EGFR TKI therapy such as, erlotinib, gefitinib, afatinib (see *Osimertinib* in this Discussion).<sup>188</sup> Acquired resistance may also be associated with histologic transformation from NSCLC to SCLC and with epithelial to mesenchymal transition (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC).<sup>189-191</sup>

DNA mutational analysis is the preferred method to assess for EGFR status.<sup>192-194</sup> Various DNA mutation detection assays can be used to determine the EGFR mutation status in tumor cells.<sup>195</sup> Direct sequencing of DNA corresponding to exons 18 to 21 (or just testing for exons 19 and 21) is a reasonable approach; however, more sensitive methods are available.<sup>174,193,196-198</sup> Mutation screening assays using multiplex PCR (eg, Sequenom's MassARRAY® system, SNaPshot® Multiplex System) can detect more than 50 point mutations, including EGFR.<sup>141</sup> NGS can also be used to detect EGFR mutations.<sup>148</sup>

The predictive effects of the drug-sensitive EGFR mutations—Exon19del (LREA deletion) and L858R—are well defined. Patients with these mutations have a significantly better response to erlotinib, gefitinib, or afatinib.<sup>169</sup> Retrospective studies have shown an objective response rate of approximately 80% with a median progression-free survival (PFS) of 13 months to single-agent EGFR TKI therapy in patients with a bronchioloalveolar variant of adenocarcinoma and a sensitizing EGFR mutation.<sup>120</sup> A prospective study has shown that the objective response rate in North American patients with non-squamous NSCLC and sensitizing EGFR mutations (53% Exon19del [LREA deletion], 26% L858R, and 21% other mutations) is 55% with a median PFS of 9.2 months.<sup>121</sup> EGFR mutation testing is not usually recommended in patients with pure squamous cell carcinoma unless they never smoked, if only a small biopsy specimen (ie, not a surgical resection) was used to assess histology, or if the histology is mixed.<sup>134</sup> Data suggest that EGFR mutations can occur in patients with adenosquamous carcinoma, which is harder to discriminate from squamous cell carcinoma in small specimens.<sup>134</sup>

Data show that erlotinib, gefitinib, or afatinib (instead of standard first-line chemotherapy) should be used as first-line systemic therapy in patients with sensitizing EGFR mutations documented before first-line therapy.<sup>173,199-203</sup> PFS is improved with use of EGFR TKI in patients with sensitizing EGFR mutations when compared with standard chemotherapy, although overall survival is not statistically different.<sup>173,199,204</sup> Patients receiving erlotinib have fewer treatment-related severe side effects and deaths when compared with those receiving chemotherapy.<sup>199,205</sup> A phase 4 trial showed that gefitinib is safe and effective in patients with sensitizing EGFR mutations.<sup>130</sup> Based on these data and the FDA approvals, erlotinib and gefitinib are recommended (category 1) as first-line systemic therapy in patients with

sensitizing EGFR mutations.<sup>130,199</sup> In a phase 3 randomized trial, patients receiving afatinib had decreased cough, decreased dyspnea, and improved health-related quality of life when compared with those receiving cisplatin/pemetrexed.<sup>205</sup> Based on these data and the FDA approval, afatinib is also recommended (category 1) as first-line systemic therapy in patients with sensitizing EGFR mutations.<sup>173</sup> However, afatinib was potentially associated with 4 treatment-related deaths, whereas there were none in the chemotherapy group.<sup>173</sup> A combined analysis (LUX 3 and LUX 6) reported a survival advantage in patients with exon 19 deletions who received afatinib when compared with chemotherapy.<sup>206</sup>

### ALK Gene Rearrangements

Estimates are that 2% to 7% of patients with NSCLC have ALK gene rearrangements, about 10,000 of whom live in the United States.<sup>88</sup> Patients with ALK rearrangements are resistant to EGFR TKIs but have similar clinical characteristics to those with EGFR mutations (ie, adenocarcinoma histology, never smokers, light smokers) except they are more likely to be men and may be younger.<sup>139</sup> In these selected populations, estimates are that about 30% of patients will have ALK rearrangements.<sup>139,207</sup> ALK rearrangements are not routinely found in patients with squamous cell carcinoma. Although rare, patients with ALK gene rearrangements can have mixed squamous cell histology.<sup>135</sup> It can be challenging to accurately determine histology in small biopsy specimens; thus, patients may have mixed squamous cell histology (or squamous components) instead of pure squamous cell. The NCCN Panel recommends testing for ALK rearrangements if small biopsy specimens were used to assess histology, mixed histology was reported, or patients never smoked. A molecular diagnostic test (using FISH) has been approved by the FDA for detecting ALK rearrangements and is a prerequisite before treatment with crizotinib.

Rapid prescreening with IHC to assess for ALK rearrangements can be done; if positive, FISH analysis can confirm ALK positivity.<sup>133,137,208-215</sup> NGS can also be used to assess whether ALK rearrangements are present, if the platform has been appropriately designed and validated to detect ALK rearrangements.<sup>216-218</sup>

Crizotinib—an inhibitor of ALK, ROS1, and some MET tyrosine kinases (high-level MET amplification or MET exon 14 skipping mutation)—is approved by the FDA for patients with locally advanced or metastatic NSCLC who have ALK gene rearrangements (ie, ALK-positive disease) or ROS1 rearrangements.<sup>123,219-225</sup> Crizotinib yields very high response rates (>60%) when used in patients with advanced NSCLC who have ALK rearrangements, including those with brain metastases.<sup>88,221,226-228</sup> Crizotinib has relatively few side effects (eg, eye disorders, edema, transient changes in renal function).<sup>227,229,230</sup> However, a few patients have had life-threatening pneumonitis; crizotinib should be discontinued in these patients.<sup>223</sup> Patients whose disease responds to crizotinib may have rapid improvement in symptoms (eg, cough, dyspnea, pain); median time to progression on crizotinib is about 7 months to 1 year.<sup>231,232</sup>

Randomized phase 3 trials have compared crizotinib with standard second-line (ie, subsequent) chemotherapy (PROFILE 1007) and with standard first-line therapy (PROFILE 1014).<sup>6,221,233</sup> First-line therapy with crizotinib improved PFS, response rate (74% vs. 45%;  $P < .001$ ), lung cancer symptoms, and quality of life when compared with chemotherapy (pemetrexed with either cisplatin or carboplatin).<sup>221</sup> Based on this trial, crizotinib is recommended (category 1) for first-line therapy in patients with ALK-positive NSCLC (see the NCCN Guidelines for NSCLC). Subsequent therapy with crizotinib improved PFS (7.7 vs. 3.0 months;  $P < .001$ ) and response rate (65% vs. 20%;  $P < .001$ ) when compared with single-agent therapy (either docetaxel or pemetrexed) in

patients with ALK-positive NSCLC who had progressed after first-line chemotherapy.<sup>222</sup> Based on this trial, crizotinib is recommended as subsequent therapy in patients with ALK-positive disease. The phrase *subsequent* therapy was recently substituted for the terms *second-line* or *beyond* systemic therapy, because the line of therapy may vary depending on previous treatment with targeted agents.

For patients who progress on crizotinib, second-generation ALK inhibitors include ceritinib and alectinib; others are in development.<sup>129,234-243</sup> Ceritinib is an orally active TKI of ALK, which also inhibits the insulin-like growth factor-1 (IGF-1) receptor but not MET. An expanded phase 1 trial showed that ceritinib was very active in 122 patients with locally advanced or metastatic NSCLC who have ALK gene rearrangements.<sup>237</sup> The overall response rate to ceritinib was 56% in patients who had previously received crizotinib; the median PFS was 7 months. Based on this study, ceritinib was approved by the FDA for patients with ALK-positive metastatic NSCLC who progress on or are intolerant to crizotinib.<sup>244</sup> The NCCN Panel recommends ceritinib for patients with ALK-positive metastatic NSCLC who have progressed on crizotinib or are intolerant to crizotinib based on the data from Shaw et al and FDA approval.<sup>237,244</sup>

Alectinib is another oral TKI of ALK, which also inhibits RET but not MET or ROS1. Two phase 2 trials in patients with ALK rearrangements showed that alectinib was very active in those who had progressed on crizotinib.<sup>129,245</sup> In the larger trial (138 patients) by Ou et al, patients on alectinib had a response rate of 50% (95% CI, 41%–59%), and median duration of response of 11.2 months (95% CI, 9.6 months to not reached).<sup>129</sup> For central nervous system (CNS) disease, the control rate was 83% (95% CI, 74%–91%), and the median duration of response was 10.3 months (95% CI, 7.6–11.2 months). Of 84 patients with baseline CNS metastases, 23 (27%) had a complete CNS response to

alectinib. Of 23 patients with baseline CNS metastases and no previous brain RT, 10 (43%) had a complete CNS response to alectinib. Most adverse events were only grade 1 to 2 (constipation, fatigue, and peripheral edema); 4 patients (3%) had grade 3 dyspnea. One death due to intestinal perforation may have been related to alectinib. The other phase 2 trial in 87 patients with ALK-positive NSCLC who had progressed on crizotinib reported that 48% of patients had an objective response to alectinib.<sup>245</sup> Of 16 patients with baseline CNS metastases, 4 (25%) achieved a complete response in the CNS; 11 of these patients had previously received RT.<sup>245</sup> One treatment-related death occurred due to hemorrhage. Based on these studies, alectinib was approved by the FDA for patients with ALK-positive metastatic NSCLC who progress on or are intolerant to crizotinib.<sup>246</sup> The NCCN Panel recommends alectinib (category 2A) for patients with ALK-positive metastatic NSCLC who have progressed on crizotinib or are intolerant to crizotinib based on these 2 trials and FDA approval.<sup>129,245,246</sup>

ALK or ROS1 rearrangements and sensitizing EGFR mutations are generally mutually exclusive.<sup>137,247,248</sup> Thus, erlotinib, gefitinib, and afatinib are not recommended as subsequent therapy in patients with ALK or ROS1 rearrangements who relapse on crizotinib (see *ALK Positive: Subsequent Therapy* in the NCCN Guidelines for NSCLC).<sup>138,139</sup> Likewise, crizotinib, ceritinib, and alectinib are not recommended for patients with sensitizing EGFR mutations who relapse on erlotinib, gefitinib, or afatinib. For patients who progress on crizotinib, subsequent treatment for ALK-positive NSCLC includes ceritinib or alectinib (see *Ceritinib* and *Alectinib* in this Discussion and the NCCN Guidelines for NSCLC).<sup>129,227,249,250</sup> Continuing crizotinib may also be appropriate for patients who progress on crizotinib.<sup>251</sup>

### ROS1 Rearrangements

Although ROS1 is a distinct receptor tyrosine kinase, it is very similar to ALK and members of the insulin receptor family (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC).<sup>124,252</sup> It is estimated that ROS1 gene rearrangements occur in about 1% to 2% of patients with NSCLC; they occur more frequently in younger women with adenocarcinoma who are never smokers and in those who are negative for EGFR mutations, KRAS mutations, and ALK gene rearrangements (also known as triple negative).<sup>124,126,168</sup> Crizotinib is very effective for patients with ROS1 rearrangements with response rates of about 70% including complete responses.<sup>124</sup> In 50 patients, crizotinib yielded a response rate of 66% (95% CI, 51%–79%); the median duration of response was 18 months.<sup>253</sup> The FDA has approved crizotinib for patients with ROS1 rearrangements.<sup>253</sup>

For the 2017 update (Version 1), the NCCN Panel moved the recommendation for ROS1 testing into the main algorithm (and deleted the footnote recommending ROS1 testing), added a new algorithm for ROS1, and added a new section on ROS1 to the molecular diagnostic studies section based on data showing the efficacy of crizotinib for patients with ROS1 rearrangements and on the recent FDA approval (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC).<sup>123,124,253</sup> Similar to testing for ALK rearrangements, testing for ROS1 is also done using FISH.<sup>126,208,254–256</sup> NGS can also be used to assess whether ROS1 rearrangements are present, if the platform has been appropriately designed and validated to detect ROS1 rearrangements.<sup>124</sup> Because a companion diagnostic test has not been approved for ROS1, clinicians should use an appropriately validated test to detect ROS1.<sup>253</sup> Alectinib and ceritinib are not effective in patients with ROS1 rearrangements whose disease becomes resistant to crizotinib.<sup>124</sup> Studies are ongoing regarding new agents for patients

with ROS1 rearrangements whose disease becomes resistant to crizotinib.<sup>257–260</sup>

### KRAS Mutations

Data suggest that approximately 25% of patients with adenocarcinomas in a North American population have KRAS mutations; KRAS is the most common mutation.<sup>86,120,147,162,167</sup> KRAS mutation prevalence is associated with cigarette smoking.<sup>261</sup> Patients with KRAS mutations appear to have a shorter survival than patients with wild-type KRAS; therefore, KRAS mutations are prognostic biomarkers.<sup>165,167,262</sup> KRAS mutational status is also predictive of lack of therapeutic efficacy with EGFR-TKIs; however, it does not appear to affect chemotherapeutic efficacy.<sup>86,120,166</sup> KRAS mutations do not generally overlap with EGFR mutations, ALK rearrangements, or ROS1 rearrangements.<sup>136,137,263</sup> Therefore, KRAS testing may identify patients who may not benefit from further molecular testing.<sup>132,166</sup> Targeted therapy is not currently available for patients with KRAS mutations, although immune checkpoint inhibitors appear to be effective; MEK inhibitors are in clinical trials.<sup>162,236,264,265</sup>

### Treatment Approaches

Surgery, RT, and systemic therapy are the 3 modalities most commonly used to treat patients with NSCLC. They can be used either alone or in combination depending on the disease status. In the following sections, the clinical trials are described that have led to the standard treatments.

### Surgery

In general, for patients with stage I or II disease, surgery provides the best chance for cure.<sup>266</sup> Thoracic surgical oncology consultation should be part of the evaluation of any patient being considered for curative local therapy. The overall plan of treatment and the necessary imaging

studies should be determined before any nonemergency treatment is initiated. It is essential to determine whether patients can tolerate surgery or whether they are medically inoperable; some patients deemed inoperable may be able to tolerate minimally invasive surgery and/or sublobar resection.<sup>266-270</sup> Although frailty is an increasingly recognized predictor of surgical and other treatment morbidity, a preferred frailty assessment system has not been established.<sup>271-273</sup>

The *Principles of Surgical Therapy* are described in the NSCLC algorithm and are summarized here (see the NCCN Guidelines for NSCLC). Determination of resectability, surgical staging, and pulmonary resection should be performed by board-certified thoracic surgeons who should participate in multidisciplinary clinics and/or tumor boards for patients with lung cancer. Surgery may be appropriate for select patients with uncommon types of lung cancer (eg, superior sulcus, chest wall involvement) (see the NCCN Guidelines for NSCLC).<sup>274</sup> Patients with pathologic stage II or greater disease can be referred to a medical oncologist for evaluation. For resected stage IIIA, consider referral to a radiation oncologist. Treatment delays, because of poor coordination among specialists, should be avoided.

The surgical procedure used depends on the extent of disease and on the cardiopulmonary reserve of the patient. Lung-sparing anatomic resection (sleeve lobectomy) is preferred over pneumonectomy, if anatomically appropriate and if margin-negative resection can be achieved; lobectomy or pneumonectomy should be done if physiologically feasible.<sup>266,275,276</sup> Sublobular resection, either segmentectomy (preferred) or wedge resection, is appropriate in select patients; the parenchymal resection margins are defined in the NSCLC algorithm (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC).<sup>277-281</sup> Resection (including wedge resection) is preferred over ablation.<sup>266,276</sup> Wide wedge resection may improve outcomes.<sup>282</sup>

Patients with medically inoperable disease may be candidates for SABR, also known as stereotactic body RT (SBRT).<sup>283</sup> If SABR is considered for patients at high risk, a multidisciplinary evaluation is recommended (see *Stereotactic Ablative Radiotherapy* in this Discussion).<sup>284-286</sup>

### **Lymph Node Dissection**

A randomized trial (ACOSOG Z0030) compared systematic mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in patients with either N0 (no demonstrable metastasis to regional lymph nodes) or N1 (metastasis to lymph nodes in the ipsilateral peribronchial and/or hilar region, including direct extension) NSCLC disease. In patients with early-stage disease who had negative nodes by systematic lymph node dissection, complete mediastinal lymph node dissection did not improve survival.<sup>287,288</sup> Thus, systematic lymph node sampling is appropriate during pulmonary resection; one or more nodes should be sampled from all mediastinal stations. For right-sided cancers, an adequate mediastinal lymphadenectomy should include stations 2R, 4R, 7, 8, and 9. For left-sided cancers, stations 4L, 5, 6, 7, 8, and 9 should be sampled.<sup>287</sup> Patients should have N1 and N2 node resection and mapping (American Thoracic Society map) with a minimum of 3 N2 stations sampled or a complete lymph node dissection. The lymph node map from the IASLC may be useful.<sup>289</sup> Formal ipsilateral mediastinal lymph node dissection is indicated for patients undergoing resection for stage IIIA (N2) disease. For patients undergoing sublobular resection, the appropriate N1 and N2 lymph node stations should be sampled unless not technically feasible because sampling would substantially increase the surgical risk.

Sublobular resection, either segmentectomy (preferred) or wedge resection, is appropriate in select patients (see *Principles of Surgical*

*Therapy* in the NCCN Guidelines for NSCLC): 1) those who are not eligible for lobectomy; and 2) those with a peripheral nodule 2 cm or less with very low-risk features. Segmentectomy (preferred) or wedge resection should achieve parenchymal resection margins that are: 1) 2 cm or more; or 2) the size of the nodule or more.

### **Stage IIIA N2 Disease**

The role of surgery in patients with pathologically documented stage IIIA (N2) disease is described in the NSCLC algorithm (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC) and summarized here. Before treatment, it is essential to carefully evaluate for N2 disease using radiologic and invasive staging (ie, EBUS-guided procedures, mediastinoscopy, thoroscopic procedures) and to discuss whether surgery is appropriate in a multidisciplinary team, which should include a board-certified thoracic surgeon.<sup>290,291</sup> Randomized controlled trials suggest that surgery does not increase survival in these patients.<sup>292,293</sup> However, one of these trials (EORTC) only enrolled patients with unresectable disease.<sup>293</sup> Most clinicians agree that resection is appropriate for patients with negative preoperative mediastinal nodes and with a single positive node (<3 cm) found at thoracotomy.<sup>294</sup> Neoadjuvant therapy is recommended for select patients. The optimal timing of RT in trimodality therapy (preoperative with chemotherapy or postoperative) is not established and controversial.<sup>295,296</sup> In patients with N2 disease, 50% of the NCCN Member Institutions use neoadjuvant chemoradiotherapy whereas 50% use neoadjuvant chemotherapy.<sup>297</sup> However, there is no evidence that adding RT to induction regimens improves outcomes for patients with stage IIIA (N2) disease when compared with using chemotherapy alone.<sup>296</sup> Clinicians also agree that resection is not appropriate for patients with multiple pathologically proven malignant lymph nodes

greater than 3 cm; definitive chemoradiotherapy is recommended for these patients.

The NCCN Panel believes that surgery may be appropriate for select patients with N2 disease, especially those whose disease responds to induction chemotherapy (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC).<sup>290,298</sup> However, it is controversial whether pneumonectomy after neoadjuvant chemoradiotherapy is appropriate.<sup>292,298-304</sup> Patients with resectable N2 disease should not be excluded from surgery, because some of them may have long-term survival or may be cured.<sup>298,305</sup>

### **Thoroscopic Lobectomy**

Video-assisted thoracic surgery (VATS), which is also known as thoroscopic lobectomy, is a minimally invasive surgical treatment that is currently being investigated in all aspects of lung cancer (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC).<sup>306,307</sup>

Published studies suggest that thoroscopic lobectomy has several advantages over standard thoracotomy.<sup>308-312</sup> Acute and chronic pain associated with thoroscopic lobectomy is minimal; thus, this procedure requires a shorter length of hospitalization.<sup>313,314</sup> Thoroscopic lobectomy is also associated with low postoperative morbidity and mortality, minimal risk of intraoperative bleeding, or minimal locoregional recurrence.<sup>315-319</sup> Thoracoscopic lobectomy is associated with less morbidity, fewer complications, and more rapid return to function than lobectomy by thoracotomy.<sup>320-323</sup>

In patients with stage I NSCLC who had thoroscopic lobectomy with lymph node dissection, the 5-year survival rate, long-term survival, and local recurrence were comparable to those achieved by routine open lung resection.<sup>324-328</sup> Thoroscopic lobectomy has also been shown to improve discharge independence in older populations and patients at

high risk.<sup>329,330</sup> Data show that thoroscopic lobectomy improves the ability of patients to complete postoperative chemotherapy regimens.<sup>331,332</sup> Based on its favorable effects on postoperative recovery and morbidity, thoroscopic lobectomy (including robotic-assisted approaches) is recommended in the NSCLC algorithm as an acceptable approach for patients who are surgically resectable (and have no anatomic or surgical contraindications) as long as standard principles of thoracic surgery are not compromised (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC).<sup>333-336</sup> Robotic VATS seems to be more expensive with longer operating times than conventional VATS.<sup>337,338</sup>

### Radiation Therapy

The *Principles of Radiation Therapy* in the NSCLC algorithm include the following: 1) general principles for early-stage, locally advanced, and advanced NSCLC; 2) target volumes, prescription doses, and normal tissue dose constraints for early-stage, locally advanced, and advanced NSCLC; and 3) RT simulation, planning, and delivery.<sup>339-344</sup> These RT principles are summarized in this section. Whole brain RT and stereotactic radiosurgery (SRS) for brain metastases are also discussed in this section. The abbreviations for RT are defined in the NSCLC algorithm (see Table 1 in *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC).

#### General Principles

Treatment recommendations should be made by a multidisciplinary team. Because RT has a potential role in all stages of NSCLC, as either definitive or palliative therapy, input from board-certified radiation oncologists who perform lung cancer RT as a prominent part of their practice should be part of the multidisciplinary evaluation or discussion for all patients with NSCLC. Uses of RT for NSCLC include: 1) definitive therapy for locally advanced NSCLC, generally combined with

chemotherapy; 2) definitive therapy for early-stage NSCLC in patients with contraindications for surgery; 3) preoperative or postoperative therapy for selected patients treated with surgery; 4) therapy for limited recurrences and metastases; and/or 5) palliative therapy for patients with incurable NSCLC.<sup>286,345-352</sup> The goals of RT are to maximize tumor control and to minimize treatment toxicity. Advanced technologies such as 4D-conformal RT simulation, intensity-modulated RT/volumetric modulated arc therapy (IMRT/VMAT), image-guided RT, motion management strategies, and proton therapy have been shown to reduce toxicity and increase survival in nonrandomized trials.<sup>353-357</sup> CT-planned 3D-conformal RT is now considered to be the minimum standard.

Definitive RT, particularly SABR, is recommended for patients with early-stage NSCLC (ie, stage I-II, N0) who are medically inoperable or those who refuse surgery (see *Stereotactic Ablative Radiotherapy* in this Discussion).<sup>283,286,352,358</sup> Interventional radiology ablation is an option for selected patients who are medically inoperable.<sup>266,359,360</sup> By extrapolation from surgical data, adjuvant chemotherapy (category 2B) may be considered after definitive RT/SABR in patients with high-risk factors for recurrence (eg, large tumors >4 cm in size).<sup>284,361</sup> SABR is also an option for patients at high surgical risk who cannot tolerate a lobectomy (eg, major medical comorbidity or severely limited lung function). However, resection is recommended for patients with early-stage NSCLC who are medically fit (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC).<sup>362</sup> Definitive chemoradiation is recommended for patients with stage II to III disease who are not appropriate surgical candidates.<sup>363</sup> Involved-field RT (also known as involved-field irradiation or IFI) is an option for treating nodal disease in patients with locally advanced NSCLC; IFI may offer advantages over elective nodal irradiation (ENI).<sup>364-367</sup>



For patients with advanced lung cancer (ie, stage IV) with extensive metastases, systemic therapy is recommended; palliative RT can be used for symptom relief and potentially for prophylaxis at primary or distant sites.<sup>352,368-370</sup> Shorter courses of palliative RT are preferred for patients with symptomatic chest disease who have poor PS and/or shorter life expectancy (eg, 17 Gy in 8.5 Gy fractions) (see Table 4 in the *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC). Higher dose and longer course thoracic RT (eg, ≥30 Gy in 10 fractions) are associated with modestly improved survival and symptoms, especially in patients with good PS.<sup>368,371</sup> The RT recommendations for patients with stages I to IV are described in the NSCLC algorithm (see *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC).

The indications for using preoperative or postoperative chemoradiation or RT alone are described in the NSCLC algorithm (see *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC). In patients with clinical stage I or II NSCLC who are upstaged to N2+ after surgery, postoperative chemotherapy can be administered followed by postoperative RT (also known as PORT) depending on the margin status (see *Adjuvant Treatment* in the NCCN Guidelines for NSCLC).<sup>341,372</sup> For clinical stage III NSCLC, definitive concurrent chemoradiation is recommended (category 1). However, the optimal management of patients with potentially operable stage IIIA NSCLC is controversial and is discussed in detail in the algorithm (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC).<sup>290,292,303,373</sup>

For patients undergoing preoperative therapy before surgical resection of stage IIIA NSCLC, some oncologists prefer chemotherapy alone rather than chemoradiotherapy for the preoperative treatment;<sup>296</sup> RT should generally be given postoperatively if not given preoperatively. The NCCN Panel recommends a preoperative RT dose of 45 to 54 Gy

based on a recent study.<sup>295</sup> NCCN Member Institutions are evenly split in their use of neoadjuvant chemotherapy versus neoadjuvant chemoradiation in patients with stage IIIA N2 NSCLC.<sup>290</sup> Similarly, some consider the need for pneumonectomy to be a contraindication to a combined modality surgical approach given the excess mortality observed in clinical trials,<sup>292</sup> but NCCN Member Institutions are split on this practice as well.

Surgery is associated with potentially greater risk of complications, particularly stump breakdown and bronchopleural fistula, in a field that has had high-dose RT (eg, 60 Gy). Thus, surgeons are often wary of resection in areas that have previously received RT doses of more than 45 to 50 Gy, especially patients who have received definitive doses of concurrent chemoradiation (ie, ≥60 Gy) preoperatively. Soft tissue flap coverage and reduced intraoperative fluid administration and ventilator pressures can reduce the risk of these complications.<sup>374-</sup>  
<sup>376</sup> When giving preoperative RT to less than definitive doses (eg, 45 Gy), one should be prepared up front to continue to a full definitive dose of RT without interruption if the patient does not proceed to surgery for some reason. For these reasons, when considering trimodality therapy, the treatment plan—including assessment for resectability and the type of resection—should be decided before initiation of any therapy.

### **Target Volumes, Prescription Doses, and Normal Tissue Dose Constraints**

The dose recommendations for preoperative, postoperative, definitive, and palliative RT are described in the *Principles of Radiation Therapy* in the NSCLC algorithm (see Table 4 in the NCCN Guidelines for NSCLC).<sup>340,342,349,374-377</sup> After surgery, lung tolerance to RT is much less than for patients with intact lungs. Although the dose volume constraints for conventionally fractionated RT for normal lungs are a useful guide

(see Table 5 in *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC), more conservative constraints should be used for postoperative RT. For the 2017 update (Version 1), the NCCN Panel noted that the doses and constraints provided in the tables are useful reference doses that have been commonly used or are from previous clinical trials rather than specific prescriptive recommendations.

For definitive RT, the commonly prescribed dose is 60 to 70 Gy in 2 Gy fractions over 6 to 7 weeks.<sup>378,379</sup> The use of higher RT doses is discussed in the NSCLC algorithm (see *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC).<sup>380-385</sup> Doses more than 74 Gy are not currently recommended for routine use.<sup>386</sup> Results from a phase 3 randomized trial (RTOG 0617) suggest that high-dose radiation using 74 Gy with concurrent chemotherapy does not improve survival, and might be harmful, when compared with a standard dose of 60 Gy.<sup>385,387-389</sup> Although optimal RT dose intensification remains a valid question, at higher RT doses, normal tissue constraints become even more important.<sup>388</sup> Although the RT dose to the heart was decreased in the RTOG 0617 trial, survival was decreased; thus, more stringent constraints may be appropriate.

Reports 50, 62, and 83 from the International Commission on Radiation Units and Measurements provide a formalism for defining RT target volumes based on grossly visible disease, potential microscopic extension, and margins for target motion and daily positioning uncertainty (see Figure 1 in *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC);<sup>390,391</sup> the ACR Practice Parameters and Technical Standards are also a helpful reference.<sup>353,392,393</sup> It is essential to evaluate the dose volume histogram (DVH) of critical structures and to limit the doses to the organs at risk (such as spinal cord, lungs, heart, esophagus, and brachial plexus) to minimize normal tissue toxicity (see Table 5 in *Principles of Radiation Therapy*).<sup>394</sup> These

constraints are mainly empirical and have for the most part not been validated rigorously.<sup>395-402</sup> However, the QUANTEC review provides the most comprehensive estimates from clinical data of dose-response relationships for normal tissue complications.<sup>403-407</sup> As previously mentioned, for patients receiving postoperative RT, stricter DVH parameters should be considered for the lungs.

### **Radiation Simulation, Planning, and Delivery**

Treatment planning should be based on CT scans obtained in the treatment position. Intravenous contrast CT scans are recommended for better target delineation whenever possible, especially in patients with central tumors or nodal involvement. FDG PET/CT can significantly improve target delineation accuracy, especially when there is atelectasis or contraindications to intravenous CT contrast.<sup>408</sup> In the NSCLC algorithm, recommendations are provided for patients receiving chemoradiation (including those with compromised lung or cardiac function), photon beams, or IMRT (see *Radiation Therapy Simulation, Planning, and Delivery* in the *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC).<sup>356,409-413</sup> Respiratory motion should be managed. The report from the AAPM Task Group 76 is a useful reference for implementing a broad range of motion management strategies as described in the NSCLC algorithm (see *Radiation Therapy Simulation, Planning, and Delivery* in the NCCN Guidelines for NSCLC).<sup>414</sup>

### **Stereotactic Ablative Radiotherapy**

SABR (also known as SBRT) uses short courses of very conformal and dose-intensive RT precisely delivered to limited-size targets.<sup>415-417</sup> Studies, including prospective multi-institutional trials, have demonstrated the efficacy of SABR for patients with inoperable stage I NSCLC or for those who refuse surgery.<sup>286,418-421</sup> With conventionally fractionated RT, 3-year survival is only about 20% to 35% in these

patients, with local failure rates of about 40% to 60%.<sup>283</sup> In prospective clinical trials, local control and overall survival appear to be considerably increased with SABR, generally more than 85% and about 60% at 3 years (median survival, 4 years), respectively, in patients who are medically inoperable.<sup>266,283,360,362,413,420,422-427</sup> Substantially higher survival has been observed in patients with potentially operable disease who are treated with SABR; survival is comparable in population-based comparisons to surgical outcomes, but locoregional recurrences are more frequent.<sup>362,419,428-433</sup> It has not been shown that use of SABR for medically operable patients provides long-term outcomes equivalent to surgery. Late recurrences have been reported more than 5 years after SABR, highlighting the need for careful surveillance.<sup>434</sup> If possible, biopsy should confirm NSCLC before use of SABR.<sup>435</sup>

SABR is recommended in the NSCLC algorithm for patients with stage I and II (T1-3,N0,M0) NSCLC who are medically inoperable; SABR is a reasonable alternative to surgery for patients with potentially operable disease who are high risk, elderly, or refuse surgery after appropriate consultation (see the NCCN Guidelines for NSCLC).<sup>266,421,423,436,437</sup> A combined analysis of 2 randomized trials (that did not complete accrual) assessed SABR compared with lobectomy in operable patients.<sup>436</sup> The analysis does not alter the fact that surgical resection is recommended and typically used for operable patients, but it helps to confirm the indication of SABR for patients with contraindications for surgery or those who refuse surgery. SABR can also be used for patients with limited lung metastases or limited metastases to other body sites.<sup>415,421,438-444</sup> After SABR, assessment of recurrences by imaging can be challenging because of benign inflammatory/fibrotic changes that can remain FDG-PET avid for 2 or more years after treatment, emphasizing the importance of follow-up by a team with experience interpreting such post-treatment effects.<sup>445,446</sup> This careful follow-up is

particularly relevant, because selected patients with localized recurrences after SABR may benefit from surgery or re-treatment with SABR.<sup>447-451</sup>

SABR fractionation regimens and a limited subset of historically used maximum dose constraints are provided in the NSCLC algorithm (see Tables 2 and 3 in the *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC).<sup>418,420,427,452-461</sup> These dose constraints are point of reference doses and are not intended to be prescriptive; they are used commonly or have been used in clinical trials. Although none of these dose constraints have been validated as maximally tolerated doses, outcomes of clinical trials to date suggest that they are safe constraints. The bronchial tree, esophagus, and brachial plexus are critical structures for SABR. For centrally located tumors—those within 2 cm in all directions of any mediastinal critical structure including the bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve—regimens of 54 to 60 Gy in 3 fractions are not safe and should be avoided; 4 to 10 fraction SABR regimens appear to be effective and safe (see *Principles of Radiation Therapy* in the NCCN Guidelines for NSCLC).<sup>284,462-464</sup> Preliminary results (RTOG 0813) suggest that 5-fraction regimens are safe.<sup>465</sup> SRS or SABR for limited oligometastases to the brain or other body sites, respectively, may be useful for patients with good PS and thoracic disease that can be treated with definitive therapy (see *Stage IV, M1b: Limited Sites* in the NCCN Guidelines for NSCLC).<sup>274,421,466,467</sup> Local therapy combined with targeted therapy is a category 2A recommendation for patients with ALK or ROS1 rearrangements or sensitizing EGFR mutations.<sup>468,469</sup> Decisions about whether to recommend SABR should be based on multidisciplinary discussion. Hypofractionated or dose-intensified conventional 3D-conformal RT is an option if an established SABR program is not available.<sup>470,471</sup> Current

nonrandomized clinical data indicate that local tumor control with SABR is higher than with interventional radiology ablation techniques. However, interventional radiology ablation may be appropriate for selected patients for whom local control is not necessarily the highest priority.<sup>266,286,360</sup>

### **Whole Brain RT and Stereotactic Radiosurgery**

Many patients with NSCLC have brain metastases (30%–50%), which substantially affect their quality of life.<sup>8,472</sup> For the 2017 update (Version 1), the NCCN Panel revised the recommendations for treatment of limited brain metastases by decreasing recommendations for whole brain RT. Options for treatment of limited brain metastases now include 1) SRS alone; and 2) surgical resection for selected patients followed by SRS or whole brain RT; selected patients include those with symptomatic metastases or whose tumor tissue is needed for diagnosis (see the NCCN Guidelines for NSCLC).<sup>441,472-480</sup> Treatment of limited brain metastases in patients with NSCLC differs from that recommended in the NCCN Guidelines for Central Nervous System Cancers, because patients with NSCLC and brain metastases often have long-term survival; therefore, the potential neurocognitive issues that may occur with whole brain RT are a concern. Clinicians are not using whole brain RT as often in patients with limited brain metastases, which is reflected in the revised recommendations in the 2017 update (Version 1).<sup>473</sup>

A recent randomized trial assessed cognitive function in 213 patients with 1 to 3 brain metastases who received SRS alone versus SRS with whole brain RT; most patients had lung cancer.<sup>473</sup> At 3 months after SRS alone, patients had less cognitive deterioration (40/63 patients [63.5%]) than those receiving SRS plus whole brain RT (44/48 patients [91.7%]; difference, -28.2%; 90% CI, -41.9% to -14.4%;  $P < .001$ ). Decisions about whether to recommend SRS alone or brain surgery

followed by whole brain RT or SRS for limited brain metastases should be based on multidisciplinary discussion, weighing the potential benefit over the risk for each individual patient.<sup>474,481-483</sup> Treatment should be individualized for patients with recurrent or progressive brain lesions.<sup>484</sup>

For multiple metastases (eg, >3), whole brain RT is recommended; SRS may be preferred for patients who have good PS and low systemic tumor burden (see the NCCN Guidelines for Central Nervous System Cancers, available at [NCCN.org](#)).<sup>485-488</sup> Whole brain RT is associated with measurable declines in neurocognitive function in clinical trials, particularly with increasing dose and advanced age of the patient.<sup>489-491</sup> However, control of brain metastases confers improved neurocognitive function.<sup>492,493</sup> For limited metastases, randomized trials have found that the addition of whole brain RT to SRS decreases intracranial recurrence but does not improve survival and may increase the risk of cognitive decline.<sup>493,494</sup> Thus, SRS or whole brain RT alone is recommended for patients with limited volume metastases.<sup>485</sup> Some have suggested that resection followed by SRS to the cavity (instead of resection followed by whole brain RT) will decrease the risk of neurocognitive problems.<sup>495,496</sup> A study suggests that using IMRT to avoid the hippocampus may help decrease memory impairment after whole brain RT.<sup>497</sup> A recent phase 3 randomized trial assessed optimal supportive care (including dexamethasone) with whole brain RT versus optimal supportive care alone in patients with NSCLC and brain metastases who were not eligible for brain surgery or SRS.<sup>498</sup> Overall survival was similar between the groups (HR, 1.06; 95% CI, 0.90–1.26). Overall quality of life, use of dexamethasone, and reported adverse events were also similar between the arms.

### Combined Modality Therapy

As previously mentioned, surgery provides the best chance for cure for patients with stage I or II disease who are medically fit and can tolerate surgery. However, SABR can be considered for patients with unresectable stage I or II disease or those who refuse surgery if their disease is node negative (see *Stereotactic Ablative Radiotherapy* in this Discussion and see the NCCN Guidelines for NSCLC). In patients with completely resected NSCLC, adjuvant chemotherapy has been shown to improve survival in patients with early-stage disease.<sup>499-501</sup> Some studies suggest that neoadjuvant chemotherapy (also referred to as preoperative chemotherapy or induction chemotherapy) is as effective as and better tolerated than adjuvant chemotherapy (see *Neoadjuvant Chemotherapy Followed by Surgery: Trial Data* in this Discussion).<sup>290,502-508</sup> A randomized trial found no difference in survival with preoperative versus postoperative chemotherapy.<sup>509</sup> The NCCN Guidelines state that patients with stage II or IIIA (T3, N1) disease may be treated with induction chemotherapy before surgery if they are candidates for adjuvant therapy after surgery.<sup>266,510</sup> Concurrent chemoradiation is superior to sequential chemoradiation for patients with unresectable stage III disease.<sup>511-514</sup>

For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial.<sup>515-520</sup> Data show that early palliative care combined with standard care improved quality of life, mood, and survival in patients with metastatic NSCLC, even though these patients had less aggressive therapy when compared with those receiving standard care alone.<sup>521</sup> Patients should receive treatment for debilitating symptoms.<sup>8,522,523</sup> A study also suggests that social support, such as being married, is as effective as chemotherapy.<sup>524</sup> Surgery is rarely recommended for patients with stage IV disease. However, surgical resection of limited brain metastases may improve survival in selected

patients with stage IV disease and is recommended for select patients in the NCCN Guidelines (see the NCCN Guidelines for NSCLC, available at [NCCN.org](http://NCCN.org)).<sup>525</sup> Definitive local therapy with surgical resection or RT is recommended for limited metastases located in sites other than the brain if definitive thoracic therapy is feasible (see *Stage IV, M1b: Limited Sites* in the NCCN Guidelines for NSCLC).<sup>274,421</sup> The trials supporting the recommendations for combined modality therapy are discussed in the following sections.

#### **Surgery Followed by Chemotherapy: Trial Data**

In the NSCLC algorithm for stage IA disease, adjuvant chemotherapy is not recommended based on the trials described in the following paragraphs. Adjuvant chemotherapy may be considered for high-risk, margin-negative, stage IB disease (see the NCCN Guidelines for NSCLC). Recommended chemotherapy regimens for neoadjuvant and adjuvant therapy are provided in the NCCN Guidelines.

The International Adjuvant Lung Cancer Trial (IALT) reported a statistically significant survival benefit with cisplatin-based adjuvant therapy in patients with completely resected stage I, II, or III NSCLC.<sup>499</sup> The study included 1867 patients with surgically resected lung cancer who were randomly assigned either to cisplatin-based adjuvant chemotherapy or to observation, with a median follow-up duration of 56 months. A higher survival rate (45% vs. 40% at 5 years; HR for death, 0.86; 95% CI, 0.76–0.98;  $P < .03$ ) and disease-free survival rate (39% vs. 34% at 5 years; HR, 0.83; 95% CI, 0.74–0.94;  $P < .003$ ) were reported for patients assigned to chemotherapy when compared with observation. IALT data suggest that cisplatin-based adjuvant chemotherapy improves survival 5 years after treatment in patients with completely resected NSCLC. However, after 7.5 years of follow-up, there were more deaths in the chemotherapy group and the benefit of

chemotherapy decreased over time.<sup>526</sup> Data show that adjuvant chemotherapy prevents recurrences.

The NCIC CTG JBR.10 trial and the ANITA trial compared the effectiveness of adjuvant vinorelbine/cisplatin versus observation in early-stage NSCLC. In the JBR.10 trial, 482 patients (ECOG PS of 0–1) with completely resected stage IB (T2, N0) or stage II (T1, N1, or T2, N1) NSCLC were randomly assigned either to vinorelbine/cisplatin or to observation.<sup>500</sup> Adjuvant chemotherapy significantly prolonged overall survival (94 vs. 73 months; HR for death, 0.69;  $P = .04$ ) and relapse-free survival (not reached vs. 47 months, HR for recurrence, 0.60;  $P < .001$ ) when compared with observation alone. The 5-year survival rates were 69% and 54%, respectively ( $P = .03$ ). When compared with observation alone, adjuvant chemotherapy is beneficial for patients with stage II disease but not for stage IB disease as shown by updated data from JBR.10 after 9 years of follow-up.<sup>527</sup> In patients with stage II disease receiving adjuvant chemotherapy, median survival is 6.8 versus 3.6 years in those who were only observed. Of note, patients receiving chemotherapy did not have an increased death rate.

In the ANITA trial, 840 patients with stage IB (T2, N0), II, or IIIA NSCLC were randomly assigned either to adjuvant vinorelbine/cisplatin or to observation.<sup>501</sup> Grade 3/4 toxicities were manageable in the chemotherapy group; however, 7 toxic deaths were reported. After a median follow-up of 76 months, median survival was 66 months in the chemotherapy group and 44 months in the observation group.<sup>501</sup> Adjuvant chemotherapy significantly improved (8.6%) the 5-year overall survival in patients with completely resected stage II and IIIA disease, although no benefit was observed in stage I. Some clinicians consider vinorelbine/cisplatin to be the preferred regimen for completely resected early-stage NSCLC based on the number of trials and the amount of

use;<sup>528</sup> however, most clinicians in the United States prefer to use regimens with less toxicity.<sup>529,530</sup>

A meta-analysis of 4,584 patients (LACE) found that postoperative cisplatin-based chemotherapy increased survival over 5 years (absolute benefit of 5.4%); there was no difference among the chemotherapy regimens (vinorelbine, etoposide, and others).<sup>531</sup> A subgroup analysis found that cisplatin/vinorelbine also increased survival.<sup>528</sup> The benefit was greater in patients with stage II and III disease and with good PS. Postoperative adjuvant chemotherapy benefited elderly patients up to 80 years of age.<sup>269,532</sup>

The CALGB 9633 trial assessed paclitaxel/carboplatin in patients with T2, N0, M0, stage IB lung cancer.<sup>533-535</sup> In this trial, 344 patients were randomly assigned either to paclitaxel/carboplatin or to observation (within 4–8 weeks of resection) with a median follow-up duration of 74 months. Adjuvant chemotherapy was well tolerated with no chemotherapy-related toxic deaths. Overall survival at 6 years was not significantly different (although a subset analysis showed a benefit for tumors 4 cm or more), although 3-year survival was significant (80% vs. 73%,  $P = .02$ ).<sup>534,535</sup> Thus, the carboplatin/paclitaxel regimen is only recommended for early-stage disease if patients cannot tolerate cisplatin (see *Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy* in the NCCN Guidelines for NSCLC).<sup>536</sup> However, it is important to note that the CALGB trial was underpowered for patients with stage 1B disease.<sup>537</sup>

### **Neoadjuvant Chemotherapy Followed by Surgery: Trial Data**

Data from adjuvant clinical trials in patients with resected NSCLCs indicate that delivery of chemotherapy is an important problem. In the postoperative setting, significant comorbidities and incomplete recovery after surgery often make it difficult for patients to tolerate systemic

therapy. This problem was demonstrated in the NATCH phase 3 trial (which compared surgery alone to preoperative or postoperative chemotherapy with paclitaxel/carboplatin), because 90% of the preoperative cohort completed 3 cycles of chemotherapy but only 61% of the postoperative cohort completed chemotherapy; however, survival was equivalent among all 3 arms.<sup>507</sup> A recent randomized trial found no difference in 3-year overall survival (67.4% vs. 67.7%) with preoperative versus postoperative chemotherapy in patients with early-stage NSCLC; response rate and quality of life were similar in both arms.<sup>509</sup> Postoperative chemotherapy (with or without RT or resection) is recommended and typically used for early-stage disease in the NCCN Guidelines.<sup>266</sup>

Several trials suggest that neoadjuvant therapy is beneficial in patients with N2 disease.<sup>290,296,506</sup> Other trials suggest that neoadjuvant therapy is beneficial in patients with earlier stage disease.<sup>503,504,508</sup> A follow-up, randomized intergroup trial (SWOG 9900) evaluated neoadjuvant paclitaxel/carboplatin in 354 patients with stage IB to IIIA (but not N2) disease versus surgery alone. The trial closed prematurely because of practice changes and was therefore not appropriately powered. However, this SWOG trial did show a trend toward improved PFS (33 vs. 20 months) and overall survival (62 vs. 41 months) with neoadjuvant chemotherapy, and no difference in resection rates between the 2 arms.<sup>508</sup>

Scagliotti et al published a phase 3 trial of preoperative cisplatin/gemcitabine versus surgery alone in 270 patients with stage IB to IIIA disease. Although the trial closed early, a significant survival benefit was seen in patients with stages IIB and IIIA disease who received chemotherapy (HR, 0.63).<sup>503</sup> Song et al published a meta-analysis of all available randomized clinical trials evaluating preoperative chemotherapy in resectable NSCLCs. This meta-analysis

evaluated 13 randomized trials; the HR suggests that overall survival in the neoadjuvant chemotherapy arm is similar to the surgery alone arm (HR, 0.84; 95% CI, 0.77–0.92;  $P = .0001$ ).<sup>502</sup> These results are similar to those reported in another meta-analysis (HR, 0.89; 95% CI, 0.81–0.98;  $P = .02$ ).<sup>503</sup> The benefit from neoadjuvant chemotherapy is similar to that attained with postoperative chemotherapy.<sup>503,509,531</sup>

### **Chemoradiation: Trial Data**

The major controversies in NSCLC relate to the management of patients with stage IIIA disease (see the *Role of Surgery in Patients with Stage IIIA (N2) NSCLC* [in *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC]). All 3 treatment modalities—surgical resection, chemotherapy, and radiation—may be used when treating stage III disease. The ongoing debate centers on which modalities to use and in what sequence.<sup>538-542</sup> For patients with unresectable stage IIIA or stage IIIB disease, combined modality therapy (chemoradiation) is superior to radiation alone.<sup>538,539,541,542</sup> Concurrent chemoradiation is superior to sequential chemoradiation.<sup>511-514</sup> However, concurrent chemoradiation has a higher rate of grade 3 or 4 esophagitis than sequential chemoradiation. Selection of patients should be based not only on the anticipated response to therapy but also on how well the patient is anticipated to tolerate therapy. Frail patients may not be able to tolerate concurrent chemoradiation.<sup>267,543</sup>

Concurrent chemoradiation regimens that may be used for all histologies for initial treatment include cisplatin/etoposide, cisplatin/vinblastine, and carboplatin/paclitaxel (see *Chemotherapy Regimens Used with Radiation Therapy* in the NCCN Guidelines for NSCLC).<sup>387,511,513,544-548</sup> For non-squamous NSCLC, additional concurrent chemoradiation regimens may be used including carboplatin/pemetrexed and cisplatin/pemetrexed.<sup>549-551</sup> A weekly paclitaxel/carboplatin regimen is another chemoradiation option.<sup>387</sup> The

different options for neoadjuvant/preoperative/induction, definitive, and adjuvant chemotherapy/RT are described in detail in the algorithm. Recently, the NCCN Panel removed the *preferred* designation for the cisplatin/etoposide and cisplatin/vinblastine regimens based on data from a phase 3 randomized trial and a recent retrospective assessment of the Veterans Administration data.<sup>544,548,552</sup>

### **Chemotherapy: Trial Data**

Patients with stage IV disease who have a good PS benefit from chemotherapy, usually with a platinum-based regimen.<sup>517-519</sup> However, chemotherapy is only recommended for patients with stage IV NSCLC and negative or unknown test results for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression. Recommended agents include platinum agents (eg, cisplatin, carboplatin), taxanes (eg, paclitaxel, albumin-bound paclitaxel, and docetaxel), vinorelbine, etoposide, pemetrexed, and gemcitabine (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC). To clarify use of systemic therapy, the NCCN Guidelines list all of the combination systemic therapy regimens and single agents that are recommended for patients with metastatic NSCLC depending on histology and PS (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC).

For the 2017 update (Version 1), these lists of systemic therapy regimens were revised by deleting options that are less effective, more toxic, and/or infrequently used in the United States based on each panel member's experience and data generated by surveying the NCCN Panel (see the NCCN Evidence Blocks™ for NSCLC, available at [NCCN.org](#)). For patients with non-squamous NSCLC and NSCLC NOS, panel members deleted carboplatin/vinorelbine, cisplatin/vinorelbine, etoposide, irinotecan, and vinorelbine. For patients with squamous cell NSCLC, panel members deleted

carboplatin/etoposide, carboplatin/vinorelbine, cisplatin/gemcitabine/necitumumab, cisplatin/vinorelbine, etoposide, irinotecan, and vinorelbine. Combinations using many of these drugs produce 1-year survival rates of 30% to 40% and are superior to single agents.<sup>536,553-556</sup> In the United States, frequently used first-line regimens for non-squamous NSCLC include: 1) cisplatin (or carboplatin)/pemetrexed; or 2) carboplatin/paclitaxel with (or without) bevacizumab.<sup>557,558</sup> Gemcitabine/cisplatin is recommended for patients with either squamous cell carcinoma or non-squamous NSCLC.<sup>556-559</sup> These regimens are recommended based on phase 3 randomized trials (eg, cisplatin/pemetrexed, carboplatin/paclitaxel [with or without bevacizumab], gemcitabine/cisplatin).<sup>556,560</sup>

For the 2017 update (Version 1), the NCCN Panel voted unanimously to delete the necitumumab/cisplatin/gemcitabine regimen from the NCCN Guidelines for patients with metastatic squamous cell NSCLC. This decision reflects the fact that the NCCN Panel feels the addition of necitumumab to the regimen is not beneficial based on toxicity, cost, and limited improvement in efficacy when compared with cisplatin/gemcitabine. A recent phase 3 randomized trial only showed a slight improvement in overall survival (11.5 months [95% CI, 10.4–12.6] vs. 9.9 months [95% CI, 8.9–11.1]).<sup>561</sup> The stratified HR was only 0.84 (95% CI, 0.74–0.96;  $P=0.01$ ). In addition, there were more grade 3 or higher adverse events in patients receiving the necitumumab regimen (388 [72%] of 538 patients) than in patients receiving only gemcitabine/cisplatin (333 [62%] of 541). Although it has been suggested that adding necitumumab to cisplatin/gemcitabine adds value and is cost effective, the NCCN Panel does not agree.<sup>562</sup>

Many oncologists use pemetrexed-based regimens for adenocarcinomas (if patients are not candidates for targeted therapy or immunotherapy), because taxane-based regimens are associated with



more toxicity (eg, neurotoxicity).<sup>556,563</sup> There are no agents for the prevention of peripheral neuropathy, and few agents are useful for treatment.<sup>564</sup> The POINTBREAK trial showed that carboplatin/pemetrexed/bevacizumab is a reasonable option and confirmed that taxane-based regimens are more toxic than pemetrexed-based regimens.<sup>565</sup> However, the POINTBREAK trial showed that both regimens are similar in regard to overall survival rates; therefore, oncologists may return to using taxane-based regimens, which are well established. A retrospective cohort study suggests that the addition of bevacizumab (to carboplatin/paclitaxel) does not increase survival in older patients ( $\geq 65$  years) with advanced non-squamous NSCLC.<sup>566</sup> However, another retrospective cohort study reported increased survival in older patients.<sup>567</sup> A combined analysis of the ECOG 4599 and POINTBREAK trials found a survival benefit with the addition of bevacizumab (to carboplatin/paclitaxel) in patients younger than 75 years but no benefit in those older than 75 years.<sup>568</sup>

For patients with advanced NSCLC who have a PS of 2 (ie, poor PS), platinum-based combinations and a few single-agent chemotherapy agents are recommended in the NCCN Guidelines; cisplatin-based regimens are not recommended in this setting.<sup>569</sup> For non-squamous NSCLC or NSCLC NOS, single-agent chemotherapy includes gemcitabine, pemetrexed, or taxanes; combination chemotherapy regimens include carboplatin/paclitaxel or carboplatin/pemetrexed.<sup>570-572</sup> However, patients with a PS of 2 are often just treated with single-agent chemotherapy because of concerns about toxicity.<sup>573</sup> Results from a trial reported that treatment with carboplatin/pemetrexed increased median overall survival when compared with pemetrexed alone (9.3 vs. 5.3 months,  $P = .001$ ) in patients with a PS of 2; however, 4 treatment-related deaths occurred in the carboplatin/pemetrexed arm.<sup>570,574</sup> For the 2017 update (Version 1), the NCCN Panel deleted

etoposide, irinotecan, and vinorelbine from the list of recommended single-agent chemotherapy for patients with all histologies because these agents are rarely used in the United States.

Phase 3 randomized trials have shown that many of the platinum-doublet combinations yield similar objective response rates and survival.<sup>575,576</sup> The platinum-doublet regimens differ slightly for toxicity, convenience, and cost; thus, clinicians can individualize therapy for their patients.<sup>559,577,578</sup> Other carboplatin-based regimens include gemcitabine/carboplatin, docetaxel/carboplatin, and pemetrexed/carboplatin;<sup>553,579-581</sup> non-platinum-based regimens such as gemcitabine/vinorelbine and gemcitabine/docetaxel are also options.<sup>582-585</sup> In spite of the development of new chemotherapy regimens, the prognosis for advanced inoperable lung cancer remains poor.

Note that albumin-bound paclitaxel can be substituted for paclitaxel or docetaxel for patients: 1) who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication; or 2) in whom the standard premedications (ie, dexamethasone, H2 blockers, H1 blockers) to prevent hypersensitivity are contraindicated.<sup>586,587</sup> A phase 3 randomized trial reported that an albumin-bound paclitaxel/carboplatin regimen is associated with less neurotoxicity and improved response rate, when compared with standard paclitaxel/carboplatin, in patients with advanced NSCLC.<sup>588</sup> The FDA has approved albumin-bound paclitaxel/carboplatin for patients with locally advanced or metastatic NSCLC who are not candidates for curative surgery or RT. Based on the trial and the FDA approval, the NCCN Panel recommends an albumin-bound paclitaxel/carboplatin regimen as first-line therapy for patients with advanced NSCLC and good PS (0–1).

### Targeted Therapies

Specific targeted therapies are available for the treatment of advanced NSCLC.<sup>131,589,590</sup> Bevacizumab is a recombinant monoclonal antibody that blocks the vascular endothelial growth factor. Erlotinib, gefitinib, and afatinib are small molecule inhibitors of EGFR; osimertinib targets T790M. Crizotinib is a small molecule inhibitor that targets ALK, ROS1, and MET (ie, high-level MET amplification, MET exon 14 skipping mutation). Ceritinib is a small molecule inhibitor that targets ALK and IGF-1 receptor. Alectinib is a small molecule inhibitor that targets ALK and RET. Erlotinib, gefitinib, afatinib, crizotinib, ceritinib, alectinib, and osimertinib are oral TKIs. Other targeted therapies are being developed (see *Emerging Targeted Agents for Patients with Genetic Alterations* in the NCCN Guidelines for NSCLC).

### Bevacizumab

In 2006, the FDA approved bevacizumab for patients with unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC.<sup>591</sup> The ECOG recommends bevacizumab in combination with paclitaxel/carboplatin for select patients with advanced non-squamous NSCLC based on the results of phase 2 to 3 clinical trials (ECOG 4599).<sup>560</sup> To receive treatment with bevacizumab and chemotherapy, patients must meet the following criteria: non-squamous NSCLC and no recent history of hemoptysis. Any regimen with a high risk for thrombocytopenia—and, therefore, possible bleeding—should be used with caution when combined with bevacizumab. Bevacizumab in combination with chemotherapy (ie, carboplatin/paclitaxel, carboplatin/pemetrexed, cisplatin/pemetrexed) is one of the recommended options for patients with a PS 0 to 1 and non-squamous NSCLC or NSCLC NOS and negative or unknown test results for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression (see *Sensitizing EGFR Mutation Positive/First-Line Therapy*

or *ALK Positive/First-Line Therapy* in the NCCN Guidelines for NSCLC). Bevacizumab is not recommended for patients with squamous cell NSCLC.

### Erlotinib and Gefitinib

In 2004, erlotinib was approved by the FDA for the treatment of patients with locally advanced or metastatic NSCLC after progression on at least one prior chemotherapy regimen.<sup>592</sup> The FDA has also approved the use of erlotinib as first-line therapy in patients with sensitizing EGFR mutations.<sup>593</sup> Erlotinib and gefitinib are recommended (category 1) in the NSCLC algorithm as first-line therapy in patients with advanced, recurrent, or metastatic non-squamous NSCLC who have known active sensitizing EGFR mutations regardless of their PS (see *Sensitizing EGFR Mutation Positive* in the NCCN Guidelines for NSCLC).<sup>86,204,594,595</sup> These recommendations are based on a phase 3 randomized trial (IPASS) in which patients with sensitizing EGFR mutations who received gefitinib had increased PFS (24.9% vs. 6.7%), response rate (71.2% vs. 47.3%), and quality of life with fewer side effects (eg, neutropenia) when compared with those receiving chemotherapy (carboplatin/paclitaxel).<sup>204</sup> Updated results from the IPASS study showed that overall survival was similar in patients receiving gefitinib or chemotherapy regardless of sensitizing EGFR mutation status.<sup>596</sup> However, these results probably occurred because patients who had been assigned to first-line chemotherapy were able to receive TKIs as subsequent therapy if they were found to have sensitizing EGFR mutations. A phase 3 randomized trial (EURTAC) in European patients with metastatic NSCLC and sensitizing EGFR mutations showed increased PFS and response rate for those receiving erlotinib when compared with chemotherapy.<sup>199</sup> For erlotinib, the median PFS was 9.7 months compared with 5.2 months for chemotherapy (HR, 0.37; 95% CI, 0.25–0.54;  $P < .0001$ ). Fewer patients receiving erlotinib had severe

adverse events or died when compared with those receiving chemotherapy.

TKIs are recommended in patients with metastatic NSCLC and sensitizing EGFR mutations, because quality of life is improved when compared with chemotherapy. Previously, erlotinib was commonly used in the United States in patients with sensitizing EGFR mutations because of restrictions on the use of gefitinib. However, gefitinib was reapproved by the FDA based on a phase 4 study and is now available in the United States.<sup>130,597</sup> Erlotinib and gefitinib are orally active TKIs that are very well tolerated by most patients.<sup>598,599</sup> An analysis of 5 clinical trials in patients, mainly from the Western hemisphere, (n = 223) with advanced NSCLC (stage IIIB or IV) found that those with sensitizing EGFR mutations who received TKIs had a 67% response rate and an overall survival of about 24 months.<sup>600</sup> The TORCH trial suggested that EGFR mutation testing should be done in patients with advanced non-squamous NSCLC.<sup>601</sup> Survival was increased in patients with wild-type EGFR who received first-line chemotherapy compared with those who received erlotinib first followed by subsequent chemotherapy (11.6 vs. 8.7 months). The OPTIMAL trial reported that PFS was increased in patients with sensitizing EGFR mutations who received erlotinib.<sup>202,203</sup> ASCO recommends that patients be tested for EGFR mutations.<sup>602</sup> However, the ESMO Guidelines specify that only patients with non-squamous NSCLC (eg, adenocarcinoma) be assessed for EGFR mutations.<sup>132,569</sup> Patients with pure squamous cell carcinoma are unlikely to have sensitizing EGFR mutations; however, those with adenosquamous carcinoma may have mutations.<sup>134</sup>

An updated study (CALGB 30406) compared erlotinib alone versus erlotinib/carboplatin/paclitaxel in patients (mainly Caucasian) with advanced NSCLC.<sup>603</sup> The data showed that erlotinib alone was associated with fewer side effects in patients with sensitizing EGFR

mutations when compared with erlotinib/chemotherapy. Thus, it is appropriate to interrupt or complete planned chemotherapy and switch to erlotinib, gefitinib, or afatinib therapy in patients found to have sensitizing EGFR mutations during chemotherapy (see *EGFR Mutation Positive/First-Line Therapy* in the NCCN Guidelines for NSCLC).<sup>604</sup> The NCCN Guidelines do not recommend adding erlotinib, gefitinib, or afatinib to current chemotherapy based on this CALGB study.<sup>603</sup> Erlotinib, gefitinib, or afatinib may be continued in patients who have progressed if patients do not have multiple systemic symptomatic lesions (see *Continuation of Erlotinib, Gefitinib, or Afatinib After Progression* in this Discussion).

A recent phase 3 trial (WJOG 5108L) assessed gefitinib versus erlotinib for patients with advanced lung cancer who had been previously treated with chemotherapy; most patients (72%) were positive for EGFR mutations.<sup>605</sup> The median PFS for gefitinib versus erlotinib was 8.3 and 10.0 months, respectively, in patients positive for EGFR mutations (HR, 1.093; 95% CI, 0.879–1.358; *P* = .424). The main grade 3 or 4 toxicities included rash (gefitinib: 2.2% vs. erlotinib: 18.1%) and increases in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels (gefitinib: 6.1%/13.0% vs. erlotinib: 2.2%/3.3%).

### *Afatinib*

A randomized phase 3 trial reported that first-line therapy with afatinib improved PFS when compared with cisplatin/pemetrexed in patients with metastatic adenocarcinoma who have sensitizing EGFR mutations (11.1 vs. 6.9 months, *P* = .001).<sup>173</sup> The FDA has approved afatinib for first-line treatment of patients with metastatic NSCLC who have sensitizing EGFR mutations.<sup>172,606</sup> Based on this phase 3 randomized trial and the FDA approval, the NCCN Panel recommends afatinib for first-line therapy (category 1) in patients with metastatic non-squamous

NSCLC who have sensitizing EGFR mutations (see the NCCN Guidelines for NSCLC).<sup>170,173,250</sup> Afatinib may also be continued in patients who have progressed if patients do not have multiple systemic symptomatic lesions (see *Continuation of Erlotinib, Gefitinib, or Afatinib After Progression* in this Discussion).<sup>169</sup> However, afatinib is not recommended as subsequent therapy based on a recent phase 3 randomized trial (see *Second-Line and Beyond (Subsequent) Systemic Therapy* in this Discussion).<sup>607</sup>

A recent phase 2B trial assessed afatinib compared with gefitinib for first-line therapy in patients with metastatic adenocarcinoma and sensitizing EGFR mutations.<sup>608</sup> The PFS was essentially the same in patients receiving afatinib when compared with those receiving gefitinib (median PFS, 11.0 months [95% CI, 10.6–12.9] with afatinib vs. 10.9 months [9.1–11.5] with gefitinib; HR, 0.73 [95% CI, 0.57–0.95];  $P=0.017$ ). These slight PFS differences are not clinically relevant and the NCCN Guidelines do not state that one EGFR TKI is more efficacious than another (see the NCCN Evidence Blocks for NSCLC, available at [NCCN.org](#)).<sup>605</sup> Overall survival data are not yet available. Patients receiving afatinib had more serious treatment-related side effects when compared with those receiving gefitinib (11% [17/160] for afatinib vs. 4% [7/159] for gefitinib). One patient receiving gefitinib died from treatment-related hepatic and renal failure; other deaths were not considered to be related to treatment (9% [15/160 vs. 6% [10/159]). More patients receiving afatinib had diarrhea (13% vs. 1%), whereas more patients receiving gefitinib had elevations in liver enzyme levels (0% vs. 9%). For the 2017 update (Version 1), the NCCN Panel revised the afatinib evidence block for efficacy to highly effective (ie, the highest rating of 5), so the value is now the same as that for erlotinib and gefitinib (see the NCCN Evidence Blocks for NSCLC, available at [NCCN.org](#)). However,

afatinib is rated as slightly less safe than erlotinib or gefitinib (ie, a rating of 3 for afatinib versus 4 for erlotinib and gefitinib).

### *Osimertinib*

As previously mentioned, most patients with sensitizing EGFR mutations and metastatic NSCLC typically progress after about 8 to 16 months of erlotinib, gefitinib, or afatinib therapy.<sup>181</sup> EGFR T790M is a mutation associated with acquired resistance to EGFR TKI therapy and has been reported in about 60% of patients with disease progression after initial response to sensitizing EGFR TKI therapy.<sup>146,180-186</sup> Osimertinib (AZD9291) is an oral TKI that inhibits both EGFR sensitizing mutations and T790M. Data from a multicenter, single-arm phase 2 clinical trial indicate that osimertinib is associated with a response rate of about 61% (78/127; 95% CI, 52–70), PFS of 9.6 months (95% CI, 8.3 to not reached), and disease control rate of about 95% (121/127; 95% CI, 90–98) in patients with EGFR T790M who have progressed on sensitizing EGFR TKI therapy; 13% (33/253) of patients had drug-related grade 3 or higher adverse events with one fatal event from pneumonia possibly related to treatment.<sup>188,609,610</sup> In patients without EGFR T790M, the response rate was 21% (13/61; 95% CI, 12–34) and the PFS was 2.8 months (95% CI, 2.1–4.3).<sup>188</sup>

The FDA has approved osimertinib for patients with metastatic EGFR T790M-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. Based on the data and FDA approval, the NCCN Panel recommends osimertinib as subsequent therapy for patients with metastatic EGFR T790M-positive NSCLC who have progressed on erlotinib, gefitinib, or afatinib therapy (see *Second-Line and Beyond (Subsequent) Systemic Therapy* in this Discussion). T790M can be assessed using an FDA-approved test or other validated laboratory test done in a CLIA-approved laboratory. Recent data suggest that plasma genotyping (also known as liquid

biopsy or plasma biopsy) may be considered instead of tissue biopsy to detect whether patients have T790M; however, if the plasma biopsy is negative, then tissue biopsy is recommended if feasible.<sup>611,612</sup> For the 2017 update (Version 1), the NCCN Panel now also recommends osimertinib for patients with T790M who have progression with symptomatic brain metastases based on case reports showing an improvement.<sup>613-616</sup>

### *Crizotinib*

Crizotinib is approved by the FDA for patients with locally advanced or metastatic NSCLC who are positive for the ALK gene rearrangement.<sup>219</sup> The approval is based on a phase 2 trial that showed dramatic response rates (>80%) to crizotinib in patients who had previously progressed.<sup>223,224</sup> Patients receiving crizotinib reported clinically significant improvements in pain, dyspnea, and cough. A phase 3 trial compared first-line crizotinib versus chemotherapy in patients with ALK rearrangements; patients receiving crizotinib had improved PFS, quality of life, and response rates when compared with those receiving chemotherapy.<sup>221</sup> The NCCN Panel recommends first-line therapy with crizotinib (category 1) based on this phase 3 trial and the FDA approval; the panel also feels that crizotinib is appropriate for patients with PS 0 to 4. Crizotinib may also be continued for patients with ALK rearrangements who have progressed if patients do not have multiple systemic symptomatic lesions.<sup>222</sup>

Crizotinib is also very effective for patients with ROS1 rearrangements with response rates of about 70% including complete responses (see *ROS1 Rearrangements* in this Discussion).<sup>124,253</sup> For the 2017 update (Version 1), the NCCN Panel moved the recommendation for ROS1 testing into the main algorithm (and deleted the footnote recommending ROS1 testing), added a new algorithm for ROS1, and added a new section on ROS1 to the molecular diagnostic studies

section based on data showing the efficacy of crizotinib for patients with ROS1 rearrangements and on the recent FDA approval (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC).<sup>123,124,253</sup> Alectinib and ceritinib are not effective in patients with ROS1 rearrangements whose disease become resistant to crizotinib.

### *Ceritinib*

Ceritinib is approved by the FDA for patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.<sup>244</sup> The approval is based on an expanded phase 1 study (ASCEND-1) showing overall response rates of 56% to ceritinib in patients (92/163) who had previously received crizotinib; the median duration of response was 8.3 months (6.8-9.7).<sup>237,617</sup> Common grade 3 to 4 adverse events included increased alanine aminotransferase (73 [30%] patients) and increased aspartate aminotransferase (25 [10%]).<sup>617</sup> Some patients with CNS lesions responded to ceritinib. Based on the study and the FDA approval, the NCCN Panel recommends ceritinib as subsequent therapy for patients with ALK-positive NSCLC who have progressed after crizotinib; patients who do not tolerate crizotinib may be switched to ceritinib or alectinib. A recent phase 2 trial (ASCEND-2) assessed ceritinib in patients who had previously received at least 2 or more treatments, had progressed on crizotinib, and had brain metastases.<sup>618</sup> The overall response rate was 38%; the duration of response was 9.7 months (95% CI, 7.1–11.1 months).<sup>618</sup> The intracranial overall response rate was 45.0% (95% CI, 23.1%–68.5%).

### *Alectinib*

Alectinib is approved by the FDA for patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.<sup>246</sup> The approval is based on two phase 2 trials showing overall response rates of 48% to 50% to alectinib in patients who had previously received crizotinib.<sup>129,245</sup> In the larger trial by Ou et al, the

control rate for CNS disease was 83% (95% CI, 74%–91%), and the median duration of response was 10.3 months (95% CI, 7.6–11.2 months).<sup>129</sup> Of 84 patients with baseline CNS metastases, 23 (27%) had a complete CNS response. Of 23 patients with baseline CNS metastases and without previous brain RT, 10 (43%) had a complete CNS response to alectinib. Based on these trials and the FDA approval, the NCCN Panel recommends alectinib as subsequent therapy for patients with ALK-positive NSCLC who have progressed after crizotinib; patients who do not tolerate crizotinib may be switched to alectinib or ceritinib.

### *Cetuximab*

Cetuximab is a monoclonal antibody that targets EGFR. A large phase 3 randomized trial (FLEX) assessed cisplatin/vinorelbine with (or without) cetuximab for patients with advanced NSCLC; most patients had stage IV disease.<sup>619</sup> Adding cetuximab was reported to slightly increase overall survival (11.3 vs. 10.1 months, HR for death, 0.87 [95% CI, 0.762–0.996];  $P = .044$ ). Patients receiving cetuximab had increased grade 4 events versus control (62% vs. 52%,  $P < .01$ ); cetuximab was also associated with grade 2 acne-like rash.

The cetuximab/cisplatin/vinorelbine regimen was recently removed from the NCCN Guidelines. The benefits of this cetuximab-based regimen are very slight, it is a difficult regimen to administer, and patients have poorer tolerance for this regimen when compared with other regimens; for example, almost 40% of patients have grade 4 neutropenia.<sup>515</sup> Patients may also have comorbid conditions that prevent them from receiving cisplatin such as poor kidney function. Cisplatin/vinorelbine with (or without) cetuximab is generally not used in the United States because of concerns about toxicity.<sup>515,529,619</sup> Some oncologists feel that although the FLEX trial results were reported to be statistically significant they were not clinically significant.<sup>515</sup> For the 2017 update

(Version 1), the NCCN Panel deleted the cisplatin/vinorelbine and carboplatin/vinorelbine regimens from the list of recommended systemic therapy regimens for metastatic NSCLC with all histologies.

### *Nivolumab*

The NCCN Panel recommends nivolumab (category 1) as subsequent therapy for patients with metastatic non-squamous NSCLC who have progressed on or after first-line chemotherapy based on data from a phase 3 randomized trial (CheckMate-057) and FDA approval.<sup>620,621</sup> The NCCN Panel recommends immune checkpoint inhibitors as preferred agents for subsequent therapy based on improved overall survival rates, longer duration of response, and fewer adverse events when compared with cytotoxic chemotherapy.<sup>621-624</sup> Human immune-checkpoint-inhibitor antibodies inhibit the PD-1 receptor or PD-1 ligand (PD-L1), which improves antitumor immunity; PD-1 receptors are expressed on activated cytotoxic T-cells.<sup>621,625,626</sup> Nivolumab inhibits PD-1 receptors.<sup>623</sup> Immune checkpoint inhibitors are associated with a delay in benefit when compared with targeted therapy or cytotoxic chemotherapy. Pseudoprogression has been reported; therefore, traditional RECIST criteria may not be applicable.<sup>627</sup>

The category 1 recommendation for nivolumab is based on the published data from CheckMate-057 and FDA approval of nivolumab for patients with metastatic non-squamous NSCLC. For patients receiving nivolumab, median overall survival was 12.2 months compared with 9.4 months for docetaxel (HR, 0.73; 95% CI, 0.59–0.89;  $P = .002$ ).<sup>621</sup> The median duration of response was 17.2 months with nivolumab compared with 5.6 months for docetaxel. At 18 months, the overall survival rate was 39% (95% CI, 34%–45%) with nivolumab compared with 23% (95% CI, 19%–28%) with docetaxel. Fewer grade 3 to 5 adverse events were reported for nivolumab (10%) when compared with docetaxel (54%) in the CheckMate-057 trial. Although many patients

with metastatic non-squamous NSCLC benefit from nivolumab, those whose tumors have PD-L1 staining of 1% to 10% or more have overall survival of 17 to 19 months compared with 8 to 9 months for docetaxel. For patients who did not have PD-L1 expression, there was no difference in overall survival for nivolumab versus docetaxel; however, nivolumab was associated with a longer duration of response and fewer side effects. To help clinicians determine which patients with non-squamous NSCLC may benefit most from treatment with nivolumab, the FDA has approved a complementary diagnostic biomarker test to assess for PD-L1 protein expression.<sup>628</sup> Testing for PD-L1 is not required for prescribing nivolumab but may provide useful information.<sup>629</sup> Current or former smoking status correlated with the response rate to immune checkpoint inhibitors.<sup>621</sup> Recent data suggest that mismatch repair deficiency is associated with response to immune checkpoint inhibitors.<sup>630</sup>

The NCCN Panel also recommends (category 1) nivolumab as subsequent therapy for patients with metastatic squamous cell NSCLC who have progressed on or after first-line chemotherapy based on data from a phase 3 randomized trial (CheckMate-017), the recent FDA approval, and results of a phase 2 trial.<sup>623,631</sup> In the CheckMate-017 trial, the median overall survival was 9.2 months with nivolumab compared with 6.0 months for docetaxel.<sup>623</sup> Patients had a response rate of 20% with nivolumab compared with 9% for docetaxel ( $P = .008$ ). PD-L1 expression was not associated with response to nivolumab in patients with squamous cell NSCLC. There were fewer grade 3 to 4 adverse events with nivolumab (7%) when compared with docetaxel (55%). No patients died in the nivolumab arm versus 3 deaths in the docetaxel arm. Immune-related adverse events, such as pneumonitis, may occur with nivolumab.<sup>626,631-637</sup> Intravenous high-dose corticosteroids should be administered based on the severity of the reaction for patients with

immune-mediated adverse events. Nivolumab should be discontinued for patients with severe or life-threatening pneumonitis and should be withheld or discontinued for other severe or life-threatening immune-mediated adverse events when indicated (see prescribing information).

### *Pembrolizumab*

For the 2017 updates (Versions 1 and 2), the NCCN Panel now recommends pembrolizumab (category 1) as first-line therapy for patients with PD-L1 expression levels of 50% or more and with negative or unknown tests results for EGFR mutations, ALK rearrangements, and ROS1 rearrangements based on a recent phase 3 randomized trial (Keynote-024) comparing pembrolizumab versus platinum-based chemotherapy; the FDA recently approved pembrolizumab for first-line therapy based on this trial.<sup>638</sup> At 6 months, the rate of overall survival was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (HR for death, 0.60; 95% CI, 0.41–0.89;  $P = .005$ ). Responses were higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%).<sup>638</sup> There were fewer severe treatment-related adverse events (grades 3-5) in patients receiving pembrolizumab compared with those receiving chemotherapy (26.6% vs. 53.3%).

For the 2017 update (Version 1), the NCCN Panel now recommends (category 2A) IHC testing for PD-L1 expression before first-line treatment in patients with metastatic NSCLC with negative or unknown tests results for EGFR mutations, ALK rearrangements, and ROS1 rearrangements.<sup>639</sup> Although it is not an optimal biomarker, PD-L1 expression is currently the best available biomarker to assess whether patients are candidates for pembrolizumab.<sup>640,641</sup> PD-L1 expression is continuously variable and dynamic; thus, a cutoff value for a positive result is artificial. Patients with PD-L1 expression levels just below and just above 50% will probably have similar responses.<sup>640</sup> Unique anti-PD-

L1 IHC assays are being developed for each one of the different immune checkpoint inhibitors currently in clinical trials.<sup>629,640</sup> The definition of a positive PD-L1 test result varies depending on which biomarker assay is used.<sup>629</sup>

Ideally, PD-L1 expression levels are assessed in patients with negative or unknown test results for EGFR mutations, ALK rearrangements, or ROS1 rearrangements. Every effort needs to be made to establish the genetic alteration status. However, if the risk of biopsy is high and genetic alteration testing is not feasible and therefore technically unknown, then it is appropriate to test for PD-L1 expression levels. Of note, there are blood assays to evaluate for EGFR mutations and ALK rearrangements although they are less sensitive than tissue assays.

The NCCN Panel also recommends pembrolizumab (category 1) as subsequent therapy for patients with metastatic non-squamous or squamous NSCLC and PD-L1 expression based on the randomized phase 2/3 trial (KEYNOTE-010), the phase 1 KEYNOTE-001 trial, and FDA approval.<sup>624,642,643</sup> In addition, the NCCN Panel recommends immune checkpoint inhibitors as preferred agents for subsequent therapy. As previously mentioned, human immune-checkpoint-inhibitor antibodies inhibit the PD-1 receptor or PD-L1, which improves antitumor immunity; PD-1 receptors are expressed on activated cytotoxic T-cells.<sup>625,626</sup> Pembrolizumab inhibits the PD-1 receptor.<sup>638</sup>

A randomized phase 2/3 trial (KEYNOTE-010) assessed pembrolizumab in patients with previously treated advanced non-squamous and squamous NSCLC who were PD-L1 positive ( $\geq 1\%$ ); most patients were current or former smokers.<sup>624</sup> There were 3 arms in this trial: pembrolizumab at 2 mg/kg, pembrolizumab at 10 mg/kg, and docetaxel at 75 mg/m<sup>2</sup> every 3 weeks. The median overall survival was 10.4 months for the lower dose of pembrolizumab, 12.7 months for the

higher dose, and 8.5 months for docetaxel. Overall survival was significantly longer for both doses of pembrolizumab when compared with docetaxel (pembrolizumab 2 mg/kg: HR, 0.71; 95% CI, 0.58–0.88;  $P=.0008$ ) (pembrolizumab 10 mg/kg: HR, 0.61; CI, 0.49–0.75;  $P<.0001$ ). For those patients with at least 50% PD-L1 expression in tumor cells, overall survival was also significantly longer at either dose of pembrolizumab when compared with docetaxel (pembrolizumab 2 mg/kg: 14.9 vs. 8.2 months; HR, 0.54; 95% CI, 0.38–0.77;  $P=.0002$ ) (pembrolizumab 10 mg/kg: 17.3 vs. 8.2 months; HR, 0.50; CI, 0.36–0.70;  $P<.0001$ ). When compared with docetaxel, there were fewer grade 3 to 5 treatment-related adverse events at either dose of pembrolizumab (pembrolizumab 2 mg/kg: 13% [43/339] of patients, pembrolizumab 10 mg/kg: 16% [55/343], and docetaxel: 35% [109/309]). A total of 6 treatment-related deaths occurred in patients receiving pembrolizumab (3 at each dose) and 5 treatment-related deaths occurred in the docetaxel arm.

A phase I trial (KEYNOTE-001) assessed the safety and efficacy of pembrolizumab for patients with metastatic NSCLC.<sup>642</sup> Among all patients, the response rate was 19%, the median duration of response was 12.5 months, PFS was 3.7 months, and median overall survival was 12.0 months. Patients with a PD-L1 expression score of at least 50% had a response rate of 45%, PFS of 6.3 months, and overall survival was not reached. Current or former smoking status also correlated with the response rate.<sup>642,644</sup> Less than 10% of patients had serious grade 3 or more toxicity.

Similar to nivolumab, immune-mediated adverse events may also occur with pembrolizumab.<sup>632,634,645</sup> For patients with immune-mediated adverse events, intravenous high-dose corticosteroids should be administered based on the severity of the reaction. Pembrolizumab should also be discontinued for patients with severe or life-threatening



pneumonitis and should be withheld or discontinued for other severe or life-threatening immune-mediated adverse events when indicated (see prescribing information). The FDA has approved pembrolizumab as subsequent therapy for patients with metastatic NSCLC whose disease has progressed after platinum-based chemotherapy if their tumors express PD-L1.<sup>643</sup> The FDA has approved a companion diagnostic biomarker test for assessing PD-L1 expression and determining which patients are eligible for pembrolizumab therapy. Other immunotherapeutic agents are being investigated.<sup>622,646-648</sup>

### *Atezolizumab*

For the 2017 update (Version 2), the NCCN Panel added a recommendation for atezolizumab (category 2A) as subsequent therapy for patients with metastatic non-squamous or squamous cell NSCLC based on preliminary data from a phase 3 randomized trial, data from a phase 2 trial, and recent FDA approval.<sup>648,649</sup> Testing for PD-L1 expression levels is not required for prescribing atezolizumab but may provide useful information. Human immune-checkpoint–inhibitor antibodies inhibit the PD-1 receptor or PD-L1, which improves antitumor immunity; PD-1 receptors are expressed on activated cytotoxic T-cells.<sup>625,626</sup> Atezolizumab inhibits PD-L1.<sup>648</sup>

A phase 3 randomized trial (OAK) assessed atezolizumab versus docetaxel alone in patients with metastatic NSCLC who had progressed during or after systemic therapy.<sup>649</sup> Most patients were current or former smokers and had received platinum-based chemotherapy; few patients (10%) had EGFR mutations and ALK rearrangements were not reported.<sup>649</sup> Preliminary data show that patients with non-squamous NSCLC who received atezolizumab had improved overall survival when compared with those receiving docetaxel (15.6 vs. 11.2 months; HR, 0.73 [0.6, 0.89];  $P = .0015$ ). Overall survival was only slightly improved in patients with squamous cell NSCLC receiving atezolizumab versus

docetaxel (8.9 vs. 7.7 months; HR, 0.73 [0.54, 0.98];  $P = .038$ ); however, there were fewer patients (112 vs. 110) in this group. There were fewer treatment-related severe adverse events (grades 3-4) for atezolizumab versus docetaxel (15% vs. 43%).

### *Ramucirumab*

A phase 3 randomized trial (REVEL) assessed ramucirumab/docetaxel versus docetaxel alone in patients with metastatic NSCLC that had progressed.<sup>650</sup> The median overall survival was reported to be slightly increased with ramucirumab/docetaxel versus docetaxel alone (10.5 vs. 9.1 months; HR, 0.86, 95% CI, 0.75–0.98;  $P < .023$ ). Ramucirumab in combination with docetaxel is approved by the FDA for patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy.<sup>651</sup> The NCCN Panel added ramucirumab/docetaxel (category 2A) as an option for subsequent therapy for metastatic NSCLC that has progressed after first-line chemotherapy based on the phase 3 randomized trial and the FDA approval.<sup>650,651</sup> Some panel members feel that the data are statistically significant but not clinically relevant. More than 70% of patients had grade 3 or higher adverse events in both groups (79% for ramucirumab/docetaxel vs. 71% for docetaxel alone). Adverse events of special concern with ramucirumab/docetaxel therapy include risk for severe hemorrhage, grade 3 to 4 gastrointestinal bleeding, gastrointestinal perforation or fistula, impaired wound healing, and poorly controlled hypertension. There were 16 deaths from grade 3 or worse pulmonary hemorrhage and other adverse events in the REVEL trial: 8 in the ramucirumab/docetaxel arm and 8 in the docetaxel alone arm.

### **Maintenance Therapy**

Maintenance therapy refers to systemic therapy that may be given for patients with advanced NSCLC after 4 to 6 cycles of first-line chemotherapy.<sup>652</sup> However, patients are only candidates for

maintenance therapy if their tumors have responded to their previous treatment (ie, tumor response) or have stable disease and their tumors have not progressed. *Continuation maintenance* therapy refers to the use of at least one of the agents that was given in the first-line regimen. *Switch maintenance* (category 2B) therapy refers to the initiation of a different agent that was not included as part of the first-line regimen. Selection of appropriate maintenance therapy depends on several factors (eg, histologic type, presence of mutations or gene rearrangements, PS). Maintenance therapy is an option in the NCCN Guidelines for select patients with tumor response or stable disease and is not recommended for all patients (eg, not recommended for PS 3–4, those with progression); close observation (category 2A) is also a valid treatment option (see the NCCN Guidelines for NSCLC).<sup>653</sup>

### *Continuation Maintenance Therapy*

For continuation maintenance therapy, select agents (which were initially given in combination with conventional chemotherapy) may be continued until evidence of disease progression or unacceptable toxicity based on the design of the clinical trials that led to their approval. Single-agent bevacizumab (category 1) may be continued beyond 4 to 6 cycles of initial therapy (ie, platinum-doublet chemotherapy given with bevacizumab) in patients with non-squamous NSCLC and negative or unknown test results for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression.<sup>560,654,655</sup> Single-agent pemetrexed (category 1) may also be given as continuation maintenance therapy in patients with non-squamous NSCLC and negative or unknown test results.<sup>654,656</sup> A phase 3 randomized trial (PARAMOUNT) found that continuation maintenance therapy with pemetrexed slightly increased PFS when compared with placebo (4.1 vs. 2.8 months).<sup>656</sup> Results show that continuation maintenance therapy with pemetrexed also improves overall survival (13.9 vs. 11.0

months).<sup>657</sup> Based on the trial and the FDA approval, the NCCN Panel recommends single-agent pemetrexed as continuation maintenance therapy (category 1) in patients with non-squamous NSCLC and negative or unknown test results for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression.

Continuation maintenance therapy using bevacizumab/pemetrexed is also an option in patients with non-squamous NSCLC and negative or unknown test results for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression; this is a category 2A recommendation. Data from the recent POINTBREAK study reported a very slight improvement in PFS (6 vs. 5.6 months) when comparing bevacizumab/pemetrexed versus bevacizumab alone as maintenance therapy; the initial regimens were either bevacizumab/carboplatin/pemetrexed or bevacizumab/carboplatin/paclitaxel.<sup>565</sup> It is important to note that the pemetrexed-based arm was associated with less toxicity (eg, less neurotoxicity, less neutropenia, less hair loss) than the paclitaxel-based arm. When using bevacizumab/pemetrexed versus bevacizumab alone as maintenance therapy, data from the AVAPERL study showed a 3.7-month increase in PFS (7.4 vs. 3.7 months); the initial regimen was bevacizumab/cisplatin/pemetrexed.<sup>658,659</sup>

A phase 3 randomized trial compared using maintenance therapy with either gemcitabine or erlotinib after first-line therapy with cisplatin-gemcitabine. Continuation maintenance therapy with single-agent gemcitabine was reported to increase PFS to a greater extent (3.8 months) than switch maintenance therapy with erlotinib (2.9 months) when compared with observation (1.9 months).<sup>660,661</sup> Another phase 3 randomized trial assessed continuation maintenance therapy with gemcitabine versus best supportive care after an initial regimen of cisplatin/gemcitabine.<sup>662</sup> The data showed a slight difference in PFS but

no difference in overall survival. The NCCN Guidelines recommend using gemcitabine (category 2B) as continuation maintenance therapy regardless of histology in patients without ALK or ROS1 rearrangements or sensitizing EGFR mutations.

Use of continuation maintenance therapy depends on several factors such as whether the patient had minimal toxicity during treatment. A drug vacation may be more appropriate for some patients.<sup>563</sup> Some clinicians feel that continuation maintenance therapy is only appropriate for select patients, because it has not been shown to improve overall survival or quality of life, although it has been shown to improve PFS.<sup>563,663</sup> In addition, maintenance therapy has not been shown to be superior to subsequent therapy, which is initiated at disease progression. Data from a phase 3 randomized trial suggest that conventional cytotoxic agents should not be continued beyond 4 to 6 cycles of therapy; however, many patients assigned to a longer duration of therapy did not receive the planned number of cycles (see *Maintenance Therapy* in this Discussion).<sup>663,664</sup>

### *Switch Maintenance Therapy*

Issues have been raised about switch maintenance therapy, including the design of the trials, modest survival benefits, quality of life, and toxicity.<sup>563,665</sup> Therefore, switch maintenance therapy is a category 2B recommendation in the NCCN Guidelines; for squamous cell NSCLC, all maintenance therapy is a category 2B recommendation. Two phase 3 randomized trials reported a benefit in PFS and overall survival with the initiation of pemetrexed or erlotinib after first-line chemotherapy (4–6 cycles) in patients with non-squamous NSCLC and no apparent disease progression.<sup>666,667</sup> Switch maintenance therapy with pemetrexed is recommended (category 2B) in patients with non-squamous cell carcinoma and negative or unknown test results for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression.<sup>667</sup>

The FDA has approved maintenance therapy with pemetrexed.<sup>668</sup> Likewise, switch maintenance therapy with erlotinib is recommended (category 2B) in patients with non-squamous NSCLC with negative or unknown test results.<sup>661,666</sup> Recently, the NCCN Panel deleted the recommendation for switch maintenance therapy with erlotinib in patients with squamous cell NSCLC, because overall survival and quality of life were not improved.<sup>660,669</sup> Both erlotinib and pemetrexed have a category 2B recommendation for switch maintenance therapy in patients with non-squamous NSCLC. The FDA has approved maintenance therapy with erlotinib.<sup>670</sup> A phase 3 trial assessed switch maintenance therapy with docetaxel given either immediately after chemotherapy or delayed until progression.<sup>671</sup> Switch maintenance therapy with docetaxel is a category 2B recommendation in the NCCN Guidelines for patients with squamous cell carcinoma, because many patients in the delayed chemotherapy arm did not receive docetaxel.

### **Clinical Evaluation**

As previously described, low-dose CT screening is recommended for asymptomatic select patients who are at high risk for lung cancer (see the NCCN Guidelines for Lung Cancer Screening, available at [NCCN.org](http://NCCN.org)). For the 2017 update (Version 1), the NCCN Panel added a new algorithm for incidental lung nodules that are detected on CT scans; the workup and evaluation of these incidental lung nodules is described in the NSCLC algorithm (see *Diagnostic Evaluation of Lung Nodules* in this Discussion and the NCCN Guidelines for NSCLC).

After patients are confirmed to have NSCLC based on a pathologic diagnosis, a clinical evaluation needs to be done (see the NCCN Guidelines for NSCLC). In patients with symptoms, the clinical stage is initially determined from disease history (ie, cough, dyspnea, chest pain, weight loss) and physical examination together with a limited battery of

tests (see *Evaluation* and *Clinical Stage* in the NCCN Guidelines for NSCLC). The NCCN Panel also recommends that smoking cessation advice, counseling, and pharmacotherapy be provided to patients.<sup>29,672-674</sup> After the clinical stage is determined, the patient is assigned to one of the pathways that are defined by the stage, specific subdivision of the particular stage, and location of the tumor. Note that for some patients, diagnosis, staging, and surgical resection are done during the same operative procedure. A multidisciplinary evaluation should be done before treatment.

### Additional Pretreatment Evaluation

#### **Mediastinoscopy**

As previously noted, evaluation of the mediastinal nodes is a key step in the further staging of the patient. FDG PET/CT scans can be used as an initial assessment of the hilar and mediastinal nodes (ie, to determine whether the N1, N2, or N3 nodes are positive for cancer, which is a key determinant of stage II and stage III disease); however, CT scans have known limitations for evaluating the extent of lymph node involvement in lung cancer (see *Mediastinoscopy* and *Other Imaging Studies* in this Discussion).<sup>675-678</sup> Mediastinoscopy is the gold standard for evaluating mediastinal nodes. Thus, mediastinoscopy is encouraged as part of the initial evaluation, particularly if the results of imaging are not conclusive and the probability of mediastinal involvement is high (based on tumor size and location). Therefore, mediastinoscopy is appropriate for patients with T2 to T3 lesions even if the FDG PET/CT scan does not suggest mediastinal node involvement. Mediastinoscopy may also be appropriate to confirm mediastinal node involvement in patients with a positive FDG PET/CT scan. In patients with solid tumors less than 1 cm or for nonsolid tumors (ie, GGOs) less than 3 cm, pathologic mediastinal lymph node evaluation is not required if the nodes are FDG-PET/CT negative.<sup>679</sup> Mediastinal evaluation can

be considered in patients with clinical stage 1A disease (T1ab, N0). In patients with peripheral T2a, central T1ab, or T2 lesions with negative FDG PET/CT scans, the risk for mediastinal lymph node involvement is higher and mediastinoscopy and/or EUS-FNA and EBUS-TBNA are recommended (see *Other Imaging Studies* in this Discussion and the NCCN Guidelines for NSCLC).

Dillemans et al have reported a selective mediastinoscopy strategy, proceeding straight to thoracotomy without mediastinoscopy for T1 peripheral tumors without enlarged mediastinal lymph nodes on preoperative CT.<sup>680</sup> This strategy resulted in a 16% incidence of positive N2 nodes discovered only at the time of thoracotomy. For identifying N2 disease, chest CT scans had sensitivity and specificity rates of 69% and 71%, respectively. However, using both the chest CT scan plus mediastinoscopy was significantly more accurate (89% vs. 71%) than using the chest CT scan alone for identifying N2 disease. When using CT scans, node positivity is based on the size of the lymph nodes. Therefore, the CT scan will miss small metastases that do not result in node enlargement. To address this issue, Arita et al specifically examined lung cancer metastases to normal size mediastinal lymph nodes in 90 patients and found an incidence of 16% (14/90) false-negative chest CT scans with histologic identification of occult N2 or N3 disease.<sup>681</sup>

Bronchoscopy is used in diagnosis and local staging of both central and peripheral lung lesions and is recommended for pretreatment evaluation of stage I to IIIA tumors. However, in patients who present with a solitary pulmonary nodule where the suspicion of malignancy is high, surgical resection without prior invasive testing may be reasonable.

### Other Imaging Studies

As previously mentioned, CT scans have known limitations for evaluating the extent of lymph node involvement in lung cancer.<sup>676</sup> PET scans have been used to help evaluate the extent of disease and to provide more accurate staging. The NCCN Panel reviewed the diagnostic performance of CT and PET scans. The NCCN Panel believes that PET scans can play a role in the evaluation and more accurate staging of NSCLC, for example, in identifying stage I (peripheral and central T1–2, N0), stage II, stage III, and stage IV diseases.<sup>675,682,683</sup> However, FDG PET/CT is even more sensitive and is recommended by NCCN.<sup>684-686</sup> PET/CT is typically done from the skull base to the knees; whole body PET/CT may also be done.

The NCCN Panel assessed studies that examined the sensitivity and specificity of chest CT scans for mediastinal lymph node staging.<sup>687</sup> Depending on the clinical scenario, a sensitivity of 40% to 65% and a specificity of 45% to 90% were reported.<sup>688</sup> Because they detect tumor physiology, as opposed to anatomy, PET scans may be more sensitive than CT scans. Moreover, if postobstructive pneumonitis is present, there is little correlation between the size of the mediastinal lymph nodes and tumor involvement.<sup>689</sup> Chin et al found that PET, when used to stage the mediastinal nodes, was 78% sensitive and 81% specific with a negative predictive value of 89%.<sup>690</sup> Kernstine et al compared PET scan to CT scan for identifying N2 and N3 disease in NSCLC.<sup>691</sup> The PET scan was found to be more sensitive than the CT scan in identifying mediastinal node disease (70% vs. 65%). FDG PET/CT has been shown to be useful in restaging patients after adjuvant therapy.<sup>692,693</sup>

When patients with early-stage disease are accurately staged using FDG PET/CT, inappropriate surgery is avoided.<sup>684</sup> However, positive FDG PET/CT scan findings for distant disease need pathologic or other

radiologic confirmation (eg, MRI of bone). If the FDG PET/CT scan is positive in the mediastinum, the lymph node status needs pathologic confirmation.<sup>675,694</sup> Transesophageal EUS-FNA and EBUS-TBNA have proven useful to stage patients or to diagnose mediastinal lesions; these techniques can be used instead of invasive staging procedures in select patients.<sup>695-698</sup> When compared with CT and PET, EBUS-TBNA has a high sensitivity and specificity for staging mediastinal and hilar lymph nodes in patients with lung cancer.<sup>699</sup> In patients with positive nodes on CT or PET, EBUS-TBNA can be used to clarify the results.<sup>700,701</sup> However, in patients with negative findings on EBUS-TBNA, conventional mediastinoscopy can be done to confirm the results.<sup>696,701-703</sup> Note that EBUS is also known as endosonography.

The routine use of bone scans (to exclude bone metastases) is not recommended. Brain MRI (with contrast), to rule out asymptomatic brain metastases, is recommended for patients with stage II, III, and IV disease to rule out metastatic disease if aggressive combined-modality therapy is being considered.<sup>704</sup> Patients with stage IB NSCLC are less likely to have brain metastases; therefore, brain MRI is optional in this setting and can be considered for select patients at high risk (eg, tumors greater than 5 cm, central location). If brain MRI cannot be done, then CT of the head with contrast is an option. Note that PET scans are not recommended for assessing whether brain metastases are present (see the NCCN Guidelines for Central Nervous System Cancers, available at [NCCN.org](#)).

### Initial Therapy

As previously mentioned, accurate pathologic assessment and staging are essential before treatment for NSCLC, because management varies depending on the stage, histology, presence of genetic alterations, and PS. Before treatment, it is strongly recommended that determination of

tumor resectability be made by board-certified thoracic surgeons who perform lung cancer surgery as a prominent part of their practice (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC). *Principles of Radiation Therapy* recommends doses for RT (see the NCCN Guidelines for NSCLC). In addition, the NCCN Guidelines also recommend regimens for chemotherapy and chemoradiation (see *Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy*, *Chemotherapy Regimens Used with Radiation Therapy*, and *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC). Targeted therapy is recommended for patients with metastatic NSCLC and positive test results for ALK or ROS1 rearrangements, or sensitizing EGFR mutations.

### Stage I, Stage II, and Stage IIIA Disease

Depending on the extent and type of comorbidity present, patients with stage I or a subset of stage II (T1–2, N1) tumors are generally candidates for surgical resection and mediastinal lymph node dissection. Definitive RT, particularly SABR, is recommended for patients with early-stage NSCLC who are medically inoperable or refuse surgery; RT can be considered as an alternative to surgery in patients at high risk of complications (see *Stereotactic Ablative Radiotherapy* in this Discussion and see *Initial Treatment for Stage I and II* in the NCCN Guidelines for NSCLC).<sup>266,283,286,352,358,705</sup> In some instances, positive mediastinal nodes (N2) are discovered at surgery; in this setting, an additional assessment of staging and tumor resectability must be made, and the treatment (ie, inclusion of systematic mediastinal lymph node dissection) must be modified accordingly. Therefore, the NCCN Guidelines include 2 different tracks for T1–3, N2 disease (ie, stage IIIA disease): 1) T1–3, N2 disease discovered unexpectedly at surgical exploration; and 2) T1–3, N2 disease confirmed before thoracotomy. In the second case, an initial brain MRI (with contrast) and FDG PET/CT

scan (if not previously done) are recommended to rule out metastatic disease.

For patients with clinical stage IIB (T3, N0) and stage IIIA tumors who have different treatment options (surgery, RT, or chemotherapy), a multidisciplinary evaluation is recommended. For the subsets of stage IIB (T3, N0) and stage IIIA (T4, N0–1) tumors, treatment options are organized according to the location of the tumor such as the superior sulcus, chest wall, proximal airway, or mediastinum.<sup>274</sup> For each location, a thoracic surgeon needs to determine whether the tumor is resectable (see *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC).

For patients with resectable tumors (T3 invasion, N0–1) in the superior sulcus, the NCCN Panel recommends preoperative concurrent chemoradiation therapy followed by surgical resection and chemotherapy (see *Initial Treatment for Superior Sulcus Tumors* in the NCCN Guidelines for NSCLC). Preoperative concurrent chemoradiation followed by surgical resection of a superior sulcus tumor has shown 2-year survival in the 50% to 70% range.<sup>274,375,377,706-709</sup> The overall 5-year survival rate is approximately 40%.<sup>377</sup> Patients with possibly resectable superior sulcus tumors should undergo preoperative concurrent chemoradiation before surgical re-evaluation (including CT ± PET/CT). For patients with unresectable tumors (T4 extension, N0–1) in the superior sulcus, definitive concurrent chemoradiation is recommended. Two additional cycles of full-dose chemotherapy can be given if full-dose chemotherapy was not given concurrently with RT.<sup>547,710</sup>

Surgical resection is the preferred treatment option for patients with tumors of the chest wall, proximal airway, or mediastinum (T3–4, N0–1). Other treatment options include chemotherapy or concurrent chemoradiation before surgical resection. For unresectable T4, N0–1

tumors without pleural effusion, definitive concurrent chemoradiation (category 1) is recommended.<sup>292,511</sup> If full-dose chemotherapy was not given as concurrent treatment, then an additional 2 cycles of full-dose chemotherapy can be administered (see *Adjuvant Treatment* in the NCCN Guidelines for NSCLC).<sup>292,378,511,547</sup>

Multimodality therapy is recommended for most patients with stage III NSCLC.<sup>543</sup> For patients with stage IIIA disease and positive mediastinal nodes (T1–3, N2), treatment is based on the findings of pathologic mediastinal lymph node evaluation (see *Adjuvant Treatment* in the NCCN Guidelines for NSCLC). Patients with negative mediastinal biopsy findings are candidates for surgery. For those patients with resectable lesions, mediastinal lymph node dissection or lymph node sampling should be performed during the operation. Those individuals who are medically inoperable should be treated according to the clinical stage (see the NCCN Guidelines for NSCLC). For patients with (T1–3) N2 node-positive disease, a brain MRI (with contrast) and FDG PET/CT scan (if not done previously) are recommended to search for distant metastases. When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy (see the NCCN Guidelines for NSCLC).<sup>351,512</sup> Recommended therapy for metastatic disease depends on whether disease is in a solitary site or is widespread (see the NCCN Guidelines for NSCLC).

When a lung metastasis is present, it usually occurs in patients with other systemic metastases; the prognosis is poor. Therefore, many of these patients are not candidates for surgery; however, systemic therapy is recommended. Although uncommon, patients with lung metastases but without systemic metastases have a better prognosis and are candidates for surgery (see *Multiple Lung Cancers* in this Discussion).<sup>711</sup> Patients with separate pulmonary nodule(s) in the same

lobe (T3, N0-1) or ipsilateral non-primary lobe (T4, N0-1) without other systemic metastases are potentially curable by surgery; 5-year survival rates are about 30%.<sup>712</sup> For those with N2 nodes after surgery, concurrent chemoradiation is recommended for those with positive margins and a R2 resection; either sequential or concurrent chemoradiation is recommended after an R1 resection. Most NCCN Member Institutions favor concurrent chemoradiation for positive margins, but sequential chemoradiation is reasonable in frailer patients.<sup>713</sup> For those with N2 nodes and negative margins, sequential chemotherapy (category 1) with RT is recommended. Chemotherapy alone is recommended for those with N0-1 nodes (see *Adjuvant Treatment* in the NCCN Guidelines for NSCLC). In patients with synchronous solitary nodules (contralateral lung), the NCCN Panel recommends treating them as 2 primary lung tumors if both are curable, even if the histology of the 2 tumors is similar (see the NCCN Guidelines for NSCLC).<sup>714</sup>

### Multiple Lung Cancers

Patients with a history of lung cancer or those with biopsy-proven synchronous lesions may be suspected of having multiple lung cancers (see *Clinical Presentation* in the NCCN Guidelines for NSCLC).<sup>715,716</sup> It is important to determine whether the multiple lung cancers are metastases or separate lung primaries (synchronous or metachronous), because most multiple lung tumors are metastases.<sup>61,274,717,718</sup> Therefore, it is essential to determine the histology of the lung tumor (see *Principles of Pathologic Review* in the NCCN Guidelines for NSCLC). Infection and other benign diseases also need to be ruled out (eg, inflammatory granulomas).<sup>719,720</sup> Although criteria have been established for diagnosing multiple lung cancers, no definitive method has been established before treatment.<sup>720-723</sup> The Martini and Melamed criteria are often used to diagnose multiple lung cancers as follows: 1) the

histologies are different; or 2) the histologies are the same but there is no lymph node involvement and no extrathoracic metastases.<sup>723</sup>

Treatment of multiple lung cancers depends on status of the lymph nodes (eg, N0–1) and on whether the lung cancers are asymptomatic, symptomatic, or at high or low risk of becoming symptomatic (see *Initial Treatment* in the NCCN Guidelines for NSCLC).<sup>717,724-726</sup> Patients should be evaluated in a multidisciplinary setting (eg, surgeons, radiation oncologists, medical oncologists). In patients eligible for definitive local therapy, parenchymal-sparing resection is preferred (see the *Principles of Surgical Therapy* in the NCCN Guidelines for NSCLC).<sup>716,717</sup> VATS or SABR are reasonable options depending on the number and distribution of the tumors requiring local treatment.<sup>727</sup> Multiple lung nodules (eg, solid, subsolid nodules) may also be detected on CT scans; some of these nodules can be followed with imaging, whereas others need to be biopsied or excised (see the *Diagnostic Evaluation of Incidental Lung Nodules* in this Discussion and the NCCN Guidelines for Lung Cancer Screening, available at [NCCN.org](http://NCCN.org)).<sup>728</sup>

### Stage IIIB Disease

Stage IIIB tumors comprise 2 unresectable groups, including: 1) T1–3, N3 tumors; and 2) T4, N2–3 tumors, which include contralateral mediastinal nodes (T4, N3). Surgical resection is not recommended in patients with T1–3, N3 disease. However, in patients with suspected N3 disease, the NCCN Guidelines recommend pathologic confirmation of nodal status (see *Pretreatment Evaluation* in the NCCN Guidelines for NSCLC).<sup>729,730</sup> In addition, FDG PET/CT scans (if not previously done) and brain MRI (with contrast) should also be included in the pretreatment evaluation. If these imaging tests are negative, then treatment options for the appropriate nodal status should be followed (see the NCCN Guidelines for NSCLC). If N3 disease is confirmed,

definitive concurrent chemoradiation (category 1) is recommended; 2 additional cycles of full-dose chemotherapy can be given if full-dose chemotherapy was not given concurrently with RT.<sup>292,511,547,731,732</sup> For metastatic disease that is confirmed by FDG PET/CT scan and brain MRI (with contrast), treatment is described in the NCCN Guidelines for limited or metastatic disease.

For patients with T4, N2–3 disease (stage IIIB), surgical resection is not recommended. The initial workup includes biopsies of the N3 and N2 nodes. If these biopsies are negative, the same treatment options may be used as for stage IIIA (T4, N0–1) disease (see the NCCN Guidelines for NSCLC). If either the contralateral or ipsilateral mediastinal node is positive, definitive concurrent chemoradiation therapy is recommended (category 1) followed by 2 cycles of full-dose chemotherapy if full-dose chemotherapy was not given concurrently with RT as initial treatment (see the NCCN Guidelines for NSCLC).<sup>292,511,547,731-733</sup>

### Stage IV Disease

In general, systemic therapy is recommended for patients with metastatic disease (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC).<sup>604</sup> In addition, palliative treatment, including RT, may be needed during the disease course to treat localized symptoms, diffuse brain metastases, or bone metastases (see *Therapy for Recurrence and Metastases* in the NCCN Guidelines for NSCLC). This section focuses on patients with limited metastatic disease; management of widespread distant metastases is described in another section (see *Treatment of Recurrences and Distant Metastases* in this Discussion and *Systemic Therapy for Metastatic Disease* in the NCCN Guidelines for NSCLC). Pleural or pericardial effusion is a criterion for stage IV, M1a disease. T4 with pleural effusion is classified as stage IV, M1a (see Table 3 in *Staging* in the NCCN Guidelines for



NSCLC).<sup>117</sup> Although pleural effusions are malignant in 90% to 95% of patients, they may be related to obstructive pneumonitis, atelectasis, lymphatic or venous obstruction, or a pulmonary embolus. Therefore, pathologic confirmation of a malignant effusion by using thoracentesis or pericardiocentesis is recommended. In certain cases where thoracentesis is inconclusive, thoracoscopy may be performed. In the absence of nonmalignant causes (eg, obstructive pneumonia), an exudate or sanguinous effusion is considered malignant regardless of the results of cytologic examination. If the pleural effusion is considered negative for malignancy (M0), recommended treatment is based on the confirmed T and N stage (see the NCCN Guidelines for NSCLC). However, all pleural effusions, whether malignant or not, are associated with unresectable disease in 95% of cases.<sup>734</sup> In patients with effusions that are positive for malignancy, the tumor is treated as M1a with local therapy (ie, ambulatory small catheter drainage, pleurodesis, and pericardial window) in addition to treatment as for stage IV disease (see the NCCN Guidelines for NSCLC).<sup>735</sup>

Management of patients with distant metastasis in limited sites (ie, stage IV, M1b) and good PS depends on the location and number of the metastases; the diagnosis is aided by mediastinoscopy, bronchoscopy, FDG PET/CT scan, and brain MRI (with contrast). The increased sensitivity of FDG PET/CT scans, compared with other imaging methods, may identify additional metastases and, thus, spare some patients from unnecessary futile surgery. However, positive FDG PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If the FDG PET/CT scan is positive in the mediastinum, the lymph node status needs pathologic confirmation. Patients with limited oligometastatic disease (eg, brain metastases) and otherwise limited disease in the chest may benefit from aggressive local therapy to both the primary chest and metastatic sites.<sup>736,737</sup> For the

2017 update (Version 1), the NCCN Panel revised the recommendations for treatment of limited brain metastases by decreasing recommendations for whole brain RT (see *Whole Brain RT and Stereotactic Radiosurgery* in this Discussion text). Clinicians are not using whole brain RT as often in patients with limited brain metastases because of concerns about neurocognitive problems.<sup>473</sup> Aggressive local therapy may comprise surgery and/or definitive RT including SRS and SABR, and may be preceded or followed by chemotherapy. After progression on TKIs, patients with EGFR mutations may be able to continue with their current TKIs; local therapy can be considered to treat their limited metastases (eg, SRS to brain metastases or other sites, SABR for thoracic disease).<sup>738,739</sup> Metastases to the adrenal gland from lung cancer are a common occurrence, with approximately 33% of patients having such disease at autopsy. In patients with otherwise resectable primary tumors, however, many solitary adrenal masses are not malignant. Any adrenal mass found on a preoperative CT scan in a patient with lung cancer should be biopsied to rule out benign adenoma. Local therapy (category 2B) of the adrenal lesion has produced some long-term survivors when an adrenal metastasis has been found and the lung lesion has been curable (see the NCCN Guidelines for NSCLC).<sup>740-743</sup> Some NCCN Panel Members feel that local therapy for adrenal metastases is only advisable if the synchronous lung disease is stage I or possibly stage II (ie, resectable). Systemic therapy is another treatment option for adrenal metastasis.

## Adjuvant Treatment

### Chemotherapy or Chemoradiation

Post-surgical treatment options for patients with stage IA tumors (T1ab, N0) and with positive surgical margins (R1, R2) include re-resection (preferred) or RT (category 2B). Observation is recommended for patients with T1ab-T2ab, N0 tumors and with negative surgical margins

(R0). Adjuvant chemotherapy is a category 2A recommendation for patients with T2ab, N0 tumors and negative surgical margins who have high-risk features (including poorly differentiated tumors, vascular invasion, wedge resection, tumors >4 cm, visceral pleural involvement, and unknown lymph node sampling [Nx]) (see *Adjuvant Treatment* in the NCCN Guidelines for NSCLC).<sup>535,744</sup> If the surgical margins are positive in patients with T2ab, N0 tumors, options include: 1) re-resection (preferred) with (or without) chemotherapy; or 2) RT with (or without) chemotherapy (chemotherapy is recommended for stage IIA).<sup>341,535</sup>

The NCCN Panel recommends chemotherapy (category 1) for patients with negative surgical margins and stage II disease, including 1) T1ab–T2a, N1; 2) T2b, N1; or 3) T3, N0 disease.<sup>531,745</sup> If surgical margins are positive in these patients, options after an R1 resection include: 1) re-resection and chemotherapy; or 2) chemoradiation (either sequential or concurrent). Options after an R2 resection include: 1) re-resection and chemotherapy; or 2) concurrent chemoradiation. Most NCCN Member Institutions favor concurrent chemoradiation for positive margins, but sequential is reasonable in frailer patients.<sup>713</sup>

Adjuvant chemotherapy can also be used in patients with stage III NSCLC who have had surgery (see the NCCN Guidelines for NSCLC). Patients with T1-3, N2 or T3, N1 disease (discovered only at surgical exploration and mediastinal lymph node dissection) and positive margins may be treated with chemoradiation; either sequential or concurrent chemoradiation is recommended for an R1 resection, whereas concurrent chemoradiation is recommended for an R2 resection (see *Adjuvant Treatment* in the NCCN Guidelines for NSCLC). Patients with negative margins may be treated with either 1) chemotherapy (category 1); or 2) sequential chemotherapy plus RT (for N2 only).<sup>531</sup>

For stage IIIA superior sulcus tumors (T4 extension, N0–1) that become resectable after preoperative concurrent chemoradiation, resection followed by chemotherapy is recommended (see the NCCN Guidelines for NSCLC). Surgical reevaluation (including imaging) is done to determine whether the tumor is resectable after treatment. If the lesion remains unresectable after preoperative concurrent chemoradiation, the full course of definitive chemo/RT should be completed; an additional 2 cycles of chemotherapy as an adjuvant treatment can be given if full doses were not given with concurrent therapy. Among patients with chest wall lesions with T3 invasion–T4 extension, N0–1 disease, those who are initially treated with surgery (preferred) may receive chemotherapy alone if the surgical margins are negative. When surgical margins are positive, they may receive either 1) sequential or concurrent chemoradiation; or 2) re-resection with chemotherapy. As previously mentioned, most NCCN Member Institutions favor concurrent chemoradiation for positive margins, but sequential is reasonable in frailer patients.<sup>713</sup> A similar treatment plan is recommended for resectable tumors of the proximal airway or mediastinum (T3–4, N0–1).

For patients with stage IIIA disease and positive mediastinal nodes (T1–3, N2) with no apparent disease progression after initial treatment, recommended treatment includes surgery with (or without) RT (if not given preoperatively) and/or with (or without) chemotherapy (category 2B for chemotherapy) (see the NCCN Guidelines for NSCLC). Alternatively, if the disease progresses, patients may be treated with either 1) local therapy using RT (if not given previously) with (or without) chemotherapy; or 2) systemic therapy. In patients with separate pulmonary nodules in the same lobe (T3, N0-1) or ipsilateral non-primary lobe (T4, N0-1), surgery is recommended. In patients with N2 disease, if the margins are negative, sequential chemotherapy (category 1) with radiation is recommended. If the resection margins are

positive in patients with N2 disease, concurrent chemoradiation is recommended for an R2 resection, whereas either concurrent or sequential chemoradiation is recommended for an R1 resection. Concurrent chemoradiation is often used for positive margins, but sequential is reasonable in frailer patients.

Because patients with stage III disease have both local and distant failures, theoretically, the use of chemotherapy may eradicate micrometastatic disease obviously present but undetectable at diagnosis. The timing of this chemotherapy varies (see the NCCN Guidelines for NSCLC). Such chemotherapy may be given alone, sequentially, or concurrently with RT. In addition, chemotherapy could be given preoperatively or postoperatively in appropriate patients.

On the basis of clinical studies on neoadjuvant and adjuvant chemotherapy for NSCLC,<sup>499-501</sup> the NCCN Panel recommends cisplatin combined with docetaxel, etoposide, gemcitabine, or vinorelbine for adjuvant chemotherapy for all histologies in the NCCN Guidelines; other options include cisplatin combined with pemetrexed for non-squamous NSCLC (see *Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy* in the NCCN Guidelines for NSCLC).<sup>536,553,556</sup> For patients with comorbidities or those who cannot tolerate cisplatin, carboplatin combined with paclitaxel is an option.<sup>536,746</sup> A number of phase 2 studies have evaluated neoadjuvant chemotherapy for stage III NSCLC, with (or without) RT, followed by surgery.<sup>747-749</sup>

Three phase 3 trials have assessed neoadjuvant chemotherapy followed by surgery compared with surgery alone in the treatment of stage III NSCLC.<sup>506,750-752</sup> The S9900 trial (a SWOG study)—one of the largest randomized trials examining preoperative chemotherapy in early-stage NSCLC—assessed surgery alone compared with surgery plus preoperative paclitaxel/carboplatin in patients with stage IB/IIA and

stage IIB/IIIA NSCLC (excluding superior sulcus tumors). PFS and overall survival were improved with preoperative chemotherapy.<sup>751,752</sup> All 3 studies showed a survival advantage for patients who received neoadjuvant chemotherapy. The 2 earlier phase 3 studies had a small number of patients, while the SWOG study was stopped early because of the positive results of the IALT study. However, the induction chemotherapy-surgery approach needs to be compared with induction chemotherapy-RT in large, randomized clinical trials.

### Radiation Therapy

After complete resection of clinical early-stage NSCLC, postoperative RT has been found to be detrimental for pathological N0 or N1 stage disease in a meta-analysis of small randomized trials using older techniques and dosing regimens and a population-based analysis of data from SEER.<sup>753</sup> However, there was an apparent survival benefit of postoperative RT in patients with N2 nodal stage diagnosed surgically.<sup>372</sup> The analysis of the ANITA trial also found that postoperative RT increased survival in patients with N2 disease who received adjuvant chemotherapy.<sup>341</sup> A recent review of the National Cancer Data Base concluded that postoperative RT and chemotherapy provided a survival advantage for patients with completely resected N2 disease when compared with chemotherapy alone.<sup>754</sup> A recent meta-analysis also concluded that postoperative RT improves survival for patients with N2 disease.<sup>755</sup> Postoperative adjuvant sequential chemotherapy with RT is recommended for patients with T1–3, N2 disease and negative margins (see *Adjuvant Treatment* in the NCCN Guidelines for NSCLC). A meta-analysis assessed postoperative chemotherapy with (or without) postoperative RT in patients mainly with stage III disease.<sup>745</sup> In this meta-analysis, 70% of the eligible trials used adjuvant chemotherapy before RT; 30% used concurrent chemo/RT.

Regimens included cisplatin/vinorelbine followed by RT or concurrent cisplatin/etoposide.

The ACR Appropriateness Criteria® provide specific recommendations for postoperative adjuvant therapy.<sup>756,757</sup> Either concurrent or sequential chemoradiation may be used for postoperative adjuvant therapy, depending on the type of resection and the setting (eg, N2 disease) (see *Adjuvant Treatment* in the NCCN Guidelines for NSCLC).

Concurrent chemo/RT is recommended for R2 resections, whereas either sequential or concurrent chemo/RT is recommended for R1 resections. Concurrent chemoradiation is often used for positive margins, but sequential is reasonable in frailer patients.<sup>713</sup>

Cisplatin/etoposide, cisplatin/vinblastine, and carboplatin/paclitaxel are chemoradiation regimens recommended by the NCCN Panel for all histologies (see *Chemotherapy Regimens Used with Radiation Therapy* in the NCCN Guidelines for NSCLC).<sup>546</sup> Pemetrexed with either cisplatin or carboplatin may be used for concurrent chemoradiation in patients with non-squamous NSCLC.<sup>549,758,759</sup> When chemoradiation is recommended in the NCCN Guidelines, these regimens may be used for stage II to III disease.<sup>342,343,511,512,547,550,551</sup> A recent phase 3 trial (PROCLAIM) assessed concurrent thoracic RT with cisplatin/pemetrexed versus cisplatin/etoposide followed by consolidation chemotherapy in patients with unresectable stage III non-squamous NSCLC.<sup>544</sup> Both regimens were equivalent in terms of survival, but the cisplatin/pemetrexed regimen was associated with less neutropenia (24.4% vs. 44.5%;  $P < .001$ ) and fewer grade 3 to 4 adverse events (64.0% vs. 76.8%;  $P = .001$ ). For the 2017 update (Version 1), the NCCN Panel deleted the cisplatin/etoposide consolidation regimen based on the PROCLAIM trial. In addition, the NCCN Panel clarified that the cisplatin/pemetrexed and

carboplatin/paclitaxel regimens may be followed by consolidation chemotherapy alone.

### Surveillance

Because recurrence is common after treatment for NSCLC, surveillance with H&P and chest CT (with or without contrast) is recommended in the NCCN Guidelines. Data from randomized phase 3 trials are not available to clarify surveillance recommendations; therefore, the most appropriate schedules are controversial.<sup>760-764</sup> For the 2017 update (Version 1), the surveillance guidelines were revised by polling the NCCN Panel regarding their practice patterns. Details regarding the specific surveillance schedules for patients with no clinical or radiographic evidence of disease after completion of definitive therapy are outlined in the algorithm based on stage (see *Surveillance* in the NCCN Guidelines for NSCLC). A chest CT scan with (or without) contrast and an H&P are recommended for the initial surveillance schedules (2–5 years) followed by an annual low-dose non-contrast-enhanced CT and an H&P.<sup>762,763,765-768</sup> Patients treated with chemotherapy with (or without) RT who have residual abnormalities may require more frequent imaging. Data show that low-dose CT screening decreased the mortality from lung cancer;<sup>53</sup> low-dose CT may be beneficial for identifying recurrences. FDG PET/CT or brain MRI is not routinely recommended for routine surveillance in patients without symptoms. But, PET may be useful for assessing CT scans that appear to show malignant neoplasms but may be radiation fibrosis, atelectasis, or other benign conditions. It is important to note that areas previously treated with RT may remain FDG avid for up to 2 years; therefore, histologic confirmation of apparent “recurrent” disease is needed.<sup>769</sup> Information about smoking cessation (eg, advice, counseling, therapy) should be provided for patients undergoing surveillance to improve their quality of life.

The NCCN Guidelines include information about the long-term follow-up care of NSCLC survivors (see *Cancer Survivorship Care* in the NCCN Guidelines for NSCLC). These recommendations include guidelines for routine cancer surveillance, immunizations, health monitoring, counseling for wellness and health promotion, and cancer screening. An analysis suggests that patients who survive lung cancer have a high symptom burden 1 year after diagnosis and therefore need management after treatment.<sup>770</sup>

### Treatment of Recurrences and Distant Metastases

Recurrences are subdivided into locoregional recurrences and distant metastases. Management of locoregional recurrences (eg, endobronchial obstruction, mediastinal lymph node recurrence, superior vena cava obstructions, severe hemoptysis) is described in the NCCN Guidelines (see *Therapy for Recurrence and Metastasis* in the NCCN Guidelines for NSCLC).<sup>8</sup> For patients with endobronchial obstruction, relieving airway obstruction may increase survival, especially in patients who are severely compromised, and may improve the quality of life.<sup>771</sup> After treatment for the locoregional recurrence, observation or systemic therapy (category 2B for systemic therapy) is recommended if disseminated disease is not evident. However, systemic therapy is recommended for disseminated disease. The type of systemic therapy depends on the histologic type, whether genetic alterations are present that can be treated with targeted therapy, and PS (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC). For the 2017 update (Version 1), the NCCN Panel now recommends response assessment after 2 cycles of systemic therapy then after every 2 to 4 cycles of therapy or when clinically indicated; assessment is done using CT with (or without contrast) of known sites of disease.

Management of distant metastases (eg, localized symptoms; bone, limited, diffuse brain, or disseminated metastases) is described in the NCCN Guidelines (see *Therapy for Recurrence and Metastasis* in the NCCN Guidelines for NSCLC). Palliation of symptoms throughout the disease course can be achieved with external-beam RT for distant metastases with localized symptoms, diffuse brain metastases, or bone metastasis (bisphosphonate or denosumab therapy can be considered).<sup>349,772,773</sup> For patients at risk of fracture in weight-bearing bone, orthopedic stabilization and palliative RT are recommended.

Of note, recurrent and metastatic disease have historically been regarded as incurable. However, selected limited locoregional recurrences may be treated with curative intent therapy (surgery or RT with [or without] chemotherapy) (see *Therapy for Recurrence and Metastasis* in the NCCN Guidelines for NSCLC). Similarly, patients with limited-site oligometastatic disease and good PS may benefit from aggressive local therapies to the metastatic and primary sites, with clinical data suggesting the possibility of long-term survival (see *Initial Treatment for Stage IV, M1b: Limited Sites* in the NCCN Guidelines for NSCLC).<sup>438,439,442,774-778</sup> In addition, emerging clinical data suggest the feasibility of definitive reirradiation of local recurrences within prior RT fields using highly conformal techniques, although this should be limited to highly selected cases in specialty centers with appropriate expertise because of the potential for severe toxicity with high cumulative radiation doses to critical structures.<sup>346,449-451,779-782</sup>

Denosumab or intravenous bisphosphonate therapy can be considered in patients with bone metastasis.<sup>131,783-786</sup> In patients with NSCLC who have bone metastases, data suggest that denosumab increases median overall survival when compared with zoledronic acid (9.5 vs. 8 months).<sup>783,787</sup> Denosumab and bisphosphonate therapy can be associated with severe hypocalcemia; patients with hypoparathyroidism

and vitamin D deficiency are at increased risk for hypocalcemia. The FDA has approved the use of zoledronic acid and denosumab in patients with bone metastases from solid tumors.<sup>788,789</sup>

For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected (see *Metastatic Disease: Histologic Subtype* in the NCCN Guidelines for NSCLC).<sup>556</sup> In addition, testing for genetic alterations (ie, driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing. Several targeted agents have category 1 recommendations for first-line therapy based on larger trials such as erlotinib, gefitinib, afatinib, and crizotinib.<sup>604</sup>

Additional targeted therapies for patients with other genetic alterations are also recommended, although there is less evidence for these agents (see *Emerging Targeted Agents for Patients with Genetic Alterations* in the NCCN Guidelines for NSCLC). The following targeted agents are recommended (category 2A) for patients with specific genetic alterations: crizotinib (for high-level MET amplification or MET exon 14 skipping mutation); dabrafenib (with or without trametinib) and vemurafenib (for BRAF V600E mutations); and cabozantinib and vandetanib (for RET rearrangements).<sup>83,88,124-126,147,150-</sup>

<sup>153,157,160,161,171,173,220,594,790-802</sup> The dabrafenib/trametinib regimen is recommended for patients with BRAF V600E mutations based on data from a recent phase II study; patients had a response rate of 63% (36/57).<sup>150,796</sup> Grade 3 to 4 adverse events included neutropenia (9%), hyponatremia (7%), and anemia (5%). For the 2017 update (Version 1), the NCCN Panel added a recommendation for vandetanib (category 2A)

based on preliminary data from a phase 2 study in 18 patients.<sup>791</sup> Partial remission (17%) was reported in 3 patients; stable disease (44%) was reported in another 8 patients. Six (33%) patients died within 3 months of enrollment of the study due to rapid tumor progression. The recommendation for cabozantinib for RET rearrangements is based on data from a phase II study.<sup>125,795</sup> Trastuzumab and afatinib (both for HER2 mutations) are category 2B recommendations, because response rates are lower and treatment is less effective when these agents are used for patients with the indicated genetic alterations.<sup>161,798</sup> Other targeted therapies (such as ceritinib, alectinib, and osimertinib) are recommended as subsequent therapies for patients whose disease becomes resistant to first-line targeted therapies; other targeted therapies are being investigated for resistance.

EGFR mutation testing (category 1) is recommended in patients with non-squamous NSCLC (ie, adenocarcinoma, large cell carcinoma) or in NSCLC NOS, because erlotinib, gefitinib, and afatinib (category 1 for all) are recommended for patients who are positive for sensitizing EGFR mutations (see *EGFR Mutation Positive/First-Line Therapy* in the NCCN Guidelines for NSCLC).<sup>86,169,201,204,803</sup> Testing for ALK rearrangements (category 1) is also recommended in patients with non-squamous NSCLC, because crizotinib is recommended (category 1) for patients who are positive for ALK rearrangements.<sup>133,804</sup> Crizotinib is also recommended for patients who are positive for ROS1 rearrangements and MET amplification.<sup>124,126,160,805</sup> For the 2017 update (Version 1), the NCCN Panel added a recommendation for testing for ROS1 rearrangements (category 2A). Testing for ROS1 has typically been done using FISH; however, a validated NGS platform that can detect this gene fusion may also be used.<sup>255</sup> The NCCN Panel recommends that EGFR mutation testing be done as part of broad molecular profiling (eg, multiplex mutation screening assays or NGS). Testing for ALK

gene rearrangements can be done with FISH or with NGS if the platform is validated and can identify gene fusions.<sup>147-149</sup> For the 2017 update (Version 1), the NCCN Panel also added a recommendation for upfront PD-L1 expression testing before first-line therapy in patients with metastatic NSCLC to assess whether patients are candidates for immune checkpoint inhibitors (see *Pembrolizumab* in this Discussion).

As previously mentioned, recent recommendations from an international panel suggest that general histologic categories be avoided (eg, NSCLC), because more effective treatment can be selected when the histology is known.<sup>61</sup> Patients with pure squamous cell carcinoma do not seem to have ALK rearrangements, ROS1 rearrangements, or sensitizing EGFR mutations; therefore, routine testing is not recommended in these patients.<sup>134,806-808</sup> However, testing for ALK rearrangements, ROS1 rearrangements, or EGFR mutations can be considered in patients with squamous cell carcinomas who never smoked and those whose histology was determined using small biopsy specimens or mixed histology specimens.<sup>134</sup> Treatment recommendations and eligibility criteria for patients with non-squamous NSCLC (or NSCLC NOS) who are negative or unknown for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression are described in the NCCN Guidelines. Treatment recommendations and eligibility criteria for patients with squamous cell carcinoma are also described in the NCCN Guidelines. These recommendations are briefly summarized in the following paragraphs. Data supporting these recommendations are described in the following section (see *Trial Data* in this Discussion).

In general, 2-drug regimens (ie, doublet chemotherapy) are recommended over single agents (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC); however, targeted therapy is sometimes added to the 2-drug regimen (eg, the

addition of bevacizumab to carboplatin/paclitaxel). Single-agent targeted therapy is recommended for patients with ALK or ROS1 rearrangements, sensitizing EGFR mutations, or other driver mutations (see *Emerging Targeted Agents for Patients With Genetic Alterations* in the NCCN Guidelines for NSCLC). Pembrolizumab is now recommended as first-line therapy for patients with PD-L1 expression of 50% or more.

Doublet chemotherapy regimens, such as cisplatin/pemetrexed, are recommended (category 1) for patients with non-squamous NSCLC who are negative or unknown for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression (also known as wild-type) (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC, the NCCN Drugs & Biologics Compendium [NCCN Compendium®] for NSCLC, and the NCCN Evidence Blocks™ for NSCLC).<sup>556</sup> For the 2017 update (Version 1), the NCCN Panel revised the lists of recommended doublet and single-agent systemic therapy regimens for patients with non-squamous NSCLC or NSCLC NOS who are negative or unknown for mutations, rearrangements, or PD-L1 expression by deleting regimens that are rarely used in the United States. Deleted regimens include carboplatin/vinorelbine, cisplatin/vinorelbine, etoposide, irinotecan, and vinorelbine.

Bevacizumab/chemotherapy is another option for patients with non-squamous NSCLC who are negative or unknown for mutations, rearrangements, or PD-L1 expression if eligibility criteria are met.<sup>809</sup> Previously, patients with brain metastases were excluded from receiving bevacizumab because of concerns about CNS hemorrhage; however, data suggest that bevacizumab can be used in patients with treated CNS metastases.<sup>810</sup> For the 2017 update (Version 1), the NCCN Panel deleted the bevacizumab/cisplatin/pemetrexed regimen because it is

rarely used. Other chemotherapy options are also recommended, although some regimens may be more appropriate for certain patients, depending on histology, PS, and other factors (see *Trial Data* in this Discussion, *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC, the NCCN Compendium® for NSCLC, and the NCCN Evidence Blocks™ for NSCLC).<sup>604,811</sup> A phase 3 randomized trial in elderly patients (70–89 years) with advanced NSCLC reported that combined therapy with weekly paclitaxel and monthly carboplatin improved survival when compared with single-agent therapy using either gemcitabine or vinorelbine (10.3 vs. 6.2 months).<sup>812</sup> Systemic therapy for elderly patients with advanced NSCLC needs to be carefully selected to avoid adverse reactions.<sup>813</sup>

Cisplatin/gemcitabine (category 1) is a recommended doublet option for patients with squamous cell carcinoma.<sup>556</sup> Carboplatin/paclitaxel, carboplatin/gemcitabine (category 1 for both), and other regimens listed in the NSCLC algorithm may also be used (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC, the NCCN Compendium® for NSCLC, and the NCCN Evidence Blocks™ for NSCLC). For the 2017 update (Version 1), the NCCN Panel revised the lists of recommended doublet systemic therapy regimens for patients with squamous cell NSCLC who are negative or unknown for mutations, rearrangements, or PD-L1 expression by deleting regimens that are rarely used. Deleted regimens include carboplatin/etoposide, carboplatin/vinorelbine, cisplatin/vinorelbine, cisplatin/gemcitabine/necitumumab, etoposide, irinotecan, and vinorelbine. Regimens containing pemetrexed or bevacizumab are not recommended for squamous cell carcinoma. Currently, there are fewer treatment options for patients with squamous cell carcinoma when compared with non-squamous NSCLC. Research is ongoing to find newer options.<sup>6,83,149,814,815</sup>

### Trial Data

In a phase 2/3 trial (ECOG 4599), 878 patients were randomly assigned to either 1) bevacizumab in combination with paclitaxel/carboplatin; or 2) paclitaxel/carboplatin alone.<sup>560,816</sup> Both regimens were well tolerated with selected toxicities. Patients receiving bevacizumab/paclitaxel/carboplatin showed an improved median survival (12.3 vs. 10.3 months,  $P = .003$ ) when compared to patients receiving paclitaxel/carboplatin alone.<sup>560</sup> The overall 1-year and 2-year survival was 51% vs. 44% and 23% vs. 15%, respectively, in favor of the bevacizumab/paclitaxel/carboplatin arm.<sup>560</sup> However, more significant toxicities were observed with bevacizumab/paclitaxel/carboplatin compared to paclitaxel/carboplatin (grade 4 neutropenia: 25.5% vs. 16.8%, grade 5 hemoptysis: 1.2% vs. 0%, and grade 3 hypertension: 6.8% vs. 0.5%). Treatment-related deaths were more common with bevacizumab/paclitaxel/carboplatin (15 patients) than with paclitaxel/carboplatin (2 patients) ( $P = .001$ ). A recent analysis of ECOG 4599 found that patients with adenocarcinoma histology receiving bevacizumab/paclitaxel/carboplatin had improved survival compared with chemotherapy alone (14.2 vs. 10.3 months).<sup>809</sup> However, a trial (AVAiL) comparing cisplatin/gemcitabine with (or without) bevacizumab did not show an increase in survival with the addition of bevacizumab.<sup>817,818</sup>

A noninferiority trial in 1725 patients with advanced NSCLC (either stage IIIB or IV; most were stage IV) assessed cisplatin/gemcitabine compared with cisplatin/pemetrexed.<sup>556</sup> Patients with either adenocarcinoma or large cell carcinoma (ie, non-squamous NSCLC) had improved survival with cisplatin/pemetrexed (adenocarcinoma: 12.6 vs. 10.9 months). Patients with squamous cell carcinoma had improved survival with the cisplatin/gemcitabine regimen (10.8 vs. 9.4 months). When compared with the cisplatin/gemcitabine regimen, the



cisplatin/pemetrexed regimen had significantly lower rates of grade 3 or 4 neutropenia, anemia, and thrombocytopenia ( $P \leq .001$ ); febrile neutropenia ( $P = .002$ ); and alopecia ( $P < .001$ ). Treatment-related deaths were similar for both regimens (cisplatin/pemetrexed, 9 patients [1.0%]; cisplatin/gemcitabine, 6 patients [0.7%]). A recent analysis of three phase 3 trials confirmed that pemetrexed improves survival for patients with non-squamous NSCLC in first-line, subsequent, and maintenance therapy.<sup>819</sup>

Data show that platinum-based combination therapy is superior to best supportive care for patients with advanced, incurable disease. Cisplatin or carboplatin have been proven effective in combination with many of the following agents: docetaxel, etoposide, gemcitabine, paclitaxel (and albumin-bound paclitaxel), pemetrexed, and vinorelbine (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC).<sup>536,553-556,579,580,588</sup> Non-platinum regimens (eg, gemcitabine/docetaxel, gemcitabine/vinorelbine) are reasonable alternatives, because data show they are active and less toxic than platinum-based regimens.<sup>582-585,820</sup>

### Number of Cycles of First-Line Systemic Therapy

Patients receiving first-line systemic therapy for advanced disease should be evaluated for tumor response with a CT scan. Approximately 25% of patients show disease progression after the initial cycle of chemotherapy; subsequent therapy is recommended for these patients (see the NCCN Guidelines for NSCLC). Patients with responsive or stable disease can continue to receive a total of 4 to 6 cycles of systemic therapy.<sup>516,664,821</sup> Currently, the NCCN Guidelines do not recommend continuing chemotherapy beyond 4 to 6 cycles.

Recent data from the PARAMOUNT trial suggest that 4 cycles of platinum-based therapy is not optimal;<sup>656</sup> tumors can shrink between 4

to 6 cycles of chemotherapy. However, patients may not be able to tolerate more than 4 cycles of chemotherapy, and most of the maintenance trials used only 4 cycles of chemotherapy.<sup>563</sup> A meta-analysis suggests that continuing the initial regimen beyond 4 to 6 cycles is associated with increased PFS; however, patients have more adverse events.<sup>822</sup> A phase 3 randomized trial suggested that continuing chemotherapy beyond 4 to 6 cycles is not beneficial; however, many patients assigned to longer duration of therapy did not receive the planned number of cycles.<sup>663,664</sup> In this phase 3 trial, taxane-based regimens were used and patients had increasing neurotoxicity as more cycles were used.<sup>664</sup>

Many patients with adenocarcinoma now receive pemetrexed-based regimens and not taxane-based regimens. Pemetrexed-based regimens are less toxic than taxane-based regimens. Thus, data suggesting that more than 6 cycles of first-line chemotherapy are not appropriate may only apply to taxane-based regimens.<sup>563</sup> Studies report that 60% of patients were able to receive 6 cycles of pemetrexed-based chemotherapy (and had a low incidence of toxicity), whereas only 42% were able to receive more than 5 cycles of taxane-based chemotherapy and often stopped therapy because of neurotoxicity.<sup>654,664</sup>

### Maintenance Therapy

For patients with non-squamous NSCLC and negative or unknown test results for ALK or ROS1 rearrangements, sensitizing EGFR mutations, or PD-L1 expression, maintenance therapy is another option for those with responsive or stable disease after first-line systemic therapy (see the NCCN Guidelines for NSCLC). Continuation maintenance therapy includes bevacizumab (category 1), pemetrexed (category 1), bevacizumab/pemetrexed, or gemcitabine (category 2B) (see the NCCN

Guidelines for NSCLC).<sup>560,565,619,656,658,660,661</sup> Switch maintenance therapy for these patients includes pemetrexed (category 2B).<sup>660,661,666,667</sup>

For the 2017 update (Version 2.2017), the NCCN Panel deleted the recommendation for erlotinib as switch maintenance therapy (and as subsequent therapy) for patients with non-squamous NSCLC and PS 0-2 but without EGFR mutations based on preliminary results from a randomized trial (IUNO) and revised indication by the FDA. The data showed that overall survival and PFS were not improved in patients receiving erlotinib when compared with placebo. A phase 3 randomized trial (n = 663) assessed the effect of best supportive care with (or without) switch maintenance pemetrexed in patients with advanced NSCLC who had received platinum-based chemotherapy but had not progressed.<sup>667</sup> In patients with non-squamous NSCLC, overall survival was increased with pemetrexed when compared with placebo (15.5 vs. 10.3 months,  $P = .002$ ). Close observation is another option. Maintenance therapy is discussed in greater detail earlier in this Discussion (see *Combined Modality Therapy: Maintenance Therapy*).

For patients with squamous cell carcinoma, gemcitabine (category 2B) is recommended as continuation maintenance therapy (see the NCCN Guidelines for NSCLC).<sup>661,666</sup> Switch maintenance therapy for these patients includes docetaxel (category 2B). Close observation is a category 2A option. As previously mentioned, a phase 3 randomized trial compared using maintenance therapy with either gemcitabine or erlotinib after first-line therapy with cisplatin-gemcitabine. Continuation maintenance therapy with single-agent gemcitabine increased PFS to a greater extent (3.8 months) than switch maintenance therapy with erlotinib (2.9 months) when compared with observation (1.9 months).<sup>660,661</sup> However, the benefits of maintenance therapy were very slight; therefore, the recommendation is only category 2B for maintenance therapy with gemcitabine. A phase 3 trial assessed switch

maintenance therapy with docetaxel given either immediately after chemotherapy or delayed until progression.<sup>671</sup> However, switch maintenance therapy with docetaxel is a category 2B recommendation in the NCCN Guidelines, because many patients in the delayed chemotherapy arm did not receive docetaxel.<sup>823</sup>

### Continuation of Erlotinib, Gefitinib, or Afatinib After Progression

Previously, erlotinib was commonly used in the United States in patients with sensitizing EGFR mutations because of restrictions on the use of gefitinib. However, gefitinib was re-approved by the FDA based on a phase 4 study and is now available in the United States.<sup>130</sup> Patients may continue to derive benefit from erlotinib, gefitinib, or afatinib after disease progression; discontinuation of these TKIs leads to more rapid progression of disease (symptoms, tumor size, and FDG-avidity on PET scan).<sup>824</sup> This strategy mirrors the experience in other oncogene-addicted cancers, particularly *HER2*-amplified breast cancer. In women with *HER2*-amplified breast cancer who have had progression of disease on trastuzumab, improved radiographic response rate, time to progression, and overall survival are observed when conventional chemotherapy is added to trastuzumab.<sup>825</sup>

After development of acquired resistance in patients with lung adenocarcinoma and sensitizing *EGFR* mutations, erlotinib, gefitinib, or afatinib may be continued, but osimertinib is also an option for select patients; local therapy should be considered (eg, SRS to brain metastases or other sites, SABR for thoracic disease).<sup>468,738,739,826</sup> The NCCN Panel recommends continuing erlotinib, gefitinib, or afatinib and considering local therapy in patients with asymptomatic progression; however, treatment varies for patients with symptomatic progression (see *Sensitizing EGFR Mutation Positive: Subsequent Therapy* in the NCCN Guidelines for NSCLC).<sup>799,827,828</sup> For the 2017 update (Version 1),

the NCCN Panel revised the recommendations for patients with sensitizing *EGFR* mutations who have progressed on erlotinib, gefitinib, or afatinib. Osimertinib is now recommended for patients with symptomatic brain metastases. Another option is to continue use of erlotinib, gefitinib, or afatinib for these patients; however, additional therapy may be added or substituted (eg, local therapy, systemic therapy). First-line systemic therapy options are recommended for patients with multiple symptomatic lesions who are negative for T790M; osimertinib is recommended for patients positive for T790M.

Accumulating data suggest how cancers become resistant to EGFR inhibitors.<sup>829</sup> The most common known mechanism is the acquisition of T790M (which is a secondary mutation in EGFR), that renders the kinase resistant to erlotinib, gefitinib, or afatinib.<sup>830,831</sup> Therefore, if patients are T790M positive, osimertinib is recommended and erlotinib, gefitinib, or afatinib are discontinued. Amplification of the MET oncogene is another validated resistance mechanism. To overcome resistance, EGFR must still be inhibited. In the case of MET amplification, new inhibitors must be added to the EGFR inhibitor; however, EGFR inhibition is still required to induce remission. Furthermore, data by Riely et al show that when cancers start to progress, which were once sensitive to EGFR inhibitors, discontinuation of the EGFR TKI can lead to a much more accelerated progression of the cancer.<sup>824,832</sup> Thus, continuing EGFR TKIs is beneficial in many patients even after they develop resistance to EGFR TKIs.<sup>826</sup>

### Second-Line and Beyond (Subsequent) Systemic Therapy

The phrase *subsequent* therapy was recently substituted for the terms *second-line*, *third-line*, and *beyond* systemic therapy, because the line of therapy may vary depending on previous treatment with targeted agents. Subsequent systemic therapy regimens for patients who have

disease progression during or after first-line therapy are described in the NSCLC algorithm and depend on the specific genetic alteration, the histologic subtype, and whether the patient has symptoms (see the NCCN Guidelines for NSCLC).<sup>833-842</sup> For the 2017 update (Version 1), the NCCN Panel now recommends response assessment of known sites of disease with CT (with contrast) every 6 to 12 weeks in patients receiving subsequent therapy. Note that traditional RECIST response criteria (1.1) are used to assess response for most types of systemic therapy but different response criteria may be useful for assessing response in patients receiving immunotherapy.<sup>843-845</sup>

The NCCN Panel recommends immune checkpoint inhibitors, as preferred agents for subsequent therapy in patients with metastatic NSCLC based on improved survival rates, longer duration of response, and fewer adverse events when compared with cytotoxic chemotherapy (see *Nivolumab*, *Pembrolizumab*, and *Atezolizumab* in this Discussion).<sup>621,623,649</sup> Human immune-checkpoint-inhibitor antibodies inhibit the PD-1 receptor or PD-L1, which improves antitumor immunity; PD-1 receptors are expressed on activated cytotoxic T-cells.<sup>621,625,626</sup> The NCCN Panel recommends nivolumab (category 1) as subsequent therapy for patients with metastatic non-squamous or squamous NSCLC based on a phase 3 randomized trial (CheckMate-057) and FDA approval.<sup>621</sup> The NCCN Panel recommends pembrolizumab (category 1) as subsequent therapy for patients with metastatic non-squamous or squamous NSCLC and PD-L1 expression based on a recent phase 2/3 randomized trial (KEYNOTE-010) trial, KEYNOTE-001 trial, and FDA approval.<sup>624,642</sup> The NCCN Panel also recommends atezolizumab as subsequent therapy for patients with metastatic non-squamous or squamous NSCLC based on preliminary data from a phase 3 randomized trial (OAK), data from a phase 2 trial (POPLAR), and recent FDA approval.<sup>648,649</sup>

The NCCN Panel recommends osimertinib as subsequent therapy for patients with metastatic EGFR T790M-positive NSCLC who have progressed on erlotinib, gefitinib, or afatinib therapy based on recent data and on the FDA approval (see *Osimertinib* in this Discussion).<sup>188</sup> Osimertinib (AZD9291) is an oral TKI that inhibits both EGFR-sensitizing mutations and T790M. Data from a recent phase 2 trial report that osimertinib is associated with a response rate of about 61% and disease control rate of about 95% in patients who have progressed on sensitizing EGFR TKI therapy; 13% of patients had drug-related grade 3 or higher adverse events with one fatal event.<sup>188,609,610</sup> The FDA has approved osimertinib for patients with metastatic EGFR T790M-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. Most patients with sensitizing EGFR mutations and metastatic NSCLC typically progress after about 8 to 16 months of erlotinib or gefitinib therapy.<sup>181</sup> EGFR T790M is associated with acquired resistance to TKI therapy and has been reported in about 60% of patients with disease progression after initial response to sensitizing EGFR TKI therapy.<sup>146,180-186</sup> T790M can be assessed using an FDA-approved test or other validated laboratory test done in a CLIA-approved laboratory.

For patients with sensitizing EGFR mutations who progress during or after first-line targeted therapy, recommended therapy depends on whether the progression is asymptomatic or symptomatic and includes: 1) continuing erlotinib, afatinib, or gefitinib with (or without) local therapy; 2) osimertinib; or 3) a first-line systemic therapy regimen for either non-squamous or squamous cell NSCLC (such as cisplatin/pemetrexed or cisplatin/gemcitabine, respectively). For the 2017 update (Version 1), the NCCN Panel now also recommends osimertinib for patients with T790M who have brain metastases.<sup>613-615</sup> Data suggest that an afatinib/cetuximab regimen may be useful for

patients who have progressed after receiving EGFR TKI therapy and chemotherapy.<sup>846</sup> Patients with T790M-positive and T790M-negative tumors had a similar response rate to an afatinib/cetuximab regimen (32% vs. 25%;  $P = .341$ ). The NCCN Panel recommends (category 2A) considering an afatinib/cetuximab regimen for patients who have progressed after receiving EGFR TKIs and chemotherapy based on these data.

Among patients with sensitizing EGFR mutations, no improvement in overall survival has been noted in the phase 3 trials assessing pembrolizumab, nivolumab, or atezolizumab compared to docetaxel, but there were not enough patients with these mutations to determine whether there were statistically significant differences (see next paragraph).<sup>621,624,649,847</sup> Immunotherapy was not worse than chemotherapy and was better tolerated. In the phase 3 trials for pembrolizumab, nivolumab, or atezolizumab versus docetaxel as subsequent therapy for patients with metastatic NSCLC, subset analyses were done in patients with EGFR mutations to determine the best subsequent therapy.<sup>621,624,649</sup> The HRs for overall survival do not favor docetaxel over nivolumab (HR, 1.18; CI, 0.69–2.0), pembrolizumab (HR, 0.88; CI, 0.45–1.7), or atezolizumab (HR, 1.24; CI, 0.7–2.2); the CIs for the HRs are wide probably because there were so few patients. The HRs for PFS do favor docetaxel for patients with EGFR mutations when compared with either pembrolizumab (HR, 1.79; CI, 0.94–3.42) or nivolumab (HR, 1.46; CI, 0.90–2.37). But again, the CIs are wide. The evidence is weak for recommending docetaxel, pembrolizumab, nivolumab, or atezolizumab as subsequent therapy for patients with EGFR mutations. Recent data suggest that patients with EGFR mutations or ALK rearrangements have a low response rate to PD-1 or PD-L1 inhibitors when compared with patients without these genetic alterations (response rate, 3.6% vs. 23%, respectively).<sup>847</sup>



# NCCN Guidelines Version 3.2017

## Non-Small Cell Lung Cancer

For patients with ALK rearrangements who progress during or after first-line targeted therapy, recommended therapy also depends on whether the progression is asymptomatic or symptomatic and includes: 1) continuing crizotinib with (or without) local therapy; 2) ceritinib; 3) alectinib; or 4) a first-line systemic therapy regimen for either non-squamous or squamous cell NSCLC. After further progression on subsequent targeted therapy, first-line combination chemotherapy options for non-squamous NSCLC or squamous cell carcinoma are recommended for patients with PS of 0 to 1 such as cisplatin/pemetrexed or cisplatin/gemcitabine (both are category 1), respectively.<sup>131,848</sup> Other chemotherapy options are also recommended for patients with PS 2, such as docetaxel (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN Guidelines for NSCLC).

Most patients with NSCLC do not have ALK rearrangements, ROS1 rearrangements, or sensitizing EGFR mutations. For patients with all histologic subtypes and PS of 0 to 2 but without these genetic alterations who have disease progression during or after first-line therapy, recommended subsequent systemic therapy options include nivolumab (category 1), pembrolizumab (category 1), atezolizumab, docetaxel with (or without) ramucirumab, or gemcitabine if not already given; pemetrexed is recommended for patients with non-squamous NSCLC. For the 2017 update (Version 2.2017), the NCCN Panel added a new recommendation for atezolizumab (category 2A) as subsequent therapy. The NCCN Panel recommends immune checkpoint inhibitors—nivolumab, pembrolizumab, and atezolizumab—as preferred options for subsequent therapy for all histologic subtypes based on improved survival rates, longer duration of response, and fewer adverse events when compared with cytotoxic chemotherapy (see *Nivolumab*, *Pembrolizumab*, and *Atezolizumab* in this Discussion).<sup>621,623,649</sup>

For the 2017 update (Version 2.2017), the NCCN Panel deleted the recommendation for erlotinib as subsequent therapy (and as switch maintenance therapy) for patients with non-squamous NSCLC and PS 0-2 but without EGFR mutations based on preliminary results from a randomized trial (IUNO) and revised indication by the FDA. The data showed that overall survival and PFS were not improved in patients receiving erlotinib when compared with placebo. Ramucirumab/docetaxel is an option for all histologic subtypes for subsequent therapy based on a phase 3 randomized trial.<sup>650</sup> The median overall survival was slightly increased with ramucirumab/docetaxel versus docetaxel alone (10.5 vs. 9.1 months, respectively). Contraindications for ramucirumab/docetaxel therapy include risk for severe hemorrhage, grade 3 to 4 gastrointestinal bleeding, gastrointestinal perforation or fistula, and poorly controlled hypertension.

Docetaxel has been proven superior to best supportive care, vinorelbine, or ifosfamide with improved survival and quality of life.<sup>839,840</sup> When compared with docetaxel, pemetrexed has similar median survival but less toxicity.<sup>841,849</sup> Pemetrexed is recommended in patients with non-squamous NSCLC.<sup>667</sup> Docetaxel is recommended for patients with wild-type EGFR tumors based on 2 randomized trials comparing erlotinib versus docetaxel.<sup>850,851</sup> In patients with PS of 3 to 4, best supportive care is recommended (see the NCCN Guidelines for NSCLC).<sup>8,522,523</sup> Patients often have a limited response to subsequent chemotherapy other than immune checkpoint inhibitors, although it may serve a useful palliative role.<sup>852</sup>

Recently, the NCCN Panel deleted erlotinib as an option for subsequent therapy for patients with squamous cell NSCLC based on a study comparing afatinib with erlotinib; this study was statistically significant but not clinically significant.<sup>607</sup> Overall survival was slightly better in the



afatinib group than in the erlotinib group (median overall survival, 7.9 months [95% CI, 7.2–8.7] vs. 6.8 months [5.9–7.8]; HR, 0.81 [95% CI, 0.69–0.95],  $P = .0077$ ); however, almost 60% of patients in each arm had grade 3 or higher adverse events. In contrast, the median overall survival was 9.2 months with nivolumab compared with 6.0 months for docetaxel for patients with squamous cell NSCLC.<sup>623</sup> In addition, only 7% of patients receiving nivolumab had grade 3 or higher adverse events. Erlotinib and afatinib are not recommended as second-line therapy for squamous cell carcinoma based on a phase 3 randomized trial showing low response rates and because they are less efficacious and safe compared to other available options.<sup>607</sup>

If patients with either ALK fusions or sensitizing EGFR mutations progress with symptomatic systemic multiple lesions after therapy with crizotinib, erlotinib, gefitinib, or afatinib and/or after ceritinib, alectinib, or osimertinib, then first-line doublet chemotherapy options are recommended for either non-squamous NSCLC or squamous cell carcinoma.<sup>560</sup> Erlotinib, gefitinib, or afatinib may be continued in patients with sensitizing EGFR mutations who have progressed after first-line therapy.<sup>169,799,827,828</sup> Osimertinib is recommended for patients with T790M whose disease becomes resistant to erlotinib, afatinib, or gefitinib.<sup>188</sup> Afatinib/cetuximab may be considered for patients with sensitizing EGFR mutations who have progressed after EGFR TKI therapy and chemotherapy.<sup>846</sup> Ceritinib or alectinib are recommended in patients with ALK-positive NSCLC who have progressed after first-line therapy with crizotinib or are intolerant to crizotinib.<sup>129,237</sup> Nivolumab, pembrolizumab, atezolizumab, docetaxel with or without ramucirumab (category 2B for both), gemcitabine (category 2B), or pemetrexed (non-squamous only) (category 2B) are recommended for subsequent therapy after second disease progression in patients with advanced

NSCLC and PS 0–2 if these agents have not already been given.<sup>834,851,853,854</sup>

### References

1. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. *Adv Exp Med Biol* 2016;893:1-19. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26667336>.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26742998>.
3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Bethesda, MD: National Cancer Institute; 2016. Available at: [http://seer.cancer.gov/csr/1975\\_2013/](http://seer.cancer.gov/csr/1975_2013/).
4. Johnson DH, Schiller JH, Bunn PA, Jr. Recent clinical advances in lung cancer management. *J Clin Oncol* 2014;32:973-982. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24567433>.
5. Reck M, Heigener DF, Mok T, et al. Management of non-small-cell lung cancer: recent developments. *Lancet* 2013;382:709-719. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23972814>.
6. Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. *Expert Rev Anticancer Ther* 2013;13:745-758. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23773106>.
7. Ettinger DS. Ten years of progress in non-small cell lung cancer. *J Natl Compr Canc Netw* 2012;10:292-295. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22393190>.
8. Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e455S-497S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649452>.
9. Ettinger DS, Cox JD, Ginsberg RJ, et al. NCCN non-small-cell lung cancer practice guidelines. The National Comprehensive Cancer Network. *Oncology (Williston Park)* 1996;10:81-111. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8953597>.
10. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e1S-29S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649439>.
11. Subramanian J, Govindan R. Lung cancer in never smokers: a review. *J Clin Oncol* 2007;25:561-570. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17290066>.
12. The Health Consequences of Smoking: A Report of the Surgeon General. (ed 2010/07/30). Atlanta (GA): U.S. Department of Health and Human Services. Centers for Disease Control and Prevention (US); 2004.
13. Secretan B, Straif K, Baan R, et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. *Lancet Oncol* 2009;10:1033-1034. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19891056>.
14. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. *Br Med J* 1976;2:1525-1536. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1009386>.
15. Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. *Int J Epidemiol* 2007;36:1048-1059. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17690135>.
16. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. (ed 2010/07/30). Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2006.

17. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. *BMJ* 1997;315:980-988. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9365295>.
18. Wald NJ, Nanchahal K, Thompson SG, Cuckle HS. Does breathing other people's tobacco smoke cause lung cancer? *Br Med J (Clin Res Ed)* 1986;293:1217-1222. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3096439>.
19. Fraumeni JF, Jr. Respiratory carcinogenesis: an epidemiologic appraisal. *J Natl Cancer Inst* 1975;55:1039-1046. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1107567>.
20. Janerich DT, Thompson WD, Varela LR, et al. Lung cancer and exposure to tobacco smoke in the household. *N Engl J Med* 1990;323:632-636. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2385268>.
21. Straif K, Benbrahim-Tallaa L, Baan R, et al. A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. *Lancet Oncol* 2009;10:453-454. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19418618>.
22. Driscoll T, Nelson DI, Steenland K, et al. The global burden of disease due to occupational carcinogens. *Am J Ind Med* 2005;48:419-431. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16299703>.
23. Humans IWGotEoCRt. Arsenic, metals, fibres, and dusts. *IARC Monogr Eval Carcinog Risks Hum* 2012;100:11-465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23189751>.
24. Omenn GS, Merchant J, Boatman E, et al. Contribution of environmental fibers to respiratory cancer. *Environ Health Perspect* 1986;70:51-56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3830113>.
25. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. *Lancet* 2009;374:1243-1251. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19767090>.
26. Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. *J Natl Cancer Inst* 2010;102:1413-1421. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20709992>.
27. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med* 2013;368:351-364. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23343064>.
28. Shiels MS, Gibson T, Sampson J, et al. Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers. *J Clin Oncol* 2014;32:3989-3995. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25385740>.
29. Leone FT, Evers-Casey S, Toll BA, Vachani A. Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e61S-77S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649454>.
30. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013;368:341-350. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23343063>.
31. Rigotti NA. Strategies to help a smoker who is struggling to quit. *JAMA* 2012;308:1573-1580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23073954>.
32. Five Major Steps to Intervention (The "5 A's"). Vol. December. Rockville, MD: Agency for Healthcare Research and Quality; 2012.



Available at: <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/5steps.html>.

33. Tao L, Wang R, Gao YT, Yuan JM. Impact of postdiagnosis smoking on long-term survival of cancer patients: the Shanghai cohort study. *Cancer Epidemiol Biomarkers Prev* 2013;22:2404-2411.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24319070>.

34. Marino KA, Little MA, Bursac Z, et al. Operating on patients who smoke: a survey of thoracic surgeons in the United States. *Ann Thorac Surg* 2016;102:911-916. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27474514>.

35. Treating Tobacco Use and Dependence. Vol. April. Rockville, MD: Agency for Healthcare Research and Quality; 2013. Available at:

<http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/update/index.html>.

36. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev* 2013;5:CD009329. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23728690>.

37. Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *JAMA* 2014;312:155-161. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25005652>.

38. Walker N, Howe C, Glover M, et al. Cytisine versus Nicotine for Smoking Cessation. *N Engl J Med* 2014;371:2353-2362. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25517706>.

39. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax* 2008;63:717-724. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18263663>.

40. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:56-63. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16820547>.

41. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:47-55. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16820546>.

42. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev* 2011:CD006103.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21328282>.

43. Ware JH, Vetrovec GW, Miller AB, et al. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. *Am J Ther* 2013;20:235-246. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23615317>.

44. Haber SL, Boomershine V, Raney E. Safety of varenicline in patients with cardiovascular disease. *J Pharm Pract* 2014;27:65-70.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24080536>.

45. Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. *Circulation* 2014;129:28-41. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24323793>.

46. Xi ZX. Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients. *Drug Healthc Patient Saf* 2010;2010:39-48. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21278851>.

47. Gonzales D, Hajek P, Pliamm L, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. *Clin Pharmacol Ther*

2014;96:390-396. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24911368>.

48. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009;31:463-491. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19393839>.

49. Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010;70:2357-2372. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21142259>.

50. Carney DN. Lung cancer--time to move on from chemotherapy. N Engl J Med 2002;346:126-128. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11784881>.

51. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10561217>.

52. National Lung Screening Trial Research T, Aberle DR, Berg CD, et al. The National Lung Screening Trial: overview and study design. Radiology 2011;258:243-253. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21045183>.

53. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21714641>.

54. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst 2010;102:1771-1779. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21119104>.

55. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice

guidelines. Chest 2013;143:e78S-92S. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23649455>.

56. Vansteenkiste J, Crino L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25:1462-1474. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24562446>.

57. Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013;63:88-105. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23378235>.

58. Moyer VA, Force USPST. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:330-338. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24378917>.

59. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243-1260. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26291008>.

60. Travis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, Volume 7. Lyon: International Agency for Research on Cancer; 2015:412.

61. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21252716>.

62. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. *J Clin Oncol* 1986;4:702-709. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3701389>.
63. Tammemagi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. *PLoS Med* 2014;11:e1001764. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25460915>.
64. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e93S-120S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649456>.
65. American College of Radiology. Lung CT Screening Reporting and Data System (Lung-RADS). Accessed on November 8, 2016; 2016. Available at:
66. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. *Radiology* 2005;237:395-400. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16244247>.
67. Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. *Radiology* 2013;266:304-317. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23070270>.
68. Blagev DP, Lloyd JF, Conner K, et al. Follow-up of incidental pulmonary nodules and the radiology report. *J Am Coll Radiol* 2014;11:378-383. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24316231>.
69. Gould MK, Tang T, Liu IL, et al. Recent trends in the identification of incidental pulmonary nodules. *Am J Respir Crit Care Med* 2015;192:1208-1214. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26214244>.
70. Gardiner N, Jogai S, Wallis A. The revised lung adenocarcinoma classification-an imaging guide. *J Thorac Dis* 2014;6:S537-546. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25349704>.
71. Seidelman JL, Myers JL, Quint LE. Incidental, subsolid pulmonary nodules at CT: etiology and management. *Cancer Imaging* 2013;13:365-373. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24061063>.
72. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. *Radiology* 2008;246:697-722. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18195376>.
73. Yankelevitz DF, Yip R, Smith JP, et al. CT screening for lung cancer: nonsolid nodules in baseline and annual repeat rounds. *Radiology* 2015;277:555-564. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26101879>.
74. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Arch Pathol Lab Med* 2013;137:668-684. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22970842>.
75. Kim HY, Shim YM, Lee KS, et al. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. *Radiology* 2007;245:267-275. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17885195>.
76. Marshall HM, Bowman RV, Yang IA, et al. Screening for lung cancer with low-dose computed tomography: a review of current status. *J*

Thorac Dis 2013;5 Suppl 5:S524-539. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24163745>.

77. Brawley OW, Flenaugh EL. Low-dose spiral CT screening and evaluation of the solitary pulmonary nodule. *Oncology (Williston Park)* 2014;28:441-446. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25004661>.

78. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. *Ann Intern Med* 2015;162:485-491. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25664444>.

79. McKee BJ, Regis SM, McKee AB, et al. Performance of ACR Lung-RADS in a Clinical CT Lung Screening Program. *J Am Coll Radiol* 2015;12:273-276. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25176499>.

80. Kazerooni EA, Austin JH, Black WC, et al. ACR-STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (Resolution 4). *J Thorac Imaging* 2014;29:310-316. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24992501>.

81. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e142S-165S. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23649436>.

82. Schwartz AM, Rezaei MK. Diagnostic surgical pathology in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e251S-262S. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23649441>.

83. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. *J Clin Oncol* 2013;31:1097-1104. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23401445>.

84. Cooper WA, O'Toole S, Boyer M, et al. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. *Pathology* 2011;43:103-115. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21233671>.

85. Fossella FV, Putnam JB, Komaki R, eds. *Lung Cancer*. M.D. Anderson Cancer Care Series. New York: Springer; 2003:316.

86. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol* 2005;23:5900-5909. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16043828>.

87. Cappuzzo F, Ligorio C, Toschi L, et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2007;2:423-429. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17473658>.

88. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693-1703. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20979469>.

89. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Arch Pathol Lab Med* 2013;137:685-705. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22913371>.

90. Cameron SE, Andrade RS, Pambuccian SE. Endobronchial ultrasound-guided transbronchial needle aspiration cytology: a state of

the art review. *Cytopathology* 2010;21:6-26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20015257>.

91. Moreira AL, Thornton RH. Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. *Clin Lung Cancer* 2012;13:334-339. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22424871>.

92. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. *JAMA* 2011;305:391-399. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21266686>.

93. Centers for Disease C, Prevention. CDC Grand Rounds: the TB/HIV syndemic. *MMWR Morb Mortal Wkly Rep* 2012;61:484-489. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22763886>.

94. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart, World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004.

95. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. *J Clin Oncol* 2013;31:992-1001. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23401443>.

96. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. *Semin Respir Crit Care Med* 2011;32:22-31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21500121>.

97. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. *Mod Pathol* 2011;24:1348-1359. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21623384>.

98. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. *Am J Surg Pathol* 2011;35:15-25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21164283>.

99. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. *Am J Surg Pathol* 2010;34:1805-1811. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21107086>.

100. Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. *Adv Anat Pathol* 2000;7:123-127. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10721419>.

101. Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. *Arch Pathol Lab Med* 2013;137:647-667. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22929121>.

102. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. *Arch Pathol Lab Med* 2009;133:1317-1331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19653732>.

103. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. *Histopathology* 2006;48:223-232. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16430468>.

104. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. *Hum Pathol* 2005;36:372-380. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15891998>.

105. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. *Am J Surg Pathol* 2003;27:1031-1051. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12883236>.

106. Rivera MP, Mehta AC, American College of Chest P. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132:131S-148S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17873165>.

107. Tan D, Zander DS. Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update. *Int J Clin Exp Pathol* 2008;1:19-31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18784820>.

108. Zhang H, Liu J, Cagle PT, et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. *Mod Pathol* 2005;18:111-118. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15309021>.

109. Guinee DG, Jr., Fishback NF, Koss MN, et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. *Am J Clin Pathol* 1994;102:406-414. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7524299>.

110. Du L, Schageman JJ, Irnov, et al. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. *J Exp Clin Cancer Res* 2010;29:75. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20624269>.

111. Amin MB, Greene FL, Edge SB, et al. *AJCC Staging Manual*, 8th ed: Springer International Publishing; 2017.

112. Edge SB, Byrd DR, Compton CC, et al. *AJCC Cancer Staging Manual*, 7th ed. New York: Springer; 2010.

113. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2016;11:39-51. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26762738>.

114. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007;2:706-714. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17762336>.

115. Dettnerbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. *Chest* 2009;136:260-271. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19584208>.

116. Rami-Porta R, Bolejack V, Goldstraw P. The new tumor, node, and metastasis staging system. *Semin Respir Crit Care Med* 2011;32:44-51. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21500123>.

117. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. *Ann Thorac Cardiovasc Surg* 2009;15:4-9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19262443>.

118. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. *Cancer* 2007;110:1532-1541. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17702091>.

119. Raz DJ, Zell JA, Ou SH, et al. Natural history of stage I non-small cell lung cancer: implications for early detection. *Chest* 2007;132:193-199. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17505036>.

120. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. *J*

Clin Oncol 2008;26:1472-1478. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18349398>.

121. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18458038>.

122. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16014883>.

123. Mazieres J, Zalcman G, Crino L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort. J Clin Oncol 2015;33:992-999. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25667280>.

124. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-1971. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25264305>.

125. Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-635. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23533264>.

126. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-870. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22215748>.

127. Ou SH, Tan J, Yen Y, Soo RA. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther 2012;12:447-456. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22500682>.

128. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-381. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22327623>.

129. Ou SI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 2016;34:661-668. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26598747>.

130. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24263064>.

131. Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014;25:1475-1484. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24669016>.

132. Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014;25:1681-1690. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24718890>.

133. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23552377>.

134. Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther 2012;11:2535-2540. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22896669>.

135. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer* 2009;115:1723-1733. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19170230>.

136. Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. *J Thorac Oncol* 2015;10:768-777. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25738220>.

137. Ali G, Proietti A, Pelliccioni S, et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. *Arch Pathol Lab Med* 2014;138:1449-1458. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24885803>.

138. Shaw AT, Forcione DG, Digumarthy SR, Iafrate AJ. Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. *N Engl J Med* 2011;365:158-167. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21751909>.

139. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol* 2009;27:4247-4253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19667264>.

140. Lovly CM, Horn L. Molecular profiling of lung cancer. *My Cancer Genome*; 2016 (updated March 28). Available at: <https://www.mycancergenome.org/content/disease/lung-cancer/>.

141. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med* 2010;2:146-158. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20432502>.

142. Aziz N, Zhao Q, Bry L, et al. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. *Arch Pathol Lab Med* 2015;139:481-493. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25152313>.

143. Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. *Cancers (Basel)* 2015;7:2023-2036. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26473927>.

144. Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. *Clin Cancer Res* 2015;21:3631-3639. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25567908>.

145. Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *J Clin Oncol* 2015;33:3660-3667. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26324357>.

146. Yu PP, Vose JM, Hayes DF. Genetic cancer susceptibility testing: increased technology, increased complexity. *J Clin Oncol* 2015;33:3533-3534. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26324366>.

147. Cardarella S, Ortiz TM, Joshi VA, et al. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. *J Thorac Oncol* 2012;7:1767-1774. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23154547>.

148. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. *J Clin Oncol* 2013;31:1039-1049. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23401433>.



149. Planchard D. Identification of driver mutations in lung cancer: first step in personalized cancer. *Target Oncol* 2013;8:3-14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23371030>.

150. Planchard D, Besse B, Groen HJ, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol* 2016;17:984-993. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27283860>.

151. Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2016;17:642-650. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27080216>.

152. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. *Cancer Discov* 2015;5:850-859. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25971938>.

153. Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. *Cancer Discov* 2015;5:842-849. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25971939>.

154. Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. *Cancer* 2015;121:448-456. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25273224>.

155. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. *Clin Cancer Res* 2013;19:4532-4540. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23833300>.

156. Kelly RJ, Carter CA, Giaccone G. HER2 mutations in non-small-cell lung cancer can be continually targeted. *J Clin Oncol* 2012;30:3318-3319. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22649146>.

157. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. *J Thorac Oncol* 2012;7:e23-24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22743296>.

158. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. *J Clin Oncol* 2011;29:2046-2051. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21483012>.

159. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nat Med* 2012;18:382-384. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22327622>.

160. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. *J Thorac Oncol* 2011;6:942-946. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21623265>.

161. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. *N Engl J Med* 2006;354:2619-2621. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16775247>.

162. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. *Ann Oncol* 2011;22:2616-2624. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22071650>.

163. Pao W. New approaches to targeted therapy in lung cancer. Proc Am Thorac Soc 2012;9:72-73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22550248>.

164. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-180. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21277552>.

165. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-565. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2199829>.

166. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013;31:1112-1121. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23401440>.

167. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-5247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18024870>.

168. Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 2013;24:2364-2370. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23788756>.

169. Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol 2013;31:3303-3306. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23980079>.

170. Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 2013;6:135-143. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23493883>.

171. De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76:123-127. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22325357>.

172. Dungo RT, Keating GM. Afatinib: first global approval. Drugs 2013;73:1503-1515. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23982599>.

173. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-3334. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23816960>.

174. Hirsch FR, Bunn PA, Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19410185>.

175. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-7241. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17189394>.

176. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12:220-229. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23371856>.

177. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 2013;8:179-184. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23328547>.

178. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, et al. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol 2012;7:1471-1473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22895145>.



179. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. *Lancet Oncol* 2012;13:e23-31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21764376>.

180. Riely GJ, Yu HA. EGFR: the paradigm of an oncogene-driven lung cancer. *Clin Cancer Res* 2015;21:2221-2226. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25979928>.

181. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. *Clin Cancer Res* 2013;19:2240-2247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23470965>.

182. Finlay MR, Anderton M, Ashton S, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. *J Med Chem* 2014;57:8249-8267. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25271963>.

183. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. *J Clin Oncol* 2013;31:3987-3996. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24101047>.

184. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:e73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15737014>.

185. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. *Clin Cancer Res* 2006;12:5764-5769. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17020982>.

186. Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET,

and HGF status. *Lung Cancer* 2010;68:198-203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19589612>.

187. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. *Clin Cancer Res* 2011;17:1160-1168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21233402>.

188. Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med* 2015;372:1689-1699. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25923549>.

189. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21430269>.

190. Oxnard GR. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. *Arch Pathol Lab Med* 2012;136:1205-1209. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23020725>.

191. Suda K, Mizuuchi H, Maehara Y, Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. *Cancer Metastasis Rev* 2012;31:807-814. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22736441>.

192. Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. *Clin Cancer Res* 2006;12:2538-2544. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16638863>.

193. Dacic S. EGFR assays in lung cancer. *Adv Anat Pathol* 2008;15:241-247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18580100>.

194. Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. *Am J Clin Pathol* 2010;133:922-934. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20472851>.

195. Westwood M, Joore M, Whiting P, et al. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2014;18:1-166. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24827857>.

196. Eberhard DA, Giaccone G, Johnson BE, Non-Small-Cell Lung Cancer Working G. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. *J Clin Oncol* 2008;26:983-994. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18281673>.

197. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. *Clin Cancer Res* 2007;13:4954-4955. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17785543>.

198. Shepherd FA, Tsao MS. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. *J Clin Oncol* 2010;28:903-905. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20100955>.

199. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012;13:239-246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22285168>.

200. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121-128. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20022809>.

201. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-2388. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20573926>.

202. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2011;12:735-742. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21783417>.

203. Zhou C, Wu YL, Chen G, et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC) [abstract]. *J Clin Oncol* 2011;29(Suppl 15):Abstract 7520. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/29/15\\_suppl/7520](http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7520).

204. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-957. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19692680>.

205. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. *J Clin Oncol* 2013;31:3342-3350. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23816967>.

206. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two

randomised, phase 3 trials. *Lancet Oncol* 2015;16:141-151. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25589191>.

207. Sun JM, Lira M, Pandya K, et al. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. *Lung Cancer* 2014;83:259-264. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24300132>.

208. Rogers TM, Russell PA, Wright G, et al. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. *J Thorac Oncol* 2015;10:611-618. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25789833>.

209. von Laffert M, Warth A, Penzel R, et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. *J Thorac Oncol* 2014;9:1685-1692. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25436802>.

210. Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. *J Thorac Oncol* 2014;9:631-638. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24722153>.

211. Zhou J, Zhao J, Sun K, et al. Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening. *PLoS One* 2014;9:e92828. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24667320>.

212. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. *Virchows Arch* 2012;461:245-257. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22825000>.

213. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization

with correlation of ALK protein expression. *J Thorac Oncol* 2011;6:1359-1366. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21587085>.

214. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. *Clin Cancer Res* 2009;15:5216-5223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19671850>.

215. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. *Clin Cancer Res* 2010;16:1561-1571. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20179225>.

216. Ali SM, Hensing T, Schrock AB, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. *Oncologist* 2016;21:762-770. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27245569>.

217. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. *Arch Pathol Lab Med* 2012;136:796-803. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22742552>.

218. Weickhardt AJ, Aisner DL, Franklin WA, et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. *Cancer* 2013;119:1467-1477. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23280244>.

219. Kazandjian D, Blumenthal GM, Chen HY, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung

cancer with anaplastic lymphoma kinase rearrangements. *Oncologist* 2014;19:e5-11. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/25170012>.

220. Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. *J Clin Oncol* 2016;34:721-730. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/26729443>.

221. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med* 2014;371:2167-2177. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25470694>.

222. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385-2394. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23724913>.

223. Crino L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract]. *J Clin Oncol* 2011;29 (Suppl 15):Abstract 7514. Available at:  
[http://meeting.ascopubs.org/cgi/content/abstract/29/15\\_suppl/7514](http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7514).

224. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract]. *J Clin Oncol* 2011;29(Suppl 15):Abstract 2501. Available at:  
[http://meeting.ascopubs.org/cgi/content/abstract/29/15\\_suppl/2501](http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/2501).

225. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. *Curr Opin Investig Drugs* 2010;11:1477-1490. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21154129>.

226. Costa DB, Shaw AT, Ou SH, et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. *J Clin Oncol* 2015;33:1881-1888. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25624436>.

227. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol* 2012;13:1011-1019. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22954507>.

228. Shaw AT, Yeap BY, Solomon BJ, et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls [abstract]. *J Clin Oncol* 2011;29(Suppl 15):Abstract 7507. Available at:  
[http://meeting.ascopubs.org/cgi/content/abstract/29/15\\_suppl/7507](http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7507).

229. Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with Alk inhibitors. *Curr Oncol* 2014;21:19-26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24523601>.

230. Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. *Cancer* 2014;120:664-674. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24258622>.

231. Bang YJ. Treatment of ALK-positive non-small cell lung cancer. *Arch Pathol Lab Med* 2012;136:1201-1204. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23020724>.

232. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010;363:1734-1739. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20979473>.

233. Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung

cancer. *Drugs* 2013;73:2031-2051. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24288180>.

234. Kim D-W, Tiseo M, Ahn M-J, et al. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA) [abstract] *J Clin Oncol* 2016;34:Abstract 9007. Available at:

235. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. *Lancet Oncol* 2014;15:1119-1128. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25153538>.

236. Stinchcombe TE. Novel agents in development for advanced non-small cell lung cancer. *Ther Adv Med Oncol* 2014;6:240-253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25342991>.

237. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med* 2014;370:1189-1197. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24670165>.

238. Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. *Clin Pharmacol Ther* 2014;95:15-23. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24091716>.

239. Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. *J Thorac Dis* 2013;5 Suppl 5:S579-592. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24163750>.

240. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci U S A*

2011;108:7535-7540. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21502504>.

241. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. *J Clin Oncol* 2010;28:4953-4960. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20940188>.

242. Zhang S, Wang F, Keats F. AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066) [abstract]. Presented at the Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; Washington, DC. Abstract LB-298.

243. Cheng M, Ott GR. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. *Anticancer Agents Med Chem* 2010;10:236-249. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20406193>.

244. Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. *Clin Cancer Res* 2015;21:2436-2439. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25754348>.

245. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol* 2016;17:234-242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26708155>.

246. Larkins E, Blumenthal GM, Chen H, et al. FDA approval: alectinib for the treatment of metastatic ALK-positive non-small cell lung cancer following crizotinib. *Clin Cancer Res* 2016;22:5171-5176. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27413075>.

247. Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. *Clin Cancer Res*



## NCCN Guidelines Version 3.2017 Non-Small Cell Lung Cancer

2013;19:4273-4281. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23729361>.

248. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. *Ann Surg Oncol* 2010;17:889-897. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20183914>.

249. Browning ET, Weickhardt AJ, Camidge DR. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. *J Thorac Oncol* 2013;8:e21. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23407562>.

250. West H, Oxnard GR, Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. *Am Soc Clin Oncol Educ Book* 2013;272-278. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23714521>.

251. Ou SH, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. *Ann Oncol* 2014;25:415-422. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24478318>.

252. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. *Oncogene* 2000;19:5548-5557. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/11114734>.

253. Kazandjian D, Blumenthal GM, Luo L, et al. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer. *Oncologist* 2016;21:974-980. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27328934>.

254. Clave S, Gimeno J, Munoz-Marmol AM, et al. ROS1 copy number alterations are frequent in non-small cell lung cancer. *Oncotarget* 2016;7:8019-8028. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26783962>.

255. Bubendorf L, Buttner R, Al-Dayel F, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. *Virchows Arch* 2016;469:489-503. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27535289>.

256. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. *Clin Cancer Res* 2012;18:4570-4579. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22919003>.

257. Solomon BJ, Bauer TM, Felip E, et al. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC) [abstract]. *J Clin Oncol* 2016;34:Abstract 9009. Available at:

<http://meetinglibrary.asco.org/content/161846-176>.

258. Farago AF, Le LP, Zheng Z, et al. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. *J Thorac Oncol* 2015;10:1670-1674. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26565381>.

259. Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. *Proc Natl Acad Sci U S A* 2015;112:3493-3498. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25733882>.

260. Katayama R, Kobayashi Y, Friboulet L, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. *Clin Cancer Res* 2015;21:166-174. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25351743>.

261. Slebos RJ, Hruban RH, Dalesio O, et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. *J Natl Cancer Inst* 1991;83:1024-1027. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/2072410>.



262. Mitsudomi T, Steinberg SM, Oie HK, et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. *Cancer Res* 1991;51:4999-5002.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1654209>.

263. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. *J Natl Compr Canc Netw* 2011;9 Suppl 5:S1-32; quiz S33. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22138009>.

264. Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. *J Thorac Oncol* 2015;10:1726-1735.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26473645>.

265. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. *Lancet Oncol* 2013;14:38-47. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23200175>.

266. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e278S-313S. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23649443>.

267. Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. *Ann Oncol* 2015;26:1091-1101. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25403592>.

268. Caillet P, Laurent M, Bastuji-Garin S, et al. Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment. *Clin Interv Aging* 2014;9:1645-1660. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25302022>.

269. Pallis AG, Gridelli C, Wedding U, et al. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. *Ann Oncol* 2014;25:1270-1283. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24638905>.

270. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e166S-190S. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23649437>.

271. Turner G, Clegg A, British Geriatrics S, et al. Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report. *Age Ageing* 2014;43:744-747. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25336440>.

272. Vairaktarakis C, Tsiamis V, Soursou G, et al. A computer-aided diagnosis system for geriatrics assessment and frailty evaluation. *Adv Exp Med Biol* 2015;820:69-77. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25417017>.

273. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol* 2014;32:2595-2603. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25071125>.

274. Kozower BD, Lerner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e369S-399S. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23649447>.

275. Boffa DJ, Allen MS, Grab JD, et al. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical

management of primary lung tumors. J Thorac Cardiovasc Surg 2008;135:247-254. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18242243>.

276. Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:234S-242S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17873171>.

277. Villamizar N, Swanson SJ. Lobectomy vs. segmentectomy for NSCLC (T<2 cm). Ann Cardiothorac Surg 2014;3:160-166. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24790839>.

278. Landreneau RJ, Normolle DP, Christie NA, et al. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. J Clin Oncol 2014;32:2449-2455. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24982447>.

279. Altorki NK, Yip R, Hanaoka T, et al. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg 2014;147:754-762; Discussion 762-754. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24280722>.

280. Siel W, Dango S, Kirschbaum A, et al. Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections. Eur J Cardiothorac Surg 2008;33:728-734. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18261918>.

281. Siel W, Stremmel C, Kirschbaum A, et al. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins--implications for patient selection for segmentectomy. Eur J Cardiothorac Surg 2007;31:522-527; discussion 527-528. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17229574>.

282. Narsule CK, Ebright MI, Fernando HC. Sublobar versus lobar resection: current status. Cancer J 2011;17:23-27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21263263>.

283. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20233825>.

284. Woody NM, Stephans KL, Marwaha G, et al. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy. Int J Radiat Oncol Biol Phys 2015;92:325-331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25841625>.

285. Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010;28:928-935. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20065181>.

286. Donington J, Ferguson M, Mazzone P, et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest 2012;142:1620-1635. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23208335>.

287. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141:662-670. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21335122>.

288. Allen MS, Darling GE, Pechet TT, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006;81:1013-1019; discussion 1019-1020. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16488712>.

289. Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. *J Thorac Oncol* 2009;4:568-577. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19357537>.

290. Martins RG, D'Amico TA, Loo BW, Jr., et al. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. *J Natl Compr Canc Netw* 2012;10:599-613. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22570291>.

291. Farjah F, Flum DR, Varghese TK, Jr., et al. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. *Ann Thorac Surg* 2009;87:995-1004; discussion 1005-1006. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19324119>.

292. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet* 2009;374:379-386. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19632716>.

293. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. *J Natl Cancer Inst* 2007;99:442-450. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17374834>.

294. Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. *Ann Thorac Surg* 2008;86:362-366; discussion 366-367. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18640297>.

295. Sher DJ, Fidler MJ, Liptay MJ, Koshy M. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. *Lung Cancer* 2015;88:267-274. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25862147>.

296. Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. *Ann Thorac Surg* 2012;93:1807-1812. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22632486>.

297. Higgins K, Chino JP, Marks LB, et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2009;75:1462-1467. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19467798>.

298. Stefani A, Alifano M, Bobbio A, et al. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. *J Thorac Cardiovasc Surg* 2010;140:356-363. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20381815>.

299. Gopal RS, Dubey S, Rosenzweig KE, et al. ACR Appropriateness Criteria(R) on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. *Int J Radiat Oncol Biol Phys* 2010;78:969-974. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20813465>.

300. Evans NR, 3rd, Li S, Wright CD, et al. The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer. *J Thorac Cardiovasc Surg* 2010;139:991-996 e991-992. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20304144>.

301. Gaisert HA, Keum DY, Wright CD, et al. POINT: Operative risk of pneumonectomy--influence of preoperative induction therapy. *J Thorac Cardiovasc Surg* 2009;138:289-294. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19619768>.

302. Mansour Z, Kochetkova EA, Ducrocq X, et al. Induction chemotherapy does not increase the operative risk of pneumonectomy! *Eur J Cardiothorac Surg* 2007;31:181-185. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17141515>.

303. Weder W, Collaud S, Eberhardt WE, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. *J Thorac Cardiovasc Surg* 2010;139:1424-1430. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20416887>.

304. Kappers I, van Sandick JW, Burgers SA, et al. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided. *Lung Cancer* 2010;68:222-227. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19664843>.

305. Decaluwe H, De Leyn P, Vansteenkiste J, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. *Eur J Cardiothorac Surg* 2009;36:433-439. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19502079>.

306. Swanson SJ, Batirel HF. Video-assisted thoracic surgery (VATS) resection for lung cancer. *Surg Clin North Am* 2002;82:541-559. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12371584>.

307. Mahtabifard A, Fuller CB, McKenna RJ, Jr. Video-assisted thoracic surgery sleeve lobectomy: a case series. *Ann Thorac Surg* 2008;85:S729-732. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18222205>.

308. Shaw JP, Dembitzer FR, Wisnivesky JP, et al. Video-assisted thoracoscopic lobectomy: state of the art and future directions. *Ann Thorac Surg* 2008;85:S705-709. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18222201>.

309. Cheng D, Downey RJ, Kernstine K, et al. Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review of controlled trials. *Innovations (Phila)* 2007;2:261-292. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22437196>.

310. Alam N, Flores RM. Video-assisted thoracic surgery (VATS) lobectomy: the evidence base. *JSLC* 2007;11:368-374. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17931521>.

311. Whitson BA, Andrade RS, Boettcher A, et al. Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer. *Ann Thorac Surg* 2007;83:1965-1970. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17532379>.

312. Whitson BA, Groth SS, Duval SJ, et al. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. *Ann Thorac Surg* 2008;86:2008-2016; discussion 2016-2008. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19022040>.

313. Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. *J Thorac Cardiovasc Surg* 2010;139:976-981; discussion 981-973. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20172539>.

314. Atkins BZ, Harpole DH, Jr., Mangum JH, et al. Pulmonary segmentectomy by thoracotomy or thoracoscopy: reduced hospital length of stay with a minimally-invasive approach. *Ann Thorac Surg* 2007;84:1107-1112; discussion 1112-1103. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17888955>.

315. Swanson SJ, Herndon JE, 2nd, D'Amico TA, et al. Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. *J Clin Oncol* 2007;25:4993-4997. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17971599>.

316. Ohtsuka T, Nomori H, Horio H, et al. Is major pulmonary resection by video-assisted thoracic surgery an adequate procedure in clinical stage I lung cancer? *Chest* 2004;125:1742-1746. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15136385>.

317. McKenna RJ, Jr. New approaches to the minimally invasive treatment of lung cancer. *Cancer J* 2005;11:73-76. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15831227>.

318. Demmy TL, Nwogu C. Is video-assisted thoracic surgery lobectomy better? Quality of life considerations. *Ann Thorac Surg* 2008;85:S719-728. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18222204>.

319. Cattaneo SM, Park BJ, Wilton AS, et al. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. *Ann Thorac Surg* 2008;85:231-235; discussion 235-236. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18154816>.

320. Cao C, Manganas C, Ang SC, et al. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. *Interact Cardiovasc Thorac Surg* 2013;16:244-249. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23169877>.

321. Ilonen IK, Rasanen JV, Knuutila A, et al. Anatomic thoracoscopic lung resection for non-small cell lung cancer in stage I is associated with less morbidity and shorter hospitalization than thoracotomy. *Acta Oncol* 2011;50:1126-1132. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21314296>.

322. Villamizar NR, Darrabie MD, Burfeind WR, et al. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. *J Thorac Cardiovasc Surg* 2009;138:419-425. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19619789>.

323. Paul S, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. *J Thorac Cardiovasc Surg* 2010;139:366-378. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20106398>.

324. Su S, Scott WJ, Allen MS, et al. Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. *J Thorac Cardiovasc Surg* 2014;147:747-752; Discussion 752-743. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24290575>.

325. Lee PC, Nasar A, Port JL, et al. Long-term survival after lobectomy for non-small cell lung cancer by video-assisted thoracic surgery versus thoracotomy. *Ann Thorac Surg* 2013;96:951-960; discussion 960-951. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23866808>.

326. Thomas P, Doddoli C, Yena S, et al. VATS is an adequate oncological operation for stage I non-small cell lung cancer. *Eur J Cardiothorac Surg* 2002;21:1094-1099. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12048091>.

327. Roviario G, Varoli F, Vergani C, et al. Long-term survival after videothoracoscopic lobectomy for stage I lung cancer. *Chest* 2004;126:725-732. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15364748>.

328. Solaini L, Prusciano F, Bagioni P, Poddie DB. Long-term results of video-assisted thoracic surgery lobectomy for stage I non-small cell lung cancer: a single-centre study of 104 cases. *Interact Cardiovasc Thorac Surg* 2004;3:57-62. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17670176>.

329. Demmy TL, Plante AJ, Nwogu CE, et al. Discharge independence with minimally invasive lobectomy. *Am J Surg* 2004;188:698-702. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15619486>.

330. Demmy TL. VATS lobectomy for frail or complex patients. *Chest Meeting Abstracts* 2003;124:234S. Available at:

<http://meeting.chestpubs.org/cgi/reprint/124/4/234S.pdf>.

331. Nicastrì DG, Wisnivesky JP, Litle VR, et al. Thoracoscopic lobectomy: report on safety, discharge independence, pain, and chemotherapy tolerance. *J Thorac Cardiovasc Surg* 2008;135:642-647. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18329487>.

332. Petersen RP, Pham D, Burfeind WR, et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. *Ann Thorac Surg* 2007;83:1245-1249; discussion 1250. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17383320>.

333. Hanna JM, Berry MF, D'Amico TA. Contraindications of video-assisted thoracoscopic surgical lobectomy and determinants of conversion to open. *J Thorac Dis* 2013;5 Suppl 3:S182-189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24040521>.

334. Yan TD, Cao C, D'Amico TA, et al. Video-assisted thoracoscopic surgery lobectomy at 20 years: a consensus statement. *Eur J Cardiothorac Surg* 2014;45:633-639. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24130372>.

335. Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. *J Clin Oncol* 2009;27:2553-2562. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19289625>.

336. Cao C, Manganas C, Ang SC, Yan TD. A meta-analysis of unmatched and matched patients comparing video-assisted thoracoscopic lobectomy and conventional open lobectomy. *Ann Cardiothorac Surg* 2012;1:16-23. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23977459>.

337. Nakamura H. Systematic review of published studies on safety and efficacy of thoracoscopic and robot-assisted lobectomy for lung cancer. *Ann Thorac Cardiovasc Surg* 2014;20:93-98. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24583699>.

338. Swanson SJ, Miller DL, McKenna RJ, Jr., et al. Comparing robot-assisted thoracic surgical lobectomy with conventional video-assisted thoracic surgical lobectomy and wedge resection: results from a multihospital database (Premier). *J Thorac Cardiovasc Surg* 2014;147:929-937. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24210834>.

339. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. *N Engl J Med* 1986;315:1377-1381. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2877397>.

340. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. *N Engl J Med* 2000;343:1217-1222. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11071672>.

341. Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. *Int J Radiat Oncol Biol Phys* 2008;72:695-701. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18439766>.

342. Bradley JD, Paulus R, Graham MV, et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. *J Clin Oncol* 2005;23:3480-3487. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15908657>.

343. Feigenberg SJ, Hanlon AL, Langer C, et al. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. *J Thorac Oncol* 2007;2:287-292. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17409799>.

344. Jaklitsch MT, Herndon JE, 2nd, DeCamp MM, Jr., et al. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. *J Surg Oncol* 2006;94:599-606. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17039491>.

345. Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. *J Clin Oncol* 2014;32:2913-2919. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25113773>.

346. McAvoy S, Ciura K, Wei C, et al. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam

therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. *Int J Radiat Oncol Biol Phys* 2014;90:819-827. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25220718>.

347. Expert Panel on Radiation Oncology-Brain M, Lo SS, Gore EM, et al. ACR Appropriateness Criteria(R) pre-irradiation evaluation and management of brain metastases. *J Palliat Med* 2014;17:880-886. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24971478>.

348. Expert Panel on Radiation Oncology-Bone M, Lo SS, Lutz ST, et al. ACR Appropriateness Criteria (R) spinal bone metastases. *J Palliat Med* 2013;16:9-19. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23167547>.

349. Expert Panel On Radiation Oncology-Bone M, Lutz ST, Lo SS, et al. ACR Appropriateness Criteria(R) non-spine bone metastases. *J Palliat Med* 2012;15:521-526. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22536988>.

350. Patel SH, Robbins JR, Gore EM, et al. ACR Appropriateness Criteria(R) follow-up and retreatment of brain metastases. *Am J Clin Oncol* 2012;35:302-306. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22609733>.

351. Chang JY, Kestin LL, Barriger RB, et al. ACR Appropriateness Criteria(R) nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. *Oncology (Williston Park)* 2014;28:706-710, 712, 714 passim. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25140629>.

352. Rosenzweig KE, Chang JY, Chetty IJ, et al. ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. *J Am Coll Radiol* 2013;10:654-664. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23890874>.

353. Gregoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU

report No. 83). *Cancer Radiother* 2011;15:555-559. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21802333>.

354. Teoh M, Clark CH, Wood K, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. *Br J Radiol* 2011;84:967-996. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22011829>.

355. Chen AB, Neville BA, Sher DJ, et al. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. *J Clin Oncol* 2011;29:2305-2311. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21537034>.

356. Liao ZX, Komaki RR, Thames HD, Jr., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 2010;76:775-781. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19515503>.

357. Terasawa T, Dvorak T, Ip S, et al. Systematic review: charged-particle radiation therapy for cancer. *Ann Intern Med* 2009;151:556-565. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19755348>.

358. Taremi M, Hope A, Dachele M, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. *Int J Radiat Oncol Biol Phys* 2012;82:967-973. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21377293>.

359. Ambrogi MC, Fanucchi O, Cioni R, et al. Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study. *J Thorac Oncol* 2011;6:2044-2051. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22052222>.

360. Bilal H, Mahmood S, Rajashanker B, Shah R. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? *Interact Cardiovasc Thorac Surg* 2012;15:258-265. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22581864>.

361. Allibhai Z, Taremi M, Bezjak A, et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2013;87:1064-1070. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24210082>.

362. Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. *Int J Radiat Oncol Biol Phys* 2012;84:1060-1070. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22975611>.

363. Gewanter RM, Rosenzweig KE, Chang JY, et al. ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. *Curr Probl Cancer* 2010;34:228-249. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20541060>.

364. Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. *J Clin Oncol* 2007;25:5557-5561. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17984185>.

365. Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. *Am J Clin Oncol* 2007;30:239-244. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17551299>.

366. Fernandes AT, Shen J, Finlay J, et al. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes. *Radiother Oncol* 2010;95:178-184. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20356642>.

367. Chen M, Bao Y, Ma HL, et al. Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective

randomized study. *Biomed Res Int* 2013;2013:371819. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23762840>.

368. Rodrigues G, Videtic GM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. *Pract Radiat Oncol* 2011;1:60-71. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24174996>.

369. Rodrigues G, Macbeth F, Burmeister B, et al. Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. *Clin Lung Cancer* 2012;13:1-5. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21729656>.

370. Chen AB, Cronin A, Weeks JC, et al. Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. *J Clin Oncol* 2013;31:558-564. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23295799>.

371. Koshy M, Malik R, Mahmood U, et al. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer. *Pract Radiat Oncol* 2015;5:374-382. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26412340>.

372. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. *J Clin Oncol* 2006;24:2998-3006. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16769986>.

373. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. *J Clin Oncol* 1995;13:1880-1892. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/7636530>.



374. Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. *Eur J Cardiothorac Surg* 2009;35:718-723; discussion 723. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19233668>.

375. Kwong KF, Edelman MJ, Suntharalingam M, et al. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. *J Thorac Cardiovasc Surg* 2005;129:1250-1257. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15942564>.

376. Sonett JR, Suntharalingam M, Edelman MJ, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. *Ann Thorac Surg* 2004;78:1200-1205; discussion 1206. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15464470>.

377. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *J Clin Oncol* 2007;25:313-318. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17235046>.

378. Bezjak A, Temin S, Franklin G, et al. Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. *J Clin Oncol* 2015;33:2100-2105. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25944914>.

379. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. *Int J Radiat Oncol Biol Phys* 2005;61:318-328. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15667949>.

380. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. *Int J Radiat Oncol Biol Phys* 2005;63:324-333. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16168827>.

381. Zhao L, West BT, Hayman JA, et al. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2007;68:103-110. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17363189>.

382. Wang L, Correa CR, Zhao L, et al. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2009;73:1383-1390. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18929449>.

383. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. *Int J Radiat Oncol Biol Phys* 2002;54:348-356. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12243807>.

384. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2006;65:1106-1111. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16730134>.

385. Bradley JD, Moughan J, Graham MV, et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. *Int J Radiat Oncol Biol Phys* 2010;77:367-372. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20457350>.

386. Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally

advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 2012;82:425-434. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20980108>.

387. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol* 2015;16:187-199. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25601342>.

388. Cox JD. Are the results of RTOG 0617 mysterious? *Int J Radiat Oncol Biol Phys* 2012;82:1042-1044. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22284026>.

389. Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. *J Clin Oncol* 2010;28:2475-2480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20368547>.

390. ICRU. ICRU Report 50. Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: International Commission on Radiation Units and Measurements; 1993.

391. ICRU. Prescribing, Recording and Reporting Photon Beam Therapy (Report 62) (Supplement to ICRU Report 50). Bethesda, MD: ICRU; 1999.

392. ICRU Report 83: Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT). Bethesda, MD: International Commission on Radiation Units and Measurements; 2010. Available at: <http://www.icru.org/testing/reports/prescribing-recording-and-reporting-intensity-modulated-photon-beam-therapy-imrt-icru-report-83>.

393. Group IDW, Holmes T, Das R, et al. American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments. *Int J Radiat Oncol Biol Phys* 2009;74:1311-1318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19616738>.

394. Kong FM, Ritter T, Quint DJ, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. *Int J Radiat Oncol Biol Phys* 2011;81:1442-1457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20934273>.

395. Kong FM, Pan C, Eisbruch A, Ten Haken RK. Physical models and simpler dosimetric descriptors of radiation late toxicity. *Semin Radiat Oncol* 2007;17:108-120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17395041>.

396. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). *Int J Radiat Oncol Biol Phys* 1999;45:323-329. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10487552>.

397. Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. *Int J Radiat Oncol Biol Phys* 2006;65:1075-1086. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16647222>.

398. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. *Int J Radiat Oncol Biol Phys* 2001;51:650-659. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11597805>.

399. Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. *Radiology* 2005;235:208-215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15703313>.

400. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). *Int J Radiat Oncol Biol Phys* 2006;66:1399-1407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16997503>.
401. Rose J, Rodrigues G, Yaremko B, et al. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. *Radiother Oncol* 2009;91:282-287. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18950881>.
402. Hall WH, Guiou M, Lee NY, et al. Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2008;72:1362-1367. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18448267>.
403. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. *Int J Radiat Oncol Biol Phys* 2010;76:S10-19. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20171502>.
404. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys* 2010;76:S70-76. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20171521>.
405. Werner-Wasik M, Yorke E, Deasy J, et al. Radiation dose-volume effects in the esophagus. *Int J Radiat Oncol Biol Phys* 2010;76:S86-93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20171523>.
406. Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. *Int J Radiat Oncol Biol Phys* 2010;76:S77-85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20171522>.
407. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. *Int J Radiat Oncol Biol Phys* 2010;76:S42-49. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20171517>.
408. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. *Radiother Oncol* 2009;91:85-94. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19100641>.
409. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2006;65:1087-1096. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16682145>.
410. Na. Abstracts. *Journal of Thoracic Oncology* 2008;3:S263-S301. Available at: <http://journals.lww.com/jto/toc/2008/11001>.
411. Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. *Chest* 2004;126:1198-1203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15486383>.
412. Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2006;65:107-111. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16458447>.
413. Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. *Radiother Oncol* 2010;95:32-40. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19733410>.
414. Keall PJ, Mageras GS, Balter JM, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. *Med Phys* 2006;33:3874-3900. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17089851>.

415. Dahele M, Senan S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. *Cancer Res Treat* 2011;43:75-82. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21811422>.
416. Heinzerling JH, Kavanagh B, Timmerman RD. Stereotactic ablative radiation therapy for primary lung tumors. *Cancer J* 2011;17:28-32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21263264>.
417. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys* 2010;76:326-332. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20117285>.
418. Guckenberger M, Andratschke N, Alheit H, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. *Strahlenther Onkol* 2014;190:26-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24052011>.
419. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? *Int J Radiat Oncol Biol Phys* 2011;81:1352-1358. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20638194>.
420. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. *J Clin Oncol* 2009;27:3290-3296. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19414667>.
421. Iyengar P, Westover K, Timmerman RD. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer. *Semin Respir Crit Care Med* 2013;34:845-854. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24258574>.
422. Nagata Y, Hiraoka M, Shibata T, et al. Stereotactic Body Radiation Therapy For T1N0M0 Non-small Cell Lung Cancer: First Report for Inoperable Population of a Phase II Trial by Japan Clinical Oncology Group (JCOG 0403). *International Journal of Radiation Oncology\* Biology\* Physics* 2012;84:S46. Available at: [http://www.redjournal.org/article/S0360-3016\(12\)01274-6/abstract](http://www.redjournal.org/article/S0360-3016(12)01274-6/abstract).
423. Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. *J Clin Oncol* 2010;28:5153-5159. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21041709>.
424. Widder J, Postmus D, Ubbels JF, et al. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. *Int J Radiat Oncol Biol Phys* 2011;81:e291-297. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21640503>.
425. Bradley JD, El Naqa I, Drzymala RE, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. *Int J Radiat Oncol Biol Phys* 2010;77:1146-1150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19800181>.
426. Senti S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. *Lancet Oncol* 2012;13:802-809. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22727222>.
427. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. *Int J Radiat Oncol Biol Phys* 2009;75:677-682. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19251380>.
428. van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for

early stage NSCLC. *J Thorac Oncol* 2015;10:826-831. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25629639>.

429. Versteegen NE, Oosterhuis JW, Palma DA, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. *Ann Oncol* 2013;24:1543-1548. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23425947>.

430. Nagata Y, Hiraoka M, Shibata T, et al. A Phase II Trial of Stereotactic Body Radiation Therapy for Operable T1N0M0 Non-small Cell Lung Cancer: Japan Clinical Oncology Group (JCOG0403). *International Journal of Radiation Oncology\*Biophysics* 2010;78:S27-S28. Available at: [http://www.redjournal.org/article/S0360-3016\(10\)01078-3/abstract](http://www.redjournal.org/article/S0360-3016(10)01078-3/abstract).

431. Lagerwaard FJ, Versteegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2012;83:348-353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22104360>.

432. Shirvani SM, Jiang J, Chang JY, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. *JAMA Surg* 2014;149:1244-1253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25321323>.

433. Timmerman RD, Paulus R, Pass HI, et al. RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients [abstract]. *J Clin Oncol* 2013;31(Suppl 15):Abstract 7523. Available at:

434. Matsuo Y, Shibuya K, Nagata Y, et al. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer. *J Thorac Oncol* 2012;7:453-456. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22252562>.

435. Rusthoven CG, Kavanagh BD, Karam SD. Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. *Ann Transl Med* 2015;3:149. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26244136>.

436. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. *Lancet Oncol* 2015;16:630-637. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25981812>.

437. Kunkler IH, Audisio R, Belkacemi Y, et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. *Ann Oncol* 2014;25:2134-2146. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24625455>.

438. Shultz DB, Filippi AR, Thariat J, et al. Stereotactic Ablative Radiotherapy for Pulmonary Oligometastases and Oligometastatic Lung Cancer. *J Thorac Oncol* 2014;9:1426-1433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25170641>.

439. Filippi AR, Badellino S, Guarneri A, et al. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases. *Technol Cancer Res Treat* 2014;13:37-45. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23819496>.

440. Chan NK, Abdullah KG, Lubelski D, et al. Stereotactic radiosurgery for metastatic spine tumors. *J Neurosurg Sci* 2014;58:37-44. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24614791>.

441. Ojerholm E, Lee JY, Kolker J, et al. Gamma Knife radiosurgery to four or more brain metastases in patients without prior intracranial radiation or surgery. *Cancer Med* 2014;3:565-571. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24510602>.

442. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. *J Clin Oncol* 2014;32:2847-2854. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25113761>.

443. Salazar OM, Sandhu TS, Lattin PB, et al. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. *Int J Radiat Oncol Biol Phys* 2008;72:707-715. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18455322>.

444. Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. *Int J Radiat Oncol Biol Phys* 2009;74:47-54. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18977095>.

445. Zhang X, Liu H, Balter P, et al. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2012;83:1558-1565. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22572078>.

446. Hoopes DJ, Tann M, Fletcher JW, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. *Lung Cancer* 2007;56:229-234. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17353064>.

447. Chen F, Matsuo Y, Yoshizawa A, et al. Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. *J Thorac Oncol* 2010;5:1999-2002. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21102261>.

448. Neri S, Takahashi Y, Terashi T, et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. *J Thorac Oncol* 2010;5:2003-2007. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21102262>.

449. Hearn JW, Videtic GM, Djemil T, Stephans KL. Salvage Stereotactic Body Radiation Therapy (SBRT) for Local Failure After Primary Lung SBRT. *Int J Radiat Oncol Biol Phys* 2014;90:402-406. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25017480>.

450. Trakul N, Harris JP, Le QT, et al. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. *J Thorac Oncol* 2012;7:1462-1465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22895143>.

451. Kilburn JM, Kuremsky JG, Blackstock AW, et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. *Radiother Oncol* 2014;110:505-510. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24444530>.

452. Baker R, Han G, Sarangkasiri S, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. *Int J Radiat Oncol Biol Phys* 2013;85:190-195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22929858>.

453. Chang JY, Bezjak A, Mornex F, Committee IART. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. *J Thorac Oncol* 2015;10:577-585. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25514807>.

454. Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". *Int J Radiat Oncol Biol Phys* 2014;88:1120-1128. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24661665>.

455. Hadziahmetovic M, Loo BW, Timmerman RD, et al. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes. *Discov Med* 2010;9:411-417. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20515609>.

456. Hara R, Itami J, Kondo T, et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. *Cancer* 2006;106:1347-1352. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16475150>.
457. Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2008;72:967-971. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18954709>.
458. Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. *Int J Radiat Oncol Biol Phys* 2009;73:442-448. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18990507>.
459. Stephans KL, Djemil T, Reddy CA, et al. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. *J Thorac Oncol* 2009;4:976-982. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19633473>.
460. Jin JY, Kong FM, Chetty IJ, et al. Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers. *Int J Radiat Oncol Biol Phys* 2010;76:782-788. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19577855>.
461. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. *J Thorac Oncol* 2007;2:S94-100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17603311>.
462. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *J Clin Oncol* 2006;24:4833-4839. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17050868>.
463. Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. *Lung Cancer* 2015;89:50-56. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25997421>.
464. Haseltine JM, Rimner A, Gelblum DY, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. *Pract Radiat Oncol* 2016;6:e27-33. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26577006>.
465. Bezjak A, Paulus R, Gaspar LE, et al. Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC) [abstract]. *Int J Radiat Oncol Biol Phys* 2016;94:5-6. Available at: <http://dx.doi.org/10.1016/j.ijrobp.2015.10.040>.
466. Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. *Int J Radiat Oncol Biol Phys* 2009;75:71-75. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19250766>.
467. Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. *Acta Oncol* 2012;51:618-623. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22263925>.
468. Iyengar P, Kavanagh BD, Wardak Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. *J Clin Oncol* 2014;32:3824-3830. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25349291>.
469. Takeda M, Okamoto I, Nakagawa K. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. *J Thorac Oncol* 2013;8:654-657. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23584297>.

470. Cheung P, Faria S, Ahmed S, et al. Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. *J Natl Cancer Inst* 2014;106. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25074417>.

471. Sura S, Yorke E, Jackson A, Rosenzweig KE. High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer. *Cancer J* 2007;13:238-242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17762758>.

472. Hu C, Chang EL, Hassenbusch SJ, 3rd, et al. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. *Cancer* 2006;106:1998-2004. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16572401>.

473. Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. *JAMA* 2016;316:401-409. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27458945>.

474. Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:33-43. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19960230>.

475. Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:17-32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19960231>.

476. Mintz A, Perry J, Spithoff K, et al. Management of single brain metastasis: a practice guideline. *Curr Oncol* 2007;14:131-143. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17710205>.

477. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990;322:494-500. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2405271>.

478. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:45-68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19960227>.

479. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. *JAMA* 2006;295:2483-2491. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16757720>.

480. Abe E, Aoyama H. The role of whole brain radiation therapy for the management of brain metastases in the era of stereotactic radiosurgery. *Curr Oncol Rep* 2012;14:79-84. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22006098>.

481. Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:71-83. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19960229>.

482. Ellis TL, Neal MT, Chan MD. The role of surgery, radiosurgery and whole brain radiation therapy in the management of patients with metastatic brain tumors. *Int J Surg Oncol* 2012;2012:952345. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22312545>.

483. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. *JAMA* 1998;280:1485-1489. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9809728>.



484. Ammirati M, Cobbs CS, Linskey ME, et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:85-96. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19957016>.

485. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. *Lancet Oncol* 2014;15:387-395. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24621620>.

486. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014;25 Suppl 3:iii27-39. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25115305>.

487. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. *Cochrane Database Syst Rev* 2012;4:CD003869. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22513917>.

488. Chang WS, Kim HY, Chang JW, et al. Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases? *J Neurosurg* 2010;113 Suppl:73-78. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21121789>.

489. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2011;81:77-84. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20800380>.

490. Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. *J*

*Clin Oncol* 2011;29:279-286. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21135267>.

491. Tallet AV, Azria D, Barlesi F, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. *Radiat Oncol* 2012;7:77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22640600>.

492. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. *J Clin Oncol* 2007;25:1260-1266. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17401015>.

493. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. *Int J Radiat Oncol Biol Phys* 2007;68:1388-1395. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17674975>.

494. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. *Lancet Oncol* 2009;10:1037-1044. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19801201>.

495. Suh JH, Videtic GM, Aref AM, et al. ACR Appropriateness Criteria: single brain metastasis. *Curr Probl Cancer* 2010;34:162-174. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20541055>.

496. Marsh JC, Gielda BT, Herskovic AM, Abrams RA. Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches. *J Oncol* 2010;2010:198208. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20671962>.

497. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment

during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. *J Clin Oncol* 2014;32:3810-3816. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25349290>.

498. Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. *Lancet* 2016;388:2004-2014. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27604504>.

499. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. *N Engl J Med* 2004;350:351-360. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14736927>.

500. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *N Engl J Med* 2005;352:2589-2597. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15972865>.

501. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIa non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006;7:719-727. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16945766>.

502. Song WA, Zhou NK, Wang W, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. *J Thorac Oncol* 2010;5:510-516. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20107424>.

503. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIa non-small-cell lung cancer. *J Clin*

*Oncol* 2012;30:172-178. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22124104>.

504. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. *J Clin Oncol* 2002;20:247-253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11773176>.

505. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIa non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. *Lung Cancer* 1999;26:7-14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10574676>.

506. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small-cell lung cancer. *J Natl Cancer Inst* 1994;86:673-680. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8158698>.

507. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. *J Clin Oncol* 2010;28:3138-3145. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20516435>.

508. Pisters KM, Vallieres E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. *J Clin Oncol* 2010;28:1843-1849. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20231678>.

509. Westeel V, Quoix E, Puyraveau M, et al. A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). *Eur J Cancer* 2013;49:2654-2664. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23735703>.

510. Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. *Lancet* 2014;383:1561-1571. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24576776>.

511. Curran WJ, Jr., Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst* 2011;103:1452-1460. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21903745>.

512. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol* 2010;28:2181-2190. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20351327>.

513. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. *Cancer* 2001;92:1213-1223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11571735>.

514. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. *J Clin Oncol* 1999;17:2692-2699. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10561343>.

515. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e341S-368S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649446>.

516. Azzoli CG, Temin S, Aliff T, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. *J*

*Clin Oncol* 2011;29:3825-3831. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21900105>.

517. Azzoli CG, Baker S, Jr., Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. *J Clin Oncol* 2009;27:6251-6266. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19917871>.

518. Group NM-AC. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. *J Clin Oncol* 2008;26:4617-4625. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18678835>.

519. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. *Lancet* 1993;342:19-21. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8100290>.

520. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. *BMJ* 1995;311:899-909. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7580546>.

521. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733-742. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20818875>.

522. Yates P, Schofield P, Zhao I, Currow D. Supportive and palliative care for lung cancer patients. *J Thorac Dis* 2013;5 Suppl 5:S623-628. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24163753>.

523. Ford DW, Koch KA, Ray DE, Selecky PA. Palliative and end-of-life care in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e498S-512S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649453>.

524. Aizer AA, Chen MH, McCarthy EP, et al. Marital status and survival in patients with cancer. *J Clin Oncol* 2013;31:3869-3876. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24062405>.
525. Magilligan DJ, Jr., Duvernoy C, Malik G, et al. Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. *Ann Thorac Surg* 1986;42:360-364. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3767508>.
526. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. *J Clin Oncol* 2010;28:35-42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19933916>.
527. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. *J Clin Oncol* 2010;28:29-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19933915>.
528. Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. *J Thorac Oncol* 2010;5:220-228. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20027124>.
529. Kreuter M, Vansteenkiste J, Fischer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. *Ann Oncol* 2013;24:986-992. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23161898>.
530. Petrelli F, Barni S. Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials. *Med Oncol* 2013;30:641. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23813019>.
531. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol* 2008;26:3552-3559. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18506026>.
532. Wisnivesky JP, Smith CB, Packer S, et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIa lung cancer: observational cohort study. *BMJ* 2011;343:d4013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21757436>.
533. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract]. *J Clin Oncol* 2004;22 (Suppl 14):Abstract 7019. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/22/14\\_suppl/7019](http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/7019).
534. Strauss GM, Herndon JE, II, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract]. *J Clin Oncol* 2006;24 (Suppl 18):Abstract 7007. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/24/18\\_suppl/7007](http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7007).
535. Strauss GM, Herndon JE, 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. *J Clin Oncol* 2008;26:5043-5051. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18809614>.
536. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol* 2007;18:317-323. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17079694>.

537. Katz A, Saad ED. CALGB 9633: an underpowered trial with a methodologically questionable conclusion. *J Clin Oncol* 2009;27:2300-2301; author reply 2301-2302. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19332712>.

538. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. *N Engl J Med* 1990;323:940-945. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/2169587>.

539. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. *J Natl Cancer Inst* 1991;83:417-423. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1847977>.

540. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. *N Engl J Med* 1992;326:524-530. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1310160>.

541. Dillman RO, Seagren SL, Herndon J, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer: Five-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. *J Clin Oncol (Meeting Abstracts)* 1993;12:329. Available at:

542. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. *J Natl Cancer Inst* 1996;88:1210-1215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8780630>.

543. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e314S-340S. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23649445>.

544. Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2016;34:953-962. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26811519>.

545. Ezer N, Smith CB, Galsky MD, et al. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer. *Radiother Oncol* 2014;112:272-278. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25150635>.

546. Albain KS, Crowley JJ, Turrisi AT, 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. *J Clin Oncol* 2002;20:3454-3460. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12177106>.

547. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. *J Clin Oncol* 2005;23:5883-5891. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16087941>.

548. Santana-Davila R, Devisetty K, Szabo A, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. *J Clin Oncol* 2015;33:567-574. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25422491>.

549. Choy H, Gerber DE, Bradley JD, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. *Lung Cancer* 2015;87:232-240. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25650301>.

550. Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without

cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. *J Clin Oncol* 2011;29:3120-3125. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21747084>.

551. Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. *Clin Lung Cancer* 2009;10:193-198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19443340>.

552. Senan S, Brade AM, Wang L, et al. Final overall survival results of the phase III PROCLAIM trial: pemetrexed, cisplatin or etoposide, cisplatin plus thoracic radiation therapy followed by consolidation cytotoxic chemotherapy in locally advanced nonsquamous non-small cell lung cancer [abstract]. *J Clin Oncol* 2015;33:Abstract 7506. Available at: <http://meetinglibrary.asco.org/content/144034-156>.

553. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003;21:3016-3024. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12837811>.

554. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. *J Clin Oncol* 2003;21:3909-3917. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14581415>.

555. Zatloukal P, Petruzella L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. *Lung Cancer* 2004;46:87-98. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15364136>.

556. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 2008;26:3543-3551. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18506025>.

557. Zornosa C, Vandergrift JL, Kalemkerian GP, et al. First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. *J Natl Compr Canc Netw* 2012;10:847-856. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22773800>.

558. Pennell NA. Selection of chemotherapy for patients with advanced non-small cell lung cancer. *Cleve Clin J Med* 2012;79 Electronic Suppl 1:eS46-50. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22614966>.

559. Leigh NB. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. *Curr Oncol* 2012;19:S52-58. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22787411>.

560. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542-2550. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17167137>.

561. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncol* 2015;16:763-774. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26045340>.

562. Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. *JAMA Oncol* 2015;1:1293-1300. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26313558>.

563. Edelman MJ, Le Chevalier T, Soria JC. Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view. *J Thorac Oncol* 2012;7:1331-1336. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22895137>.

564. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2014;32:1941-1967. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24733808>.

565. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2013;31:4349-4357. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24145346>.

566. Zhu J, Sharma DB, Gray SW, et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. *JAMA* 2012;307:1593-1601. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22511687>.

567. Langer C, Ravelo A, Hazard SJ, et al. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. *Lung Cancer* 2014;86:350-357. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25439437>.

568. Langer CJ, Socinski MA, Patel JD, et al. Isolating the role of bevacizumab in elderly patients with previously untreated nonsquamous non-small cell lung cancer: secondary analyses of the ECOG 4599 and PointBreak trials. *Am J Clin Oncol* 2016;39:441-447. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25628268>.

569. Felip E, Gridelli C, Baas P, et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-

line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. *Ann Oncol* 2011;22:1507-1519. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21536661>.

570. Lilenbaum R, Zukin M, Pereira JR, et al. A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2 [abstract]. *J Clin Oncol* 2012;30(Suppl 15):Abstract 7506. Available at:

[http://meeting.ascopubs.org/cqi/content/abstract/30/15\\_suppl/7506](http://meeting.ascopubs.org/cqi/content/abstract/30/15_suppl/7506).

571. Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. *J Thorac Oncol* 2008;3:623-630. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18520802>.

572. Lilenbaum R, Villaflor VM, Langer C, et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. *J Thorac Oncol* 2009;4:869-874. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19487960>.

573. Roth BJ, Krilov L, Adams S, et al. Clinical cancer advances 2012: annual report on progress against cancer from the American Society of Clinical Oncology. *J Clin Oncol* 2013;31:131-161. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23213095>.

574. Zukin M, Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. *J Clin Oncol* 2013;31:2849-2853. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23775961>.

575. Kelly K, Crowley J, Bunn PA, Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. *J Clin Oncol* 2001;19:3210-3218. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11432888>.

576. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 2002;346:92-98. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11784875>.

577. Grossi F, Kubota K, Cappuzzo F, et al. Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. *Oncologist* 2010;15:1102-1112. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20930102>.

578. de Marinis F, Rossi A, Di Maio M, et al. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. *Lung Cancer* 2011;73:1-10. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21440325>.

579. Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. *Cancer* 2003;98:542-553. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12879472>.

580. Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BT0G1). *Ann Oncol* 2006;17:1111-1119. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16603599>.

581. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy

in advanced non-small-cell lung cancer. *J Clin Oncol* 2009;27:3217-3224. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19433683>.

582. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. *J Clin Oncol* 2005;23:2926-2936. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15728229>.

583. Greco FA, Spigel DR, Kuzur ME, et al. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. *Clin Lung Cancer* 2007;8:483-487. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17922972>.

584. Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. *Cancer* 2002;95:340-353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12124835>.

585. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. *Ann Oncol* 2005;16:602-610. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15741225>.

586. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. *J Clin Oncol* 2008;26:639-643. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18235124>.

587. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. *Ann Oncol* 2006;17:1263-1268. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16740598>.



588. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22547591>.

589. Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. *Clin Cancer Res* 2004;10:4258s-4262s. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15217970>.

590. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. *J Clin Oncol* 2005;23:3235-3242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15886311>.

591. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. *Oncologist* 2007;12:713-718. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17602060>.

592. Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. *Oncologist* 2005;10:461-466. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16079312>.

593. Khozin S, Blumenthal GM, Jiang X, et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. *Oncologist* 2014;19:774-779. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24868098>.

594. Sequist LV, Joshi VA, Janne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. *Oncologist* 2007;12:90-98. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17285735>.

595. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. *J Clin Oncol* 2009;27:1394-1400. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19224850>.

596. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol* 2011;29:2866-2874. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21670455>.

597. Kazandjian D, Blumenthal GM, Yuan W, et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. *Clin Cancer Res* 2016;22:1307-1312. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26980062>.

598. Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. *Oncologist* 2015;20:400-410. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25795635>.

599. Haspinger ER, Agustoni F, Torri V, et al. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. *Crit Rev Oncol Hematol* 2015;94:213-227. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25523487>.

600. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. *Clin Cancer Res* 2009;15:5267-5273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19671843>.

601. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. *J Clin Oncol* 2012;30:3002-3011. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22778317>.

602. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. *J Clin Oncol* 2011;29:2121-2127. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21482992>.

603. Janne PA, Wang X, Socinski MA, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. *J Clin Oncol* 2012;30:2063-2069. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22547605>.

604. Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2015;33:3488-3515. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26324367>.

605. Urata Y, Katakami N, Morita S, et al. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. *J Clin Oncol* 2016;34:3248-3257. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27022112>.

606. FDA approves afatinib for advanced lung cancer. *Oncology (Williston Park)* 2013;27:813-814. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24133833>.

607. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised

controlled phase 3 trial. *Lancet Oncol* 2015;16:897-907. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26156651>.

608. Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol* 2016;17:577-589. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/27083334>.

609. Yang JC, Ahn M, Ramalingam SS, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study Phase II extension cohort [abstract]. Presented at the 16th World Conference on Lung Cancer; 6-9 September 2015; Denver, CO. Abstract 943.

610. Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study [abstract]. Presented at the 16th World Conference on Lung Cancer; 6-9 September 2015; Denver, CO. Abstract 1406.

611. Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. *J Clin Oncol* 2016;34:3375-3382. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/27354477>.

612. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. *JAMA Oncol* 2016;2:1014-1022. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27055085>.

613. Hochmair MJ, Holzer S, Filipits M, et al. EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib [abstract]. *J Clin Oncol* 2016;34:Abstract e20572. Available at:

614. Ricciuti B, Chiari R, Chiarini P, et al. Osimertinib (AZD9291) and CNS response in two radiotherapy-naïve patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer. *Clin Drug*

Investig 2016;36:683-686. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/27177916>.

615. Reichegger H, Jochum W, Forbs D, et al. Rapid intracranial response to osimertinib in a patient with epidermal growth factor receptor T790M-positive adenocarcinoma of the lung. *Oncol Res Treat* 2016;39:461-463. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/27486808>.

616. Ballard P, Yates JW, Yang Z, et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. *Clin Cancer Res* 2016;22:5130-5140. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/27435396>.

617. Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol* 2016;17:452-463. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26973324>.

618. Crino L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. *J Clin Oncol* 2016;34:2866-2873. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/27432917>.

619. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet* 2009;373:1525-1531. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19410716>.

620. Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy.

Oncologist 2016;21:634-642. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26984449>.

621. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med* 2015;373:1627-1639. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26412456>.

622. Melosky B, Chu Q, Juergens R, et al. Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. *J Clin Oncol* 2016;34:1676-1688. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/26884577>.

623. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med* 2015;373:123-135. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26028407>.

624. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387:1540-1550. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26712084>.

625. Ribas A. Releasing the Brakes on Cancer Immunotherapy. *N Engl J Med* 2015;373:1490-1492. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26348216>.

626. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. *Future Oncol* 2015;11:1307-1326. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25798726>.

627. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. *J Clin Oncol* 2015;33:3541-3543. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26261262>.

628. Phillips T, Simmons P, Inzunza HD, et al. Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small

Cell Lung Cancer. Appl Immunohistochem Mol Morphol 2015;23:541-549. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26317305>.

629. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015;10:985-989. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26134220>.

630. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26028255>.

631. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257-265. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25704439>.

632. Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of Programmed Cell Death 1 Inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27540850>.

633. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-Programmed Death-1/Programmed Death Ligand 1 therapy. J Clin Oncol 2016. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27646942>.

634. Sgambato A, Casaluce F, Sacco PC, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management. Curr Drug Saf 2016;11:62-68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26412670>.

635. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-

small-cell lung cancer. J Clin Oncol 2015;33:2004-2012. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25897158>.

636. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-1982. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25605845>.

637. Chapman PB, D'Angelo SP, Wolchok JD. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 2015;372:2073-2074. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25891305>.

638. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-1833. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27718847>.

639. Gadgeel SM, Stevenson J, Langer C, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C [abstract]. J Clin Oncol 2016;34:Abstract 9016. Available at: <http://meetinglibrary.asco.org/content/167088-176>.

640. Kerr KM, Nicolson MC. Non-small cell lung cancer, PD-L1, and the pathologist. Arch Pathol Lab Med 2016;140:249-254. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26927720>.

641. Kerr KM, Hirsch FR. Programmed death ligand-1 immunohistochemistry: friend or foe? Arch Pathol Lab Med 2016;140:326-331. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26756647>.

642. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25891174>.

643. Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1.

Oncologist 2016;21:643-650. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/27026676>.

644. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25765070>.

645. Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J Immunother Cancer 2015;3:36. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26288737>.

646. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-895. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/27269741>.

647. Antonia SJ, Kim S-W, Spira AI, et al. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non-small-cell lung cancer [abstract]. J Clin Oncol 2016;34:Abstract 9029. Available at:  
<http://meetinglibrary.asco.org/content/163695-176>.

648. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-1846. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26970723>.

649. Barlesi F, Park K, Ciardiello F. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC [abstract] [abstract]. Presented at the 2016 Annual Meeting European Society for Medical Oncology (ESMO) Copenhagen, Denmark. LBA44.

650. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of

stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-673. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24933332>.

651. Larkins E, Scepora B, Blumenthal GM, et al. U.S. Food and Drug Administration Approval Summary: ramucirumab for the treatment of metastatic non-small cell lung cancer following disease progression on or after platinum-based chemotherapy. Oncologist 2015;20:1320-1325. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26446239>.

652. Gridelli C, de Marinis F, Di Maio M, et al. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer 2012;76:269-279. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22266040>.

653. Hashemi-Sadraei N, Pennell NA. Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all? Curr Treat Options Oncol 2012;13:478-490. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22972369>.

654. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-3289. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19433684>.

655. Nadler E, Yu E, Ravelo A, et al. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist 2011;16:486-496. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21441299>.

656. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

Lancet Oncol 2012;13:247-255. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22341744>.

657. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-2902. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23835707>.

658. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013;31:3004-3011. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23835708>.

659. Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 2014;25:1044-1052. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24585722>.

660. Perol M, Chouaid C, Perol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3516-3524. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22949150>.

661. Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 7507. Available at:  
[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7507](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7507).

662. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16569462>.

663. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:5116-5123. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21041704>.

664. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-1343. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11870177>.

665. Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 2013;31:1009-1020. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23401441>.

666. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20493771>.

667. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19767093>.

668. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 2010;15:1352-1358. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21148615>.

669. Rittmeyer A. Quality of Life in Patients with NSCLC Receiving Maintenance Therapy. *Cancers (Basel)* 2015;7:950-962. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26035509>.

670. Cohen MH, Johnson JR, Chattopadhyay S, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). *Oncologist* 2010;15:1344-1351. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21148614>.

671. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. *J Clin Oncol* 2009;27:591-598. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19075278>.

672. Rigotti NA, Regan S, Levy DE, et al. Sustained care intervention and postdischarge smoking cessation among hospitalized adults: a randomized clinical trial. *JAMA* 2014;312:719-728. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25138333>.

673. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. *Cochrane Database Syst Rev* 2013;8:CD002850. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23934971>.

674. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. *Cochrane Database Syst Rev* 2012;10:CD008286. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23076944>.

675. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e211S-250S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649440>.

676. Patterson GA, Ginsberg RJ, Poon PY, et al. A prospective evaluation of magnetic resonance imaging, computed tomography, and

mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. *J Thorac Cardiovasc Surg* 1987;94:679-684. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3669696>.

677. Gonzalez-Stawinski GV, Lemaire A, Merchant F, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2003;126:1900-1905. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14688703>.

678. Tournoy KG, Maddens S, Gosselin R, et al. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. *Thorax* 2007;62:696-701. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17687098>.

679. Meyers BF, Haddad F, Siegel BA, et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. *J Thorac Cardiovasc Surg* 2006;131:822-829; discussion 822-829. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16580440>.

680. Dillemans B, Deneffe G, Verschakelen J, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. *Eur J Cardiothorac Surg* 1994;8:37-42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8136168>.

681. Arita T, Kuramitsu T, Kawamura M, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. *Thorax* 1995;50:1267-1269. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8553299>.

682. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. *N Engl J Med* 2000;343:254-261. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10911007>.

683. Manente P, Vicario G, Piazza F, et al. Does PET/CT modify the therapeutic approach in medical oncology [abstract]? . J Clin Oncol 2008;26(Suppl 15):Abstract 17525. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/26/15\\_suppl/17525](http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/17525).

684. Maziak DE, Darling GE, Incelet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009;151:221-228, W-248. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19581636>.

685. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-39. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19571281>.

686. De Wever W, Stroobants S, Coolen J, Verschakelen JA. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 2009;33:201-212. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19118231>.

687. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-323. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1732943>.

688. Seely JM, Mayo JR, Miller RR, Muller NL. T1 lung cancer: prevalence of mediastinal nodal metastases and diagnostic accuracy of CT. Radiology 1993;186:129-132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8416552>.

689. Kerr KM, Lamb D, Wathen CG, et al. Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. Thorax 1992;47:337-341. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1609375>.

690. Chin R, Jr., Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir

Crit Care Med 1995;152:2090-2096. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8520780>.

691. Kernstine KH, Stanford W, Mullan BF, et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 1999;68:1022-1028. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10510001>.

692. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006;24:3333-3339. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16849747>.

693. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006;131:1229-1235. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16733150>.

694. Darling GE, Maziak DE, Incelet RI, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol 2011;6:1367-1372. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21587082>.

695. Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg 2011;142:1393-1400 e1391. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21963329>.

696. Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of



lung cancer: a randomized trial. JAMA 2010;304:2245-2252. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21098770>.

697. Tournoy KG, Keller SM, Annema JT. Mediastinal staging of lung cancer: novel concepts. Lancet Oncol 2012;13:e221-229. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22554550>.

698. Vilmann P, Krasnik M, Larsen SS, et al. Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of mediastinal lesions. Endoscopy 2005;37:833-839. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16116534>.

699. Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006;130:710-718. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16963667>.

700. Ernst A, Eberhardt R, Krasnik M, Herth FJ. Efficacy of endobronchial ultrasound-guided transbronchial needle aspiration of hilar lymph nodes for diagnosing and staging cancer. J Thorac Oncol 2009;4:947-950. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19590457>.

701. Rintoul RC, Tournoy KG, El Daly H, et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol 2009;4:44-48. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19096305>.

702. Defranchi SA, Edell ES, Daniels CE, et al. Mediastinoscopy in patients with lung cancer and negative endobronchial ultrasound guided needle aspiration. Ann Thorac Surg 2010;90:1753-1757. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21095301>.

703. Medford AR, Bennett JA, Free CM, Agrawal S. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr

Opin Pulm Med 2009;15:334-342. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19395972>.

704. Mayr NA, Hussey DH, Yuh WT. Cost-effectiveness of high-contrast-dose MR screening of asymptomatic brain metastasis. AJNR Am J Neuroradiol 1995;16:215-217. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7755752>.

705. Videtic GM, Chang JY, Chetty IJ, et al. ACR appropriateness Criteria(R) early-stage non-small-cell lung cancer. Am J Clin Oncol 2014;37:201-207. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25180631>.

706. Rusch VW, Kraut MJ, Crowley J, et al. Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus (pancoast tumors): Mature results of Southwest Oncology Group trial 9416 (Intergroup trial 0160) [abstract]. Proc Am Soc Clin Oncol 2003 22:Abstract 2548. Available at: [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=23&abstractID=103854](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=103854).

707. Barnes JB, Johnson SB, Dahiya RS, et al. Concomitant weekly cisplatin and thoracic radiotherapy for Pancoast tumors of the lung: pilot experience of the San Antonio Cancer Institute. Am J Clin Oncol 2002;25:90-92. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11823705>.

708. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001;121:472-483. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11241082>.

709. Pourel N, Santelmo N, Naafa N, et al. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg

2008;33:829-836. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18367406>.

710. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. *J Clin Oncol* 2003;21:2004-2010. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12743155>.

711. Nakagawa T, Okumura N, Miyoshi K, et al. Prognostic factors in patients with ipsilateral pulmonary metastasis from non-small cell lung cancer. *Eur J Cardiothorac Surg* 2005;28:635-639. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16126398>.

712. Lee JG, Lee CY, Kim DJ, et al. Non-small cell lung cancer with ipsilateral pulmonary metastases: prognosis analysis and staging assessment. *Eur J Cardiothorac Surg* 2008;33:480-484. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18249000>.

713. Hancock JG, Rosen JE, Antonicelli A, et al. Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery. *Ann Thorac Surg* 2015;99:406-413. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25528723>.

714. Bhaskarla A, Tang PC, Mashtare T, et al. Analysis of second primary lung cancers in the SEER database. *J Surg Res* 2010;162:1-6. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20400118>.

715. Aziz TM, Saad RA, Glasser J, et al. The management of second primary lung cancers. A single centre experience in 15 years. *Eur J Cardiothorac Surg* 2002;21:527-533. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11888775>.

716. Adebonojo SA, Moritz DM, Danby CA. The results of modern surgical therapy for multiple primary lung cancers. *Chest* 1997;112:693-701. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9315801>.

717. Nakata M, Sawada S, Yamashita M, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. *Ann Thorac Surg* 2004;78:1194-1199. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15464469>.

718. Ginsberg MS, Griff SK, Go BD, et al. Pulmonary nodules resected at video-assisted thoracoscopic surgery: etiology in 426 patients. *Radiology* 1999;213:277-282. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10540672>.

719. Allen MS. Multiple benign lung tumors. *Semin Thorac Cardiovasc Surg* 2003;15:310-314. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12973710>.

720. Asamura H. Multiple primary cancers or multiple metastases, that is the question. *J Thorac Oncol* 2010;5:930-931. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20581574>.

721. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. *Chest* 2010;137:46-52. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19376842>.

722. Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. *Clin Lung Cancer* 2011;12:380-386. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21729655>.

723. Martini N, Melamed MR. Multiple primary lung cancers. *J Thorac Cardiovasc Surg* 1975;70:606-612. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/170482>.

724. Chang YL, Wu CT, Lee YC. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. *J Thorac Cardiovasc Surg* 2007;134:630-637. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17723810>.

725. Tanvetyanon T, Robinson L, Sommers KE, et al. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. *J Thorac Oncol* 2010;5:1018-1024. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20453687>.

726. Rea F, Zuin A, Callegaro D, et al. Surgical results for multiple primary lung cancers. *Eur J Cardiothorac Surg* 2001;20:489-495. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11509268>.

727. Gibbs IC, Loo BW, Jr. CyberKnife stereotactic ablative radiotherapy for lung tumors. *Technol Cancer Res Treat* 2010;9:589-596. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21070081>.

728. Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. *Radiology* 2009;253:606-622. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19952025>.

729. Pearson FG, DeLarue NC, Ilves R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. *J Thorac Cardiovasc Surg* 1982;83:1-11. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7054602>.

730. Rice TW. Thoracoscopy in the staging of thoracic malignancies. In: Kaiser LR, Daniel TM, eds, eds. *Thoracoscopic Surgery*. Philadelphia: Lippincott Williams & Wilkins; 1993:153-162.

731. Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). *Clin Lung Cancer* 2006;8:116-121. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17026812>.

732. Mina LA, Neubauer MA, Ansari RH, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable

stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023--Updated results [abstract]. *J Clin Oncol* 2008;26 (Suppl 15):Abstract 7519. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/26/15\\_suppl/7519](http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/7519).

733. Hanna NH, Neubauer M, Ansari R, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 [abstract]. *J Clin Oncol* 2007;25 (Suppl 18):Abstract 7512. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/25/18\\_suppl/7512](http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7512).

734. Decker DA, Dines DE, Payne WS, et al. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. *Chest* 1978;74:640-642. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/216532>.

735. Demmy TL, Gu L, Burkhalter JE, et al. Optimal management of malignant pleural effusions (results of CALGB 30102). *J Natl Compr Canc Netw* 2012;10:975-982. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22878823>.

736. Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. *Clin Lung Cancer* 2014;15:346-355. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24894943>.

737. de Vin T, Engels B, Gevaert T, et al. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. *Ann Oncol* 2014;25:467-471. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24355488>.

738. Simone CB, 2nd, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. *Transl Lung Cancer Res* 2015;4:545-552. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26629423>.

739. Campo M, Al-Halabi H, Khandekar M, et al. Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung cancer. *Oncologist* 2016;21:964-973. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27354669>.

740. Raz DJ, Lanuti M, Gaissert HC, et al. Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. *Ann Thorac Surg* 2011;92:1788-1792; discussion 1793. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21944257>.

741. Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. *J Clin Oncol* 2008;26:1142-1147. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18309950>.

742. Raviv G, Klein E, Yellin A, et al. Surgical treatment of solitary adrenal metastases from lung carcinoma. *J Surg Oncol* 1990;43:123-124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1689433>.

743. Reyes L, Parvez Z, Nemoto T, et al. Adrenalectomy for adrenal metastasis from lung carcinoma. *J Surg Oncol* 1990;44:32-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2342373>.

744. Park SY, Lee JG, Kim J, et al. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. *J Cardiothorac Surg* 2013;8:151. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23759129>.

745. Group NM-aC, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. *Lancet* 2010;375:1267-1277. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20338627>.

746. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for

patients with previously untreated advanced non-small-cell lung cancer. *J Clin Oncol* 2008;26:468-473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18202422>.

747. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. *J Clin Oncol* 1992;10:580-586. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1312587>.

748. Bonomi P, Faber L. Neoadjuvant chemoradiation therapy in non-small cell lung cancer: The Rush University experience. *Lung Cancer* 1993;9:383-390. Available at:

749. Rusch VW, Albain KS, Crowley JJ, et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. *J Thorac Cardiovasc Surg* 1993;105:97-104; discussion 104-106. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8380477>.

750. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. *N Engl J Med* 1994;330:153-158. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8043059>.

751. Pisters K, Vallieres E, Bunn P, et al. S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results [abstract]. *J Clin Oncol* 2005;23 (Suppl 16):Abstract LBA7012. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/23/16\\_suppl/LBA7012](http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/LBA7012).

752. Pisters K, Vallieres E, Bunn PA, Jr., et al. S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial [abstract]. *J Clin Oncol* 2007;25 (Suppl 18):Abstract 7520. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/25/18\\_suppl/7520](http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7520).

753. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. *Lancet* 1998;352:257-263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9690404>.

754. Robinson CG, Patel AP, Bradley JD, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. *J Clin Oncol* 2015;33:870-876. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25667283>.

755. Patel SH, Ma Y, Wernicke AG, et al. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. *Lung Cancer* 2014;84:156-160. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24674156>.

756. Decker RH, Langer CJ, Rosenzweig KE, et al. ACR Appropriateness Criteria(R) postoperative adjuvant therapy in non-small cell lung cancer. *Am J Clin Oncol* 2011;34:537-544. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21946673>.

757. Weisenburger TH, Graham MV, Sause WT, et al. Postoperative radiotherapy in non-small cell lung cancer. *American College of Radiology. ACR Appropriateness Criteria. Radiology* 2000;215 Suppl:1295-1318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11037548>.

758. Choy H, Schwartzberg LS, Dakhil SR, et al. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. *J Thorac Oncol* 2013;8:1308-1316. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23981966>.

759. Garrido P, Engel-Riedel W, Serke M, et al. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally

advanced non-squamous non-small cell lung cancer (NSCLC). *Lung Cancer* 2015;88:160-166. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25758556>.

760. Crabtree TD, Puri V, Chen SB, et al. Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer? *J Thorac Cardiovasc Surg* 2015;149:45-52, 53 e41-43. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25218540>.

761. Erb CT, Su KW, Soulos PR, et al. Surveillance practice patterns after curative intent therapy for stage I non-small-cell lung cancer in the medicare population. *Lung Cancer* 2016;99:200-207. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27565940>.

762. Colt HG, Murgu SD, Korst RJ, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e437S-454S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649451>.

763. Lou F, Huang J, Sima CS, et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. *J Thorac Cardiovasc Surg* 2013;145:75-81; discussion 81-72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23127371>.

764. Srikantharajah D, Ghuman A, Nagendran M, Maruthappu M. Is computed tomography follow-up of patients after lobectomy for non-small cell lung cancer of benefit in terms of survival? *Interact Cardiovasc Thorac Surg* 2012;15:893-898. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22859511>.

765. Hanna WC, Paul NS, Darling GE, et al. Minimal-dose computed tomography is superior to chest x-ray for the follow-up and treatment of patients with resected lung cancer. *J Thorac Cardiovasc Surg* 2014;147:30-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24139896>.

766. Calman L, Beaver K, Hind D, et al. Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. *J Thorac Oncol* 2011;6:1993-2004. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21892108>.

767. Dane B, Grechushkin V, Plank A, et al. PET/CT vs. non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small-cell lung cancer. *Am J Nucl Med Mol Imaging* 2013;3:408-416. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24116349>.

768. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. *Lancet* 1999;354:99-105. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10408484>.

769. Ulaner GA, Lyall A. Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT. *Radiographics* 2013;33:1817-1834. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24108564>.

770. Shi Q, Smith TG, Michonski JD, et al. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. *Cancer* 2011;117:2779-2790. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21495026>.

771. Gelb AF, Tashkin DP, Epstein JD, et al. Physiologic characteristics of malignant unilateral main-stem bronchial obstruction. Diagnosis and Nd-YAG laser treatment. *Am Rev Respir Dis* 1988;138:1382-1385. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2462389>.

772. Howell DD, James JL, Hartsell WF, et al. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14. *Cancer* 2013;119:888-896. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23165743>.

773. Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. *J Clin Oncol* 2007;25:1423-1436. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17416863>.

774. Griffioen GH, Toguri D, Dahele M, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. *Lung Cancer* 2013;82:95-102. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23973202>.

775. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. *Lung Cancer* 2013;82:197-203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24051084>.

776. Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. *Ann Oncol* 2014;25:1954-1959. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25114022>.

777. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. *Lancet Oncol* 2013;14:e28-37. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23276369>.

778. De Ruyscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). *J Thorac Oncol* 2012;7:1547-1555. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22982655>.

779. Kelly P, Balter PA, Rebuena N, et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. *Int J Radiat Oncol Biol Phys* 2010;78:1387-1393. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20381271>.

780. Meijneke TR, Petit SF, Wentzler D, et al. Reirradiation and stereotactic radiotherapy for tumors in the lung: dose summation and

toxicity. *Radiother Oncol* 2013;107:423-427. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23647748>.

781. Peulen H, Karlsson K, Lindberg K, et al. Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. *Radiother Oncol* 2011;101:260-266. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22056534>.

782. Reingold M, Wu AJ, McLane A, et al. Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). *Radiat Oncol* 2013;8:99. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23617949>.

783. Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. *Support Care Cancer* 2014;22:679-687. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24162260>.

784. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol* 2011;29:1125-1132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21343556>.

785. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. *Cancer* 2004;100:2613-2621. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15197804>.

786. Henry DH, von Moos R, Hungria V, et al. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer [abstract]. *J Clin Oncol* 2010;28 (Suppl 15):Abstract 9133. Available at:

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9133](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9133).

787. Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. *J Thorac Oncol* 2012;7:1823-1829. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23154554>.

788. Casas A, Llombart A, Martin M. Denosumab for the treatment of bone metastases in advanced breast cancer. *Breast* 2013;22:585-592. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23759273>.

789. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. *Clin Cancer Res* 2003;9:2394-2399. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12855610>.

790. Platt A, Morten J, Ji Q, et al. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. *BMC Cancer* 2015;15:171. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25881079>.

791. Lee S-H, Lee J-K, Ahn M-J, et al. A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement [abstract]. *J Clin Oncol* 2016;34:Abstract 9013. Available at:

<http://meetinglibrary.asco.org/content/166941-176>.

792. Falchook GS, Ordonez NG, Bastida CC, et al. Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. *J Clin Oncol* 2016;34:e141-144. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25366691>.

793. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *N Engl J Med* 2015;373:726-736. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26287849>.

794. Gautschi O, Milia J, Cabarrou B, et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European

EURAF Cohort. J Thorac Oncol 2015;10:1451-1457. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26200454>.

795. Drlon AE, Sima CS, Somwar R, et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers [abstract]. J Clin Oncol 2015;33:Abstract 8007. Available at:  
<http://meetinglibrary.asco.org/content/147349-156>.

796. Planchard D, Groen HJM, Kim TM, et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2015;33:Abstract 8006. Available at:  
<http://meetinglibrary.asco.org/content/147124-156>.

797. Robinson SD, O'Shaughnessy JA, Cowey CL, Konduri K. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 2014;85:326-330. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24888229>.

798. Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31:1997-2003. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23610105>.

799. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-538. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22452896>.

800. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15118125>.

801. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 2013;31:e341-344. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23733758>.

802. Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract]. J Clin Oncol 2013;31(Suppl 15):Abstract 8009. Available at:  
[http://meeting.ascopubs.org/cqi/content/abstract/31/15\\_suppl/8009](http://meeting.ascopubs.org/cqi/content/abstract/31/15_suppl/8009).

803. Sakuma Y, Matsukuma S, Yoshihara M, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007;128:100-108. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17580276>.

804. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-1012. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21933749>.

805. Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics 2013;7:91-101. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23671386>.

806. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:Unit 10 11. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18428421>.

807. Lee SY, Kim MJ, Jin G, et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010;5:1734-1740. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20881644>.



808. Rekhman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. *Clin Cancer Res* 2012;18:1167-1176. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22228640>.

809. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. *J Thorac Oncol* 2010;5:1416-1423. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20686429>.

810. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. *J Clin Oncol* 2009;27:5255-5261. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19738122>.

811. Pilkington G, Boland A, Brown T, et al. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. *Thorax* 2015;70:359-367. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25661113>.

812. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. *Lancet* 2011;378:1079-1088. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21831418>.

813. Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for advanced non-small cell lung cancer in the elderly population. *Cochrane Database Syst Rev* 2015;10:CD010463. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26482542>.

814. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012;366:2455-2465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22658128>.

815. Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. *J Thorac Oncol* 2012;7:924-933. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22722794>.

816. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 2004;22:2184-2191. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15169807>.

817. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol* 2009;27:1227-1234. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19188680>.

818. Mezger J, von Pawel J, Reck M. Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): Results from an exploratory analysis of the AVAIL study [abstract]. *J Clin Oncol* 2009;27 (Suppl 15):Abstract e19001. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e19001>.

819. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. *J Thorac Oncol* 2011;6:64-70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21119545>.

820. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. *Lancet Oncol* 2008;9:1135-1142. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19013107>.

821. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer

guideline: update 2003. J Clin Oncol 2004;22:330-353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14691125>.

822. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-3283. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19470938>.

823. Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol 2011;3:139-157. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21904577>.

824. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-5155. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17785570>.

825. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19289619>.

826. Becker K, Xu Y. Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World J Clin Oncol 2014;5:560-567. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25302160>.

827. Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31:3335-3341. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23816963>.

828. Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 2013;8:229-237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23328549>.

829. Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012;83:407-421. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22257651>.

830. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281-289. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19632948>.

831. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28 Suppl 1:S24-31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19680293>.

832. Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298-6303. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21856766>.

833. Meoni G, Cecere FL, Lucherini E, Di Costanzo F. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents. J Geriatr Oncol 2013;4:282-290. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24070465>.

834. Weiss JM, Stinchcombe TE. Second-Line Therapy for Advanced NSCLC. Oncologist 2013;18:947-953. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23918070>.

835. van Putten JW, Baas P, Codrington H, et al. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. *Lung Cancer* 2001;33:289-298. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11551424>.

836. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. *J Clin Oncol* 1999;17:2081-2085. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10561261>.

837. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. *Non-Small Cell Lung Cancer. Br J Cancer* 2000;83:447-453. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10945489>.

838. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. *Lung Cancer* 2000;29:67-73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10880849>.

839. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol* 2000;18:2354-2362. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10856094>.

840. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol* 2000;18:2095-2103. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10811675>.

841. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol* 2004;22:1589-1597. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15117980>.

842. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353:123-132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16014882>.

843. Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results? *E Cancer medical science* 2015;9:604. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26715941>.

844. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228-247. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19097774>.

845. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 2009;15:7412-7420. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19934295>.

846. Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. *Cancer Discov* 2014;4:1036-1045. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25074459>.

847. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. *Clin Cancer Res* 2016;22:4585-4593. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27225694>.



848. Sacher AG, Janne PA, Oxnard GR. Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. *Cancer* 2014;120:2289-2298. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24752335>.

2006;1:1042-1058. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17409993>.

849. Demarinis F, Paul S, Hanna N, et al. Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC) [abstract]. *J Clin Oncol* 2006;24 (Suppl 18):Abstract 7133. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/24/18\\_suppl/7133](http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7133).

850. Garassino MC, Martelli O, Broggin M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. *Lancet Oncol* 2013;14:981-988. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23883922>.

851. Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). *J Clin Oncol* 2014;32:1902-1908. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24841974>.

852. Eccles BK, Geldart TR, Laurence VM, et al. Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer. *Ther Adv Med Oncol* 2011;3:163-170. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21904578>.

853. Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). *Cancer Treat Rev* 2013;39:252-260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22703830>.

854. Noble J, Ellis PM, Mackay JA, et al. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. *J Thorac Oncol*